http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#OperatingIncomeLoss http://fasb.org/us-gaap/2022#OperatingIncomeLoss http://www.ecolab.com/20221231#InterestExpenseNet http://www.ecolab.com/20221231#InterestExpenseNet http://www.ecolab.com/20221231#InterestExpenseNet http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://www.ecolab.com/20221231#InterestExpenseNet http://www.ecolab.com/20221231#InterestExpenseNet http://www.ecolab.com/20221231#InterestExpenseNet 0000031462--12-31 2022 FY false http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense P17Y P14Y http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#OtherNonrecurringIncomeExpense http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent P34Y 0 http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://www.ecolab.com/20221231#OperatingLeaseLiabilityNoncurrentExcludedFromLongTermDebt http://fasb.org/us-gaap/2022#OperatingIncomeLoss 0000031462 us-gaap:CostOfSalesMember ecl:COVID19Member 2022-01-01 2022-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:COVID19Member 2022-01-01 2022-12-31 0000031462 us-gaap:CostOfSalesMember ecl:COVID19Member 2021-01-01 2021-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:COVID19Member 2021-01-01 2021-12-31 0000031462 us-gaap:CostOfSalesMember ecl:COVID19Member 2020-01-01 2020-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:COVID19Member 2020-01-01 2020-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-12-31 0000031462 ecl:EuroNotesMember us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-12-31 0000031462 us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0000031462 ecl:EuroNotesMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0000031462 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0000031462 ecl:EuroNotesMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-12-31 0000031462 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-12-31 0000031462 srt:MaximumMember us-gaap:CommonStockMember 2022-11-30 0000031462 us-gaap:CommonStockMember 2015-02-28 0000031462 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000031462 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000031462 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000031462 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000031462 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000031462 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000031462 us-gaap:RetainedEarningsMember 2022-12-31 0000031462 us-gaap:ParentMember 2022-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2022-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000031462 us-gaap:RetainedEarningsMember 2021-12-31 0000031462 us-gaap:ParentMember 2021-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2021-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000031462 us-gaap:RetainedEarningsMember 2020-12-31 0000031462 us-gaap:ParentMember 2020-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2020-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000031462 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000031462 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2019-12-31 0000031462 us-gaap:RetainedEarningsMember 2019-12-31 0000031462 us-gaap:ParentMember 2019-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2019-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000031462 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000031462 us-gaap:CommercialPaperMember 2021-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2019-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2021-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2020-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2022-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000031462 ecl:RestrictedStockAwardsMember 2022-12-31 0000031462 ecl:PBRSUAwardsMember 2022-12-31 0000031462 ecl:RestrictedStockAwardsMember 2021-12-31 0000031462 ecl:PBRSUAwardsMember 2021-12-31 0000031462 ecl:RestrictedStockAwardsMember 2020-12-31 0000031462 ecl:PBRSUAwardsMember 2020-12-31 0000031462 ecl:RestrictedStockAwardsMember 2019-12-31 0000031462 ecl:PBRSUAwardsMember 2019-12-31 0000031462 ecl:RestrictedStockAwardsMember 2022-01-01 2022-12-31 0000031462 ecl:RestrictedStockAwardsMember 2021-01-01 2021-12-31 0000031462 ecl:PBRSUAwardsMember 2021-01-01 2021-12-31 0000031462 srt:MinimumMember ecl:RestrictedStockAwardsMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember ecl:RestrictedStockAwardsMember 2022-01-01 2022-12-31 0000031462 ecl:CIDLinesMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignPlanMember 2022-01-01 2022-12-31 0000031462 ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:LatinAmericaMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:EuropeMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:AsiaPacificMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ServiceAndLeaseMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ProductAndEquipmentMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:IndiaMiddleEastAndAfricaMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CN 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CA 2022-01-01 2022-12-31 0000031462 srt:LatinAmericaMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 srt:EuropeMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 srt:EuropeMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 srt:EuropeMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 srt:EuropeMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 srt:AsiaPacificMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 country:US ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 country:US ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 country:US ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 country:US ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 country:CN ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 country:CN ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 country:CN ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 country:CN ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 country:CA ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 country:CA ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 country:CA ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 country:CA ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:LatinAmericaMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:EuropeMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:AsiaPacificMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ServiceAndLeaseMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ProductAndEquipmentMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:IndiaMiddleEastAndAfricaMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:US 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CN 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CA 2021-01-01 2021-12-31 0000031462 srt:LatinAmericaMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 srt:EuropeMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 srt:EuropeMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 srt:EuropeMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 srt:EuropeMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 srt:AsiaPacificMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 country:US ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 country:US ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 country:US ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 country:US ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 country:CN ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 country:CN ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 country:CN ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 country:CN ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 country:CA ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 country:CA ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 country:CA ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 country:CA ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:LatinAmericaMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:EuropeMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember srt:AsiaPacificMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ServiceAndLeaseMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:ProductAndEquipmentMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember ecl:IndiaMiddleEastAndAfricaMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:US 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CN 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember country:CA 2020-01-01 2020-12-31 0000031462 srt:LatinAmericaMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 srt:LatinAmericaMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 srt:EuropeMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 srt:EuropeMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 srt:EuropeMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 srt:EuropeMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 srt:AsiaPacificMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 srt:AsiaPacificMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ServiceAndLeaseMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:IndiaMiddleEastAndAfricaMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 country:US ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 country:US ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 country:US ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 country:US ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 country:CN ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 country:CN ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 country:CN ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 country:CN ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 country:CA ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 country:CA ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 country:CA ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 country:CA ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 us-gaap:OtherRestructuringMember ecl:InstitutionalAdvancementProgramMember 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:EuropeCostSavingsProgramMember 2022-12-31 0000031462 us-gaap:OtherRestructuringMember 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2022-12-31 0000031462 ecl:PriorYearPlansMember 2022-12-31 0000031462 ecl:EuropeCostSavingsProgramMember 2022-12-31 0000031462 us-gaap:OtherRestructuringMember ecl:InstitutionalAdvancementProgramMember 2021-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2021-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:RestructuringPlan2018Member 2021-12-31 0000031462 us-gaap:OtherRestructuringMember 2021-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2021-12-31 0000031462 ecl:PriorYearPlansMember 2021-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2021-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2020-12-31 0000031462 us-gaap:OtherRestructuringMember 2020-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2020-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2020-12-31 0000031462 us-gaap:OtherRestructuringMember 2019-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2019-12-31 0000031462 us-gaap:FacilityClosingMember 2022-01-01 2022-12-31 0000031462 us-gaap:FacilityClosingMember 2021-01-01 2021-12-31 0000031462 us-gaap:FacilityClosingMember 2020-01-01 2020-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:RestructuringPlan2018Member 2022-12-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2022-01-01 2022-12-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember ecl:AccumulatedDefinedBenefitPlansAdjustmentSettlementChargesMember 2022-01-01 2022-12-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-01-01 2021-12-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember ecl:AccumulatedDefinedBenefitPlansAdjustmentSettlementChargesMember 2021-01-01 2021-12-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-01-01 2020-12-31 0000031462 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-12-31 0000031462 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000031462 srt:MinimumMember ecl:MerchandisingAndCustomerEquipmentMember 2022-01-01 2022-12-31 0000031462 srt:MinimumMember ecl:BuildingsAndLeaseHoldsMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember ecl:MerchandisingAndCustomerEquipmentMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember ecl:BuildingsAndLeaseHoldsMember 2022-01-01 2022-12-31 0000031462 ecl:UndesignatedPreferredStockMember 2022-12-31 0000031462 ecl:PuroliteMember 2021-12-01 2021-12-31 0000031462 ecl:CIDLinesMember 2020-05-11 2020-05-11 0000031462 2021-09-01 2021-09-30 0000031462 ecl:PriorYearPlansMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-10-01 2022-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000031462 ecl:ServiceAndLeaseMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000031462 ecl:OperatingIncomeMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-10-01 2021-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-04-01 2021-06-30 0000031462 ecl:ServiceAndLeaseMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000031462 ecl:OperatingIncomeMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000031462 ecl:OperatingIncomeMember 2020-01-01 2020-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000031462 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0000031462 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2022-01-01 2022-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2022-01-01 2022-12-31 0000031462 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2021-01-01 2021-12-31 0000031462 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0000031462 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000031462 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:MaterialReconcilingItemsMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:CorporateNonSegmentMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:MaterialReconcilingItemsMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:CorporateNonSegmentMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:MaterialReconcilingItemsMember us-gaap:ScenarioAdjustmentMember 2021-01-01 2021-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:CorporateNonSegmentMember us-gaap:ScenarioAdjustmentMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2021Member srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000031462 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForSegmentChangesMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:OtherReportableSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalInstitutionalMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalIndustrialMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember ecl:GlobalHealthcareAndLifeSciencesMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:MaterialReconcilingItemsMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member us-gaap:CorporateNonSegmentMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:OperatingSegmentsMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:MaterialReconcilingItemsMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member us-gaap:CorporateNonSegmentMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:OperatingSegmentsMember us-gaap:ScenarioAdjustmentMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:MaterialReconcilingItemsMember us-gaap:ScenarioAdjustmentMember 2020-01-01 2020-12-31 0000031462 ecl:ComparabilityAdjustmentsForChangesInForeignCurrencyTranslationRateMember us-gaap:CorporateNonSegmentMember us-gaap:ScenarioAdjustmentMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2021Member us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2020Member srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 ecl:ManagementRates2019Member srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0000031462 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0000031462 2022-01-01 2022-06-30 0000031462 srt:LatinAmericaMember 2022-12-31 0000031462 srt:EuropeMember 2022-12-31 0000031462 ecl:MeaMember 2022-12-31 0000031462 ecl:AsiaPacificExcludingGreaterChinaMember 2022-12-31 0000031462 country:US 2022-12-31 0000031462 country:CN 2022-12-31 0000031462 country:CA 2022-12-31 0000031462 srt:LatinAmericaMember 2021-12-31 0000031462 srt:EuropeMember 2021-12-31 0000031462 ecl:MeaMember 2021-12-31 0000031462 ecl:AsiaPacificExcludingGreaterChinaMember 2021-12-31 0000031462 country:US 2021-12-31 0000031462 country:CN 2021-12-31 0000031462 country:CA 2021-12-31 0000031462 ecl:NalcoHoldingCompanyMember 2022-01-01 2022-12-31 0000031462 srt:MinimumMember ecl:NalcoHoldingCompanyMember 2022-06-01 0000031462 srt:MaximumMember ecl:NalcoHoldingCompanyMember 2022-06-01 0000031462 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000031462 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000031462 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000031462 ecl:DelayedDrawTermLoanMember 2021-12-31 0000031462 us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0000031462 ecl:MultiCurrencyRevolvingCreditFacilityMember 2022-12-31 0000031462 srt:MaximumMember 2022-12-31 0000031462 srt:MinimumMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:TradeNamesMember 2022-12-31 0000031462 ecl:NalcoHoldingCompanyMember us-gaap:TrademarksMember 2022-06-30 0000031462 us-gaap:TradeNamesMember 2021-12-31 0000031462 ecl:NalcoHoldingCompanyMember us-gaap:TrademarksMember 2022-01-01 2022-12-31 0000031462 ecl:OtherReportableSegmentMember 2022-01-01 2022-12-31 0000031462 ecl:GlobalInstitutionalMember 2022-01-01 2022-12-31 0000031462 ecl:GlobalIndustrialMember 2022-01-01 2022-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2022-01-01 2022-12-31 0000031462 ecl:OtherReportableSegmentMember 2021-01-01 2021-12-31 0000031462 ecl:GlobalInstitutionalMember 2021-01-01 2021-12-31 0000031462 ecl:GlobalIndustrialMember 2021-01-01 2021-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2021-01-01 2021-12-31 0000031462 ecl:OtherReportableSegmentMember 2022-12-31 0000031462 ecl:GlobalInstitutionalMember 2022-12-31 0000031462 ecl:GlobalIndustrialMember 2022-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2022-12-31 0000031462 ecl:OtherReportableSegmentMember 2021-12-31 0000031462 ecl:GlobalInstitutionalMember 2021-12-31 0000031462 ecl:GlobalIndustrialMember 2021-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2021-12-31 0000031462 ecl:OtherReportableSegmentMember 2020-12-31 0000031462 ecl:GlobalInstitutionalMember 2020-12-31 0000031462 ecl:GlobalIndustrialMember 2020-12-31 0000031462 ecl:GlobalHealthcareAndLifeSciencesMember 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000031462 us-gaap:TrademarksMember 2022-01-01 2022-12-31 0000031462 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-12-31 0000031462 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000031462 ecl:OtherTechnologyMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0000031462 us-gaap:TrademarksMember 2022-12-31 0000031462 us-gaap:PatentsMember 2022-12-31 0000031462 us-gaap:CustomerRelationshipsMember 2022-12-31 0000031462 ecl:OtherTechnologyMember 2022-12-31 0000031462 us-gaap:TrademarksMember 2021-12-31 0000031462 us-gaap:PatentsMember 2021-12-31 0000031462 us-gaap:CustomerRelationshipsMember 2021-12-31 0000031462 ecl:OtherTechnologyMember 2021-12-31 0000031462 ecl:NotesDue2023Member 2021-09-01 2021-09-30 0000031462 ecl:NotesDue2022Member 2021-09-01 2021-09-30 0000031462 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000031462 us-gaap:ParentMember 2022-01-01 2022-12-31 0000031462 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000031462 us-gaap:ParentMember 2021-01-01 2021-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000031462 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000031462 ecl:HolchemGroupMember 2020-01-01 2020-12-31 0000031462 ecl:ServiceAndLeaseMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2020-01-01 2020-12-31 0000031462 ecl:HolchemGroupLimitedMember 2020-06-30 0000031462 ecl:SeniorEuroNotesMember us-gaap:NetInvestmentHedgingMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember 2022-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember 2022-12-31 0000031462 ecl:CrossCurrencyInterestRateContractMaturingIn2026Member us-gaap:NetInvestmentHedgingMember 2022-10-31 0000031462 ecl:CrossCurrencyInterestRateContractMaturingBetween2026And2030Member us-gaap:NetInvestmentHedgingMember 2022-10-31 0000031462 us-gaap:InterestRateSwapMember 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember 2021-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember 2021-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2021-12-31 0000031462 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember ecl:InterestExpenseNetMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember ecl:InterestExpenseNetMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember ecl:InterestExpenseNetMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-01-01 2022-12-31 0000031462 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000031462 ecl:InterestExpenseNetMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-01-01 2021-12-31 0000031462 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000031462 ecl:InterestExpenseNetMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-01-01 2020-12-31 0000031462 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000031462 ecl:InterestExpenseNetMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000031462 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-12-31 0000031462 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000031462 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000031462 us-gaap:RealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:RealEstateMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:PrivateEquityFundsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:DebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:DistressedDebtInvestmentMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:RealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:RealEstateMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:PrivateEquityFundsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:DefinedBenefitPlanDebtSecurityMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:DebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:DistressedDebtInvestmentMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:SegmentDiscontinuedOperationsMember 2020-01-01 2020-12-31 0000031462 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel3Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FairValueInputsLevel3Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:NonqualifiedPlanMember 2022-12-31 0000031462 us-gaap:NonqualifiedPlanMember 2021-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2020-01-01 2020-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2021-01-01 2021-12-31 0000031462 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000031462 ecl:NewFiveYearNotesMember 2022-11-01 2022-11-30 0000031462 ecl:TwoYear2021SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyYear2021SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyYear2020SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyYear2017SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyYear2016SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyYear2011SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ThirtyFouryear2021seniornotesMember 2022-01-01 2022-12-31 0000031462 ecl:TenYear2020SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:TenYear2020SeniorNotesMaturing2031Member 2022-01-01 2022-12-31 0000031462 ecl:TenYear2017SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:TenYear2016SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:TenYear2015SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:SixYear2021SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:SevenYear2016SeniorEuroNotesMember 2022-01-01 2022-12-31 0000031462 ecl:FiveYear2022SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:ElevenYear2021SeniorNotesMember 2022-01-01 2022-12-31 0000031462 ecl:Privateplacement34year2021seniornotesMember 2021-08-31 2021-08-31 0000031462 srt:MinimumMember 2022-04-30 0000031462 srt:MaximumMember 2022-04-30 0000031462 ecl:NotesDue2023Member 2021-09-30 0000031462 ecl:NotesDue2022Member 2021-09-30 0000031462 ecl:ThirtyFouryear2021seniornotesMember 2021-08-31 0000031462 us-gaap:SeniorNotesMember 2022-12-31 0000031462 ecl:NewFiveYearNotesMember 2022-11-30 0000031462 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2022-04-30 0000031462 us-gaap:NotesPayableOtherPayablesMember 2021-12-31 0000031462 ecl:WithNotesPayableDue2051Member 2021-12-31 0000031462 ecl:WithNotesPayableDue2032Member 2021-12-31 0000031462 ecl:WithNotesPayableDue2027Member 2021-12-31 0000031462 ecl:WithNotesPayableDue2023Member 2021-12-31 0000031462 ecl:Privateplacement34year2021seniornotesMember 2021-08-31 0000031462 ecl:TwoYear2021SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyYear2021SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyYear2020SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyYear2017SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyYear2016SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyYear2011SeniorNotesMember 2022-12-31 0000031462 ecl:ThirtyFouryear2021seniornotesMember 2022-12-31 0000031462 ecl:TenYear2020SeniorNotesMember 2022-12-31 0000031462 ecl:TenYear2020SeniorNotesMaturing2031Member 2022-12-31 0000031462 ecl:TenYear2017SeniorNotesMember 2022-12-31 0000031462 ecl:TenYear2016SeniorNotesMember 2022-12-31 0000031462 ecl:TenYear2015SeniorNotesMember 2022-12-31 0000031462 ecl:SixYear2021SeniorNotesMember 2022-12-31 0000031462 ecl:SevenYear2016SeniorEuroNotesMember 2022-12-31 0000031462 ecl:OtherLongTermDebtMember 2022-12-31 0000031462 ecl:FiveYear2022SeniorNotesMember 2022-12-31 0000031462 ecl:ElevenYear2021SeniorNotesMember 2022-12-31 0000031462 ecl:TwoYear2021SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyYear2021SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyYear2020SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyYear2017SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyYear2016SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyYear2011SeniorNotesMember 2021-12-31 0000031462 ecl:ThirtyFouryear2021seniornotesMember 2021-12-31 0000031462 ecl:TenYear2020SeniorNotesMember 2021-12-31 0000031462 ecl:TenYear2020SeniorNotesMaturing2031Member 2021-12-31 0000031462 ecl:TenYear2017SeniorNotesMember 2021-12-31 0000031462 ecl:TenYear2016SeniorNotesMember 2021-12-31 0000031462 ecl:TenYear2015SeniorNotesMember 2021-12-31 0000031462 ecl:SixYear2021SeniorNotesMember 2021-12-31 0000031462 ecl:SevenYear2016SeniorEuroNotesMember 2021-12-31 0000031462 ecl:OtherLongTermDebtMember 2021-12-31 0000031462 ecl:ElevenYear2021SeniorNotesMember 2021-12-31 0000031462 ecl:ServiceAndLeaseMember 2022-01-01 2022-12-31 0000031462 ecl:ProductAndEquipmentMember 2022-01-01 2022-12-31 0000031462 ecl:ServiceAndLeaseMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember 2021-01-01 2021-12-31 0000031462 ecl:ServiceAndLeaseMember 2020-01-01 2020-12-31 0000031462 ecl:ProductAndEquipmentMember 2020-01-01 2020-12-31 0000031462 ecl:WarewashingProductsMember ecl:SalesRevenueTotalMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000031462 ecl:WarewashingProductsMember ecl:SalesRevenueTotalMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000031462 ecl:WarewashingProductsMember ecl:SalesRevenueTotalMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000031462 us-gaap:TreasuryStockMember 2022-12-31 0000031462 us-gaap:CommonStockMember 2022-12-31 0000031462 us-gaap:TreasuryStockMember 2021-12-31 0000031462 us-gaap:CommonStockMember 2021-12-31 0000031462 us-gaap:TreasuryStockMember 2020-12-31 0000031462 us-gaap:CommonStockMember 2020-12-31 0000031462 us-gaap:TreasuryStockMember 2019-12-31 0000031462 us-gaap:CommonStockMember 2019-12-31 0000031462 us-gaap:CommonStockMember 2022-12-31 0000031462 us-gaap:CommonStockMember 2021-12-31 0000031462 us-gaap:CommonStockMember 2020-12-31 0000031462 ecl:USCommercialPaperProgramMember 2021-12-31 0000031462 ecl:PuroliteMember us-gaap:TrademarksMember 2021-12-01 0000031462 ecl:PuroliteMember us-gaap:CustomerRelationshipsMember 2021-12-01 0000031462 ecl:PuroliteMember ecl:OtherTechnologyMember 2021-12-01 0000031462 ecl:CIDLinesMember us-gaap:TrademarksMember 2020-05-11 0000031462 ecl:CIDLinesMember us-gaap:CustomerRelationshipsMember 2020-05-11 0000031462 ecl:CIDLinesMember ecl:AcquiredTechnologiesAndProductRegistrationsMember 2020-05-11 0000031462 2020-05-11 0000031462 ecl:PuroliteMember 2022-12-31 0000031462 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2022-12-31 0000031462 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2020-12-31 0000031462 2019-12-31 0000031462 ecl:PuroliteMember us-gaap:TrademarksMember 2021-12-01 2021-12-01 0000031462 ecl:PuroliteMember us-gaap:CustomerRelationshipsMember 2021-12-01 2021-12-01 0000031462 ecl:PuroliteMember ecl:AcquiredTechnologiesAndProductRegistrationsMember 2021-12-01 2021-12-01 0000031462 ecl:PuroliteMember 2021-12-01 2021-12-01 0000031462 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-01-01 2021-12-31 0000031462 us-gaap:TrademarksMember 2020-05-11 2020-05-11 0000031462 us-gaap:CustomerRelationshipsMember 2020-05-11 2020-05-11 0000031462 ecl:OtherTechnologyMember 2020-05-11 2020-05-11 0000031462 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-01-01 2020-12-31 0000031462 ecl:OperatingLeasesRecordedInPropertyPlantAndEquipmentMember 2022-12-31 0000031462 ecl:OperatingLeasesRecordedInPropertyPlantAndEquipmentMember 2021-12-31 0000031462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2022-12-31 0000031462 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000031462 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignCountryMember 2020-01-01 2020-12-31 0000031462 us-gaap:ForeignCountryMember 2022-12-31 0000031462 ecl:RussiaAndUkraineMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000031462 ecl:RussiaAndUkraineMember ecl:OtherNonrecurringIncomeExpenseMember 2022-01-01 2022-12-31 0000031462 ecl:RussiaAndUkraineMember 2022-01-01 2022-12-31 0000031462 ecl:SpecificLegalReserveAndRelatedLegalChargesMember 2022-01-01 2022-12-31 0000031462 ecl:SpecificLegalReserveAndRelatedLegalChargesMember 2021-01-01 2021-12-31 0000031462 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000031462 ecl:SpecificLegalReserveAndRelatedLegalChargesMember 2020-01-01 2020-12-31 0000031462 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000031462 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000031462 ecl:RestrictedStockAwardsMember 2020-01-01 2020-12-31 0000031462 ecl:PBRSUAwardsMember 2020-01-01 2020-12-31 0000031462 ecl:PBRSUAwardsMember 2022-01-01 2022-12-31 0000031462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2022-01-01 2022-12-31 0000031462 ecl:ImmaterialRestructuringPlanMember 2022-01-01 2022-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:RestructuringPlan2018Member 2021-01-01 2021-12-31 0000031462 ecl:ImmaterialRestructuringPlanMember 2021-01-01 2021-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:RestructuringPlan2018Member 2020-01-01 2020-12-31 0000031462 ecl:ImmaterialRestructuringPlanMember 2020-01-01 2020-12-31 0000031462 us-gaap:FacilityClosingMember ecl:InstitutionalAdvancementProgramMember 2022-01-01 2022-12-31 0000031462 us-gaap:FacilityClosingMember ecl:InstitutionalAdvancementProgramMember 2021-01-01 2021-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember ecl:RestructuringPlan2018Member 2022-01-01 2022-12-31 0000031462 ecl:EuropeCostSavingsProgramMember 2023-02-14 0000031462 ecl:RestructuringPlan2018Member 2022-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2022-12-31 0000031462 ecl:EuropeCostSavingsProgramMember 2022-11-30 0000031462 ecl:PublicNotesMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0000031462 ecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember 2022-01-01 2022-12-31 0000031462 srt:MinimumMember ecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember 2022-01-01 2022-12-31 0000031462 srt:MaximumMember ecl:EcolabSavingsPlanAndEmployeeStockOwnershipPlanMember 2022-01-01 2022-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:PuroliteMember 2022-01-01 2022-12-31 0000031462 ecl:CIDLinesMember 2021-01-01 2021-12-31 0000031462 ecl:NalcoHoldingCompanyMember 2022-06-01 0000031462 2022-06-01 0000031462 2020-04-01 2020-06-30 0000031462 us-gaap:InterestExpenseMember 2021-10-01 2021-12-31 0000031462 us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0000031462 2022-10-01 2022-12-31 0000031462 2022-07-01 2022-09-30 0000031462 2022-04-01 2022-06-30 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2022-01-01 2022-12-31 0000031462 2022-01-01 2022-03-31 0000031462 2021-10-01 2021-12-31 0000031462 2021-07-01 2021-09-30 0000031462 2021-04-01 2021-06-30 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0000031462 2021-01-01 2021-03-31 0000031462 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000031462 ecl:COVID19Member 2022-01-01 2022-12-31 0000031462 ecl:COVID19Member 2021-01-01 2021-12-31 0000031462 ecl:COVID19Member 2020-01-01 2020-12-31 0000031462 ecl:HolchemGroupMember ecl:OtherNonrecurringIncomeExpenseMember 2020-01-01 2020-12-31 0000031462 ecl:HolchemGroupLimitedMember 2020-04-01 2020-06-30 0000031462 us-gaap:ParentMember 2020-01-01 2020-12-31 0000031462 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000031462 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000031462 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000031462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2020-06-03 2020-06-03 0000031462 country:US us-gaap:NonqualifiedPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:RealEstateMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:PrivateEquityFundsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:BondsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 ecl:EmergingMarketsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 ecl:DistressedDebtInvestmentMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000031462 us-gaap:RealEstateMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 us-gaap:PrivateEquityFundsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 us-gaap:BondsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:EmergingMarketsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 ecl:DistressedDebtInvestmentMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2022-01-01 2022-12-31 0000031462 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:BondsMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:USTreasuryAndGovernmentMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:BondsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InternationalEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 ecl:EmergingMarketsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2022-12-31 0000031462 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:BondsMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InsuranceContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:USTreasuryAndGovernmentMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FixedIncomeSecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FairValueInputsLevel2Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:FairValueInputsLevel1Member country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:CashAndCashEquivalentsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:BondsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:SmallCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:LargeCapEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InternationalEquitySecuritiesMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:InsuranceContractsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 ecl:EmergingMarketsMember country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 country:US ecl:PensionAndPostRetirementBenefitPlansDefinedBenefitMember 2021-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2022-12-31 0000031462 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000031462 country:US us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2021-12-31 0000031462 ecl:PuroliteMember 2021-12-31 0000031462 us-gaap:DomesticCountryMember 2022-12-31 0000031462 srt:MinimumMember us-gaap:CorporateDebtSecuritiesMember country:US 2022-01-01 2022-12-31 0000031462 srt:MaximumMember us-gaap:CorporateDebtSecuritiesMember country:US 2022-01-01 2022-12-31 0000031462 us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000031462 us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000031462 ecl:ThirtyFouryear2021seniornotesMember 2021-08-01 2021-08-31 0000031462 us-gaap:CostOfSalesMember 2022-10-01 2022-12-31 0000031462 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000031462 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0000031462 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000031462 us-gaap:CostOfSalesMember 2021-10-01 2021-12-31 0000031462 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000031462 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0000031462 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0000031462 us-gaap:CommercialPaperMember 2022-12-31 0000031462 ecl:USCommercialPaperProgramMember 2022-12-31 0000031462 ecl:EuropeanCommercialPaperMember 2022-12-31 0000031462 us-gaap:OtherRestructuringMember ecl:InstitutionalAdvancementProgramMember 2022-01-01 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2022-01-01 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:EuropeCostSavingsProgramMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2022-01-01 2022-12-31 0000031462 ecl:EuropeCostSavingsProgramMember 2022-01-01 2022-12-31 0000031462 us-gaap:OtherRestructuringMember ecl:InstitutionalAdvancementProgramMember 2021-01-01 2021-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2021-01-01 2021-12-31 0000031462 us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2021-01-01 2021-12-31 0000031462 us-gaap:OtherRestructuringMember ecl:InstitutionalAdvancementProgramMember 2020-01-01 2020-12-31 0000031462 us-gaap:EmployeeSeveranceMember ecl:InstitutionalAdvancementProgramMember 2020-01-01 2020-12-31 0000031462 us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000031462 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-12-31 0000031462 ecl:InstitutionalAdvancementProgramMember 2020-01-01 2020-12-31 0000031462 ecl:PuroliteMember 2021-12-01 0000031462 ecl:CIDLinesMember 2020-05-11 0000031462 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember 2022-01-01 2022-12-31 0000031462 us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000031462 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember 2021-01-01 2021-12-31 0000031462 ecl:ProductAndEquipmentMember us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000031462 ecl:BioquellMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000031462 ecl:OtherNonrecurringIncomeExpenseMember 2020-01-01 2020-12-31 0000031462 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-12-31 0000031462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2021-01-01 2021-12-31 0000031462 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ecl:ChampionxBusinessMember 2020-01-01 2020-12-31 0000031462 2020-12-31 0000031462 2021-01-01 2021-12-31 0000031462 2020-01-01 2020-12-31 0000031462 2022-12-31 0000031462 2021-12-31 0000031462 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000031462 ecl:EuroNotesDue2025Member 2022-01-01 2022-12-31 0000031462 ecl:EuroNotesDue2024Member 2022-01-01 2022-12-31 0000031462 2022-06-30 0000031462 2023-01-31 0000031462 2022-01-01 2022-12-31 xbrli:shares iso4217:USD xbrli:pure ecl:location iso4217:USD xbrli:shares iso4217:EUR ecl:item ecl:country ecl:segment

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 10-K

​

​ | ​
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

​ | ​
For the fiscal year ended December 31, 2022 |

OR

​

​ | ​
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

​

Commission File No. 1-9328

​

ECOLAB INC.

(Exact name of registrant as specified in its charter)

​

​ ​ | ​ | ​ | ​ | ​
​ | ​ | ​
Delaware | ​ | 41-0231510
(State or other jurisdiction of incorporation or organization) | ​ | (I.R.S. Employer Identification No.)
​ | ​ | ​
1 Ecolab Place, St. Paul, Minnesota 55102
(Address of principal executive offices) (Zip Code)
​
Registrant’s telephone number, including area code: 1-800-232-6522
​
Securities registered pursuant to Section 12(b) of the Act:
​ ​ | ​ | ​ | ​ | ​
Title of each class | ​ | Trading symbol(s) | ​ | Name of each exchange on which registered
Common Stock, $1.00 par value 2.625% Euro Notes due 2025 1.000% Euro Notes due 2024 | ​ | ECL ECL 25 ECL 24 | ​ | New York Stock Exchange New York Stock Exchange New York Stock Exchange

​

Securities registered pursuant to Section 12(g) of the Act: None

​

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ⌧ Yes ◻ No

​

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ◻ Yes ⌧ No

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ⌧ Yes ◻ No

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files. ⌧ Yes ◻ No

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ | ​ | ​
Large accelerated filer ☒ | ​ | Accelerated filer ☐
Non-accelerated filer ☐ | ​ | Smaller reporting company ☐
​ | ​ | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

​

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

​

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ YES ☒ NO

​

Aggregate market value of voting and non-voting common equity held by non-affiliates of registrant on June 30, 2022, the last business day of the Registrant’s most recently completed second fiscal quarter: $43,775,885,223 (see Item 12, under Part III hereof), based on a closing price of registrant’s Common Stock of $153.76 per share.

​

The number of shares of registrant’s Common Stock, par value $1.00 per share, outstanding as of January 31, 2023: 284,462,087 shares.

​

DOCUMENTS INCORPORATED BY REFERENCE

​

Portions of the registrant’s Proxy Statement for the Annual Meeting of Stockholders to be held May 4, 2023, and to be filed within 120 days after the registrant’s fiscal year ended December 31, 2022 (hereinafter referred to as “Proxy Statement”), are incorporated by reference into Part III.

​

​

​

Table of Contents

ECOLAB INC.

FORM 10-K

For the Year Ended December 31, 2022

TABLE OF CONTENTS

​ | ​ | ​
​ | ​ | Beginning Page
PART I | ​
​ | Item 1. Business. | 3
​ | Item 1A. Risk Factors. | 17
​ | Item 1B. Unresolved Staff Comments. | 23
​ | Item 2. Properties. | 23
​ | Item 3. Legal Proceedings. | 25
​ | Item 4. Mine Safety Disclosures. | 25
​ | ​
PART II | ​
​ | Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. | 26
​ | Item 6. [Reserved]. | 26
​ | Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. | 26
​ | Item 7A. Quantitative and Qualitative Disclosures about Market Risk. | 50
​ | Item 8. Financial Statements and Supplementary Data. | 50
​ | Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. | 102
​ | Item 9A. Controls and Procedures. | 102
​ | Item 9B. Other Information. | 102
​ | Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. | 102
​ | ​
PART III | ​
​ | Item 10. Directors, Executive Officers and Corporate Governance. | 103
​ | Item 11. Executive Compensation. | 103
​ | Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. | 103
​ | Item 13. Certain Relationships and Related Transactions, and Director Independence. | 103
​ | Item 14. Principal Accounting Fees and Services. | 103
​ | ​
PART IV | ​
​ | Item 15. Exhibit and Financial Statement Schedules. | 104
​ | Item 16. Form 10-K Summary. | 110

​

​

​

2

Table of Contents

PART I

​

Except where the context otherwise requires, references in this Form 10-K to (i) “Ecolab,” “Company,” “we” and “our” are to Ecolab Inc. and its subsidiaries, collectively; (ii) “Nalco” are to Nalco Company LLC, a wholly-owned subsidiary of the Company; (iii) “Nalco transaction” and “Nalco merger” are to the merger of Ecolab and Nalco Holding Company completed in December 2011; (iv) “Purolite” are to Purolite LLC, a wholly-owned subsidiary of the Company and its subsidiaries, collectively; and (v) “Purolite transaction” are to the Company’s acquisition of the shares of the subsidiaries and certain other affiliated entities of Purolite Corporation and substantially all of the assets of Purolite Corporation used or held for use in connection with its filtration and purification resins business in December 2021.

​

​

Item 1. Business.

​

General Development of Business.

​

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31. International subsidiaries are included in the consolidated financial statements on the basis of their U.S. GAAP (accounting principles generally accepted in the United States of America) November 30 fiscal year ends to facilitate the timely inclusion of such entities in our consolidated financial reporting.

​

In June 2020, we completed the separation of our Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX business, followed immediately by the merger (the “Merger”) of ChampionX with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

​

As discussed in Note 5 Discontinued Operations, the ChampionX business met the criteria to be reported as discontinued operations in 2020 because the separation of ChampionX was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we reported the historical results of ChampionX, including the results of operations and cash flows as discontinued operations, and related assets and liabilities were retrospectively reclassified for all periods presented herein. Unless otherwise noted, the accompanying financial information has been revised to reflect the effect of the separation of ChampionX and prior year balances have been revised accordingly to reflect continuing operations only.

​

On December 1, 2021, we acquired Purolite for total consideration of $3.7 billion in cash, net of cash acquired. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions that is highly complementary to our current offering and critical to safe, high quality drug production and biopharma product purification in the life sciences industries. It also provides purification and separation solutions for critical industrial markets like microelectronics, nuclear power and food and beverage. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within our Life Sciences operating segment.

​

​

Narrative Description of Business.

​

General

​

A trusted partner for millions of customers, we are a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, we have annual sales of $14 billion, employ more than 47,000 associates and operate in more than 170 countries around the world. We deliver comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Our innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets.

​

We pursue a “Circle the Customer – Circle the Globe” strategy by providing an array of innovative programs, products and services designed to meet the specific operational and sustainability needs of our customers throughout the world. Through this strategy and our varied product and service mix, one customer may utilize the offerings of several of our operating segments. Important in our business proposition for customers is our ability to produce improved results while reducing their water and energy use. With that in mind, we focus on continually innovating to optimize both our own operations and the solutions we provide to customers, aligning with our corporate strategy to address some of the world’s most pressing and complex sustainability challenges such as water scarcity and climate change. The work we do matters, and the way we do it matters to our employees, customers, investors and the communities in which we and our customers operate.

​

Sustainability is core to our business strategy. We deliver sustainable solutions that help companies around the world achieve their business goals while reducing environmental impacts. We partner with customers around the world to reduce water and energy use as well as greenhouse gas emissions through our high-efficiency solutions. By partnering with our customers to help them do more with less through the use of our innovative and differentiated solutions, we aim to help our customers conserve more than 300 billion gallons of water annually by 2030. In 2021, we helped our customers conserve more than 215 billion gallons of water and avoid more than 3.5 million metric tons of greenhouse gas emissions.

​

3

Table of Contents

The following description of our business is based upon our reportable segments as reported in our consolidated financial statements for the year ended December 31, 2022, which are located in Item 8 of Part II of this Form 10-K. Operating segments that share similar economic characteristics and future prospects, including the nature of the products and production processes, end-use markets, channels of distribution and regulatory environment, have been aggregated into three reportable segments: Global Industrial, Global Institutional & Specialty and Global Healthcare & Life Sciences. Operating segments that were not aggregated and do not exceed the quantitative criteria to be separately reported have been combined into Other. We provide similar information for Other as compared to our three reportable segments as we consider the information regarding its underlying operating segments useful in understanding our consolidated results.

​

​

Global Industrial

​

This reportable segment consists of the Water, Food & Beverage, Downstream and Paper operating segments, which provide water treatment and process applications, and cleaning and sanitizing solutions, primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the four operating segments which comprise our Global Industrial reportable segment follow below.

​

Water

​

Water serves customers across industrial and institutional markets. Within Water, our light industry markets include food and beverage, manufacturing and transportation, institutional clients including commercial buildings, hospitals, universities and hotels, and global high technology serving customers including data centers and microelectronics. Heavy industries served include power, chemicals and primary metals and mining.

​

Water provides water treatment products and technology programs for cooling water, wastewater, boiler water and process water applications. Our cooling water treatment programs are designed to control challenges associated with cooling water systems — corrosion, scale and microbial fouling and contamination — in open recirculating, once-through and closed systems. Our wastewater products and programs focus on improving overall plant economics, addressing compliance issues, optimizing equipment efficiency and improving operator capabilities and effectiveness. We provide integrated chemical and digitally-based solutions, process improvements and mechanical component modifications to optimize boiler performance and control corrosion and scale build-up. Our programs assist in more effectively managing water use for plant processes by optimizing the performance of treatment chemicals and equipment in order to minimize costs and maximize returns on investment.

​

Our offerings include specialty products such as scale and corrosion inhibitors, antifoulants, pre-treatment solutions, membrane treatments, coagulants and flocculants, and anti-foamers, as well as our 3D TRASARTM technologies, which combines chemistry, remote services and monitoring and control. We provide products and programs for water treatment and process applications aimed at combining environmental benefits with economic gains for our customers. Typically, water savings, energy savings and operating efficiency are among our primary sources of value creation for our customers, with product quality and production enhancement improvements also providing key differentiating features for many of our offerings. Our offerings are sold primarily by our corporate account and field sales employees.

​

We believe we are one of the leading global suppliers of products and programs for chemical applications within the industrial water treatment industry.

​

Food & Beverage

​

Food & Beverage provides cleaning and sanitation products and programs to facilitate the processing of products for human consumption. Food & Beverage provides detergents, cleaners, sanitizers, lubricants and animal health products, as well as cleaning systems, digitally-based dispensers, monitors and chemical injectors for the application of chemical products, primarily to dairy plants; dairy, swine and poultry farms; breweries and soft-drink bottling plants as well as meat, poultry and other food processors. Food & Beverage is also a leading developer and marketer of antimicrobial products used in direct contact with meat, poultry, seafood and produce during processing in order to reduce microbial contamination. Food & Beverage also designs, engineers and installs CIP (“clean-in-place”) process control systems and facility cleaning systems for its customer base. Water savings, energy savings, and operating efficiency are among our sources of value creation for our customers. Products for use in processing facilities are sold primarily by our corporate account and field sales employees, while products for use on farms are sold through dealers and independent, third-party distributors.

​

We believe we are one of the leading global suppliers of cleaning and sanitizing products to the dairy plant, dairy, swine and poultry farm, beverage/brewery, food, meat and poultry, and beverage/brewery processing industries.

​

4

Table of Contents

Downstream

​

Downstream provides products and programs for process and water treatment applications specific to the petroleum refining and fuels industry, enabling our customers to profitably refine and upgrade hydrocarbons. We solve our customers’ toughest process and water challenges so they can reliably, sustainably and profitably refine fuels and process petrochemicals. Our proven chemistry and digital technologies combined with service increase refinery and petrochemical plant reliability and the useful life of customer assets while improving product quality and yields. Our product portfolio includes corrosion inhibitors, antifoulants, hydrogen sulfide removal, cold flow improvers, lubricity inhibitors, crude desalting, reactive monomer inhibitors, olefins, anti-polymerants, anti-oxidants and water treatment.

​

Our customers include many of the largest publicly traded oil, refining and petrochemical companies, as well as national refining and petrochemical companies, and large independent refining companies. Our downstream offerings are sold primarily by our corporate account and field sales employees and, to a lesser extent, through engineering, procurement, and construction contractors (EPC), technology licensors, distributors, sales agents and joint ventures.

​

We believe we are one of the leading global providers of products and programs for specialty chemical applications to downstream refineries and petrochemicals operations.

​

Paper

​

Paper provides water and process applications for the pulp and paper industries, offering a comprehensive portfolio of programs that are used in all principal steps of the papermaking process and across all grades of paper, including graphic grades, board and packaging, and tissue and towel. While Paper provides its customers similar types of products and programs for water treatment and wastewater treatment as those offered by Water, Paper also offers two specialty programs that differentiate its offerings from Water—pulp applications and paper applications. Our pulp applications maximize process efficiency and increase pulp cleanliness and brightness in bleaching operations, as well as predict and monitor scaling potential utilizing on-line monitoring to design effective treatment programs and avoid costly failures. Our paper process applications focus on improving our customers’ operational efficiency, in part through water savings, energy savings and operating efficiency. Advanced digital sensing, monitoring and automation combine with innovative chemistries and detailed process knowledge to provide a broad range of customer solutions. Specialty products include flocculants, coagulants, dewatering aids and digester yield additives. Our offerings are sold primarily by our corporate account and field sales employees.

​

We believe we are one of the leading global suppliers of water treatment products and process aids to the pulp and papermaking industry.

​

​

Global Institutional & Specialty

​

This reportable segment consists of the Institutional and Specialty operating segments, which provide specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government, education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Institutional & Specialty reportable segment follow below.

​

Institutional

​

Institutional sells specialized cleaners and sanitizers for washing dishes, glassware, flatware, foodservice utensils and kitchen equipment (“warewashing”), plus specialized cleaners for various applications throughout food service operations, on-premise laundries (typically used by hotel and healthcare customers) and general housekeeping functions. We also sell food safety products and equipment, water filters, dishwasher racks and related kitchen sundries to the foodservice, lodging, educational and healthcare industries. Institutional also provides pool and spa treatment programs for hospitality and other commercial customers, as well as a broad range of janitorial cleaning and floor care products and programs to customers in hospitality, healthcare and commercial facilities. Institutional develops various digital monitoring and chemical dispensing systems which are used by our customers to efficiently and safely dispense our cleaners and sanitizers, and through these products, systems and our on-site sales and service expertise, develop better results for our customers including water savings, energy savings and operating efficiency. In addition, Institutional markets a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance. Through our EcoSure Food Safety Management business, Institutional also provides customized on-site evaluations, training and quality assurance services to foodservice operations. With the Lobster Ink business, Institutional provides our customers with end-to-end digital training solutions designed to drive corrective actions and optimal frontline execution.

​

Institutional sells its products and programs primarily through its direct field sales and corporate account sales personnel. Corporate account sales personnel establish relationships and negotiate contracts with larger multi-unit or “chain” customers. We also utilize independent, third-party foodservice, broad-line and janitorial distributors to provide logistics to end customers that prefer to work through these distributors. Many of these distributors also participate in marketing our product and service offerings to the end customers. Through our field sales personnel, we generally provide the same customer support to end-use customers supplied by these distributors as we do to direct customers.

​

We believe we are one of the leading global suppliers of warewashing and laundry products and programs to the food service, hospitality and lodging markets.

​

5

Table of Contents

Specialty

​

Specialty supplies cleaning and sanitizing chemical products and related items primarily to regional, national and international quick service restaurant (“QSR”) chains and food retailers (i.e., supermarkets and grocery stores). Its products include specialty and general purpose hard surface cleaners, degreasers, sanitizers, polishes, hand care products and assorted cleaning tools and equipment which are primarily sold under the “Ecolab” and “Kay” brand names. Specialty’s cleaning and sanitation programs are customized to meet the needs of the market segments it serves and are designed to provide highly effective cleaning performance, promote food safety, reduce labor, water and energy costs and enhance user and guest safety. A number of dispensing options are available for products in the core product range. Specialty supports its product sales with training programs and technical support designed to meet the special needs of its customers.

​

Both Specialty’s QSR business and its food retail business utilize their corporate account sales force which manages relationships with customers at the corporate and regional office levels (and, in the QSR market segment, at the franchisee level) and their field sales force which provides program support at the individual restaurant or store level. QSR customers are primarily supplied through third party distributors while most food retail customers utilize their own distribution networks. While Specialty’s customer base has broadened significantly over the years, Specialty’s business remains largely dependent upon a limited number of major QSR chains and franchisees and large food retail customers.

​

Food Safety Solutions supplies a variety of products, tools and equipment for food preparation, food rotation, temperature management, cleaning and employee safety across all food service customers. Food Safety Solutions also offers digital applications that automate kitchen procedures for efficiency and compliance.

​

We believe we are one of the leading suppliers of cleaning and sanitizing products to the global QSR market and a leading supplier of cleaning and sanitizing products to the global food retail market.

​

​

Global Healthcare & Life Sciences

​

This reportable segment consists of the Healthcare and Life Sciences operating segments, which provide specialized cleaning and sanitizing products to the healthcare, personal care and pharmaceutical industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Healthcare & Life Sciences reportable segment follow below.

​

Healthcare

​

Healthcare provides infection prevention and surgical solutions to acute care hospitals, surgery centers and medical device Original Equipment Manufacturers (“OEM”). Healthcare’s proprietary infection prevention and surgical solutions (hand hygiene, hard surface disinfection, digital monitoring systems, instrument cleaning, patient drapes, equipment drapes and surgical fluid warming and cooling systems) are sold primarily under the "Ecolab," "Microtek," and “Anios” brand names to various departments within the acute care environment (Infection Control, Environmental Services, Central Sterile and Operating Room). Healthcare sells its products and programs principally through its field sales personnel and corporate account personnel but also sells through healthcare distributors.

​

We believe we are one of the leading suppliers of infection prevention and surgical solutions in the United States and Europe.

​

Life Sciences

​

Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. These products are primarily sold under the “Ecolab” brand name, and include detergents, cleaners, sanitizers, disinfectants, surface wipes, as well as cleaning systems, electronic dispensers and chemical injectors for the application of chemical products. With the acquisition of Purolite, the portfolio now includes premium fluid treatment and purification solutions with a broad range of unique products sold under the “Purolite” brand name, particularly focusing on biopharma purification solutions, active pharmaceutical ingredients (“API’s”) and high value industrial applications. The Life Sciences portfolio also includes decontamination systems and services utilizing hydrogen peroxide vapor, which are sold under the “Bioquell” brand name. The pharmaceutical clean room environment is the primary area that Ecolab and Bioquell products are utilized. Purolite products are primarily used in the purification of biologic therapeutics, API’s and high value industrial applications. Products and programs are sold primarily through our field sales and corporate account personnel, and to a lesser extent through distributors.

​

Life Sciences is comprised of customers and accounts related to manufacturing in the following industries: pharmaceutical, animal health and medicine, blood purification and dialysis, biologic products, cosmetics and medical devices. Our tailored, comprehensive solutions and technical know-how focus on ensuring product quality, safety and compliance standards are met while improving operational efficiency in customers’ cleaning, sanitation and disinfection processes. We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions.

​

​

6

Table of Contents

Other

​

Other consists of the Pest Elimination, Textile Care and Colloidal Technologies Group operating segments. These operating segments do not meet the quantitative criteria to be separately reported. We disclose these operating segments within Other as we consider the information useful in understanding our consolidated results.

​

Pest Elimination

​

Pest Elimination provides services designed to detect, eliminate and prevent pests such as rodents and insects, in restaurants, food and beverage processors, educational, life science and healthcare facilities, hotels, quick service restaurant and grocery operations and other institutional and commercial customers. The services of Pest Elimination are sold and performed by our field sales and service personnel.

​

In addition to the United States, which constitutes our largest operation, we operate in various countries in Asia Pacific, Greater China, Western Europe, Latin America and South Africa.

​

We believe Pest Elimination is a leading supplier of high-quality outcome pest elimination programs to the commercial, hospitality and institutional markets in the geographies it serves.

​

Textile Care

​

Textile Care provides products and services that manage the entire wash process through custom designed programs, premium products, dispensing equipment, water and energy management and reduction, and real time data management for large scale, complex commercial laundry operations including uniform rental, hospitality, linen rental and healthcare laundries. Textile Care’s programs are designed to meet our customers’ needs for exceptional cleaning, while extending the useful life of linen and reducing our customers’ overall operating costs. Products and programs are marketed primarily through our field sales employees and, to a lesser extent, through distributors. We believe we are one of the leading global suppliers in the laundry markets in which we compete.

​

Colloidal Technologies Group

​

The Colloidal Technologies Group (“CTG”) produces and sells colloidal silica, which is comprised of nano-sized particles of silica in water. These products and associated programs are used primarily for binding and polishing applications. CTG serves customers across various industries, including semiconductor manufacturing, catalyst manufacturing, chemicals and aerospace component manufacturing.

​

CTG incorporates strong collaboration with customers to develop customized solutions that meet the technical demands of their operations. Our silica-based applications are widely used for polishing of silicon wafers, semiconductor substrates and the precision surface finishing of optics, watch crystals and other glass components. We offer a variety of silica-based particles that can be used as binders in heterogeneous catalyst systems and as silica nutrients for manufacturing specialty zeolites. Our silica products are used worldwide as a binder for precision investment casting slurries, which ultimately facilitate the manufacture of near net-shape metal parts such as turbine blades and golf club heads.

​

Our products are sold primarily by our corporate account employees. We believe we are one of the leading global suppliers of colloidal silica.

​

​

Additional Information

​

International Operations

​

We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner. In certain countries, selected products are sold by our export operations to distributors, agents or licensees, although the volume of those sales is not significant in terms of our overall revenues. In general, our businesses conducted outside the United States are similar to those conducted in the United States.

​

Our business operations outside the United States are subject to the usual risks of foreign operations, including possible changes in trade and foreign investment laws, international business laws and regulations, tax laws, currency exchange rates and economic and political conditions. The profitability of our international operations is generally lower than the profitability of our businesses in the United States, due to (i) the additional cost of operating in numerous and diverse foreign jurisdictions with varying laws and regulations, (ii) higher costs of importing certain raw materials and finished goods in some regions, (iii) the smaller scale of international operations where certain operating locations are smaller in size, and (iv) the additional reliance on distributors and agents in certain countries which can negatively impact our margins. Proportionately larger investments in sales and technical support are also necessary in certain geographies in order to facilitate the growth of our international operations.

​

7

Table of Contents

Competition

​

In general, the markets in which the businesses in our Global Industrial reportable segment compete are led by a few large companies, with the rest of the market served by smaller entities focusing on more limited geographic regions or a smaller subset of products and services. Our businesses in this segment compete on the basis of their demonstrated value, technical expertise, innovation, digital technology, chemical formulations, global customer support, detection equipment, monitoring capabilities, and dosing and metering equipment. Through the combination of our digitally enabled end-to-end water management and hygiene solutions, data-driven insights and personalized service, our Global Industrial businesses deliver outcomes that help our customers optimize water and energy use, improve productivity, advance food safety, and achieve sustainability and net zero goals, while optimizing total cost of operations.

​

The businesses in our Global Institutional & Specialty reportable segment and Other have two significant classes of competitors. First, we compete with a small number of large companies selling directly or through distributors on a national or international scale. Second, we have numerous smaller regional or local competitors which focus on more limited geographies, product lines and/or end-use customer segments. We believe we compete principally by providing superior value, premium customer support, training, service, and innovative and differentiated products to help our customers protect their brand reputation and improve their operational efficiency.

​

Within the Global Healthcare & Life Sciences reportable segment, the Healthcare business competes geographically with companies primarily focused on a smaller range of product categories, with few globally scaled competitors. The Life Sciences business competes in the European market versus several mid-size and regional competitors and competes against two large and other mid-size or regional competitors in North America. Outside of North America and Europe competitors are much more fragmented and do not offer the same level of service or coverage as Ecolab. Our businesses in this segment compete by enabling our customers success through improved hygiene, digitally enabled programs in operating room and patient room space as well as a tailored approach to delivering key inputs that directly impact our customers patients globally.

​

Sales

​

Our products, systems and services are primarily marketed in domestic and international markets by our Company-trained direct field sales personnel who also advise and assist our customers in the proper and most efficient use of the products and systems in order to meet a full range of cleaning and sanitation, water treatment and process chemistry needs. Independent, third-party distributors and, to a lesser extent, sales agents, are utilized in several markets, as described in the segment descriptions found above.

​

Customers and Classes of Products

​

We believe our business is not materially dependent upon a single customer. Additionally, although we have a diverse customer base and no customer or distributor constituted 10 percent or more of our consolidated revenues in 2022, 2021 or 2020, we do have customers and independent third-party distributors, the loss of which could have a material adverse effect on results of operations for the affected earnings periods; however, we consider it unlikely that such an event would have a material adverse impact on our financial position. No material part of our business is subject to renegotiation or termination at the election of a governmental unit.

​

We sold one class of products within the Global Institutional & Specialty reportable segment which comprised 10% or more of consolidated net sales in the last three years. Sales of warewashing products were approximately 12%, 10%, and 11% of consolidated net sales in 2022, 2021 and 2020, respectively.

​

Human Capital

​

As of December 31, 2022, Ecolab employed approximately 47,000 employees, including approximately 26,000 sales and service and 1,100 research, development, and engineering employees. Approximately 41% of the employees are employed in North America, 21% in Europe, 7% in Asia Pacific, 17% in Latin America, 6% in India, Middle East and Africa, and 8% in Greater China.

​

We are committed to developing a culture that is diverse, equitable, inclusive, and fully leverages our employees’ talents as we work together to serve the needs of our customers. We believe in providing comprehensive training and career development opportunities and in compensating and rewarding our employees equitably. Our commitment to the safety of our employees, contractors and customers is evident in all we do, from the way we operate, to the products we develop and to the customers we serve. In addition, we are committed to promoting the health and well-being of our employees, our customers, and their customers by contributing to programs and initiatives that enhance the quality of life in the communities where they work and live. In support of these overall objectives, key areas of focus include:

​

Diversity, Equity, and Inclusion: We have a long-standing belief that a diverse, equitable, and inclusive workforce is a critical foundation for the shared success of our employees, our company, our customers, and our communities. To build that strong foundation, we have worked to embed diversity and inclusion throughout all people processes, including recruitment, promotional practices, training and development, and total rewards. To help guide our work and ensure a broad commitment to progress, Ecolab utilizes a Diversity Council made up of senior leaders throughout our company and chaired by our CEO. We review key metrics and practices, including diverse representation, hiring practices, and retention with the Council and with senior executives and business leads monthly. We set diversity goals at or above market availability and utilize diverse slates for all hiring activity.

​

​

​

8

Table of Contents

We have a vibrant and growing community of Employee Resource Groups (ERGs) to help employees connect with colleagues, take part in career and leadership development experiences, and provide important insights in support of advancing our work in diversity, equity, and inclusion. These employee-led ERGs create community and focus across several dimensions of diversity, including gender, race/ethnicity, gender identity, sexual orientation, ability/disability, military service and more. All employees are welcome and encouraged to join, participate or become leaders within any of our 12 ERGs.

​

Employee Training and Development: At our core, Ecolab’s growth is rooted in decades of science, learning and innovation. We have ambitious solution-oriented teams and we continually look for ways to help our employees learn and grow. Beyond rigorous technical, functional, and business-specific training courses, our Global Corporate Flagship Development Programs are designed to deepen leadership capability and prepare successors for key leadership roles.

​

Safety, Health and Wellness: At Ecolab, the safety of our employees and contractors is a top priority and is embedded into our company values. Our safety goals are simple: zero accidents, zero injuries and zero violations. We communicate that this is a collective goal all employees commit to, own, and deliver on every day. Our leadership teams and a network of Safety, Health and Environment professionals around the world support employees with robust safety programs, processes, and platforms. Understanding underlying and potential risks is a critical component to improving safety outcomes. Our Global Safety Dashboard tracks our performance on a range of leading and lagging safety indicators and helps us measure the effectiveness of our safety programs.

​

Additionally, a Be Well Program is available to U.S. employees and their families to empower, educate and support their personal journey to overall well-being by making positive lifestyle choices while creating a culture of wellness throughout Ecolab. Over the last few years, we’ve expanded our offerings to include comprehensive child and elder caregiver resources to help employees balance the demands of work and personal responsibilities. To ensure the safety of our employees amidst an ongoing COVID-19 pandemic environment, we follow CDC and local guidance. We’ve continued to help our global employees garner access to vaccines and COVID-19 testing, have provided the option for employees who can do their work remotely to work from home on a hybrid schedule, and have implemented additional safety measures for our employees working in the field and in our plant and warehouse locations.

​

Future of Work: Ecolab is committed to building a best-in-class, thriving work environment for all employees —from those who work in the field serving our customers, to those who work in our manufacturing facilities, to our employees who work in an office environment— our focus extends across all segments of our workforce. The Future of Work at Ecolab will embrace enhanced tools and technology and evolved practices to optimize performance, productivity, and collaboration. We offer a hybrid work model that balances evolving work practices and norms while preserving the practices we believe are core and fundamental to our success.

​

For additional detail regarding our Human Capital Management metrics and focus areas, please refer to our website for additional detail regarding our Human Capital Management metrics and focus areas, Diversity, Equity and Inclusion initiatives and other information and metrics, including our latest Corporate Responsibility GRI Report and EEO-1 report.

​

Patents and Trademarks

​

We own and license a number of patents, trademarks and other intellectual property, including intellectual property from our recent acquisition of Purolite. While we have an active program to protect our intellectual property by filing for patents or trademarks and pursuing legal action, when appropriate, to prevent infringement, except for the items listed below, we do not believe our overall business is materially dependent on any individual patent or trademark.

​

| ● | Patents related to our TRASAR and 3D TRASAR technology, which are material to our Global Industrial reportable segment. U.S. and foreign patents protect aspects of our key TRASAR and 3D TRASAR technology until at least 2024.

​

| ● | Trademarks related to Ecolab, Nalco and 3D TRASAR, which collectively are material to all of our reportable segments. The Ecolab, Nalco and 3D TRASAR trademarks are registered or applied for in all of our key markets and we anticipate maintaining them indefinitely.

​

Seasonality

​

We experience variability in our quarterly operating results due to seasonal sales volume and business mix fluctuations in our operating segments. Part II, Item 8, Note 20, entitled “Quarterly Financial Data” of this Form 10-K is incorporated herein by reference.

​

Investments in Equipment

​

We have invested, and plan to continue to invest, in process control and monitoring equipment consisting primarily of systems used by customers to dispense our products as well as to monitor water systems. The investment in such equipment is discussed under the heading "Investing Activities" in Management's Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-K.

​

9

Table of Contents

Manufacturing and Distribution

​

We manufacture most of our products and related equipment in Company-operated manufacturing facilities. Some products are also produced for us by third-party contract manufacturers. Other products and equipment are purchased from third-party suppliers. Additional information on product/equipment sourcing is found in the segment discussions above and additional information on our manufacturing facilities is located under Part I, Item 2. “Properties,” of this Form 10-K.

​

Deliveries to customers are made from our manufacturing plants and a network of distribution centers and third-party logistics service providers. We use common carriers, our own delivery vehicles, and distributors for transport. Additional information on our plant and distribution facilities is located under Part I, Item 2. “Properties,” of this Form 10-K.

​

Raw Materials

​

Raw materials purchased for use in manufacturing our products are inorganic chemicals, including alkalis, acids, biocides, phosphonates, phosphorous materials, silicates and salts; and organic chemicals, including acids, alcohols, amines, fatty acids, surfactants, solvents, monomers and polymers. Healthcare purchases plastic films and parts to manufacture medical devices that serve the surgical and infection prevention markets. Pesticides used by Pest Elimination are purchased as finished products under contract or purchase order from the producers or their distributors. We also purchase packaging materials for our manufactured products and components for our specialized cleaning equipment and systems. We purchase more than 10,000 raw materials, with the largest single raw material representing approximately four percent of raw material purchases. Our raw materials, with the exception of a few specialized chemicals which we manufacture, are generally purchased on an annual contract basis and are ordinarily available in adequate quantities from a diverse group of suppliers globally. We have encountered supply chain disruptions with impacts of the COVID-19 pandemic, war in Ukraine and the overall energy crisis (mainly in Europe). These events have impacted the availability and cost of many raw materials. When practical, global sourcing is used so that purchasing or production locations can be shifted to control product costs.

​

Research and Development

​

Our research and development program consists principally of developing and validating the performance of new products, processes, techniques and equipment, improving the efficiency of those already existing, improving service program content, evaluating the environmental compatibility of products and technical support. Key disciplines include analytical and formulation chemistry, microbiology, data science and predictive analytics, process and packaging engineering, digital and remote monitoring engineering and product dispensing technology. Substantially all of our principal products have been developed by our research, development and engineering personnel.

​

We believe continued research and development activities are critical to maintaining our leadership position within the industry and will provide us with a competitive advantage as we seek additional business with new and existing customers.

​

Joint Ventures

​

Over time, we have entered into partnerships or joint ventures in order to meet local ownership requirements, to achieve quicker operational scale, to expand our ability to provide our customers a more fully integrated offering or to provide other benefits to our business or customers. During 2022, the impact on our consolidated net income of our joint ventures, in the aggregate, was approximately three percent. We will continue to evaluate the potential for partnerships and joint ventures that can assist us in increasing our geographic, technological and product reach.

​

Environmental and Regulatory Considerations

​

Our businesses are subject to various legislative enactments and regulations relating to the protection of the environment and public health. While we cooperate with governmental authorities and take commercially practicable measures to meet regulatory requirements and avoid or limit environmental effects, some risks are inherent in our businesses. Among the risks are costs associated with transporting and managing hazardous materials and waste disposal and plant site clean-up, fines and penalties if we are found to be in violation of law, as well as modifications, disruptions or discontinuation of certain operations or types of operations including product recalls and reformulations. Similarly, the need for certain of our products and services is dependent upon or might be limited by governmental laws and regulations. Changes in such laws and regulations, including among others, air, water, chemical and product regulations, could impact the sales of some of our products or services. In addition to an increase in costs of manufacturing and delivering products, a change in production regulations or product regulations could result in interruptions to our business and potentially cause economic or consequential losses should we be unable to meet the demands of our customers for products.

​

Additionally, although we are not currently aware of any such circumstances, there can be no assurance that future legislation or enforcement policies will not have a material adverse effect on our consolidated results of operations, financial position or cash flows. Environmental and regulatory matters most significant to us are discussed below.

​

Ingredient Legislation: Various laws and regulations have been enacted by state, local and foreign jurisdictions pertaining to the sale of products which contain phosphorous, volatile organic compounds, or other ingredients that may impact human health or the environment. Under California Proposition 65, for example, label disclosures are required for certain products containing chemicals listed by California. Chemical management initiatives that promote pollution prevention through research and development of safer chemicals and safer chemical processes are being advanced by several states.

​

10

Table of Contents

Environmentally preferable purchasing programs for cleaning products have been enacted in a number of states to date, and in recent years have been considered by several other state legislatures. Cleaning product ingredient disclosure legislation has been introduced in the U.S. Congress in each of the past few years but has not passed, and several states are considering further regulations in this area. In 2017, California passed the Cleaning Product Right to Know Act of 2017, that required ingredient transparency on-line and on-label by 2020 and 2021, respectively. New York has proposed similar ingredient disclosure regulation. The U.S. Government is monitoring “green chemistry” initiatives through a variety of initiatives, including its “Design for the Environment” (“DfE”)/“Safer Choice” program. DfE/Safer Choice has three broad areas of work (recognition of safer products on a DfE/Safer Choice label, development of best practices for industrial processes and evaluation of safer chemicals), and we are involved in these to varying degrees. Our Global Institutional and Global Industrial cleaning products are subject to the regulations and may incur additional stay-in-market expenses associated with conducting the required alternatives analyses for chemicals of concern. To date, we generally have been able to comply with such legislative requirements by reformulation or labeling modifications. Such legislation has not had a material adverse effect on our consolidated results of operations, financial position or cash flows to date.

​

TSCA: The nation’s primary chemicals management law, the Toxic Substances Control Act (“TSCA”), was updated for the first time in 40 years with the passage of the Frank R. Lautenberg Chemical Safety for the 21st Century Act (“LCSA”) in 2016. The LCSA modernizes the original 1976 legislation, aiming to establish greater public confidence in the safety of chemical substances in commerce and improve the U.S. Environmental Protection Agency’s (“EPA”) capability and authority to regulate existing and new chemical substances. For Ecolab, the TSCA changes mainly impact testing and submission costs for new and existing chemical substances in the United States. As a result of reform and administration changes, EPA reviews are resulting in the majority of new substances being regulated in some manner by the agency. Compliance with new requirements under TSCA are similar to the costs associated with REACH in the European Union, which is discussed below.

​

REACH: The European Union has enacted a regulatory framework for the Registration, Evaluation and Authorization of Chemicals (“REACH”), which aims to manage chemical safety risks. REACH established a European Chemicals Agency (“ECHA”) in Helsinki, Finland, which is responsible for evaluating data to determine hazards and risks and to manage this program for authorizing chemicals for sale and distribution in Europe. We met all REACH registration requirements. To help manage this program, we have been simplifying our product lines and working with chemical suppliers to comply with registration requirements. In addition, Korea, Taiwan, Turkey, India, Chile and Colombia and other countries have implemented or are implementing similar requirements. In addition, the European Green Deal will include the revision of chemical management regulation to achieve a circular economy and toxic-free environment (Chemical Strategy for Sustainability) which may impact sales in Ecolab’s raw material portfolio. Potential costs to us are not yet fully quantifiable but are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

​

GHS: In 2003, the United Nations adopted a standard on hazard communication and labeling of chemical products known as the Globally Harmonized System of Classification and Labeling of Chemicals (“GHS”). GHS is designed to facilitate international trade and increase safe handling and use of hazardous chemicals through a worldwide system that classifies chemicals based on their intrinsic hazards and communicates information about those hazards through standardized product labels and safety data sheets (“SDSs”). Most countries in which we operate have adopted or are expected to adopt GHS-related legislation by 2023. The primary cost of compliance revolves around reclassifying products and revising SDSs and product labels. We have met applicable deadlines and are working toward a phased-in approach to mitigate the costs of GHS implementation in remaining countries (e.g., Peru, Chile, India). Potential costs to us are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

​

Pesticide and Biocide Legislation: Various international, federal and state environmental laws and regulations govern the manufacture and/or use of pesticides. We manufacture and sell certain disinfecting, sanitizing and material preservation products that kill or reduce microorganisms (bacteria, viruses, fungi) on hard environmental surfaces, in process fluids and on certain food products. Such products constitute “pesticides” or “antimicrobial pesticides” under the current definitions of the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), as amended by the Food Quality Protection Act of 1996, the principal federal statute governing the manufacture, labeling, handling and use of pesticides. We maintain several hundred product registrations with the U.S. Environmental Protection Agency (“EPA”). Registration entails the necessity to meet certain efficacy, toxicity and labeling requirements and to pay on-going registration fees. In addition, each state in which these products are sold requires registration and payment of a fee. In general, the states impose no substantive requirements different from those required by FIFRA. However, California and certain other states have adopted additional regulatory programs, and California imposes a tax on total pesticide sales in that state. While the cost of complying with rules as to pesticides has not had a material adverse effect on our consolidated results of operations, financial condition, or cash flows to date, the costs and delays in receiving necessary approvals for these products continue to increase. Total fees paid to the EPA and the states to obtain or maintain pesticide registrations are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position.

​

In Europe, the Biocidal Products Regulation established a program to evaluate and authorize marketing of biocidal active substances and products. We are working with suppliers and industry groups to manage these requirements and have met all relevant deadlines of the program by the timely submission of dossiers for active substances and biocide products. Anticipated registration costs, which will be incurred through the multi-year phase-in period, will be significant; however, these costs are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position. The same is true for emerging biocide regulations in Asia.

​

11

Table of Contents

In addition, Pest Elimination applies restricted-use pesticides that it generally purchases from third parties. That business must comply with certain standards pertaining to the use of such pesticides and to the licensing of employees who apply such pesticides. Such regulations are enforced primarily by the states or local jurisdictions in conformity with federal regulations. We have not experienced material difficulties in complying with these requirements.

​

FDA Antimicrobial Product Requirements: Various laws and regulations have been enacted by federal, state, local and foreign jurisdictions regulating certain products manufactured and sold by us for controlling microbial growth on humans, animals and foods. In the United States, these requirements generally are administered by the U.S. Food and Drug Administration ("FDA"). However, the U.S. Department of Agriculture and EPA also may share in regulatory jurisdiction of antimicrobials applied to food. The FDA codifies regulations for these product categories in order to ensure product quality, safety and effectiveness. The FDA also has been expanding requirements applicable to such products, including proposing regulations for over-the-counter antiseptic drug products, which may impose additional requirements associated with antimicrobial hand care products and associated costs when finalized by the FDA. FDA regulations associated with the Food Safety Modernization Act may impose additional requirements related to safety product lines. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

Medical Device and Drug Product Requirements: As a manufacturer, distributor and marketer of medical devices and human drugs, we also are subject to regulation by the FDA and corresponding regulatory agencies of the state, local and foreign governments in which we sell our products. These regulations govern the development, testing, manufacturing, packaging, labeling, distribution and marketing of medical devices and medicinal products, including Advanced Pharmaceutical Ingredients (“API”), excipients and resins for biopharmaceutical processing. We also are required to register with the FDA as a medical device and drug manufacturer, comply with post-market reporting (e.g., Adverse Event Reporting, MDR and Recall) requirements, and to comply with the FDA’s current Good Manufacturing Practices and Quality System Regulations which require that we have a quality system for the design and production of our products intended for commercial distribution in the United States and satisfy recordkeeping requirements with respect to our manufacturing, testing and control activities. Countries in the European Union require that certain products being sold within their jurisdictions obtain a “CE mark,” an international symbol of adherence to quality assurance standards, and be manufactured in compliance with certain requirements (e.g., Medical Device Directive 93/42/EE, Medical Device Regulation (EU) 2017/745 (“MDR”), and ISO 13485). We have CE mark approval to sell various medical device and medicinal products in Europe. Implementation of the MDR will require additional certifications and investments, including system, product and process upgrades. Our other international non-European operations also are subject to government regulation and country-specific rules and regulations. Regulators at the federal, state and local level have imposed, are currently considering and are expected to continue to impose regulations on medical devices and drug products. No prediction can be made of the potential effect of any such future regulations, and there can be no assurance that future legislation or regulations will not increase the costs of our products or prohibit the sale or use of certain products.

​

Equipment: Ecolab’s products are dispensed by equipment that is subject to state and local regulatory requirements, as well as being subject to UL, NSF, and other approval requirements. For certain digitally connected product offerings, Federal Communication Commission (“FCC”) and corresponding international requirements are applicable. We have both dedicated manufacturing facilities and third-party production of our equipment. We are developing processes to monitor and manage changing regulatory regimes and assist with equipment systems compliance. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

Other Environmental Legislation: Our manufacturing plants are subject to federal, state, local or foreign jurisdiction laws and regulations relating to discharge of hazardous substances into the environment and to the transportation, handling and disposal of such substances. The primary federal statutes that apply to our activities in the United States are the Clean Air Act, the Clean Water Act and the Resource Conservation and Recovery Act. We are also subject to the Superfund Amendments and Reauthorization Act of 1986, which imposes certain reporting requirements as to emissions of hazardous substances into the air, land and water. The products we produce and distribute into Europe are also subject to directives governing electrical waste (WEEE Directive 2012/19/EU) and restrictive substances (RoHS Directive 2011/65/EU). Similar legal requirements apply to Ecolab’s facilities globally. We make capital investments and expenditures to comply with environmental laws and regulations, to promote employee safety and to carry out our announced environmental sustainability principles. To date, such expenditures have not had a significant adverse effect on our consolidated results of operations, financial position or cash flows. Our capital expenditures for environmental, health and safety projects worldwide were approximately $35 million in 2022, $28 million in 2021 and $18 million in 2020. Approximately $41 million has been budgeted globally for projects in 2023. The increase in the projected spend reflects a return to historical annual expenditure levels prior to the COVID-19 pandemic.

​

Climate Change: Various laws and regulations pertaining to climate change have been implemented or are being considered for implementation at the international, national, regional and state levels, particularly as they relate to the reduction of greenhouse gas (GHG) emissions. These include proposed regulations introduced by the SEC in March 2022 relating to climate change disclosure and the European Commission’s Corporate Sustainability Reporting Directive, which came into force in December 2022 and will apply to both EU and certain non-EU companies with a phased introduction. These laws may directly impact the Company. We continue to monitor the development and implementation of such laws and regulations; however, as a matter of corporate policy, we support a balanced approach to reducing GHG emissions while sustaining economic growth.

​

​

12

Table of Contents

Furthermore, climate-related risks are assessed within our Enterprise Risk Management process and Annual Business Significance Risks Assessment, which is aligned with recommendations of the Financial Stability Board (FSB) Task Force on Climate-related Financial Disclosures (TCFD). We report TCFD disclosures in our annual CDP Climate report located at https://www.ecolab.com/sustainability/sustainability-reporting-resources. We are evaluating further application of the recommendations of the TCFD in alignment with the recommended timeline from the TCFD.

​

Ecolab recognizes that climate change poses potential risks and creates potential opportunities to our organization. Ecolab has taken steps to further identify and assess the nature and magnitude of these risks and opportunities. Ecolab has been focused on assessing climate risks for the past three years, leading up to our TCFD-aligned climate risk assessment conducted in 2021. We expect to continue our efforts to assess additional climate-related risks and opportunities including, exploring our supply chain resiliency, as appropriate. Subsequently, Ecolab plans to review the results of our analysis and consider adaptation and management plans for any relevant climate change risks and to further benefit from identified opportunities for customer impact.

​

To further our climate commitment, in 2019 we announced new goals to reduce our GHG emissions by half by 2030 and achieve net zero by 2050, in alignment with the United Nations Global Compact’s Business Ambition for 1.5⁰C. In 2020, we further committed to attempt to move to 100% renewable energy by 2030 and set a science-based target (SBT) addressing our Scope 1, 2 and 3 GHG emissions. Our SBT targets reduction of absolute Scope 1 and 2 emissions by 50% by 2030 from a 2018 base year, and to work with our suppliers representing 70% of our Scope 3 emissions to set science-based reduction targets by 2024. In 2021, we invested over $1.2 million in continuous improvement projects focused on water and energy reductions at over 20 of our facilities across the globe. In all, these projects reduced annual energy consumption by almost 5.4 billion BTUs, reduced GHG emissions by 324 MT CO2e and saved 27 million gallons (~103,000 cubic meters) of water across our global supply chain manufacturing facilities. The scope of energy consumption reductions is calculated using a combination of direct measurements and estimations using best-practice methodologies. The scope of reduction in GHG emissions consumption data is an estimated annual impact and includes both Scope 1 and 2 emissions. Water reduction is calculated using the water meters and utilities data that measure the savings since our base year of calculations which was 2018.

​

In addition to managing our operational and supply chain sustainability performance, we partner with customers at more than three million customer locations around the world to reduce energy and GHG emissions through our high-efficiency solutions in cleaning and sanitation, water, paper, and energy services. Showcasing our global team’s dedication to helping our customers thrive and make a positive impact in the world, we have set a 2030 goal to help our customers reduce their GHG emissions by 6.0 million metric tons. Ecolab recognizes the climate-water nexus. As part of our 2030 Impact Goals, we have planned to restore greater than 50% of our water withdrawal and achieve Alliance for Water Stewardship Standard certification in high-risk watersheds. In addition, we aim to reduce net water withdrawals by 40% per unit of production across our enterprise. We also magnify our impact through the water-saving solutions we deliver to our customers and have set a goal to help our customers conserve more than 300 billion gallons of water annually by 2030.

​

The science of sustainability is an evolving one. For a discussion of the factors that may cause our sustainability initiatives, goals and targets to differ from those expressed above, see Item 1A of this Form 10-K, entitled “Risk Factors.”

​

Environmental Remediation and Proceedings: Along with numerous other potentially responsible parties (“PRP”), we are currently involved with waste disposal site clean-up activities imposed by the federal Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) or state equivalents at 17 sites in the United States. Additionally, we have similar liability at five sites outside the United States. In general, under CERCLA, we and each other PRP that actually contributed hazardous substances to a Superfund site are jointly and severally liable for the costs associated with cleaning up the site. Customarily, the PRPs will work with the EPA to agree and implement a plan for site remediation.

​

Based on an analysis of our experience with such environmental proceedings, our estimated share of all hazardous materials deposited on the sites referred to in the preceding paragraph, and our estimate of the contribution to be made by other PRPs which we believe have the financial ability to pay their shares, we have accrued our best estimate of our probable future costs relating to such known sites. In establishing accruals, potential insurance reimbursements are not included. The accrual is not discounted. It is not feasible to predict when the amounts accrued will be paid due to the uncertainties inherent in the environmental remediation and associated regulatory processes.

​

We have also been named as a defendant in a number of lawsuits alleging personal injury due to exposure to hazardous substances, including multi-party lawsuits alleging personal injury in connection with our products and services. While we do not believe that any of these suits will be material to us based upon present information, there can be no assurance that these environmental matters could not have, either individually or in the aggregate, a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

We have also been named as a defendant in lawsuits where our products have not caused injuries, but the claimants wish to be monitored for potential future injuries. We cannot predict with certainty the outcome of any such tort claims or the involvement we or our products might have in such matters in the future, and there can be no assurance that the discovery of previously unknown conditions will not require significant expenditures. In each of these chemical exposure cases, our insurance carriers have accepted the claims on our behalf (with or without reservation) and our financial exposure should be limited to the amount of our deductible; however, we cannot predict the number of claims that we may have to defend in the future and we may not be able to continue to maintain such insurance.

13

Table of Contents

Our worldwide net expenditures for contamination remediation were approximately $1.4 million in 2022, $0.5 million in 2021 and $0.6 million in 2020. Our worldwide accruals at December 31, 2022 for probable future remediation expenditures, excluding potential insurance reimbursements, totaled approximately $9.6 million. We review our exposure for contamination remediation costs periodically and our accruals are adjusted as considered appropriate. While the final resolution of these issues could result in costs below or above current accruals and, therefore, have an impact on our consolidated financial results in a future reporting period, we believe the ultimate resolution of these matters will not have a material effect on our consolidated results of operations, financial position or cash flows.

​

​

Available Information.

​

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC at https://www.sec.gov.

​

General information about us, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available free of charge through our website at https://investor.ecolab.com as soon as reasonably practicable after we file them with, or furnish them to, the SEC.

​

In addition, the following governance materials are available on our web site at https://investor.ecolab.com/corporate-governance: (i) charters of the Audit, Compensation, Finance, Governance and Safety, Health and Environment Committees of our Board of Directors; (ii) our Board's Corporate Governance Principles; and (iii) our Code of Conduct.

​

We include our website addresses throughout this report for reference only. The information contained on our websites, including the corporate responsibility, EEO-1, and climate reports identified in this report, is not incorporated by reference into this report.

​

​

14

Table of Contents

Information about our Executive Officers.

​

The persons listed in the following table are our current executive officers. Officers are elected annually. There is no family relationship among any of the directors or executive officers and no executive officer has been involved during the past ten years in any legal proceedings described in applicable Securities and Exchange Commission regulations.

Name |  | Age |  | Office |  | Positions Held Since Jan. 1, 2018
​ | ​ | ​ | ​ | ​ | ​ | ​
Christophe Beck | ​ | 55 | ​ | Chairman and Chief Executive Officer | ​ | Oct. 2022 – Present
​ | ​ | ​ | ​ | Chairman, Chief Executive Officer and President | ​ | May 2022 – Oct. 2022
​ | ​ | ​ | ​ | President and Chief Executive Officer | ​ | Jan. 2021 – May 2022
​ | ​ | ​ | ​ | President and Chief Operating Officer | ​ | Apr. 2019 – Dec. 2020
​ | ​ | ​ | ​ | Executive Vice President and President – Industrial | ​ | May 2018 – Mar. 2019
​ | ​ | ​ | ​ | Executive Vice President and President – Global Nalco Water | ​ | Jan. 2018 – May 2018
​ | ​ | ​ | ​ | ​ | ​ | ​
Larry L. Berger | ​ | 62 | ​ | Executive Vice President and Chief Technical Officer | ​ | Jan. 2018 – Present
​ | ​ | ​ | ​ | ​ | ​ | ​
Jennifer J. Bradway | ​ | 46 | ​ | Senior Vice President and Corporate Controller | ​ | Jan. 2022 – Present
​ | ​ | ​ | ​ | Senior Vice President and Controller, Global Institutional | ​ | Jan. 2020 – Dec. 2021
​ | ​ | ​ | ​ | Vice President Finance, Institutional North America | ​ | May 2018 – Dec. 2019
​ | ​ | ​ | ​ | Vice President and Controller, Institutional U.S. | ​ | Jan. 2018 – Apr. 2018
​ | ​ | ​ | ​ | ​ | ​ | ​
Darrell R. Brown | ​ | 59 | ​ | President and Chief Operating Officer | ​ | Oct. 2022 – Present
​ | ​ | ​ | ​ | Executive Vice President and President – Global Industrial | ​ | Apr. 2019 – Oct. 2022
​ | ​ | ​ | ​ | Executive Vice President and President – Energy Services | ​ | Jan. 2018 – Mar. 2019
​ | ​ | ​ | ​ | ​ | ​ | ​
Angela M. Busch | ​ | 56 | ​ | Executive Vice President – Corporate Strategy & Business Development | ​ | Aug. 2018 – Present
​ | ​ | ​ | ​ | Senior Vice President – Corporate Development | ​ | Jan. 2018 – Aug. 2018
​ | ​ | ​ | ​ | ​ | ​ | ​
Alexander A. De Boo | ​ | 55 | ​ | Executive Vice President and President – Global Markets | ​ | Feb. 2021 – Present
​ | ​ | ​ | ​ | Executive Vice President and President – Western Europe | ​ | Apr. 2020 – Jan. 2021
​ | ​ | ​ | ​ | Senior Vice President and General Manager – Industrial, Europe | ​ | Oct. 2018 – Apr. 2020
​ | ​ | ​ | ​ | Senior Vice President and General Manager – Food & Beverage, Europe | ​ | Jan. 2018 – Oct. 2018
​ | ​ | ​ | ​ | ​ | ​ | ​
Machiel Duijser (1) | ​ | 51 | ​ | Executive Vice President and Chief Supply Chain Officer | ​ | Feb. 2020 – Present
​ | ​ | ​ | ​ | ​ | ​ | ​
Scott D. Kirkland | ​ | 49 | ​ | Chief Financial Officer | ​ | Jan. 2022 – Present
​ | ​ | ​ | ​ | Senior Vice President and Corporate Controller | ​ | June 2019 – Dec. 2021
​ | ​ | ​ | ​ | Senior Vice President – Finance, Global Energy Services | ​ | Jan. 2018 – May 2019
​ | ​ | ​ | ​ | ​ | ​ | ​
Laurie M. Marsh | ​ | 59 | ​ | Executive Vice President – Human Resources | ​ | Jan. 2018 – Present
​ | ​ | ​ | ​ | ​ | ​ | ​
Lanesha T. Minnix (2) | ​ | 47 | ​ | Executive Vice President, General Counsel and Secretary | ​ | June 2022 – Present
​ | ​ | ​ | ​ | ​ | ​ | ​
Gail Peterson | ​ | 44 | ​ | Senior Vice President – Global Marketing & Communications | ​ | Jan. 2021 – Present
​ | ​ | ​ | ​ | Vice President – Marketing Global Healthcare | ​ | Jan. 2018 – Dec. 2020
​ | ​ | ​ | ​ | ​ | ​ | ​
Gergely Sved (3) | ​ | 49 | ​ | Executive Vice President and President – Global Healthcare and Life Sciences | ​ | Apr. 2022 – Present
​ | ​ | ​ | ​ | SVP and General Manager - Global Healthcare | ​ | Jan. 2019 – Mar. 2022
​ | ​ | ​ | ​ | ​ | ​ | ​

​

(1) Prior to joining Ecolab in February 2020, Mr. Duijser was employed by Reckitt Benckiser Group plc (RB), a global provider of health, hygiene and home products, as Chief Supply Officer since November 2018. Mr. Duijser joined RB from Amazon.com, Inc., a global service provider for e-commerce, cloud computing, digital streaming, and artificial intelligence, where he served as Vice President Worldwide Engineering from 2017 to 2018.

​

(2) Prior to joining Ecolab in June 2022, Ms. Minnix was employed by Flowserve Corporation, a global industrial manufacturer of engineered flow control systems, as Senior Vice President, Chief Legal Officer and Corporate Secretary from 2018 until 2022. Ms. Minnix joined Flowserve from BCM Stock Holdings, Inc., a buildings material company, where she served as Senior Vice President, General Counsel and Corporate Secretary from 2017 to 2018.

​

(3) Prior to joining Ecolab in January 2019, Mr. Sved was employed by GE HealthCare Technologies Inc., a global medical technology company, where he served as Chief Executive Officer Europe Services from 2013 until 2018, and held numerous other commercial leadership roles, including COO for Services Europe and GM for Northern Europe.

15

Table of Contents

Forward-Looking Statements

​

This Form 10-K, including Part I, Item 1, entitled “Business,” and the MD&A within Part II, Item 7, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations concerning items such as:

​

| ● | amount, funding and timing of cash expenditures relating to our restructuring and other initiatives, as well as savings from such initiatives

| ● | future cash flows, access to capital, targeted credit rating metrics and impact of credit rating downgrade

| ● | adequacy of cash reserves

| ● | uses for cash, including dividends, share repurchases, debt repayments, capital investments and strategic business acquisitions

| ● | global market risk

| ● | long-term potential of our business

| ● | impact of changes in exchange rates and interest rates

| ● | customer retention rate

| ● | bad debt experience, non-performance of counterparties and losses due to concentration of credit risk

| ● | disputes, claims and litigation

| ● | environmental contingencies

| ● | impact and cost of complying with laws and regulations

| ● | sustainability and human capital targets

| ● | returns on pension plan assets

| ● | contributions to pension and postretirement healthcare plans

| ● | amortization expense

| ● | impact of new accounting pronouncements

| ● | income taxes, including tax attributes, valuation allowances, uncertain tax positions, permanent reinvestment assertions and goodwill deductibility

| ● | recognition of share-based compensation expense

| ● | payments under operating leases

| ● | future benefit plan payments

| ● | market position

| ● | the impact of the Covid-19 pandemic, including global economic recovery, supply shortages, inflation and delivered product costs

​

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will be,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof), “intends,” “could,” or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further discussion of these and other factors which could cause results to differ from those expressed in any forward-looking statement, see Item 1A of this Form 10-K, entitled “Risk Factors.” Except as may be required under applicable law, we undertake no duty to update our forward-looking statements.

​

Forward-looking and other statements in this document may also address our sustainability initiatives, goals, targets and progress, and the inclusion of such statements is not an indication that these contents are necessarily material to investors or required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future and performance against our goals and targets may differ from such forward-looking statements in such event.

​

​

16

Table of Contents

Item 1A. Risk Factors.

​

The following are important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-K. See the section entitled “Forward-Looking Statements” set forth above.

​

We may also refer to this disclosure to identify factors that may cause results to differ materially from those expressed in other forward-looking statements including those made in oral presentations, including telephone conferences and/or webcasts open to the public.

​

Economic & Operational Risks

​

Our results are impacted by general worldwide economic factors.

​

The COVID pandemic, geopolitical instability, including the conflict between Russia and Ukraine, and other global events have significantly increased economic and demand uncertainty. Some of the results of these events, including supply chain challenges, inflation, high interest rates, foreign currency exchange volatility, and volatility in global capital markets, have affected our business in the past and could continue to have a material adverse impact on our business in the future. Countries such as Russia, Turkey and Argentina have recently experienced economic upheaval and similar upheaval in other countries with Ecolab operations could have a material adverse impact on our consolidated results of operations, financial position and cash flows by negatively impacting economic activity, including in our key end-markets, and by further weakening the local currency versus the U.S. dollar, resulting in reduced sales and earnings from our foreign operations, which are generated in the local currency, and then translated to U.S. dollars.

​

Our results depend upon the continued vitality of the markets we serve.

​

Economic downturns, and in particular downturns in our larger markets including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our customers. In particular, we expect a more challenging macroeconomic environment, especially in Europe, as the war and the energy crisis are having a significant impact on costs and demand. Additionally, the last three years we have experienced the negative impact of the COVID-19 pandemic on the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In prior years, the weaker global economic environment has also negatively impacted certain of our end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

​

Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.

​

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in more than 170 countries and, in 2022, approximately 47% of our net sales originated outside the United States. There are inherent risks in our international operations, including:

​

| ● | exchange controls and currency restrictions;

| ● | currency fluctuations and devaluations;

| ● | tariffs and trade barriers;

| ● | export duties and quotas;

| ● | changes in the availability and pricing of raw materials, energy and utilities;

| ● | changes in local economic conditions;

| ● | changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;

| ● | difficulties in managing international operations and the burden of complying with international and foreign laws;

| ● | requirements to include local ownership or management in our business;

| ● | economic and business objectives that differ from those of our joint venture partners;

| ● | exposure to possible expropriation, nationalization or other government actions;

| ● | restrictions on our ability to repatriate dividends from our subsidiaries;

| ● | unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict; and

| ● | countries whose governments have been hostile to U.S.-based businesses.

​

In light of Russia’s invasion of Ukraine and the United States’ and other countries’ sanctions against Russia, we announced in April 2022 that we will focus our Russian business on operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We may further narrow our presence in Russia depending on developments in the conflict or otherwise. Our Russian operations represented approximately 1% for both our 2022 and 2021 annual sales. During 2022 we recorded pre-tax charges of $13.1 million related to recoverability risk of certain assets in both Russia and Ukraine. Depending on developments, we may incur further charges relating to our Russia and Ukraine businesses. The conflict in Ukraine may escalate and/or expand in scope and the broader consequences of this conflict, which have included and/or may in the future include sanctions, embargoes, regional instability and geopolitical shifts; potential retaliatory action by the Russian government against companies, including us, such as nationalization of foreign businesses in Russia; and increased tensions between the United States and countries in which we operate cannot be predicted, nor can we predict the conflict’s impact on the global economy and on our business and financial results. The Russia and Ukraine conflict may also heighten many other risks disclosed in our report on Form 10-K, any of which could

17

Table of Contents

materially and adversely affect our business and financial results. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including increased inflation, constraints on the availability of commodities, supply chain disruption and decreased business spending; disruptions to our or our business partners’ global technology infrastructure, including through cyber-attack or cyber-intrusion; adverse changes in international trade policies and relations; claims, litigation and regulatory enforcement; our ability to implement and execute our business strategy; terrorist activities; our exposure to foreign currency fluctuations; reputational risk; and constraints, volatility, or disruption in the capital markets.

​

Additionally, changes in U.S. or foreign government policy on international trade, including the imposition or continuation of tariffs, could materially and adversely affect our business. In 2018, the U.S. imposed tariffs on certain imports from China and other countries, resulting in retaliatory tariffs by China and other countries. While the U.S. and China signed a Phase One trade agreement in January 2020, which included the suspension and rollback of tariffs, the CHIPS and Science Act of 2022 with objectives including countering China’s technical ambitions was signed into law in August 2022. Any new tariffs or policies imposed by the U.S., China or other countries or any additional retaliatory measures by any of these countries, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

​

Further, our operations outside the United States require us to comply with a number of United States and non-U.S. laws and regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and non-U.S. economic sanctions regulations. We have internal policies and procedures relating to such laws and regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

​

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

Our results could be materially and adversely affected by difficulties in securing the supply of certain raw materials or by fluctuations in the cost of raw materials.

​

The prices of raw materials used in our business fluctuate, and in recent years we have experienced periods of significant increased raw material costs. Changes in raw material prices, unavailability of adequate and reasonably priced raw materials or substitutes for those raw materials, or the inability to obtain or renew supply agreements on favorable terms has materially and adversely affected our business and can in the future materially and adversely affect our consolidated results of operations, financial position or cash flows. In addition, volatility and disruption in economic activity and conditions could disrupt or delay the performance of our suppliers and thus impact our ability to obtain raw materials at favorable prices or on favorable terms, which may materially and adversely affect our business.

​

We depend on key personnel to lead our business; the labor market is very dynamic.

​

Our continued success will largely depend on our ability to attract, retain and develop a high caliber of talent and on the efforts and abilities of our executive officers and certain other key employees, particularly those with sales and sales management responsibilities to drive business growth, development and profitability. As we continue to grow our business, make acquisitions, expand our geographic scope and offer new products and services, we need the organizational talent necessary to ensure effective succession for executive officer and key employee roles in order to meet the growth, development and profitability goals of our business. Our operations could be materially and adversely affected if for any reason we were unable to attract, retain or develop such officers or key employees and successfully execute organizational change and management transitions at leadership levels. More generally, in the wake of the COVID-19 pandemic, expectations from qualified talent in many areas of the labor market have evolved. In light of this, if we are unable to attract and retain employees on terms and conditions that are consistent with our historical operating model, our business could be disrupted or our costs could increase, which may materially and adversely affect our business

​

We are subject to information technology system failures, network disruptions and breaches in data security.

​

We rely to a large extent upon information technology systems and infrastructure to operate our business. The size and complexity of our information technology systems and those of strategic vendors make them vulnerable to failure, malicious intrusion and random attack. Acquisitions have resulted in further de-centralization of systems and additional complexity in our systems infrastructure. Likewise, data security breaches by employees or others with permitted access to our systems or to the systems of strategic vendors pose a risk that sensitive data may be exposed to unauthorized persons or to the public. Geopolitical tensions or conflicts, such as Russia’s invasion of Ukraine, may further heighten the risk of cybersecurity attacks. While we have invested in protection of data and information technology, we have experienced immaterial cybersecurity attacks and incidents, and there can be no assurance that our efforts will prevent failures, cybersecurity attacks or breaches in our systems or in the systems of strategic vendors that could cause reputational damage, business

18

Table of Contents

disruption or legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets or sensitive information; or could otherwise adversely affect our business. Certain of our customer offerings include digital components, such as remote monitoring of certain customer operations. A breach of those remote monitoring systems could expose customer data giving rise to potential third-party claims and reputational damage. There may be other related challenges and risks as we complete implementation of our ERP system upgrade.

​

The COVID-19 pandemic and measures taken in response thereto have materially and adversely impacted, and we expect may continue to materially and adversely impact, our business and results of operations, and the full impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.

​

Beginning in March 2020, the COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. There is continued uncertainty regarding the duration, scope and severity of the pandemic, particularly with the emergence of new variants of COVID-19 and periodic spikes in COVID-19 cases in various geographic regions, and the impacts on our business and the global economy from the effects of the pandemic and response measures. Travel and logistics restrictions, lockdowns, vaccine requirements and other measures from time to time implemented by foreign and domestic authorities have resulted in, and may continue to result in, supply chain and transportation disruptions, production delays and capacity limitations at Ecolab and some of its customers and suppliers, as well as reduced workforce availability or productivity at Ecolab and customer sites, and additional data, information and cyber security risks associated with an extensive workforce working remotely.

​

The degree to which the pandemic ultimately impacts our business, financial condition and results of operations and the global economy will depend on future developments beyond our control, which are highly uncertain and difficult to predict, including the severity, duration and any resurgence of the pandemic, the extent, duration and effectiveness of periodic lockdowns and other containment actions, the availability, public adoption and efficacy of COVID vaccines, how quickly and to what extent normal economic and operating activity can resume, and the severity and duration of resulting global economic volatility.

​

Besides the COVID-19 pandemic, the United States and other countries have experienced, and may experience in the future, public health outbreaks such as Zika virus, Avian Flu, SARS and H1N1 influenza. A prolonged occurrence of a contagious disease such as these could result in a significant downturn in the foodservice, hospitality and travel industries and also may result in health or other government authorities imposing restrictions on travel further impacting our end markets. Any of these events could result in a significant drop in demand for some of our products and services and materially and adversely affect our business.

​

Strategic Risks

​

If we are unsuccessful in integrating acquisitions, including Purolite, our business could be materially and adversely affected.

​

In December 2021 we acquired Purolite, which operates in the highly regulated life sciences, pharma and biopharma industries and has extensive international operations which complicate integration execution. If we have difficulty integrating Purolite operations or lose key employees or customers, our business could be materially and adversely affected. Additionally, as part of our long-term strategy, we seek to acquire complementary businesses. There can be no assurance that we will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses into existing businesses. If the underlying business performance of such acquired businesses deteriorates, the expected synergies from such transactions do not materialize or we fail to successfully integrate new businesses into our existing businesses, our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

​

If we are unsuccessful in executing on key business initiatives, including restructurings and our Enterprise Resource Planning (“ERP”) system upgrades, our business could be materially and adversely affected.

​

We continue to execute key business initiatives, including restructurings and investments to develop business systems, as part of our ongoing efforts to improve our efficiency and returns. In particular, we are undertaking the three restructuring plans, i.e. the Europe Program, the Institutional Advancement Program and Accelerate 2020 plan to simplify and automate processes and tasks, reduce complexity and management layers, consolidate facilities and focus on key long term growth areas by leveraging technology and structural improvements as discussed under Note 3 entitled “Special (Gains) and Charges” of this Form 10-K. Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

​

Our growth depends upon our ability to compete successfully with respect to value, innovation and customer support.

​

We have numerous global, national, regional and local competitors. Our ability to compete depends in part on providing high quality and high value-added products, technology and service. We must also continue to identify, develop and commercialize innovative, profitable and high value-added products for niche applications and commercial digital applications. We have made significant investments in commercial digital product offerings, and our culture and expertise must continue to evolve to develop, support and profitably deploy commercial digital offerings, which are becoming an increasingly important part of our business. There can be no assurance that we will

19

Table of Contents

be able to accomplish our technology development goals or that technological developments by our competitors will not place certain of our products, technology or services at a competitive disadvantage in the future. In addition, certain of the new products that we have under development will be offered in markets in which we do not currently compete, and there can be no assurance that we will be able to compete successfully in those new markets. If we fail to introduce new technologies or commercialize our digital offerings on a timely and profitable basis, we may lose market share and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

​

Consolidation of our customers and vendors could materially and adversely affect our results.

​

Customers and vendors in the foodservice, hospitality, travel, healthcare, energy, life sciences, food processing and pulp and paper industries, as well as other industries we serve, have consolidated in recent years and that trend may continue. This consolidation could have a material adverse impact on our ability to retain customers and on our pricing, margins and consolidated results of operations.

​

We enter into multi-year contracts with customers that could impact our results.

​

Our multi-year contracts with some of our customers include terms affecting our pricing flexibility. There can be no assurance that these restraints will not have a material adverse impact on our margins and consolidated results of operations.

​

Legal, Regulatory & Compliance Risks

​

Our business depends on our ability to comply with laws and governmental regulations and meet our contractual commitments and failure to do so could materially and adversely impact our business; and we may be materially and adversely affected by changes in laws and regulations.

​

Our business is subject to numerous laws and regulations relating to the environment, including evolving climate change standards, and to the manufacture, storage, distribution, sale and use of our products as well as to the conduct of our business generally, including employment and labor laws and anti-corruption laws. Furthermore, increasing public and governmental awareness and concern regarding the effects of climate change has led to significant legislative and regulatory efforts to limit greenhouse gas emissions and will likely result in further environmental and climate change laws and regulations. Compliance with these laws and regulations exposes us to potential financial liability and increases our operating costs. A violation of these laws and regulations could expose us to financial liability that may have a material adverse effect on our results of operations and cash flows. Regulation of our products and operations continues to increase with more stringent standards, causing increased costs of operations and potential for liability if a violation occurs. The potential cost to us relating to environmental and product registration laws and regulations is uncertain due to factors such as the unknown magnitude and type of possible contamination and clean-up costs, the complexity and evolving nature of laws and regulations, and the timing and expense of compliance. Changes to current laws (including tax laws), regulations and policies could impose new restrictions, costs or prohibitions on our current practices which would have a material adverse effect on our consolidated results of operations, financial position or cash flows. Changes to labor and employment laws and regulations, as well as related rulings by courts and administrative bodies, could materially and adversely affect our operations and expose us to potential financial liability.

​

Defense of litigation, particularly certain types of actions such as antitrust, patent infringement, personal injury, product liability, breach of contract, wage hour and class action lawsuits, can be costly and time consuming even if ultimately successful, and if not successful could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

A chemical spill or release could materially and adversely impact our business.

​

As a manufacturer and supplier of chemical products, there is a potential for chemicals to be accidentally spilled, released or discharged, either in liquid or gaseous form, during production, transportation, storage or use. Such a release could result in environmental contamination as well as a human or animal health hazard. Accordingly, such a release could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

​

Potential indemnification liabilities pursuant to the separation and split-off of our Upstream Energy business could materially and adversely affect our business and financial statements.

​

With respect to the separation and subsequent split-off of our Upstream Energy business, we entered into a separation and distribution agreement with ChampionX Holding Inc. and ChampionX Corporation (f/k/a Apergy Corporation and taken together with ChampionX Holding Inc., “ChampionX”) as well as certain other agreements to govern the separation and related transactions and our relationship with ChampionX going forward. These agreements provide for specific indemnity and certain other obligations of each party and could lead to disputes between ChampionX and us. If we are required to indemnify ChampionX under the circumstances set forth in these agreements, we may be subject to substantial related liabilities. In addition, with respect to the liabilities for which ChampionX has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against ChampionX will be sufficient to protect us against the full amount of such liabilities, or that ChampionX will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our business and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

​

20

Table of Contents

Extraordinary events may significantly impact our business.

​

The occurrence of (a) litigation or claims, (b) the loss or insolvency of a major customer or distributor, (c) repeated or prolonged federal government shutdowns or similar events, (d) war (including acts of terrorism or hostilities which impact our markets), (e) natural or manmade disasters, (f) water shortages or (g) severe weather conditions affecting our operations or the energy, foodservice, hospitality and travel industries may have a material adverse effect on our business.

​

While we have a diverse customer base and no customer or distributor constitutes 10 percent or more of our consolidated revenues, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on our consolidated results of operations or cash flows for the affected earnings periods.

​

Government shutdowns can have a material adverse effect on our consolidated results of operations or cash flows by disrupting or delaying new product launches, renewals of registrations for existing products and receipt of import or export licenses for raw materials or products.

​

War (including acts of terrorism or hostilities), natural or manmade disasters, water shortages or severe weather conditions, including the effects of climate change, affecting the energy, foodservice, hospitality, travel, health care, food processing, pulp and paper, mining, steel and other industries can cause a downturn in the business of our customers, which in turn can have a material adverse effect on our consolidated results of operations, financial position or cash flows. In particular, the U.S. Gulf Coast is a region with significant refining, petrochemicals and chemicals operations which provide us raw materials, as well as being an important customer base for our Downstream and Water operating segments. Hurricanes or other severe weather events impacting the Gulf Coast, such as the winter freeze in Texas and the Gulf Coast in February 2021, can materially and adversely affect our ability to obtain raw materials at reasonable cost, or at all, and could adversely affect our business with our customers in the region.

​

Our commitments, goals, targets, objectives and initiatives related to sustainability, and our public statements and disclosures regarding them, expose us to numerous risks.

​

We have developed, and will continue to establish, goals, targets, and other objectives related to sustainability matters, including our sustainability goals in alignment with the United Nations Global Compact’s Business Ambition for 1.5⁰C and our commitments to science-based targets addressing Scope 1, 2 and 3 GHG emissions, discussed in Item 1 of Part I of this Form 10-K, entitled “Business.” Achieving these goals and commitments will require evolving our business, capital investment and the development of technology that might not currently exist. We might incur additional expense or be required to recognize impairment charges in connection with our efforts. These commitments, goals, targets and other objectives reflect our current plans and there is no guarantee that they will be achieved. Our efforts to research, establish, accomplish, and accurately report on these commitments, goals, targets, and objectives expose us to operational, reputational, financial, legal, and other risks. Our ability to achieve any stated commitment, goal, target, or objective is subject to factors and conditions, many of which are outside of our control, including the pace of changes in technology, the availability of requisite financing, and the availability of suppliers that can meet our sustainability and other standards.

​

Our business may face increased scrutiny from the investment community, other stakeholders, regulators, and the media related to our sustainability activities, including our commitments, goals, targets, and objectives, and our methodologies and timelines for pursuing them. If our sustainability practices do not meet investor or other stakeholder expectations and standards, which continue to evolve, our reputation, our ability to attract or retain employees, and our attractiveness as an investment, business partner, or as an acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our commitments, goals, targets, and objectives, to comply with ethical, environmental, or other standards, regulations, or expectations, or to satisfy reporting standards with respect to these matters, within the timelines we announce, or at all, could have operational, reputational, financial and legal impacts.

​

Financial Risks

​

If the separation and split-off of our Upstream Energy business or certain internal transactions undertaken in anticipation of the divestiture are determined to be taxable in whole or in part, we and our stockholders may incur significant tax liabilities.

​

In connection with the separation and split-off of our Upstream Energy business that was consummated on June 3, 2020, we obtained opinions of outside tax counsel that the related merger and exchange offer will qualify as tax-free transactions to us and our stockholders, except to the extent that cash was paid to Ecolab stockholders in lieu of fractional shares. We have not sought or obtained a ruling from the Internal Revenue Service (IRS) on the tax consequences of these transactions. An opinion of counsel is not binding on the IRS or the courts, which may disagree with the opinion. Even if the merger and exchange offer otherwise qualified as tax-free transactions, they may become taxable to us if certain events occur that affect either Ecolab or ChampionX Corporation. While ChampionX Corporation has agreed not to take certain actions that could cause the transactions not to qualify as tax-free transactions and is generally obligated to indemnify us against any tax consequences if it breaches this agreement, the potential tax liabilities could have a material adverse effect on us if we were not entitled to indemnification or if the indemnification obligations were not fulfilled. If the merger or exchange offer were determined to be taxable, we could be subject to a substantial tax liability, and each U.S. holder of our common stock who participated in the exchange offer could be treated as exchanging the Ecolab shares surrendered for ChampionX Corporation shares in a taxable transaction.

​

21

Table of Contents

Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.

​

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, such as the Inflation Reduction Act (IRA) signed into law on August 16, 2022, which includes a corporate alternative minimum tax on certain large corporations, incentives to address climate change mitigation and other non-income tax provisions, including an excise tax on the repurchase of corporate stock. We are also subject to changes in tax law outside the United States and actions taken with respect to tax-related matters by associations such as the Organization for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries, and the European Commission which influence tax policies in countries where we operate. For example, approximately 140 countries have agreed to the OECD’s two-pillar base erosion and profit shifting project (“BEPS”). This framework, which could be implemented in some countries as early as 2023, is focused on a number of issues, including shifting taxing rights on income from residence countries to source countries and establishing a minimum 15% global tax rate. Some of the BEPS and related proposals, if enacted into law in the United States and in the foreign countries where we do business, could increase the burden and costs of our tax compliance, the amount of taxes we incur in those jurisdictions and our global effective tax rate. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

​

Future events may impact our deferred tax position, including the utilization of foreign tax credits and undistributed earnings of international affiliates that are considered to be reinvested indefinitely.

​

We evaluate the recoverability of deferred tax assets and the need for deferred tax liabilities based on available evidence. This process involves significant management judgment about assumptions that are subject to change from period to period based on changes in tax laws or variances between future projected operating performance and actual results. We are required to establish a valuation allowance for deferred tax assets if we determine, based on available evidence at the time the determination is made, that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this determination, we evaluate all positive and negative evidence as of the end of each reporting period. Future adjustments (either increases or decreases), to the deferred tax asset valuation allowance are determined based upon changes in the expected realization of the net deferred tax assets. The realization of the deferred tax assets ultimately depends on the existence of sufficient taxable income in either the carry-back or carry-forward periods under the tax law. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record adjustments to the valuation allowance in future reporting periods. Changes to the valuation allowance or the amount of deferred tax liabilities could have a material adverse effect on our consolidated results of operations or financial position. Further, should we change our assertion regarding the permanent reinvestment of the undistributed earnings of international affiliates, a deferred tax liability may need to be established.

​

Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial statements.

​

As of December 31, 2022, we had approximately $8.6 billion in outstanding indebtedness, with approximately $1.5 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

​

| ● | requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;

​

| ● | reducing our flexibility in planning for or reacting to changes in our business and market conditions;

​

| ● | exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at December 31, 2022 would increase future interest expense by approximately $15 million per year; and

​

| ● | increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

​

If we add new debt, the risks described above could increase.

​

We incur significant expenses related to the amortization of intangible assets and may be required to report losses resulting from the impairment of goodwill or other assets recorded in connection with the Nalco and Purolite transactions and other acquisitions.

​

We expect to continue to complete selected acquisitions and joint venture transactions in the future. In connection with acquisition and joint venture transactions, applicable accounting rules generally require the tangible and intangible assets of the acquired business to be recorded on the balance sheet of the acquiring company at their fair values. Intangible assets other than goodwill are required to be amortized over their estimated useful lives and this expense may be significant. Any excess in the purchase price paid by the acquiring company over the fair value of tangible and intangible assets of the acquired business is recorded as goodwill. If it is later determined that the anticipated future cash flows from the acquired business may be less than the carrying values of the assets and goodwill of the acquired business, the assets or goodwill may be deemed to be impaired. In this case, the acquiring company may be required under applicable accounting rules to write down the value of the assets or goodwill on its balance sheet to reflect the extent of the impairment. This write-down of assets or goodwill is generally recognized as a non-cash expense in the statement of operations of the acquiring company for the accounting period during which the write down occurs. As of December 31, 2022, we had goodwill of $8.0 billion which

22

Table of Contents

is maintained in various reporting units, including goodwill from the Nalco and Purolite transactions. If we determine that any of the assets or goodwill recorded in connection with the Nalco transaction or any other prior or future acquisitions or joint venture transactions have become impaired, we will be required to record a loss resulting from the impairment. Impairment losses could be significant and could have a material adverse effect on our consolidated results of operations and financial position.

​

​

Item 1B. Unresolved Staff Comments.

​

We have no unresolved comments from the staff of the Securities and Exchange Commission.

​

​

Item 2. Propertie s.

​

Our manufacturing philosophy is to manufacture products wherever an economic, process or quality assurance advantage exists or where proprietary manufacturing techniques dictate in-house production. Currently, most products that we sell are manufactured at our facilities. We position our manufacturing locations and warehouses in a manner to permit ready access to our customers.

​

Our manufacturing facilities produce chemical products as well as medical devices and equipment for all of our operating segments, although Pest Elimination purchases the majority of their products and equipment from outside suppliers. Our chemical production process consists of blending purchased raw materials into finished products in powder, liquid, and solid form. Additionally, intermediates from reaction chemistries are used in some of the blends and are also packaged directly into finished goods. Our devices and equipment manufacturing operations consist of producing chemical product dispensers and injectors and other mechanical equipment, medical devices, dishwasher racks, related sundries, dish machine refurbishment and water monitoring and maintenance equipment system from purchased components and subassemblies.

​

The following table profiles our more significant physical properties with approximately 70,000 square feet or more with ongoing production activities, as well as certain other facilities important in terms of specialization and sources of supply. In general, manufacturing facilities located in the United States serve our U.S. markets and facilities located outside of the United States serve our international markets. However, most of the United States facilities do manufacture products for export.

​

PLANT PROFILES

Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased
Joliet, IL USA |  | 610,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Asheville, NC USA | ​ | 478,000 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Leased
Tai Cang, CHINA |  | 468,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Hongzhou, CHINA | ​ | 430,125 | ​ | Global Healthcare & Life Sciences | ​ | Owned
Sainghin, FRANCE |  | 360,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Mandras, GREECE | ​ | 355,435 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned
Victoria, ROMANIA | ​ | 343,605 | ​ | Global Healthcare & Life Sciences | ​ | Owned
South Beloit, IL USA |  | 313,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences, Other |  | Owned
Jianghai, CHINA |  | 296,000 |  | Global Industrial |  | Owned
Chalons, FRANCE |  | 280,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Clearing, IL USA |  | 270,000 |  | Global Industrial, Global Healthcare & Life Sciences, Other (Colloidal) |  | Owned
Nanjing, CHINA |  | 240,000 |  | Global Industrial |  | Owned
Garland, TX USA |  | 239,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Philadelphia, PA USA | ​ | 232,000 | ​ | Global Healthcare & Life Sciences | ​ | Owned
Martinsburg, WV USA |  | 228,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Elwood City, PA USA |  | 222,000 |  | Global Industrial |  | Owned
Weavergate, UNITED KINGDOM |  | 222,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Celra, SPAIN |  | 218,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Greensboro, NC USA |  | 193,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned

23

Table of Contents

Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased
Fresno, TX USA |  | 192,000 |  | Global Industrial |  | Owned
Santiago, CHILE | ​ | 188,000 | ​ | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences | ​ | Owned
Las Americas, DOMINICAN REPUBLIC |  | 182,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned
Jacksonville, FL USA |  | 181,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased
Garyville, LA USA |  | 178,000 |  | Global Industrial |  | Owned
Gul Lane, SINGAPORE | ​ | 169,000 | ​ | Global Industrial |  | Owned
Nieuwegein, NETHERLANDS |  | 168,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
La Romana, DOMINICAN REPUBLIC |  | 160,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased
Middleton, UNITED KINGDOM | ​ | 157,575 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned
Tessenderlo, BELGIUM |  | 153,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Cheltenham, AUSTRALIA |  | 145,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Suzano, BRAZIL |  | 142,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
McDonough, GA USA |  | 141,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Darra, AUSTRALIA |  | 138,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Burlington, ON CANADA |  | 136,000 |  | Global Industrial |  | Owned
Eagan, MN USA |  | 133,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences, Other |  | Owned
Huntington, IN USA |  | 127,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Rozzano, ITALY |  | 126,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
City of Industry, CA USA |  | 125,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Mississauga, ON CANADA |  | 120,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased
Elk Grove Village, IL USA |  | 115,000 |  | Global Institutional & Specialty |  | Leased
Biebesheim, GERMANY |  | 109,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Fort Worth, TX USA |  | 101,000 |  | Global Institutional & Specialty |  | Leased
Johannesburg, SOUTH AFRICA |  | 100,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Andover, UNITED KINGDOM | ​ | 99,762 | ​ | Global Industrial, Global Healthcare & Life Sciences | ​ | Owned
Pilar, ARGENTINA | ​ | 96,000 | ​ | Global Institutional & Specialty, Global Industrial | ​ | Owned
Hamilton, NEW ZEALAND |  | 96,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Konnagar, INDIA | ​ | 88,000 | ​ | Global Industrial |  | Owned
Kwinana, AUSTRALIA |  | 87,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Yangsan, KOREA |  | 85,000 |  | Global Industrial |  | Owned
Cuautitlan, MEXICO |  | 76,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned
Barueri, BRAZIL |  | 75,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Leased
Citereup, INDONESIA | ​ | 74,000 | ​ | Global Industrial | ​ | Owned
King of Prussia, PA | ​ | 74,000 | ​ | Global Healthcare & Life Sciences | ​ | Owned
Mullingar, IRELAND |  | 74,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased
Mosta, MALTA |  | 73,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased
Aubagne, FRANCE |  | 65,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased
Siegsdorf, GERMANY |  | 56,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned

24

Table of Contents

Location |  | Approximate Size (Sq. Ft.) |  | Segment |  | Majority Owned or Leased
Verona, ITALY |  | 55,000 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Owned
Guangzhou, CHINA |  | 55,000 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Navanakorn, THAILAND |  | 53,000 |  | Global Institutional & Specialty, Global Industrial |  | Leased
Lerma, MEXICO |  | 49,000 |  | Global Industrial |  | Owned
Maribor, SLOVENIA |  | 46,400 |  | Global Institutional & Specialty, Global Industrial |  | Owned
Leeds, UNITED KINGDOM |  | 25,000 |  | Global Institutional & Specialty |  | Owned
Baglan, UNITED KINGDOM |  | 24,400 |  | Global Institutional & Specialty, Global Healthcare & Life Sciences |  | Leased
Noda, JAPAN |  | 22,000 |  | Global Institutional & Specialty, Global Industrial, Global Healthcare & Life Sciences |  | Owned

​

Generally, our manufacturing facilities are adequate to meet our existing in-house production needs. We continue to invest in our plant sites to maintain viable operations and to add capacity as necessary to meet business imperatives.

​

Most of our manufacturing plants also serve as distribution centers. In addition, we operate distribution centers around the world, most of which are leased, and utilize third party logistics service providers to facilitate the distribution of our products and services.

​

Our corporate headquarters is comprised of a 17-story building that we own in St. Paul, Minnesota. We also own a 115-acre campus in Eagan, Minnesota that houses a significant research and development center, a data center and training facilities as well as several of our administrative functions. We also have a significant business presence in Naperville, Illinois, where our Water and Paper operating segments maintain their principal administrative offices and research center, as well as in Greensboro, North Carolina, where our Specialty operating segment maintains its principal administrative offices and a research center. Our Downstream operating segment leases administrative and research facilities in Sugar Land, Texas and maintains additional Company-owned research facilities in Fresno, Texas.

​

Significant regional administrative and/or research facilities are located in Campinas, Brazil; Leiden, Netherlands; and Pune, India, which we own, and in Dubai, UAE; Monheim, Germany; Singapore; Shanghai, China; and Zurich, Switzerland, which we lease. We also have a network of small leased sales offices in the United States and, to a lesser extent, in other parts of the world.

​

​

Item 3. Lega l Proceedings.

​

Discussion of legal proceedings is incorporated by reference from Part II, Item 8, Note 16, “Commitments and Contingencies,” of this Form 10-K and should be considered an integral part of Part I, Item 3, “Legal Proceedings.”

​

Discussion of other environmental-related legal proceedings is incorporated by reference from Part I, Item 1 above, under the heading “Environmental and Regulatory Considerations.”

​

​

Item 4. Mine Safety Disclosures.

​

Not applicable.

​

25

Table of Contents

​

PART II

​

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

​

Market Information

​

Our common stock is listed on the New York Stock Exchange under the symbol “ECL.” Our common stock is also traded on an unlisted basis on certain other United States exchanges.

​

Holders

​

On January 31, 2023, we had 5,031 holders of record of our Common Stock.

​

Issuer Purchases of Equity Securities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Total number of shares | ​ | Maximum number of |
​ | ​ | ​ | ​ | ​ | ​ | purchased as part of | ​ | shares that may yet be |
​ | ​ | Total number of | ​ | Average price paid | ​ | publicly announced | ​ | purchased under the |
Period | ​ | shares purchased (1) | ​ | per share (2) | ​ | plans or programs (3) | ​ | plans or programs (3) |
October 1-31, 2022 |  | 1,362 | ​ | ​ | $157.0872 | ​ | - |  | 3,404,297 | ​
November 1-30, 2022 |  | 487,200 | ​ | ​ | 147.8301 | ​ | 487,200 |  | 12,917,097 | ​
December 1-31, 2022 |  | 3,723 | ​ | ​ | 149.8621 | ​ | - |  | 12,917,097 | ​
Total |  | 492,285 | ​ | ​ | $147.8711 |  | 487,200 |  | 12,917,097 | ​

​

(1) | Includes 5,085 shares reacquired from employees and/or directors to satisfy the exercise price of stock options or shares surrendered to satisfy statutory tax obligations under our stock incentive plans.

​

(2) | The average price paid per share includes brokerage commissions associated with publicly announced plan purchases plus the value of such other reacquired shares.

​

(3) | As announced on February 24, 2015, our Board of Directors authorized the repurchase of up to 20,000,000 common shares. As announced on November 3, 2022, our Board of Directors authorized the repurchase of up to an additional 10,000,000 shares. Subject to market conditions, we expect to repurchase all shares under these authorizations, for which no expiration date has been established, in open market or privately negotiated transactions, including pursuant to Rule 10b5-1 and accelerated share repurchase program.

​

​

Item 6. [Reserved].

​

​

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

​

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

​

The discussion should be read in conjunction with the consolidated financial statements and related notes included in this Form 10-K. Our consolidated financial statements are prepared in accordance with U.S. GAAP. This discussion contains various Non-GAAP Financial Measures and also contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements and information set forth in the sections entitled “Non-GAAP Financial Measures” at the end of this MD&A, and “Forward-Looking Statements” and “Risk Factors” within Items 1 and 1A of this Form 10-K. We also refer readers to the tables within the section entitled “Results of Operations” of this MD&A for reconciliation information of Non-GAAP measures to U.S. GAAP.

​

​

26

Table of Contents

Comparability of Results

​

Purolite acquisition

​

In December 2021, we acquired Purolite for total consideration of $3.7 billion in cash, net of cash acquired. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions for pharmaceutical and industrial applications. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within our Life Sciences operating segment. Acquisition and integration charges are recorded within special (gains) and charges. The 2021 impacts of the Purolite acquisition including operating results, acquisition-related amortization and interest expense related to the transaction were also excluded from 2021 adjusted results.

​

ChampionX Transaction

​

In June 2020, we completed the previously announced separation of our Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

​

The ChampionX business met the criteria to be reported as discontinued operations because the separation of ChampionX was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we reported the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for 2020. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and 2020 balances have been revised accordingly to reflect continuing operations only.

​

Comparability of Reportable Segments

​

We have also made immaterial changes to our segment reporting, including the movement of certain customers and cost allocations between reportable segments.

​

Impact of Acquisitions and Divestitures

​

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, the results of our divested businesses from the twelve months prior to divestiture. Further, we have excluded the results of our Purolite business for all of 2022 to remain comparable to 2021 when Purolite’s results were excluded from adjusted results. As part of the separation of the ChampionX business, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

​

Fixed Currency Foreign Exchange Rates

​

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

​

​

​

27

Table of Contents

EXECUTIVE SUMMARY

​

In 2022, we delivered double-digit sales growth as we accelerated our pricing and drove volume growth. Our strong pricing increases offset continued significant delivered product cost increases on a dollar basis. Our team generated double-digit sales growth in the Institutional & Specialty, Industrial and Other segments while Healthcare & Life Sciences segment sales were stable. Operating income was stable, as accelerating pricing was offset by higher delivered product costs and investments in the business.

​

Sales

​

Reported sales increased 11% to $14.2 billion in 2022 from $12.7 billion in 2021. When measured in fixed rates of foreign currency exchange, fixed currency sales increased 16% compared to the prior year. Acquisition adjusted fixed currency sales increased 13% compared to the prior year.

​

Gross Margin

​

Our reported gross margin was 37.8% of sales for 2022, compared to our 2021 reported gross margin of 40.2%. Excluding the impact of special (gains) and charges and the 2021 impacts from the Purolite transaction included in cost of sales, our adjusted gross margin was 38.2% in 2022 and 40.9% in 2021. Our gross profit increased as our strong pricing exceeded substantial delivered product cost inflation.

​

Operating Income

​

Reported operating income remained stable at $1.6 billion in 2022, compared to $1.6 billion in 2021. Adjusted operating income, excluding the impact of special (gains) and charges and the 2021 impacts of the Purolite transaction, decreased 1% in 2022, as strong pricing offset substantial delivered product inflation and investments in the business. When measured in fixed rates of foreign currency exchange, adjusted fixed currency operating income increased 4% in 2022.

​

Earnings from Continuing Operations Attributable to Ecolab Per Common Share (“EPS”)

​

Reported diluted EPS decreased 3% to $3.81 in 2022 compared to $3.91 in 2021. Special (gains) and charges had an impact on both years. Special (gains) and charges in 2022 were driven primarily by restructuring and pension settlement expense and 2021 was driven primarily by COVID-19 related charges, restructuring charges and pension settlement expense. Adjusted diluted EPS, which exclude the impact of special (gains) and charges, the 2021 impacts of the Purolite transaction and discrete tax items decreased 4% to $4.49 in 2022 compared to $4.69 in 2021, as unfavorable foreign currency translation and increases in interest expense further offset our operating income performance.

​

Balance Sheet

​

We remain committed to maintaining “A” range ratings metrics over the long-term, supported by our current credit ratings of A-/A3/A- by Standard & Poor’s, Moody’s Investor Services and Fitch, respectively. Our strong balance sheet has allowed us continued access to capital at attractive rates.

​

Cash Flow

​

Cash flow from continuing operations operating activities was $1.8 billion in 2022 compared to $2.1 billion in 2021. We continued to generate strong cash flow from operations, allowing us to fund our ongoing operations, investments in our business, acquisitions, debt repayments, pension obligations and return cash to our shareholders through share repurchases and dividend payments.

​

Dividends

​

Dividends declared per common share in 2022 was $2.06 per share. In December 2022 we increased our quarterly cash dividend by 4% to $0.53 per share, representing our 31st consecutive annual dividend rate increase. We have paid cash dividends on our common shares for 86 consecutive years. Our outstanding dividend history reflects our long term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

​

​

​

​

28

Table of Contents

CRITICAL ACCOUNTING ESTIMATES

​

Our consolidated financial statements are prepared in accordance with U.S. GAAP. We have adopted various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 2 of the Notes to the Consolidated Financial Statements (“Notes”).

​

Preparation of our consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions to be made about matters that are highly uncertain at the time the accounting estimate is made, and (2) different estimates that we reasonably could have used for the accounting estimate in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, have a material impact on the presentation of our financial condition or results of operations.

​

In March 2020, COVID-19 was declared a pandemic by the World Health Organization. As the impact of the pandemic continues to evolve, estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require judgment. These estimates and assumptions may change in future periods and will be recognized in the consolidated financial information as new events occur and additional information becomes known. To the extent actual results differ materially from those estimates and assumptions, our future financial statements could be affected.

​

Besides estimates that meet the “critical” estimate criteria, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues or expenses as well as disclosures of contingent assets and liabilities. Estimates are based on experience and other information available prior to the issuance of the financial statements. Materially different results can occur as circumstances change and additional information becomes known, even from estimates not deemed critical. Our critical accounting estimates include the following:

​

Revenue Recognition

​

Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing service. Revenue from product and sold equipment is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment. Revenue from service and leased equipment is recognized when the services are provided, or the customer receives the benefit from the leased equipment, which is over time. Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized over time using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue for leased equipment is accounted for under Topic 842 Leases and recognized on a straight-line basis over the length of the lease contract.

​

Our revenue policies do not provide for general rights of return. We record estimated reductions to revenue for customer programs and incentive offerings including pricing arrangements, promotions and other volume-based incentives based primarily on historical experience and anticipated performance over the contract period. Depending on market conditions, we may increase customer incentive offerings, which could reduce gross profit margins over the term of the incentive. We also record estimated reserves for product returns and credits based on specific circumstances and credit conditions. We record an allowance for uncollectible accounts based on our estimates of expected future credit losses.

​

The revenue standard can be applied to a portfolio of contracts with similar characteristics if it is reasonable that the effects of applying the standard at the portfolio would not be significantly different than applying the standard at the individual contract level. We apply the portfolio approach primarily within each operating segment by geographical region. Application of the portfolio approach was focused on those characteristics that have the most significant accounting consequences in terms of their effect on the timing of revenue recognition or the amount of revenue recognized. We determined the key criteria to assess with respect to the portfolio approach, including the related deliverables, the characteristics of the customers and the timing and transfer of goods and services, which most closely aligned within the operating segments. In addition, the accountability for the business operations, as well as the operational decisions on how to go to market and the product offerings, are performed at the operating segment level. For additional information on revenue recognition, refer to Note 18.

​

29

Table of Contents

Litigation and Environmental Liabilities

​

Our business and operations are subject to extensive environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use and handling of hazardous substances, waste disposal and the investigation and remediation of soil and groundwater contamination. Some risk of environmental liability is inherent in our operations.

​

We record liabilities related to pending litigation, environmental claims and other contingencies when a loss is probable and can be reasonably estimated. Estimates used to record such liabilities are based on our best estimate of probable future costs. We record the amounts that represent the points in the range of estimates that we believe are most probable or the minimum amount when no amount within the range is a better estimate than any other amount. Potential insurance reimbursements generally are not anticipated in our accruals for environmental liabilities or other insured losses. Expected insurance proceeds are recorded as receivables when recovery is deemed certain. While the final resolution of litigation and environmental contingencies could result in amounts different than current accruals, and therefore have an impact on our consolidated financial results in a future reporting period, we believe the ultimate outcome will not have a significant impact on our consolidated financial position. For additional information on our commitments and contingencies, refer to Note 16.

​

Actuarially Determined Liabilities

​

Pension and Postretirement Healthcare Benefit Plans

​

The measurement of our pension and postretirement benefit obligations are dependent on a variety of assumptions determined by management and used by our actuaries. These assumptions affect the amount and timing of future pension contributions, benefit payments and expense or income recognized.

​

The significant assumptions used in developing the required estimates are the discount rates, expected returns on assets, projected salary and health care cost increases and mortality tables.

​

● | The discount rate assumptions for our U.S. plans are assessed using a yield curve constructed from a subset of bonds yielding greater than the median return from a population of non-callable, corporate bonds that have an average rating of AA when averaging available Moody’s Investor Services, Standard & Poor’s and Fitch ratings. The discount rates are calculated by matching each plans’ projected cash flows to the bond yield curve. For 2022 and 2021, we measured service and interest costs by applying the specific spot rates along that yield curve to the plans’ liability cash flows. We believe this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. In determining our U.S. pension obligations for 2022, our weighted-average discount rate increased to 5.17% from 2.86% at year-end 2021. In determining our U.S. postretirement health care obligation for 2022, our weighted-average discount rate increased to 5.14% from 2.75% at year-end 2021.

​

● | The expected rate of return on plan assets reflects asset allocations, investment strategies and views of investment advisors, and represents our expected long-term return on plan assets. Our weighted-average expected returns on U.S. plan assets used in determining the U.S. pension and U.S. postretirement health care expenses was 7.00% for 2022, 7.00% for 2021 and 7.25% for 2020.

​

● | Projected salary is based on our long-term actual experience, the near-term outlook and assumed inflation. Our weighted-average projected salary increase used in determining the U.S. pension expenses was 4.03% for 2022, 2021 and 2020.

​

● | For postretirement benefit measurement purposes as of December 31, 2022, the annual rates of increase in the per capita cost of covered health care were assumed to be 6.75% for pre-65 costs. Post-65 costs are no longer used. The rates are assumed to decrease each year until they reach 4.5% in 2032 and remain at those levels thereafter.

​

● | The Company uses mortality tables appropriate in the circumstances, which generally are the recently available mortality tables as of the respective U.S. and international measurement dates. Our year-end U.S. valuations reflect mortality tables that estimate the impacts of COVID in an endemic state. This represents a change from prior year when the impact of COVID on future mortality could not be reasonably estimated.

​

The effects of actual results differing from our assumptions, as well as changes in assumptions, are reflected in the unrecognized gains or losses and amortized into earnings in the future. Significant differences in actual experience or significant changes in assumptions may materially affect future pension and other postretirement obligations and income or expense. The unrecognized net losses on our U.S. qualified and non-qualified pension plans increased to $412 million as of December 31, 2022 from $397 million as of December 31, 2021 (both before tax), primarily due to lower actual return on assets partially offset by current year net actuarial gains.

30

Table of Contents

The effect of a decrease in the discount rate or decrease in the expected return on assets assumption as of December 31, 2022, on the December 31, 2022 defined benefit obligation and 2023 expense is shown below, assuming no changes in benefit levels. Expense amounts reflect the accounting for gains or losses as a component of other comprehensive income or expense and recognition of the impacts into earnings over time:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Effect on U.S. Pension Plans
​ | ​ | ​ | ​ | Increase in | ​ | Higher
​ | ​ | Assumption | ​ | Recorded | ​ | 2023
(millions) | ​ | Change | ​ | Obligation | ​ | Expense
Discount rate |  | -.25 pts | ​ | ​ | $42.4 | ​ | ​ | ​ | $1.1 | ​
Expected return on assets |  | -.25 pts | ​ | ​ | N/A | ​ | ​ | ​ | (4.7) | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Effect on U.S. Postretirement
​ | ​ | Health Care Benefits Plans
​ | ​ | ​ | ​ | Increase in | ​ | Higher
​ | ​ | Assumption | ​ | Recorded | ​ | 2023
(millions) | ​ | Change | ​ | Obligation | ​ | Expense
Discount rate |  | -.25 pts |  | ​ | $2.7 | ​ |  | ​ | $- | ​
Expected return on assets |  | -.25 pts | ​ |  | N/A | ​ | ​ | ​ | - | ​

​

Our international pension obligations and underlying plan assets represent approximately one third of our global pension plans, with the majority of the amounts held in the U.K. and Eurozone countries. We use assumptions similar to our U.S. plan assumptions to measure our international pension obligations, however, the assumptions used vary by country based on specific local country requirements and information.

​

Refer to Note 17 for further discussion concerning our accounting policies, estimates, funded status, contributions and overall financial positions of our pension and postretirement plan obligations.

​

Self-Insurance

​

Globally we have insurance policies with varying deductible levels for property and casualty losses. We are insured for losses in excess of these deductibles, subject to policy terms and conditions and have recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. We are self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. We determine our liabilities for claims on an actuarial basis.

​

Income Taxes

​

Judgment is required to determine the annual effective income tax rate, deferred tax assets and liabilities, valuation allowances recorded against net deferred tax assets and uncertain tax positions.

​

Effective Income Tax Rate

​

Our effective income tax rate is based on annual income, statutory tax rates and tax planning available in the various jurisdictions in which we operate. Our annual effective income tax rate includes the impact of reserve provisions. We recognize the amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority. We adjust these reserves in light of changing facts and circumstances.

​

Tax regulations require items to be included in our tax returns at different times than the items are reflected in our financial statements. As a result, the effective income tax rate reflected in our financial statements differs from that reported in our tax returns. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense.

​

Deferred Tax Assets and Liabilities and Valuation Allowances

​

Deferred tax assets and liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities, applying enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Based on the evaluation of available evidence, both positive and negative, we recognize tax assets, such as net operating loss carryforwards and tax credit carryforwards, to the extent that realizing these benefits is considered to be more likely than not. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes.

​

31

Table of Contents

Uncertain Tax Positions

​

A number of years may elapse before a particular tax matter, for which we have established a liability for uncertain tax position, is audited and finally resolved. The number of tax years with open tax audits varies depending on the tax jurisdiction. The Internal Revenue Service (“IRS”) has completed examinations of our U.S. federal income tax returns through 2016 and the years 2017 through 2020 are currently under audit. In addition to the U.S. federal examinations, we have ongoing audit activity in several U.S. state and foreign jurisdictions.

​

The tax positions we take are based on our interpretations of tax laws and regulations in the applicable federal, state and international jurisdictions. We believe our tax returns properly reflect the tax consequences of our operations, and our liabilities for uncertain tax positions are appropriate and sufficient for the positions taken. Because of the uncertainty of the final outcome of these examinations, we have estabilished a liability for potential reductions of tax benefits (including related interest and penalties) for amounts that do not meet the more-likely-than-not thresholds for recognition and measurement as required by authoritative guidance. The liability for uncertain tax positions is reviewed throughout the year, taking into account new legislation, regulations, case law and audit results. Settlement of any particular issue could result in offsets to other balance sheet accounts, cash payments or receipts and/or adjustments to tax expense. Liabilities for uncertain tax positions are presented in the Consolidated Balance Sheets within other non-current liabilities. Our gross liability for uncertain tax positions was $24.9 million and $25.1 million as of December 31, 2022 and 2021, respectively. For additional information on income taxes refer to Note 13.

​

Long-Lived Assets, Intangible Assets and Goodwill

​

Long-Lived and Amortizable Intangible Assets

​

Purchased long-lived and amortizable intangible assets not acquired as part of a business combination are recorded as of their acquisition date at cost, whereas long-lived and amortizable assets acquired as part of a business combination are recorded as of their acquisition date at their fair values based on the fair value requirements defined in U.S. GAAP. This requires us to make significant estimates and assumptions relating to the present value of its future cash flows, such as growth rates, royalty rates or discount rates.

​

We review our long-lived and amortizable intangible assets, the net value of which was $6.3 billion and $6.8 billion as of December 31, 2022 and 2021, respectively, for impairment when significant events or changes in business circumstances indicate that the carrying amount of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which asset or asset groups are being used or history of operating or cash flow losses associated with the use of the asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset’s or assets group’s carrying amount over its estimated fair value.

​

We use the straight-line method to recognize amortization expense related to our amortizable intangible assets, including our customer relationships. We consider various factors when determining the appropriate method of amortization for our customer relationships, including projected sales data, customer attrition rates and length of key customer relationships.

​

Globally, we have a broad customer base. Our retention rate of significant customers has aligned with our acquisition assumptions, including the customer bases acquired from our Nalco, Anios, CID Lines and Purolite transactions, which make up the majority of our unamortized customer relationships. Our historical retention rates, coupled with our consistent track record of keeping long-term relationships with our customers, supports our expectation of consistent sales generation for the foreseeable future from the acquired customer bases. If our customer retention rates or other post-acquisition operational activities change materially, we would evaluate the financial impacts and significance of the events given rise to the change which could result in impairment of our customer relationship intangible assets, or absent an impairment, an acceleration of amortization expense.

​

In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets.

​

Goodwill and Indefinite Life Intangible Assets

​

Goodwill arises from our acquisitions and represents the excess of the fair value of the purchase consideration exchanged over the fair value of net assets acquired. We had total goodwill of $8.0 billion and $8.1 billion as of December 31, 2022 and 2021, respectively. We test our goodwill for impairment at the reporting unit level. Our reporting units are largely our operating segments. Following the acquisition of Purolite on December 1, 2021, our Life Sciences Operating Segment consists of the Purolite and Global Life Sciences Reporting Units. We assess goodwill for impairment on an annual basis during the second quarter. If circumstances change or events occur that demonstrate it is more likely than not that the carrying amount of a reporting unit exceeds its fair value, we complete an interim goodwill impairment assessment of that reporting unit prior to the next annual assessment. If the results of an annual or interim goodwill impairment assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, we will recognize an impairment loss for the amount by which the reporting unit’s carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

​

32

Table of Contents

For our annual 2022 goodwill impairment assessment, we completed our impairment assessment for eleven of our twelve reporting units using discounted cash flow analyses that incorporated assumptions regarding future growth rates, terminal values and discount rates. Our goodwill impairment assessments for 2022 indicated the estimated fair values of each of these eleven reporting units exceeded the carrying amounts of the respective reporting units by a significant margin. Given the recent acquisition of Purolite, our annual goodwill impairment assessment of the Purolite Reporting Unit was qualitative in nature and considered information regarding its operations, financial performance and the macroeconomic environment. After weighting both positive and negative information, it is more likely than not that the fair value of the Purolite Reporting Unit exceeds its carrying amount. We evaluate the need to complete interim goodwill impairment assessments when significant events or changes in business circumstances indicate that it is more likely than not that the carrying amount of a reporting unit may be higher than its fair value. No events were noted during the second half of 2022 that required completion of an interim goodwill impairment assessment in the second half of 2022 for any of our twelve reporting units. There has been no impairment of goodwill in any of the periods presented.

​

The Nalco trade name is our only indefinite-lived intangible asset, which is tested for impairment on an annual basis during the second quarter. For our annual 2022 indefinite-lived intangible asset impairment assessment, we completed our impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions regarding future sales projections, royalty rates and discount rates. Our Nalco tradename impairment assessment for 2022 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. No events were noted during the second half of 2022 that required completion of an interim impairment assessment of our Nalco trade name in the second half of 2022. There has been no impairment of the Nalco trade name intangible since it was acquired.

​

​

RESULTS OF OPERATIONS

​

Net Sales

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Percent Change
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020 | ​ | 2022 | ​ | 2021
Product and equipment sales | ​ | ​ | $11,446.2 | ​ |  | ​ | $10,153.3 | ​ |  | ​ | $9,466.6 | ​ |  | ​ | ​ | ​ | ​ | ​
Service and lease sales | ​ | ​ | 2,741.6 | ​ | ​ | ​ | 2,579.8 | ​ | ​ | ​ | 2,323.6 | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported GAAP net sales | ​ | ​ | 14,187.8 | ​ | ​ | ​ | 12,733.1 | ​ | ​ | ​ | 11,790.2 | ​ | ​ | 11 | % | ​ | 8 | %
2021 impact of Purolite on net sales | ​ | ​ | - | ​ | ​ | ​ | 12.0 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted net sales | ​ | ​ | 14,187.8 | ​ | ​ | ​ | 12,721.1 | ​ | ​ | ​ | 11,790.2 | ​ | ​ | 12 | % | ​ | 8 | %
Effect of foreign currency translation | ​ |  | 285.3 | ​ |  |  | (249.5) | ​ | ​ |  | (15.4) | ​ | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted fixed currency sales | ​ | ​ | $14,473.1 | ​ | ​ | ​ | $12,471.6 | ​ | ​ | ​ | $11,774.8 | ​ | ​ | 16 | % | ​ | 6 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​

​

The percentage components of the year-over-year sales change are shown below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(percent) | ​ | 2022 | ​ | 2021
Volume | ​ |  | ​ | 2 | % | ​ |  | 3 | %
Price changes | ​ |  | ​ | 10 | ​ | ​ |  | 2 | ​
Acquisition adjusted fixed currency sales change | ​ |  | ​ | 13 | ​ | ​ |  | 5 | ​
Acquisitions & divestitures | ​ |  | ​ | 3 | ​ | ​ |  | 1 | ​
Fixed currency sales change | ​ |  | ​ | 16 | ​ | ​ |  | 6 | ​
Foreign currency translation | ​ |  | ​ | (4) | ​ | ​ |  | 2 | ​
Reported GAAP net sales change | ​ |  | ​ | 11 | % | ​ |  | 8 | %

​

Amounts do not necessarily sum due to rounding.

​

Cost of Sales (“COS”) and Gross Profit Margin (“Gross Margin”)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | 2022 | ​ | 2021 | ​ | 2020
​ | ​ | ​ | ​ |  | Gross | ​ | ​ | ​ | ​ |  | Gross | ​ | ​ | ​ | ​ |  | Gross
(millions/percent) | ​ | COS | ​ | ​ | Margin | ​ | ​ | COS | ​ | ​ | Margin | ​ | ​ | COS | ​ | ​ | Margin
Product and equipment cost of sales | ​ | $7,212.8 | ​ | ​ | ​ | ​ | ​ | ​ | $6,100.9 | ​ | ​ | ​ | ​ | ​ | ​ | $5,481.3 | ​ | ​ | ​ | ​
Service and lease cost of sales | ​ | 1,618.2 | ​ | ​ | ​ | ​ | ​ | ​ | 1,514.9 | ​ | ​ | ​ | ​ | ​ | ​ | 1,424.5 | ​ | ​ | ​ | ​
Reported GAAP COS and gross margin | ​ | 8,831.0 | ​ | ​ | 37.8 | % | ​ | ​ | 7,615.8 | ​ | ​ | 40.2 | % | ​ | ​ | 6,905.8 | ​ | ​ | 41.4 | %
Special (gains) and charges | ​ | 69.9 | ​ | ​ | ​ | ​ | ​ | ​ | 93.9 | ​ | ​ | ​ | ​ | ​ | ​ | 48.2 | ​ |  | ​ | ​
2021 impact of Purolite on COS | ​ | - | ​ | ​ | ​ | ​ | ​ | ​ | 7.6 | ​ | ​ | ​ | ​ | ​ | ​ | - | ​ | ​ | ​ | ​
Non-GAAP adjusted COS and gross margin | ​ | $8,761.1 | ​ | ​ | 38.2 | % | ​ | ​ | $7,514.3 | ​ | ​ | 40.9 | % | ​ | ​ | $6,857.6 | ​ | ​ | 41.8 | %

​

Our COS values and corresponding gross margin are shown above. Our gross margin is defined as sales less cost of sales divided by sales.

​

33

Table of Contents

Our reported gross margin was 37.8%, 40.2%, and 41.4% for 2022, 2021 and 2020, respectively. Our 2022, 2021 and 2020 reported gross margins were negatively impacted by special (gains) and charges of $69.9 million, $93.9 million, and $48.2 million, respectively. Special (gains) and charges items impacting COS are shown within the “Special (Gains) and Charges” table below.

​

Excluding the impact of special (gains) and charges and the 2021 impacts of the Purolite transaction, our 2022 adjusted gross margin was 38.2% compared against a 2021 adjusted gross margin of 40.9%. The decrease primarily reflected accelerating pricing that was more than offset by higher delivered product cost and unfavorable mix.

​

Excluding the impact of special (gains) and charges and the 2021 impacts of the Purolite transaction, our adjusted gross margin was 40.9% and 41.8% for 2021 and 2020, respectively. The decrease primarily reflected increased pricing and higher volumes which were more than offset by significantly higher delivered product costs and supply constraints.

​

Selling, General and Administrative Expenses (“SG&A”)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(percent) |  | 2022 | ​ | 2021 | ​ | 2020
SG&A Ratio |  | 25.8 | % | ​ | 26.8 | % | ​ | 28.1 | %

​

The decreased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2022 against 2021 was driven primarily by strong productivity including cost savings initiatives, partially offset by higher cost of compensation compared to last year. The decreased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2021 against 2020 was driven primarily by higher net sales, cost savings initiatives and reduction in bad debt, partially offset by higher variable compensation compared to last year.

​

Special (Gains) and Charges

​

Special (gains) and charges reported on the Consolidated Statements of Income included the following items:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
Cost of sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ |  | $21.4 | ​ | ​ |  | $24.7 | ​ | ​ | ​ | $7.4 | ​
Acquisition and integration activities | ​ | ​ | 25.0 | ​ | ​ | ​ | 4.2 | ​ | ​ | ​ | 3.9 | ​
COVID-19 activities, net | ​ | ​ | 16.3 | ​ | ​ | ​ | 64.7 | ​ | ​ | ​ | 12.5 | ​
Russia/Ukraine | ​ | ​ | 7.2 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other | ​ | ​ | - | ​ | ​ | ​ | 0.3 | ​ | ​ | ​ | 24.4 | ​
Cost of sales subtotal | ​ |  | 69.9 | ​ | ​ |  | 93.9 | ​ |  |  | 48.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ |  | 85.8 | ​ | ​ |  | 11.9 | ​ | ​ | ​ | 71.4 | ​
Acquisition and integration activities | ​ | ​ | 14.5 | ​ | ​ | ​ | 29.9 | ​ | ​ | ​ | 8.5 | ​
Disposal and impairment activities | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 41.4 | ​
COVID-19 activities, net | ​ | ​ | 10.2 | ​ | ​ | ​ | 42.4 | ​ | ​ | ​ | 23.6 | ​
Russia/Ukraine | ​ | ​ | 5.9 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other | ​ |  | 24.1 | ​ | ​ |  | 18.4 | ​ | ​ | ​ | 34.7 | ​
Special (gains) and charges subtotal | ​ |  | 140.5 | ​ | ​ |  | 102.6 | ​ |  |  | 179.6 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income subtotal | ​ | ​ | 210.4 | ​ | ​ | ​ | 196.5 | ​ | ​ | ​ | 227.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other (income) expense | ​ | ​ | 50.6 | ​ | ​ | ​ | 37.2 | ​ | ​ | ​ | 0.4 | ​
Interest expense, net | ​ | ​ | - | ​ | ​ | ​ | 33.1 | ​ | ​ | ​ | 83.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total special (gains) and charges | ​ | ​ | $261.0 | ​ | ​ | ​ | $266.8 | ​ | ​ | ​ | $312.0 | ​

​

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

​

Restructuring Activities

​

Restructuring activities are primarily related to the Europe Program, Institutional Advancement Program, Accelerate 2020 and other immaterial restructuring programs which are described below. These activities have been included as a component of cost of sales, special (gains) and charges, and other (income) expense on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

​

Further details related to our restructuring charges are included in Note 3.

​

​

​

​

​

34

Table of Contents

Europe Program

​

In November 2022 we approved a Europe Program (the “Europe Program”) targeting $80 million of annualized pre-tax savings after completion of the program. In connection with these actions, we expect to incur pre-tax charges of $130 million ($110 million after tax) or $0.38 per diluted share. The Europe Program charges are expected to be primarily cash expenditures related to severance and asset disposals. Actual costs may vary from these estimates depending on actions taken.

​

In 2022 we recorded total restructuring charges of $67.2 million ($56.0 million after tax) or $0.20 per diluted share primarily related to severance. The liability related to the Europe Program was $62.0 million as of December 31, 2022 and is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

​

The Europe Program has delivered $5 million of cumulative cost savings with estimated annual cost savings of $80 million in continuing operations by 2024.

​

On February 14, 2023, we expanded our previously announced Europe cost savings program to focus on our Institutional and Healthcare businesses in other regions. In connection with the expanded program, we now expect to incur pre-tax charges of $195 million ($150 million after tax) or $0.52 per diluted share. We expect that these restructuring actions will be completed by 2024. Program actions include headcount reductions from terminations, not filing certain positions and facility closures. The expanded program charges are expected to be primarily cash expenditures related to severance and asset disposals. We now expect an estimated annual total cost savings of $175 million by 2024.

​

Institutional Advancement Program

​

We approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance our Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging our ongoing investments in digital technology. In February 2021, we expanded the Institutional Plan, and expect that these restructuring charges will be completed in 2023, with total anticipated costs of $70 million ($55 million after tax) or $0.19 per diluted share. The remaining costs are expected to be primarily cash expenditures for severance and non-cash costs related to equipment disposals. Actual costs may vary from these estimates depending on actions taken.

​

In 2022 and 2021, we recorded total restructuring charges of $6.3 million ($4.8 million after tax) or $0.02 per diluted share and $12.6 million ($10.2 million after tax) or $0.04 per diluted share, respectively, primarily related to severance, disposals of equipment and office closures. We have recorded $54.1 million ($41.4 million after tax), or $0.14 per diluted share of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $1.9 million as of December 31, 2022 and is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

​

The Institutional Plan has delivered $49 million of cumulative cost savings.

​

Accelerate 2020

​

During 2018, we formally commenced a restructuring plan Accelerate 2020 (“the A2020 Plan”), to leverage technology and system investments and organizational changes. The goals of the Plan are to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilities and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. We completed the plan with actual costs of $254 million ($198 million after tax), or $0.69 per diluted share.

​

We recorded restructuring charges of $9.9 million ($8.4 million after tax) or $0.03 per diluted share, $5.3 million ($6.2 million after tax) or $0.02 per diluted share and $41.8 million ($33.0 million after tax) or $0.11 per diluted share in 2022, 2021 and 2020, respectively. Of these expenses, $0.3 million ($0.2 million after tax) or less than $0.01 per diluted share during 2020 is recorded in other (income) expense and related to pension settlements and curtailments. The liability related to the Plan was $18.1 million and $32.7 million as of December 31, 2022 and 2021, respectively. We have recorded $254.4 million ($198.4 million after tax), or $0.69 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

​

The Accelerate 2020 Plan has delivered $315 million of cumulative cost savings.

​

Other Restructuring Activities

​

During 2022, we incurred restructuring charges of $23.8 million ($17.9 million after tax), or $0.06 per diluted share, related to other immaterial restructuring activity. The charges primarily related to severance and asset write-offs.

​

During 2021, we incurred restructuring charges of $18.7 million ($17.0 million after tax), or $0.06 per diluted share, related to other immaterial restructuring activity. The charges primarily related to severance and asset write-offs.

​

During 2020, we incurred restructuring charges of $1.8 million ($1.2 million after tax), or less than $0.01 per diluted share, related to other immaterial restructuring plan. The charges are comprised of severance, facility closure costs, including asset disposals, and consulting fees.

​

35

Table of Contents

The restructuring liability balance for all other restructuring plans excluding the Europe Program, A2020 Plan and the Institutional Plan were $23.2 million and $4.6 million as of December 31, 2022 and 2021, respectively. The increase in liability was driven primarily by severance expense. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2022 related to all other restructuring plans excluding the Europe Program, A2020 and Institutional Plan were $5.2 million.

​

Acquisition and integration related costs

​

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2022 include $14.5 million ($11.4 million after tax) or $0.04 per diluted share. Charges are related primarily to the Purolite Corporation (“Purolite”) acquisition and consist of integration related costs and advisory and legal fees. Acquisition and integration related costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2022 include $25.0 million ($19.6 million after tax) or $0.07 per diluted share. Charges are related primarily to the recognition of fair value step-up in the Purolite inventory and other integration costs.

​

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2021 include $29.9 million ($23.5 million after tax) or $0.08 per diluted share. Charges are primarily related to the Purolite acquisition and consisted of deal costs, integration costs and advisory and legal fees. Acquisition and integration related costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2021 include $4.2 million ($3.3 million after tax) or $0.01 per diluted share and are related to the recognition of fair value step-up in the Purolite inventory. In conjunction with its acquisitions, we incurred $0.8 million ($0.6 million after tax), or less than $0.01 per diluted share, of special (gains) and charges reported in interest expense in 2021.

​

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2020 include $8.5 million ($6.9 million after tax) or $0.02 per diluted share. Charges are related to Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), Bioquell PLC (“Bioquell”) and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs and advisory and legal fees. Acquisition and integration related costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2020 include $3.9 million ($3.2 million after tax) or $0.01 per diluted share and are related to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility. In conjunction with our acquisitions, we incurred $0.7 million ($0.6 million after tax), or less than $0.01 per diluted share, of special (gains) and charges reported in interest expense in 2020.

​

Disposal and impairment charges

​

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statements of Income include $41.4 million ($41.5 million after tax) or $0.14 per diluted share in the 2020. During 2020, we recorded a $28.6 million ($28.6 million after tax) or $0.10 per diluted share impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, we recorded charges of $12.8 million ($12.9 million after tax) or $0.04 per diluted share related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees during 2020. Further information related to the disposal is included in Note 4.

​

COVID-19 activities

​

We have recorded inventory reserves of $15 million and $60 million during 2022 and 2021, respectively, for excess sanitizer inventory and estimated disposal costs. During 2022, 2021 and 2020, we recorded charges of $2.4 million, $36.8 million and $57.1 million, respectively, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $9.8 million, $16.5 million and $2.4 million related to employee COVID-19 testing and related expenses during 2022, 2021 and 2020, respectively. In addition, we received subsidies and government assistance, which were recorded as a special (gain) of ($0.7) million, ($6.2) million and ($23.4) million during 2022, 2021 and 2020, respectively. COVID-19 pandemic charges are recorded in product and equipment cost of sales, service and lease cost of sales, and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges related to COVID-19 pandemic were $20.2 million or $0.07 per diluted share, $81.3 million or $0.28 per diluted share and $27.4 million or $0.09 per diluted share during 2022, 2021 and 2020, respectively.

​

Russia/Ukraine

​

In light of Russia’s invasion of Ukraine and the sanctions against Russia by the United States and other countries, we have made the determination that we will limit our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We incurred charges of $13.1 million ($12.6 million after tax) or $0.04 per diluted share during 2022, primarily related to recoverability risk of certain assets in both Russia and Ukraine.

​

Other operating activities

​

Other special charges of $24.1 million ($18.2 million after tax) or $0.06 per diluted share in 2022, $18.4 million ($14.1 million after tax) or $0.05 per diluted share in 2021 and $34.7 million ($33.9 million after tax) or $0.12 per diluted share recorded in 2020 relate primarily to certain legal charges, which are recorded in special (gains) and charges on the Consolidated Statements of Income. In 2020, we recorded special charges of $24.4 million ($16.0 million after tax) or $0.06 per diluted share in product and equipment cost of sales on the Consolidated Statements of Income related to a Healthcare product recall in Europe.

​

36

Table of Contents

We also recorded during 2020 a $7.2 million or $0.02 per diluted share, special charge related to the separation of ChampionX as a tax expense on the Consolidated Statements of Income.

​

Other (income) expense

​

During 2022 and 2021, we incurred settlement expense recorded in other (income) expense on the Consolidated Statements of Income of $50.6 million ($38.2 million after tax) or $0.13 per diluted share and $37.2 million ($28.7 million after tax) or $0.10 per diluted share, respectively, related to U.S. pension plan lump-sum payments to retirees.

​

Interest expense, net

​

During 2021 and 2020, we recorded special charges of $32.3 million ($28.4 million after tax) or $0.10 per diluted share and $83.1 million ($64.0 million after tax) or $0.22 per diluted share, respectively, in interest expense on the Consolidated Statements of Income related to debt issuance and refinancing charges.

​

Operating Income and Operating Income Margin

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | Percent Change
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020 | ​ | ​ | 2022 | ​ | 2021
Reported GAAP operating income | ​ | ​ | $1,562.5 | ​ | ​ | ​ | $1,598.6 | ​ | ​ | ​ | $1,395.7 | ​ | ​ | ​ | ​ | (2) | % | ​ | ​ | 15 | %
Special (gains) and charges |  | ​ | 210.4 | ​ | ​ | ​ | 196.5 | ​ | ​ | ​ | 227.8 | ​ | ​ | ​ |  | ​ | ​ | ​ |  | ​ | ​
2021 impact of Purolite on operating income | ​ | ​ | ​ | ​ | ​ | ​ | 3.8 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted operating income |  | ​ | 1,772.9 | ​ | ​ | ​ | 1,798.9 | ​ | ​ | ​ | 1,623.5 | ​ | ​ | ​ |  | (1) | ​ | ​ |  | 11 | ​
Effect of foreign currency translation |  | ​ | 50.1 | ​ | ​ | ​ | (47.5) | ​ | ​ | ​ | (9.8) | ​ | ​ | ​ |  | ​ | ​ | ​ |  | ​ | ​
Non-GAAP adjusted fixed currency operating income | ​ | ​ | $1,823.0 | ​ | ​ | ​ | $1,751.4 | ​ | ​ | ​ | $1,613.7 | ​ | ​ | ​ | ​ | 4 | % | ​ | ​ | 9 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(percent) |  | 2022 | ​ | 2021 | ​ | 2020 | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported GAAP operating income margin | ​ | ​ | 11.0 | % | ​ | ​ | 12.6 | % | ​ | ​ | 11.8 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted operating income margin | ​ | ​ | 12.5 | % | ​ | ​ | 14.1 | % | ​ | ​ | 13.8 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted fixed currency operating income margin | ​ | ​ | 12.6 | % | ​ | ​ | 14.0 | % | ​ | ​ | 13.7 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by sales.

​

Our reported operating income decreased 2% when comparing 2022 to 2021 primarily driven by accelerating pricing covering substantially higher delivered product costs, which was offset by investments in the business. Our reported operating income increased 15% when comparing 2021 to 2020 primarily driven by increased pricing and higher volume which more than offset significantly higher delivered product costs and supply constraints and higher variable compensation compared to last year. Our reported operating income for 2022, 2021 and 2020 was impacted by special (gains) and charges. Excluding the impact of special (gains) and charges and the 2021 impacts of the Purolite transaction, 2022 adjusted operating income decreased 1% when compared to 2021 adjusted operating income and 2021 adjusted operating income increased 11% when compared to 2020 adjusted operating income.

​

Other (Income) Expense

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020
Reported GAAP other (income) expense | ​ | ​ | ($24.5) | ​ | ​ | ​ | ($33.9) | ​ | ​ | ​ | ($55.9)
Special (gains) and charges | ​ | ​ | 50.6 | ​ | ​ |  | 37.2 | ​ | ​ |  | 0.4
Non-GAAP adjusted other (income) expense | ​ | ​ | ($75.1) | ​ | ​ | ​ | ($71.1) | ​ | ​ | ​ | ($56.3)

​

Our reported other income was $24.5 million, $33.9 million and $55.9 million in 2022, 2021 and 2020, respectively. Other (income) expense decreased when comparing 2022 against 2021 primarily due to increased pension settlement charges in 2022 as a result of a higher volume of pension settlement activity and higher interest costs associated with rising interest rates throughout 2022. Other (income) expense decreased when comparing 2021 against 2020 reflecting lower interest costs associated with future payments of employee pension obligations. Excluding the impact of settlements and curtailments recorded in special (gains) and charges during 2022, 2021 and 2020, our adjusted other income was $75.1 million, $71.1 million and $56.3 million, respectively.

​

​

37

Table of Contents

Interest Expense, Net

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020
Reported GAAP interest expense, net | ​ | ​ | $243.6 | ​ | ​ | ​ | $218.3 | ​ | ​ | ​ | $290.2
Special (gains) and charges | ​ | ​ | - | ​ | ​ |  | 33.1 | ​ | ​ |  | 83.8
2021 impact of Purolite on interest expense | ​ | ​ | - | ​ | ​ | ​ | 3.5 | ​ | ​ | ​ | -
Non-GAAP adjusted interest expense, net | ​ | ​ | $243.6 | ​ | ​ | ​ | $181.7 | ​ | ​ | ​ | $206.4

​

Our reported net interest expense totaled $243.6 million, $218.3 million and $290.2 million during 2022, 2021 and 2020, respectively.

​

We incurred $33.1 million ($29.0 million after tax) or $0.10 per diluted share and $83.8 million ($64.6 million after tax) or $0.22 per diluted share, of interest expense special charges in conjunction with our debt issuances and refinancing activities during 2021 and 2020, respectively.

​

Adjusted for special (gains) and charges, the increase in interest expense when comparing 2022 against 2021 was driven primarily by the interest on debt issued to fund the Purolite acquisition and the impact from higher average interest rates on floating rate debt. Adjusted for special (gains) and charges and the 2021 Purolite transaction, the decrease in interest expense when comparing 2021 against 2020 was driven primarily by a reduction in average debt levels and average interest rates.

​

Provision for Income Taxes

​

The following table provides a summary of our tax rate:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(percent) |  | 2022 | ​ | 2021 |  | 2020
Reported GAAP tax rate | ​ | 17.5 | % | ​ | 19.1 | % | ​ | 15.2 | %
Tax rate impact of: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges |  | 0.5 | ​ | ​ | 0.1 |  |  | 0.7 |
Discrete tax items | ​ | 0.7 | ​ | ​ | (0.3) | ​ | ​ | 3.8 | ​
Non-GAAP adjusted tax rate |  | 18.7 | % | ​ | 18.9 | % |  | 19.7 | %

​

Our reported tax rate was 17.5%, 19.1%, and 15.2%, for 2022, 2021 and 2020, respectively. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

​

We recognized a net tax benefit related to discrete tax items of $11.8 million during 2022. This included a deferred tax benefit of $14.6 million associated with utilization of tax attributes as a result of legal entity rationalization and share-based compensation excess tax benefits of $6.0 million. The amount of the excess tax benefit is subject to variation in stock price and award exercises. The remaining discrete tax expense of $8.8 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements and other changes in estimates.

​

We recognized net tax expense of $5.8 million related to discrete tax items during 2021. This included a non-cash deferred tax expense of $25.1 million associated with transferring certain intangible property between affiliates. Share-based compensation excess tax benefit was $29.1 million. The remaining discrete tax expense of $9.8 million was primarily related to the filing of federal, state, and foreign tax returns and other income tax adjustments including the impact of changes in tax law, audit settlements and other changes in estimates.

​

We recognized a total net benefit related to discrete tax items of $55.8 million during 2020. The tax benefit related to share-based compensation excess tax benefit contributed $57.3 million. We recorded changes in reserves in non-U.S. and U.S. jurisdictions due to audit settlements and expiration of statutes of limitations which resulted in a $9.8 million tax benefit. Additionally, we recognized a net tax expense of $11.3 million primarily related to the filing of the prior year federal, state and foreign tax returns and other income tax adjustments.

​

The change in our adjusted tax rates from 2020 to 2022 was primarily driven by global tax planning projects and geographic income mix. Future comparability of our adjusted tax rate may be impacted by various factors, including but not limited to other changes in global tax rules, further tax planning projects and geographic income mix.

​

​

38

Table of Contents

Net Income from Discontinued Operations, net of tax

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020
Reported GAAP net loss from discontinued operations, net of tax | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ​ | ($2,172.5)
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 2,210.7
Discrete tax net expense | ​ | ​ | - | ​ | ​ |  | - | ​ | ​ |  | 22.7
Non-GAAP adjusted net income from discontinued operations, net of tax | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ​ | $60.9

​

Special charges reported in discontinued operations consist of ChampionX separation charges.

​

Net Income from Continuing Operations Attributable to Ecolab

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Percent Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 | ​ | 2021
Reported GAAP net income from continuing operations attributable to Ecolab | ​ | ​ | $1,091.7 | ​ | ​ | ​ | $1,129.9 | ​ | ​ | $967.4 | ​ | (3) | % | ​ | 17 | %
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges, after tax | ​ |  | 207.3 | ​ | ​ | ​ | 213.5 | ​ | ​ | 254.1 | ​ | ​ | ​ | ​ | ​ | ​
Discrete tax net (benefit) expense | ​ | ​ | (11.8) | ​ | ​ | ​ | 5.8 | ​ | ​ | (55.8) | ​ | ​ | ​ | ​ | ​ | ​
2021 impact of Purolite on net income | ​ |  | - | ​ | ​ | ​ | 5.6 | ​ | ​ | - | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted net income from continuing operations attributable to Ecolab | ​ | ​ | $1,287.2 | ​ | ​ | ​ | $1,354.8 | ​ | ​ | $1,165.7 | ​ | (5) | % | ​ | 16 | %

​

Diluted EPS from Continuing Operations

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Percent Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(dollars) |  | 2022 |  | 2021 |  | 2020 |  | 2022 | ​ | 2021
Reported GAAP diluted EPS from continuing operations | ​ | ​ | $3.81 | ​ | ​ | ​ | $3.91 | ​ | ​ | $3.33 | ​ | (3) | % | ​ | 17 | %
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges, after tax | ​ |  | 0.72 | ​ | ​ |  | 0.74 | ​ |  | 0.88 | ​ | ​ | ​ | ​ | ​ | ​
Discrete tax net (benefit) expense | ​ |  | (0.04) | ​ | ​ |  | 0.02 | ​ |  | (0.19) | ​ | ​ | ​ | ​ | ​ | ​
2021 impact of Purolite on diluted EPS | ​ | ​ | - | ​ | ​ | ​ | 0.02 | ​ | ​ | - | ​ | ​ | ​ | ​ | ​ | ​
Non-GAAP adjusted diluted EPS from continuing operations | ​ | ​ | $4.49 | ​ | ​ | ​ | $4.69 | ​ | ​ | $4.02 | ​ | (4) | % | ​ | 17 | %

​

Per share amounts do not necessarily sum due to rounding.

​

Currency translation had an unfavorable $(0.26) impact on reported and adjusted diluted EPS when comparing 2022 to 2021 and favorable $0.11 impact when comparing 2021 to 2020.

​

39

Table of Contents

SEGMENT PERFORMANCE

​

The non-U.S. dollar functional currency international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates established by management for 2022. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2. Additional information about our reportable segments is included in Note 19.

​

Fixed currency net sales and operating income for 2022, 2021 and 2020 for our reportable segments are shown in the following tables.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Percent Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 | ​ | 2021
Global Industrial | ​ | ​ | $6,944.0 | ​ |  | ​ | $6,086.8 |  | ​ | $5,845.7 | ​ | 14 | % | ​ | 4 | %
Global Institutional & Specialty |  | ​ | 4,480.0 | ​ | ​ |  | 3,908.8 | ​ |  | 3,559.8 |  | 15 | ​ | ​ | 10 | ​
Global Healthcare & Life Sciences | ​ | ​ | 1,570.0 | ​ | ​ | ​ | 1,149.6 | ​ | ​ | 1,190.1 | ​ | 37 | ​ | ​ | (3) | ​
Other |  | ​ | 1,355.0 | ​ | ​ |  | 1,201.0 | ​ |  | 1,079.8 |  | 13 | ​ | ​ | 11 | ​
Corporate | ​ | ​ | 124.1 | ​ | ​ | ​ | 137.4 | ​ | ​ | 99.4 | ​ | (10) | ​ | ​ | 38 | ​
Subtotal at fixed currency |  | ​ | 14,473.1 | ​ | ​ |  | 12,483.6 | ​ |  | 11,774.8 |  | 16 | ​ | ​ | 6 | ​
Effect of foreign currency translation |  | ​ | (285.3) | ​ | ​ |  | 249.5 | ​ |  | 15.4 |  | ​ | ​ | ​ | ​ | ​
Total reported net sales |  | ​ | $14,187.8 | ​ | ​ | ​ | $12,733.1 | ​ | ​ | $11,790.2 |  | 11 | % | ​ | 8 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Percent Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 | ​ | 2021
Global Industrial | ​ | ​ | $977.0 | ​ |  | ​ | $985.7 |  | ​ | $1,079.1 | ​ | (1) | % | ​ | (9) | %
Global Institutional & Specialty |  | ​ | 634.5 | ​ | ​ |  | 545.7 | ​ |  | 316.3 |  | 16 | ​ | ​ | 73 | ​
Global Healthcare & Life Sciences | ​ | ​ | 205.0 | ​ | ​ | ​ | 152.3 | ​ | ​ | 207.6 | ​ | 35 | ​ | ​ | (27) | ​
Other |  | ​ | 212.8 | ​ | ​ |  | 184.0 | ​ |  | 130.6 |  | 16 | ​ | ​ | 41 | ​
Corporate |  | ​ | (416.7) | ​ | ​ |  | (316.6) | ​ |  | (347.7) |  | 32 | ​ | ​ | (9) | ​
Subtotal at fixed currency |  | ​ | 1,612.6 | ​ | ​ |  | 1,551.1 | ​ |  | 1,385.9 |  | 4 | ​ | ​ | 12 | ​
Effect of foreign currency translation |  | ​ | (50.1) | ​ | ​ |  | 47.5 | ​ |  | 9.8 |  | ​ | ​ | ​ | ​ | ​
Total reported operating income |  | ​ | $1,562.5 | ​ | ​ | ​ | $1,598.6 | ​ | ​ | $1,395.7 |  | (2) | % | ​ | 15 | %

​

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended
​ | ​ | December 31
Net Sales | ​ | 2022 | ​ | 2021
(millions) |  | Fixed Currency | ​ | Impact of Acquisitions and Divestitures | ​ | Acquisition Adjusted | ​ | Fixed Currency | ​ | Impact of Acquisitions and Divestitures | ​ | Acquisition Adjusted
Global Industrial | ​ | $6,944.0 | ​ | (21.0) | ​ | $6,923.0 | ​ | $6,086.8 | ​ | - | ​ | $6,086.8
Global Institutional & Specialty |  | 4,480.0 | ​ | - | ​ | 4,480.0 | ​ | 3,908.8 | ​ | - | ​ | 3,908.8
Global Healthcare & Life Sciences | ​ | 1,570.0 | ​ | (434.9) | ​ | 1,135.1 | ​ | 1,149.6 | ​ | (12.0) | ​ | 1,137.6
Other |  | 1,355.0 | ​ | - | ​ | 1,355.0 | ​ | 1,201.0 | ​ | - | ​ | 1,201.0
Corporate | ​ | 124.1 | ​ | (124.1) | ​ | - | ​ | 137.4 | ​ | (137.4) | ​ | -
Subtotal at fixed currency |  | 14,473.1 | ​ | (580.0) | ​ | 13,893.1 | ​ | 12,483.6 | ​ | (149.4) | ​ | 12,334.2
Effect of foreign currency translation |  | (285.3) | ​ | ​ | ​ | ​ | ​ | 249.5 | ​ | ​ | ​ | ​
Total reported net sales |  | $14,187.8 | ​ | ​ | ​ | ​ | ​ | $12,733.1 | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ | 2022 | ​ | 2021
(millions) |  | Fixed Currency | ​ | Impact of Acquisitions and Divestitures | ​ | Acquisition Adjusted | ​ | Fixed Currency | ​ | Impact of Acquisitions and Divestitures | ​ | Acquisition Adjusted
Global Industrial | ​ | $977.0 | ​ | (3.4) | ​ | $973.6 | ​ | $985.7 | ​ | - | ​ | $985.7
Global Institutional & Specialty |  | 634.5 | ​ | - | ​ | 634.5 | ​ | 545.7 | ​ | - | ​ | 545.7
Global Healthcare & Life Sciences |  | 205.0 | ​ | (106.3) | ​ | 98.7 | ​ | 152.3 | ​ | 3.8 | ​ | 156.1
Other | ​ | 212.8 | ​ | - | ​ | 212.8 | ​ | 184.0 | ​ | - | ​ | 184.0
Corporate |  | (206.3) | ​ | 86.6 | ​ | (119.7) | ​ | (120.1) | ​ | - | ​ | (120.1)
Non-GAAP adjusted fixed currency operating income |  | 1,823.0 | ​ | (23.1) | ​ | 1,799.9 | ​ | 1,747.6 | ​ | 3.8 | ​ | 1,751.4
Special (gains) and charges |  | 210.4 | ​ | ​ | ​ | ​ | ​ | 196.5 | ​ | ​ | ​ | ​
Subtotal at fixed currency |  | 1,612.6 | ​ | ​ | ​ | ​ | ​ | 1,551.1 | ​ | ​ | ​ | ​
Effect of foreign currency translation |  | (50.1) | ​ | ​ | ​ | ​ | ​ | 47.5 | ​ | ​ | ​ | ​
Total reported operating income |  | $1,562.5 | ​ | ​ | ​ | ​ | ​ | $1,598.6 | ​ | ​ | ​ | ​

40

Table of Contents

Global Industrial

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2020
Sales at fixed currency (millions) | ​ | ​ | $6,944.0 | ​ | ​ | ​ | $6,086.8 | ​ | ​ | ​ | $5,845.7 | ​
Sales at public currency (millions) | ​ | ​ | 6,805.0 | ​ | ​ | ​ | 6,237.8 | ​ | ​ | ​ | 5,867.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Volume | ​ |  | 1 | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Price changes | ​ |  | 13 | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency sales change | ​ | ​ | 14 | % | ​ | ​ | 4 | % | ​ | ​ | ​ | ​
Acquisitions and divestitures | ​ |  | - | % | ​ | ​ | - | % | ​ | ​ | ​ | ​
Fixed currency sales change | ​ |  | 14 | % | ​ | ​ | 4 | % | ​ | ​ | ​ | ​
Foreign currency translation | ​ | ​ | (5) | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Public currency sales change | ​ |  | 9 | % | ​ | ​ | 6 | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income at fixed currency (millions) | ​ | ​ | $977.0 | ​ | ​ | ​ | $985.7 | ​ | ​ | ​ | $1,079.1 | ​
Operating income at public currency (millions) | ​ | ​ | 951.8 | ​ | ​ | ​ | 1,020.3 | ​ | ​ | ​ | 1,086.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fixed currency operating income change | ​ | ​ | (1) | % | ​ | ​ | (9) | % | ​ | ​ | ​ | ​
Fixed currency operating income margin | ​ |  | 14.1 | % | ​ |  | 16.2 | % | ​ |  | 18.5 | %
Acquisition adjusted fixed currency operating income change | ​ |  | (1) | % | ​ |  | (8) | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency operating income margin | ​ |  | 14.1 | % | ​ |  | 16.2 | % | ​ | ​ | * | ​
Public currency operating income change | ​ | ​ | (7) | % | ​ | ​ | (6) | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

​

Net Sales

​

Fixed currency sales for Global Industrial increased in 2022 as strong double-digit growth across all divisions was driven by accelerating pricing and new business wins. The 2021 sales increase was impacted by strong growth in Paper and Water, led by recovering market conditions, strong pricing and new business wins, along with a good growth in Food & Beverage, were offset by a decrease in Downstream sales growth.

​

All operating segments reported double-digit growth, Water fixed currency sales increased 13% in 2022 driven by strong pricing and new business wins. Water fixed currency sales increased 6% in 2021 as strong new business wins and accelerating pricing leveraged recovering markets. Light industry water treatment reported strong sales and had solid growth in 2021. Heavy industry sales also recorded strong sales in 2022 led by double-digit growth in power and chemicals and a strong increase in 2021 driven by primary metals. Food & Beverage fixed currency sales increased 14% in 2022 reflecting accelerating pricing. Fixed currency sales increased 3% in 2021 primarily reflecting accelerating pricing, recovering markets and new business wins. Downstream fixed currency sales increased 14% in 2022 driven by accelerating pricing and new business wins​. Fixed currency sales decreased 3% in 2021 due to lower demand from COVID and impacts from the Texas freeze and Hurricane Ida. Paper fixed currency sales increased 16% in 2022 driven by accelerating pricing, new business wins and continued growth in ecommerce markets​. Fixed currency sales increased 11% in 2021 driven by increased pricing, strong new business wins and growth in ecommerce markets.

Operating Income

Fixed currency operating income and fixed currency operating income margins for Global Industrial decreased in 2022 and 2021 when compared to prior periods.

​

Acquisition adjusted fixed currency operating income margins decreased 2.1 percentage points during 2022 compared to 2021, as the 9.0 percentage point positive impacts of accelerating pricing was more than offset by the 12.7 percentage point negative impacts of higher delivered product costs, unfavorable mix and investments in the business. Acquisition adjusted fixed currency operating income margins decreased in 2021 compared to 2020, as the positive impact from accelerating pricing was more than offset by the negative impact of significantly higher delivered product costs and supply constraints.

​

41

Table of Contents

Global Institutional & Specialty

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2020
Sales at fixed currency (millions) | ​ | ​ | $4,480.0 | ​ | ​ | ​ | $3,908.8 | ​ | ​ | ​ | $3,559.8 | ​
Sales at public currency (millions) | ​ | ​ | 4,421.9 | ​ | ​ | ​ | 3,955.9 | ​ | ​ | ​ | 3,562.5 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Volume | ​ |  | 6 | % | ​ | ​ | 7 | % | ​ | ​ | ​ | ​
Price changes | ​ |  | 8 | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency sales change | ​ | ​ | 15 | % | ​ | ​ | 9 | % | ​ | ​ | ​ | ​
Acquisitions and divestitures | ​ |  | - | % | ​ | ​ | - | % | ​ | ​ | ​ | ​
Fixed currency sales change | ​ |  | 15 | % | ​ | ​ | 10 | % | ​ | ​ | ​ | ​
Foreign currency translation | ​ | ​ | (3) | % | ​ | ​ | 1 | % | ​ | ​ | ​ | ​
Public currency sales change | ​ |  | 12 | % | ​ | ​ | 11 | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income at fixed currency (millions) | ​ | ​ | $634.5 | ​ | ​ | ​ | $545.7 | ​ | ​ | ​ | $316.3 | ​
Operating income at public currency (millions) | ​ | ​ | 624.0 | ​ | ​ | ​ | 550.9 | ​ | ​ | ​ | 320.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fixed currency operating income change | ​ | ​ | 16 | % | ​ | ​ | 73 | % | ​ | ​ | ​ | ​
Fixed currency operating income margin | ​ |  | 14.2 | % | ​ |  | 14.0 | % | ​ |  | 8.9 | %
Acquisition adjusted fixed currency operating income change | ​ |  | 16 | % | ​ |  | 73 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency operating income margin | ​ |  | 14.2 | % | ​ |  | 14.0 | % | ​ | ​ | * | ​
Public currency operating income change | ​ | ​ | 13 | % | ​ | ​ | 72 | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

​

Net Sales

​

Fixed currency sales for Global Institutional & Specialty increased in 2022 driven by accelerating pricing and new business wins. The 2021 sales increased driven by strong growth in the Institutional operating segment reflecting recovering markets, new business wins and accelerating pricing.

At an operating segment level, Institutional fixed currency sales increased 18% in 2022, driven by accelerating pricing and new business wins. Fixed currency sales increased 15% in 2021, driven by strong growth in the Institutional operating segment reflecting recovering markets in the U.S. and Europe, new business wins including gains from the Ecolab Science Certified programs and accelerating pricing. Specialty fixed currency sales increased 7% in 2022 driven by strong quick service sales and modest growth in food retail sales. Fixed currency sales decreased 3% in 2021, as modest quickservice sales growth were more than offset by lower food retail sales.

​

Operating Income

​

Fixed currency operating income for our Global Institutional & Specialty segment increased in both 2022 and 2021 when compared to prior periods. Fixed currency operating income margins increased in both 2022 and 2021.

​

Acquisition adjusted fixed currency operating income margins increased 0.2 percentage points during 2022, as the 8.2 percentage point positive impacts from accelerating pricing and volume growth overcame the 7.9 percentage point negative impacts of higher delivered product costs and investments in the business. Acquisition adjusted fixed currency operating income margins increased during 2021, as the positive impact from higher volume, accelerating pricing, and favorable mix more than offset negative impact of the comparison to lower variable compensation last year and higher delivered product costs.

​

​

​

​

42

Table of Contents

Global Healthcare & Life Sciences

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2020
Sales at fixed currency (millions) | ​ | ​ | $1,570.0 | ​ | ​ | ​ | $1,149.6 | ​ | ​ | ​ | $1,190.1 | ​
Sales at public currency (millions) | ​ | ​ | 1,510.5 | ​ | ​ | ​ | 1,181.6 | ​ | ​ | ​ | 1,185.5 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Volume | ​ |  | (7) | % | ​ | ​ | (9) | % | ​ | ​ | ​ | ​
Price changes | ​ |  | 7 | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency sales change | ​ | ​ | - | % | ​ | ​ | (7) | % | ​ | ​ | ​ | ​
Acquisitions and divestitures | ​ |  | 37 | % | ​ | ​ | 3 | % | ​ | ​ | ​ | ​
Fixed currency sales change | ​ |  | 37 | % | ​ | ​ | (3) | % | ​ | ​ | ​ | ​
Foreign currency translation | ​ | ​ | (8) | % | ​ | ​ | 4 | % | ​ | ​ | ​ | ​
Public currency sales change | ​ |  | (28) | % | ​ | ​ | (0) | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income at fixed currency (millions) | ​ | ​ | $205.0 | ​ | ​ | ​ | $152.3 | ​ | ​ | ​ | $207.6 | ​
Operating income at public currency (millions) | ​ | ​ | 193.4 | ​ | ​ | ​ | 158.4 | ​ | ​ | ​ | 205.7 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fixed currency operating income change | ​ | ​ | 35 | % | ​ | ​ | (27) | % | ​ | ​ | ​ | ​
Fixed currency operating income margin | ​ |  | 13.1 | % | ​ |  | 13.2 | % | ​ |  | 17.4 | %
Acquisition adjusted fixed currency operating income change | ​ |  | (37) | % | ​ |  | (22) | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency operating income margin | ​ |  | 8.7 | % | ​ |  | 13.7 | % | ​ | ​ | * | ​
Public currency operating income change | ​ | ​ | 22 | % | ​ | ​ | (23) | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

​

Net Sales

​

Acquisition adjusted fixed currency sales for Global Healthcare & Life Sciences were flat in 2022 compared 2021 as growth in Life Sciences was offset by slightly lower Healthcare sales.

​

At an operating segment level, Healthcare fixed currency sales decreased 1% in 2022 due primarily to lower procedural and hand hygiene volumes, partially offset by increased pricing. Fixed currency sales decreased 5% in 2021 reflecting the comparison against strong 2020 COVID-19 related hand and surface disinfection sales as well as softer elective surgical procedures activity in 2021 due to the rise in COVID variants during the year. Life Sciences fixed currency sales increased 163% (9% acquisition adjusted) in 2022 reflecting the acquisition of Purolite. Excluding the acquisition of Purolite, the Life Sciences business growth was driven by accelerating pricing and growth in consumable pharmaceutical and personal care products, partially offset by normalizing demand for Bioquell’s biocontamination systems. Fixed currency sales decreased 5% in 2021 as accelerating pricing was more than offset by volume declines versus the very strong 2020 driven by extraordinary COVID-19 demand last year.

​

Operating Income

​

Fixed currency operating income for our Global Healthcare & Life Sciences segment increased in 2022 and decreased in 2021 when compared to prior periods. Fixed currency operating income margins decreased in both 2022 and 2021.

​

Acquisition adjusted fixed currency operating income margins decreased 5.0 percentage points in 2022, as the 5.5 percentage point positive impact from accelerating pricing was more than offset by the 10.2 percentage point negative impacts from higher delivered product costs, unfavorable mix, lower Healthcare volumes and targeted investments in the business. Acquisition adjusted fixed currency operating income margins decreased in 2021, as positive impact from accelerating pricing was more than offset by the negative impact of volume declines due to strong comparison against 2020.

​

​

43

Table of Contents

Other

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2020
Sales at fixed currency (millions) | ​ | ​ | $1,355.0 | ​ | ​ | ​ | $1,201.0 | ​ | ​ | ​ | $1,079.8 | ​
Sales at public currency (millions) | ​ | ​ | 1,326.6 | ​ | ​ | ​ | 1,218.6 | ​ | ​ | ​ | 1,075.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Volume | ​ |  | 6 | % | ​ | ​ | 9 | % | ​ | ​ | ​ | ​
Price changes | ​ |  | 7 | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency sales change | ​ | ​ | 13 | % | ​ | ​ | 11 | % | ​ | ​ | ​ | ​
Acquisitions and divestitures | ​ |  | - | % | ​ | ​ | - | % | ​ | ​ | ​ | ​
Fixed currency sales change | ​ |  | 13 | % | ​ | ​ | 11 | % | ​ | ​ | ​ | ​
Foreign currency translation | ​ | ​ | (4) | % | ​ | ​ | 2 | % | ​ | ​ | ​ | ​
Public currency sales change | ​ |  | 9 | % | ​ | ​ | 13 | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income at fixed currency (millions) | ​ | ​ | $212.8 | ​ | ​ | ​ | $184.0 | ​ | ​ | ​ | $130.6 | ​
Operating income at public currency (millions) | ​ | ​ | 208.1 | ​ | ​ | ​ | 186.8 | ​ | ​ | ​ | 130.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fixed currency operating income change | ​ | ​ | 16 | % | ​ | ​ | 41 | % | ​ | ​ | ​ | ​
Fixed currency operating income margin | ​ |  | 15.7 | % | ​ |  | 15.3 | % | ​ |  | 12.1 | %
Acquisition adjusted fixed currency operating income change | ​ |  | 16 | % | ​ |  | 41 | % | ​ | ​ | ​ | ​
Acquisition adjusted fixed currency operating income margin | ​ |  | 15.7 | % | ​ |  | 15.3 | % | ​ | ​ | * | ​
Public currency operating income change | ​ | ​ | 11 | % | ​ | ​ | 43 | % | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

​

Net Sales

​

Fixed currency sales for Other increased in 2022 reflecting double-digit growth in Pest Elimination, Textile Care and Colloidal Technologies. Fixed currency sales increased in 2021 led by strong growth in Pest Elimination as it benefited from new business wins and a recovering market.

​

At an operating segment level, Pest Elimination fixed currency sales increased 11% in 2022 reflecting strong growth across food retail, food & beverage, hospitality and restaurants from accelerating pricing and new business wins​. Fixed currency sales increased 11% in 2021 reflecting strong growth in food and beverage plants, restaurants and hospitality markets. Textile Care fixed currency sales increased 19% and 10% in 2022 and 2021, respectively. Colloidal Technologies Group fixed currency sales increased 14% and 16% in 2022 and 2021, respectively.

​

Operating Income

​

Fixed currency operating income in Other increased in both 2022 and 2021 as compared to the prior year. Fixed currency operating income margins increased in both 2022 and 2021.

​

Acquisition adjusted fixed currency operating income margins in Other increased 0.4 percentage points in 2022, as the 5.8 percentage point positive impacts from accelerating pricing overcame the 5.2 percentage point negative impacts of higher delivered product costs and investments in business. Acquisition adjusted fixed currency operating income margins increased in 2021, as the positive impacts from higher volume and increased pricing more than offset the negative impact of the comparison to lower variable compensation last year.

​

​

Corporate

​

Consistent with our internal management reporting, Corporate amounts in the table on page 40 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 5, intangible asset amortization specifically from the Nalco and Purolite transactions and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 34.

​

​

​

​

44

Table of Contents

FINANCIAL POSITION, CASH FLOW AND LIQUIDITY

​

Financial Position

​

Total assets were $21.5 billion as of December 31, 2022, compared to total assets of $21.2 billion as of December 31, 2021.

Total liabilities were $14.2 billion as of December 31, 2022, compared to total liabilities of $14.0 billion as of December 31, 2021. Total debt was $8.6 billion as of December 31, 2022 and $8.8 billion as of December 31, 2021. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to EBITDA is shown in the following table. EBITDA is a non-GAAP measure discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​ | 2020
(ratio) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net debt to EBITDA |  | ​ | 3.2 | ​ |  | ​ | 3.4 | ​ |  | ​ | 2.4 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total debt | ​ | ​ | $8,580.4 | ​ | ​ | ​ | $8,758.2 | ​ | ​ | ​ | $6,686.6 | ​
Cash | ​ |  | 598.6 | ​ | ​ | ​ | 359.9 | ​ | ​ | ​ | 1,260.2 | ​
Net debt | ​ | ​ | $7,981.8 | ​ | ​ | ​ | $8,398.3 | ​ | ​ | ​ | $5,426.4 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income including noncontrolling interest | ​ | ​ | $1,108.9 | ​ | ​ | ​ | $1,144.0 | ​ | ​ | ​ | $984.8 | ​
Provision for income taxes | ​ |  | 234.5 | ​ | ​ | ​ | 270.2 | ​ | ​ | ​ | 176.6 | ​
Interest expense, net | ​ |  | 243.6 | ​ | ​ | ​ | 218.3 | ​ | ​ | ​ | 290.2 | ​
Depreciation | ​ |  | 618.5 | ​ | ​ | ​ | 604.4 | ​ | ​ | ​ | 594.3 | ​
Amortization | ​ |  | 320.2 | ​ | ​ | ​ | 238.7 | ​ | ​ | ​ | 218.4 | ​
EBITDA | ​ |  | $2,525.7 | ​ | ​ | ​ | $2,475.6 | ​ | ​ | ​ | $2,264.3 | ​

​

Cash Flows

​

Operating Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Dollar Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 | ​ | 2021 |  | 2020 |  | 2022 |  | 2021
Cash provided by operating activities | ​ | ​ | $1,788.4 | ​ | ​ | ​ | $2,061.9 | ​ | ​ | ​ | $1,741.8 | ​ | ​ | ​ | ($273.5) | ​ | ​ | ​ | $320.1 | ​

​

We continue to generate cash flow from operations allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases.

​

Cash provided by operating activities decreased $274 million in 2022 compared to 2021, driven primarily by $277 million increase in working capital excluding the impact of non-cash special charges. The increase in working capital is primarily driven by past due receivables higher than last year due to pricing and energy surcharge rollout. Additionally, inventory impacted by inflationary environment and higher stock holding to mitigate supply disruption.

​

Cash provided by operating activities increased $320 million in 2021 compared to 2020, driven primarily by $159 million in increased net income, $94 million in higher tax expense accruals associated with higher income, and an increase in accruals for variable compensation, partially offset by $83 million of increased investment in working capital.

​

The impact on operating cash flows of pension and postretirement plan contributions, cash activity related to restructuring, cash paid for income taxes and cash paid for interest, are shown in the following table:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Dollar Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 |  | 2020 |  | 2022 |  | 2021
Pensions and postretirement plan contributions |  |  | $64.3 | ​ | ​ | ​ | $60.2 | ​ |  | ​ | $70.7 | ​ | ​ |  | $4.1 | ​ |  | ​ | ($10.5) | ​
Restructuring payments | ​ |  | 41.0 | ​ | ​ |  | 78.3 | ​ | ​ |  | 71.1 | ​ | ​ |  | (37.3) | ​ | ​ |  | 7.2 | ​
Income tax payments | ​ |  | 308.9 | ​ | ​ |  | 275.7 | ​ | ​ |  | 366.9 | ​ | ​ |  | 33.2 | ​ | ​ |  | (91.2) | ​
Interest payments | ​ |  | 222.4 | ​ | ​ |  | 208.7 | ​ | ​ |  | 262.5 | ​ | ​ |  | 13.7 | ​ | ​ |  | (53.8) | ​

​

​

45

Table of Contents

Investing Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Dollar Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 | ​ | 2021 |  | 2020 |  | 2022 |  | 2021
Cash used for investing activities | ​ | ​ | ($716.8) | ​ | ​ | ​ | ($4,579.7) | ​ | ​ | ​ | ($857.7) | ​ | ​ | ​ | $3,862.9 | ​ | ​ | ​ | ($3,722.0) | ​

​

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as from capital investments in the business.

​

We continue to make capital investments in the business, including merchandising and customer equipment and manufacturing facilities. Total capital expenditures were $713 million, $643 million and $489 million in 2022, 2021 and 2020, respectively.

​

Total cash paid for acquisitions, net of cash acquired and net of cash received from dispositions, in 2022, 2021 and 2020 was $7 million, $3,924 million and $487 million, respectively. Our acquisitions and divestitures are discussed further in Note 4. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

Financing Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Dollar Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 | ​ | 2021 |  | 2020 |  | 2022 |  | 2021
Cash provided by (used for) financing activities | ​ | ​ | ($837.3) | ​ | ​ | ​ | $1,603.2 | ​ | ​ | ​ | ($340.2) | ​ | ​ | ​ | ($2,440.5) | ​ | ​ | ​ | $1,943.4 | ​

​

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

​

We issued $500 million par value and received $494 million in proceeds of long-term debt. We issued $2,800 million par value and received $2,775 million in proceeds of long-term debt and repaid $900 million of long-term debt in 2021. We issued $1,850 million par value and received $1,856 million in proceeds of long-term debt and repaid $1,570 million of long-term debt in 2020. The proceeds received from the debt issuances were used for the Purolite acquisition, repayment of outstanding debt, repayment of commercial paper and general corporate purposes. In addition, we had net repayments of $404 million and net issuances $394 million of commercial paper and notes payable in 2022 and 2021, respectively, and net repayments of $66 million in 2020.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We repurchased a total of $518 million, $107 million, and $146 million of shares in 2022, 2021 and 2020, respectively.

​

The impact on financing cash flows of commercial paper and notes payable repayments, long-term debt borrowings and long-term debt repayments, are shown in the following table:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Dollar Change |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 |  | 2020 |  | 2022 |  | 2021
Net (repayments) issuances of commercial paper and notes payable | ​ |  | ($404.3) | ​ | ​ | ​ | $393.6 | ​ |  | ​ | ($65.5) | ​ | ​ |  | ($797.9) | ​ |  | ​ | $459.1 | ​
Long-term debt borrowings | ​ |  | 494.0 | ​ | ​ |  | 2,775.0 | ​ | ​ |  | 1,855.9 | ​ | ​ |  | (2,281.0) | ​ | ​ |  | 919.1 | ​
Long-term debt repayments | ​ |  | - | ​ | ​ |  | (1,017.9) | ​ | ​ |  | (1,570.0) | ​ | ​ |  | 1,017.9 | ​ | ​ |  | 552.1 | ​

In December 2022, we increased our quarterly dividend rate by 4%. This represents the 31st consecutive year we have increased our dividend. We have paid dividends on our common stock for 86th consecutive years. We paid dividends of $603 million, $566 million and $561 million in 2022, 2021 and 2020, respectively. Cash dividends declared per share of common stock, by quarter, for each of the last three years were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | First | ​ | Second | ​ | Third | ​ | Fourth | ​ |  | ​ |
​ | ​ | Quarter | ​ | Quarter | ​ | Quarter | ​ | Quarter | ​ | Year
2022 | ​ | ​ | $0.51 | ​ | ​ | ​ | $0.51 | ​ | ​ | ​ | $0.51 | ​ | ​ | ​ | $0.53 | ​ | ​ | ​ | $2.06 | ​
2021 | ​ |  | $0.48 | ​ | ​ | ​ | $0.48 | ​ | ​ | ​ | $0.48 | ​ | ​ | ​ | $0.51 | ​ | ​ | ​ | $1.95 | ​
2020 | ​ |  | $0.47 | ​ | ​ | ​ | $0.47 | ​ | ​ | ​ | $0.47 | ​ | ​ | ​ | $0.48 | ​ | ​ | ​ | $1.89 | ​

​

​

46

Table of Contents

Liquidity and Capital Resources

​

We currently expect to fund all of our cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

​

As of December 31, 2022, we had $599 million of cash and cash equivalents on hand, of which $122 million was held outside of the U.S. As of December 31, 2021, we had $360 million of cash and cash equivalents on hand, of which $181 million was held outside of the U.S. We will continue to evaluate our cash position in light of future developments.

​

As of December 31, 2022, we had a $2.0 billion multi-year credit facility, which expires in April 2026. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At year end, we had no commercial paper outstanding under our U.S. program or our Euro program. There were no borrowings under our credit facility as of December 31, 2022 or 2021. As of December 31, 2022, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

​

Additionally, we have uncommitted credit lines with major international banks and financial institutions. These credit lines support our daily global funding needs, primarily our global cash pooling structures. As of December 31, 2022 we had $144 million of bank supported letters of credit, surety bonds and guarantees outstanding in support of our commercial business transactions. We do not have any other significant unconditional purchase obligations or commercial commitments.

​

As of December 31, 2022, Standard & Poor’s, Fitch and Moody’s rated our long-term credit at A- (negative outlook), A- (stable outlook) and A3 (negative outlook), respectively. A reduction in our credit ratings could limit or preclude our ability to issue commercial paper under our current programs or could also adversely affect our ability to renew existing, or negotiate new, credit facilities in the future and could increase the cost of these facilities.

As of December 31, 2022, we were in compliance with our debt covenants and other requirements of our credit agreements and indentures.

A schedule of our various obligations as of December 31, 2022 are summarized in the following table:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Payments Due by Period |
​ | ​ | ​ | ​ | ​ | Less | ​ | ​ | ​ | ​ | ​ | ​ | ​ | More |
​ | ​ | ​ | ​ | ​ | Than | ​ | 2-3 | ​ | 4-5 | ​ | Than |
(millions) | ​ | Total | ​ | 1 Year | ​ | Years | ​ | Years | ​ | 5 Years |
Notes payable | ​ | ​ | $4 | ​ | ​ | $4 |  | ​ | $- | ​ | ​ | $- | ​ | ​ | $- | ​
One-time transition tax | ​ |  | 67 | ​ |  | - | ​ |  | 35 | ​ | ​ | 32 | ​ |  | - | ​
Long-term debt | ​ |  | 8,577 | ​ |  | 501 | ​ |  | 1,204 | ​ |  | 1,651 | ​ |  | 5,221 | ​
Operating leases | ​ |  | 503 | ​ |  | 124 | ​ |  | 173 | ​ | ​ | 85 | ​ |  | 121 | ​
Interest* | ​ |  | 3,970 | ​ |  | 280 | ​ | ​ | 529 | ​ |  | 467 | ​ |  | 2,694 | ​
Total | ​ | ​ | $13,121 | ​ | ​ | $909 | ​ | ​ | $1,941 | ​ | ​ | $2,235 | ​ | ​ | $8,036 | ​

​

| * | Interest on variable rate debt was calculated using the interest rate at year end 2022.

​

As of December 31, 2022, our gross liability for uncertain tax positions was $25 million. We are not able to reasonably estimate the amount by which the liability will increase or decrease over an extended period of time or whether a cash settlement of the liability will be required. Therefore, these amounts have been excluded from the schedule of contractual obligations.

We do not have required minimum cash contribution obligations for our qualified pension plans in 2022. We are required to fund certain international pension benefit plans in accordance with local legal requirements. We estimate contributions to be made to our international plans will approximate $41 million in 2023. These amounts have been excluded from the schedule of contractual obligations.

We lease certain sales and administrative office facilities, distribution centers, research and manufacturing facilities and other equipment under longer-term operating leases. Vehicle leases are generally shorter in duration. Vehicle leases have residual value requirements that have historically been satisfied primarily by the proceeds on the sale of the vehicles.

Market Risk

​

We enter into contractual arrangements (derivatives) in the ordinary course of business to manage foreign currency exposure and interest rate risks. We do not enter into derivatives for speculative or trading purposes. Our use of derivatives is subject to internal policies that provide guidelines for control, counterparty risk, and ongoing monitoring and reporting, and is designed to reduce the volatility associated with movements in foreign exchange and interest rates on our income statement and cash flows.

47

Table of Contents

We enter into foreign currency forward contracts to hedge certain intercompany financial arrangements, and to hedge against the effect of exchange rate fluctuations on transactions related to cash flows denominated in currencies other than U.S. dollars. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations. As of December 31, 2022, we had a total of €1,150 million senior notes designated as net investment hedges.

​

We enter into cross-currency swap derivative contracts to hedge certain Euro denominated exposures from our investments in certain of its Euro denominated functional currency subsidiaries. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations. As of December 31, 2022, we had €625 million of cross-currency swap derivative contracts outstanding designated as a net investment hedge.

​

We manage interest expense using a mix of fixed and floating rate debt. To help manage borrowing costs, we may enter into interest rate swap agreements. Under these arrangements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. As of December 31, 2022, we had $1,500 million of interest rate swaps outstanding.

Refer to Note 9 for further information on our hedging activity.

Based on a sensitivity analysis (assuming a 10% change in market rates) of our foreign exchange and interest rate derivatives and other financial instruments, changes in exchange rates or interest rates would increase/decrease our financial position and liquidity by approximately $220 million. The effect on our results of operations would be substantially offset by the impact of the hedged items.

​

​

GLOBAL ECONOMIC AND POLITICAL ENVIRONMENT

​

Coronavirus disease 2019 (COVID-19)

​

In March 2020, the coronavirus disease (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets and industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic, including supply shortages, inflation and other challenges, such as those resulting from the introduction of vaccination mandates. While many government restrictions in the U.S. have eased, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a resurgence of cases triggering additional government mandated lockdowns or similar restrictions on activity, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. These conditions have had and may continue to have a negative impact on market conditions and customer demand throughout the world.

​

Global Economies

​

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results. We expect a more challenging macroeconomic environment, especially in Europe, as the war and the energy crisis are having a significant impact on costs and demand. We also assume continued high delivered product costs and unfavorable currency translation and interest rate impacts that persist well into 2023.

​

Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During 2022, sales in Argentina represented less than 1% of our consolidated net sales. Assets held in Argentina at the end of 2022 represented less than 1% of our consolidated assets. Turkey was also classified as a highly inflationary economy in accordance with U.S. GAAP. During 2022, sales in Turkey represented less than 1% of our consolidated net sales. Assets held in Turkey at the end of 2022 represented less than 1% of our consolidated assets.

​

In light of Russia’s invasion of Ukraine and the sanctions against Russia by the United States and other countries, we have made the determination that we will limit our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We may further narrow our presence in Russia depending on future developments. Our Russian and Ukraine operations represented approximately 1% of our 2022 consolidated net sales. We recorded charges of $13.1 million in 2022 primarily related to recoverability risk of certain assets in both Russia and Ukraine.

​

​

NEW ACCOUNTING PRONOUNCEMENTS

​

Information regarding new accounting pronouncements is included in Note 2.

​

​

48

Table of Contents

NON-GAAP FINANCIAL MEASURES

​

This MD&A includes financial measures that have not been calculated in accordance with U.S. GAAP. These non-GAAP measures include:

● Fixed currency sales

● Adjusted net sales

● Adjusted fixed currency sales

● Acquisition adjusted fixed currency sales or organic sales

● Adjusted cost of sales

● Adjusted gross margin

● Fixed currency operating income

● Fixed currency operating income margin

● Adjusted operating income

● Adjusted operating income margin

● Adjusted fixed currency operating income

● Adjusted fixed currency operating income margin

● Acquisition adjusted fixed currency operating income or organic income

● Acquisition adjusted fixed currency operating income margin or organic margin

● Adjusted other (income) expense

● Adjusted interest expense, net

● EBITDA

● Adjusted tax rate

● Adjusted net income from discontinued operations, net of tax

● Adjusted net income from continuing operations attributable to Ecolab

● Adjusted diluted EPS from continuing operations

​

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP adjusted financial measure for net sales excludes 2021 Purolite sales. Our non-GAAP adjusted financial measures for cost of sales, gross margin, operating income, other (income) expense and interest expense exclude the impact of special (gains) and charges and (with the exception of other (income) expense) the 2021 impact of the Purolite transaction, and our non-GAAP measures for tax rate, net income from continuing operations attributable to Ecolab and diluted EPS from continuing operations further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including non-controlling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

​

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-K are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2022. We also provide our segment results based on public currency rates for informational purposes.

​

Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to our reportable segments.

​

Acquisition adjusted fixed currency growth rates, also known as organic growth rates, are at fixed currency and exclude the results of our acquired businesses from the first twelve months post acquisition and the results of our divested businesses from the twelve months prior to divestiture. Further, we have excluded the results of our Purolite business for all of 2022 to remain comparable to 2021 when Purolite’s results were excluded from our adjusted results. In addition, as part of the Transaction, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

​

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts in this MD&A.

​

​

​

​

49

Table of Contents

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

​

The discussion under the heading entitled "Market Risk" and “Global Economic and Political Environment” is incorporated by reference from Part II, Item 7 of this Form 10-K.

​

Item 8. Financial Statements and Supplementary Data.

​

REPORTS OF MANAGEMENT

​

To our Shareholders:

​

Management’s Responsibility for Financial Statements

​

Management is responsible for the integrity and objectivity of the consolidated financial statements. The statements have been prepared in accordance with accounting principles generally accepted in the United States of America and, accordingly, include certain amounts based on management’s best estimates and judgments.

​

The Board of Directors, acting through its Audit Committee composed solely of independent directors, is responsible for determining that management fulfills its responsibilities in the preparation of financial statements and maintains internal control over financial reporting. The Audit Committee recommends to the Board of Directors the appointment of the Company’s independent registered public accounting firm, subject to ratification by the shareholders. It meets regularly with management, the internal auditors and the independent registered public accounting firm.

​

The independent registered public accounting firm has audited the consolidated financial statements included in this annual report and have expressed their opinion regarding whether these consolidated financial statements present fairly in all material respects our financial position and results of operation and cash flows as stated in their report presented separately herein.

​

Management’s Report on Internal Control Over Financial Reporting

​

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of management, including the principal executive officer and principal financial officer, an evaluation of the design and operating effectiveness of internal control over financial reporting was conducted based on the 2013 framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation under the framework in Internal Control — Integrated Framework, management concluded that internal control over financial reporting was effective as of December 31, 2022.

​

The Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022 as stated in their report which is included herein.

​

Christophe Beck | Scott D. Kirkland
Chairman and Chief Executive Officer | Chief Financial Officer

​

50

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

​

To the Board of Directors and Shareholders of Ecolab Inc.

​

Opinions on the Financial Statements and Internal Control over Financial Reporting

​

We have audited the accompanying consolidated balance sheets of Ecolab Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

​

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

​

Basis for Opinions

​

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

​

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

​

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

​

Definition and Limitations of Internal Control over Financial Reporting

​

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

​

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

​

51

Table of Contents

Goodwill Impairment Assessment – Downstream Reporting Unit

As described in Note 2 to the consolidated financial statements, the carrying value of goodwill was $8.0 billion as of December 31, 2022, a portion of which is allocated to the Downstream reporting unit. During the second quarter of 2022, management completed its annual goodwill impairment assessment for eleven of its twelve reporting units using discounted cash flow analyses that incorporated assumptions, including future growth rates, terminal values and discount rates. The annual goodwill impairment assessment of the Purolite reporting unit was qualitative in nature and considered information regarding its operations, financial performance and the macroeconomic environment. If the results of an annual or interim goodwill assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, the Company will recognize an impairment loss for the amount by which the reporting unit’s carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Downstream reporting unit is a critical audit matter are (i) the significant judgment by management when determining the fair value of the Downstream reporting unit; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’s significant assumption related to the discount rate; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill impairment assessment, including controls over management’s valuation of the Downstream reporting unit. These procedures also included, among others (i) testing management’s process for determining the fair value of the Downstream reporting unit; (ii) evaluating the appropriateness of the discounted cash flow analysis; and (iii) evaluating the reasonableness of the significant assumption used by management related to the discount rate. Evaluating management’s significant assumption related to the discount rate involved evaluating whether the significant assumption used was reasonable considering the cost of capital of comparable businesses and relevant industry factors. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the discounted cash flow analysis and (ii) the reasonableness of the discount rate significant assumption.

​

​

​

/s/ PricewaterhouseCoopers LLP

Minneapolis, Minnesota

February 24, 2023

​

We have served as the Company’s auditor since 1970.

​

52

Table of Contents

​

CONSOLIDATED STATEMENTS OF INCOME

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions, except per share amounts) | ​ | 2022 | ​ | 2021 | ​ | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and equipment sales | ​ | ​ | $11,446.2 | ​ | ​ | ​ | $10,153.3 | ​ | ​ | $9,466.6
Service and lease sales | ​ | ​ | 2,741.6 | ​ | ​ | ​ | 2,579.8 | ​ | ​ | 2,323.6
Net sales | ​ | ​ | 14,187.8 | ​ | ​ | ​ | 12,733.1 | ​ | ​ | 11,790.2
Product and equipment cost of sales | ​ | ​ | 7,212.8 | ​ | ​ | ​ | 6,100.9 | ​ | ​ | 5,481.3
Service and lease cost of sales | ​ | ​ | 1,618.2 | ​ | ​ | ​ | 1,514.9 | ​ | ​ | 1,424.5
Cost of sales (including special (gains) and charges (a)) | ​ | ​ | 8,831.0 | ​ | ​ | ​ | 7,615.8 | ​ | ​ | 6,905.8
Selling, general and administrative expenses | ​ | ​ | 3,653.8 | ​ | ​ |  | 3,416.1 | ​ |  | 3,309.1
Special (gains) and charges | ​ | ​ | 140.5 | ​ | ​ |  | 102.6 | ​ |  | 179.6
Operating income | ​ | ​ | 1,562.5 | ​ | ​ |  | 1,598.6 | ​ |  | 1,395.7
Other (income) expense (b) | ​ | ​ | (24.5) | ​ | ​ | ​ | (33.9) | ​ | ​ | (55.9)
Interest expense, net (c) | ​ | ​ | 243.6 | ​ | ​ | ​ | 218.3 | ​ | ​ | 290.2
Income before income taxes | ​ | ​ | 1,343.4 | ​ | ​ |  | 1,414.2 | ​ |  | 1,161.4
Provision for income taxes | ​ | ​ | 234.5 | ​ | ​ |  | 270.2 | ​ |  | 176.6
Net income from continuing operations, including noncontrolling interest | ​ | ​ | 1,108.9 | ​ | ​ | ​ | 1,144.0 | ​ | ​ | 984.8
Net income from continuing operations attributable to noncontrolling interest | ​ | ​ | 17.2 | ​ | ​ | ​ | 14.1 | ​ | ​ | 17.4
Net income from continuing operations attributable to Ecolab | ​ | ​ | 1,091.7 | ​ | ​ |  | 1,129.9 | ​ |  | 967.4
Net loss from discontinued operations, net of tax (Note 5) (d) | ​ | ​ | - | ​ | ​ |  | - | ​ |  | (2,172.5)
Net income (loss) attributable to Ecolab | ​ | ​ | $1,091.7 | ​ | ​ | ​ | $1,129.9 | ​ | ​ | ($1,205.1)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings (loss) attributable to Ecolab per common share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | ​ | $3.83 | ​ | ​ | ​ | $3.95 | ​ | ​ | $3.37
Discontinued operations | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ($7.57)
Earnings attributable to Ecolab | ​ | ​ | $3.83 | ​ | ​ | ​ | $3.95 | ​ | ​ | ($4.20)
Diluted | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | ​ | $3.81 | ​ | ​ | ​ | $3.91 | ​ | ​ | $3.33
Discontinued operations | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ($7.48)
Earnings attributable to Ecolab | ​ | ​ | $3.81 | ​ | ​ | ​ | $3.91 | ​ | ​ | ($4.15)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average common shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | 285.2 | ​ | ​ |  | 286.3 | ​ |  | 287.0
Diluted | ​ | ​ | 286.6 | ​ | ​ |  | 289.1 | ​ |  | 290.3
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

(a) | Cost of sales includes special (gains) and charges of $65.0 in 2022, $91.9 in 2021, and $39.3 in 2020, which is recorded in product and equipment cost of sales. Cost of sales includes special (gains) and charges of $4.9 in 2022, $2.0 in 2021 and $8.9 in 2020, which is recorded in service and lease cost of sales.

(b) | Other (income) expense includes special charges of $50.6 in 2022, $37.2 in 2021 and $0.4 in 2020.

(c) | Interest expense, net includes special charges of $33.1 in 2021, and $83.8 in 2020.

(d) | Net income (loss) from discontinued operations, net of tax includes noncontrolling interest of $2.2 in 2020.

​

The accompanying notes are an integral part of the consolidated financial statements.

​

​

53

Table of Contents

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | ​ | 2022 | ​ | 2021 | ​ | 2020 | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss) attributable to Ecolab | ​ | ​ | ​ | $1,091.7 | ​ | ​ | ​ | $1,129.9 | ​ | ​ | ($1,205.1) | ​
Net income from continuing operations attributable to noncontrolling interest | ​ | ​ | ​ | 17.2 | ​ | ​ | ​ | 14.1 | ​ | ​ | 17.4 | ​
Net income from discontinued operations attributable to noncontrolling interest | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 2.2 | ​
Net income (loss) attributable to Ecolab, including noncontrolling interest |  | ​ | ​ | $1,108.9 | ​ | ​ | ​ | $1,144.0 | ​ | ​ | ($1,185.5) | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other comprehensive income (loss), net of tax |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency translation adjustments |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency translation |  |  |  | (333.4) | ​ | ​ |  | (10.9) | ​ |  | 50.0 | ​
Separation of ChampionX | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 229.9 | ​
Gain (loss) on net investment hedges |  |  |  | 108.3 | ​ | ​ |  | 51.6 | ​ |  | (87.7) | ​
Total foreign currency translation adjustments |  |  |  | (225.1) | ​ | ​ |  | 40.7 | ​ |  | 192.2 | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivatives and hedging instruments |  |  |  | (1.2) | ​ | ​ |  | 26.0 | ​ |  | (17.0) | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Pension and postretirement benefits |  |  |  | 130.3 | ​ | ​ |  | 289.7 | ​ |  | (78.1) | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Subtotal |  |  |  | (96.0) | ​ | ​ |  | 356.4 | ​ |  | 97.1 | ​
​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total comprehensive income (loss), including noncontrolling interest |  |  |  | 1,012.9 | ​ | ​ |  | 1,500.4 | ​ |  | (1,088.4) | ​
Comprehensive income attributable to noncontrolling interest |  |  |  | 13.0 | ​ | ​ |  | 10.9 | ​ |  | 21.4 | ​
Comprehensive income (loss) attributable to Ecolab |  | ​ | ​ | $999.9 | ​ | ​ | ​ | $1,489.5 | ​ | ​ | ($1,109.8) | ​

​

​

The accompanying notes are an integral part of the consolidated financial statements.

​

54

Table of Contents

CONSOLIDATED BALANCE SHEET S

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions, except per share amounts) | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ASSETS | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current assets | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $598.6 | ​ | ​ | ​ | $359.9 | ​
Accounts receivable, net |  | 2,698.1 | ​ | ​ |  | 2,478.4 | ​
Inventories |  | 1,792.8 | ​ | ​ |  | 1,491.8 | ​
Other current assets | ​ | 404.7 | ​ | ​ | ​ | 357.0 | ​
Total current assets |  | 5,494.2 | ​ | ​ |  | 4,687.1 | ​
Property, plant and equipment, net |  | 3,293.4 | ​ | ​ |  | 3,288.5 | ​
Goodwill |  | 8,012.7 | ​ | ​ |  | 8,063.9 | ​
Other intangible assets, net |  | 3,680.7 | ​ | ​ |  | 4,224.1 | ​
Operating lease assets | ​ | 448.2 | ​ | ​ | ​ | 396.8 | ​
Other assets | ​ | 535.1 | ​ | ​ | ​ | 546.0 | ​
Total assets | ​ | $21,464.3 | ​ | ​ | ​ | $21,206.4 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND EQUITY | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Short-term debt | ​ | $505.1 | ​ | ​ | ​ | $411.0 | ​
Accounts payable | ​ | 1,728.2 | ​ | ​ | ​ | 1,384.2 | ​
Compensation and benefits | ​ | 493.6 | ​ | ​ | ​ | 509.5 | ​
Income taxes | ​ | 197.6 | ​ | ​ | ​ | 104.3 | ​
Other current liabilities | ​ | 1,285.9 | ​ | ​ | ​ | 1,144.2 | ​
Total current liabilities | ​ | 4,210.4 | ​ | ​ | ​ | 3,553.2 | ​
Long-term debt | ​ | 8,075.3 | ​ | ​ | ​ | 8,347.2 | ​
Pension and postretirement benefits | ​ | 670.3 | ​ | ​ | ​ | 894.2 | ​
Deferred income taxes | ​ | 505.6 | ​ | ​ | ​ | 622.0 | ​
Operating lease liabilities | ​ | 337.8 | ​ | ​ | ​ | 282.6 | ​
Other liabilities | ​ | 406.3 | ​ | ​ | ​ | 254.1 | ​
Total liabilities | ​ | 14,205.7 | ​ | ​ | ​ | 13,953.3 | ​
Commitments and contingencies (Note 16) | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Equity (a) | ​ | ​ | ​ | ​ | ​ | ​ | ​
Common stock | ​ | 364.7 | ​ | ​ | ​ | 364.1 | ​
Additional paid-in capital | ​ | 6,580.2 | ​ | ​ | ​ | 6,464.6 | ​
Retained earnings | ​ | 9,318.8 | ​ | ​ | ​ | 8,814.5 | ​
Accumulated other comprehensive loss | ​ | (1,726.6) | ​ | ​ | ​ | (1,634.8) | ​
Treasury stock | ​ | (7,301.0) | ​ | ​ | ​ | (6,784.2) | ​
Total Ecolab shareholders’ equity | ​ | 7,236.1 | ​ | ​ | ​ | 7,224.2 | ​
Noncontrolling interest | ​ | 22.5 | ​ | ​ | ​ | 28.9 | ​
Total equity | ​ | 7,258.6 | ​ | ​ | ​ | 7,253.1 | ​
Total liabilities and equity | ​ | $21,464.3 | ​ | ​ | ​ | $21,206.4 | ​

​

(a) | Common stock, 800.0 shares authorized, $1.00 par value, 284.5 shares outstanding at December 31, 2022 and 286.9 shares outstanding at December 31, 2021. Shares outstanding are net of treasury stock.

​

​

The accompanying notes are an integral part of the consolidated financial statements.

​

​

55

Table of Contents

CONSOLIDATED STATEMENTS OF CASH FLOWS

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
OPERATING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss) including noncontrolling interest | ​ | ​ | $1,108.9 | ​ | ​ | ​ | $1,144.0 | ​ | ​ | ($1,185.5) | ​
Less: Net loss from discontinued operations, including noncontrolling interest | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (2,170.3) | ​
Net income from continuing operations, including noncontrolling interest | ​ | ​ | $1,108.9 | ​ | ​ | ​ | $1,144.0 | ​ | ​ | $984.8 | ​
Adjustments to reconcile net income to cash provided by operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation |  |  | 618.5 | ​ | ​ | ​ | 604.4 | ​ | ​ | 594.3 | ​
Amortization |  |  | 320.2 | ​ | ​ | ​ | 238.7 | ​ | ​ | 218.4 | ​
Deferred income taxes |  |  | (142.6) | ​ | ​ | ​ | (1.1) | ​ | ​ | (45.8) | ​
Share-based compensation expense |  |  | 87.8 | ​ | ​ | ​ | 89.5 | ​ | ​ | 82.1 | ​
Pension and postretirement plan contributions |  |  | (64.3) | ​ | ​ | ​ | (60.2) | ​ | ​ | (70.7) | ​
Pension and postretirement plan expense, net |  |  | 45.5 | ​ | ​ | ​ | 42.4 | ​ | ​ | 42.0 | ​
Restructuring charges, net of cash paid |  |  | 66.2 | ​ | ​ | ​ | (41.7) | ​ | ​ | 7.8 | ​
Debt refinancing | ​ | ​ | - | ​ | ​ | ​ | 29.4 | ​ | ​ | 77.1 | ​
Other, net |  |  | 24.9 | ​ | ​ | ​ | 15.9 | ​ | ​ | 61.0 | ​
Changes in operating assets and liabilities, net of effect of acquisitions: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable |  |  | (319.6) | ​ | ​ | ​ | (178.2) | ​ | ​ | 155.6 | ​
Inventories |  |  | (402.9) | ​ | ​ | ​ | (73.0) | ​ | ​ | (179.5) | ​
Other assets |  |  | (278.2) | ​ | ​ | ​ | (92.9) | ​ | ​ | 42.3 | ​
Accounts payable |  |  | 394.7 | ​ | ​ | ​ | 200.4 | ​ | ​ | 55.9 | ​
Other liabilities |  |  | 329.3 | ​ | ​ | ​ | 144.3 | ​ | ​ | (283.5) | ​
Cash provided by operating activities - continuing operations |  |  | 1,788.4 | ​ | ​ | ​ | 2,061.9 | ​ | ​ | 1,741.8 | ​
Cash provided by operating activities - discontinued operations | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 118.4 | ​
Cash provided by operating activities | ​ | ​ | 1,788.4 | ​ | ​ | ​ | 2,061.9 | ​ | ​ | 1,860.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
INVESTING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Capital expenditures |  |  | (712.8) | ​ | ​ | ​ | (643.0) | ​ | ​ | (489.0) | ​
Property and other assets sold |  |  | 2.2 | ​ | ​ | ​ | 12.2 | ​ | ​ | 5.3 | ​
Acquisitions and investments in affiliates, net of cash acquired |  |  | (7.2) | ​ | ​ | ​ | (3,923.7) | ​ | ​ | (487.0) | ​
Divestiture of businesses | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 116.2 | ​
Other, net | ​ | ​ | 1.0 | ​ | ​ | ​ | (25.2) | ​ | ​ | (3.2) | ​
Cash used for investing activities - continuing operations |  |  | (716.8) | ​ | ​ | ​ | (4,579.7) | ​ | ​ | (857.7) | ​
Cash provided by investing activities - discontinued operations | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 443.2 | ​
Cash used for investing activities | ​ | ​ | (716.8) | ​ | ​ | ​ | (4,579.7) | ​ | ​ | (414.5) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
FINANCING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net (repayments) issuances of commercial paper and notes payable |  |  | (404.3) | ​ | ​ | ​ | 393.6 | ​ | ​ | (65.5) | ​
Long-term debt borrowings |  |  | 494.0 | ​ | ​ | ​ | 2,775.0 | ​ | ​ | 1,855.9 | ​
Long-term debt repayments |  |  | - | ​ | ​ | ​ | (1,017.9) | ​ | ​ | (1,570.0) | ​
Reacquired shares |  |  | (518.2) | ​ | ​ | ​ | (106.6) | ​ | ​ | (146.2) | ​
Dividends paid |  |  | (602.8) | ​ | ​ | ​ | (566.4) | ​ | ​ | (560.8) | ​
Exercise of employee stock options |  |  | 29.1 | ​ | ​ | ​ | 143.5 | ​ | ​ | 241.5 | ​
Debt refinancing | ​ | ​ | - | ​ | ​ | ​ | (29.4) | ​ | ​ | (77.1) | ​
Hedge settlements | ​ | ​ | 172.0 | ​ | ​ | ​ | 25.9 | ​ | ​ | (8.4) | ​
Other, net | ​ | ​ | (7.1) | ​ | ​ | ​ | (14.5) | ​ | ​ | (9.6) | ​
Cash (used for) provided by financing activities - continuing operations |  |  | (837.3) | ​ | ​ | ​ | 1,603.2 | ​ | ​ | (340.2) | ​
Cash used for financing activities - discontinued operations | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (1.6) | ​
Cash (used for) provided by financing activities | ​ | ​ | (837.3) | ​ | ​ | ​ | 1,603.2 | ​ | ​ | (341.8) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Effect of exchange rate changes on cash and cash equivalents |  |  | 4.4 | ​ | ​ |  | 14.3 | ​ |  | (30.1) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Increase (decrease) in cash and cash equivalents |  |  | 238.7 | ​ | ​ | ​ | (900.3) | ​ | ​ | 1,073.8 | ​
Cash and cash equivalents, beginning of period - continuing operations | ​ | ​ | 359.9 | ​ | ​ | ​ | 1,260.2 | ​ | ​ | 118.8 | ​
Cash and cash equivalents, beginning of period - discontinued operations | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 67.6 | ​
Cash and cash equivalents, beginning of period |  |  | 359.9 | ​ | ​ | ​ | 1,260.2 | ​ | ​ | 186.4 | ​
Cash and cash equivalents, end of period - continuing operations | ​ | ​ | 598.6 | ​ | ​ | ​ | 359.9 | ​ | ​ | 1,260.2 | ​
Cash and cash equivalents, end of period - discontinued operations | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | - | ​
Cash and cash equivalents, end of period | ​ | ​ | $598.6 | ​ | ​ | ​ | $359.9 | ​ | ​ | $1,260.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
SUPPLEMENTAL CASH FLOW INFORMATION | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income taxes paid | ​ | ​ | $308.9 | ​ | ​ | ​ | $275.7 | ​ | ​ | $366.9 | ​
Net interest paid |  |  | 222.4 | ​ | ​ |  | 208.7 | ​ |  | 262.5 | ​

​

The accompanying notes are an integral part of the consolidated financial statements.

​

56

Table of Contents

CONSOLIDATED STATEMENTS OF EQUITY

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31, 2021, 2020 and 2019
(millions, except per share amounts) |  | Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | AOCI (Loss) |  | Treasury Stock |  | Ecolab Shareholders' Equity |  | Non-Controlling Interest |  | Total Equity
Balance, December 31, 2019 | ​ | ​ | $359.6 | ​ |  | $5,907.1 | ​ |  | $9,993.7 | ​ |  | ($2,089.7) | ​ |  | ($5,485.4) | ​ |  | $8,685.3 | ​ |  | $40.5 | ​ |  | $8,725.8
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
New accounting guidance adoption (a) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (4.3) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (4.3) | ​ |  | ​ | ​ |  | (4.3)
Net (loss) income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,205.1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (1,205.1) | ​ |  | 19.6 | ​ |  | (1,185.5)
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 95.3 | ​ | ​ | ​ | ​ |  | 95.3 | ​ |  | 1.8 | ​ |  | 97.1
Cash dividends declared (b) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (541.3) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (541.3) | ​ |  | (21.0) | ​ |  | (562.3)
Separation of ChampionX | ​ | ​ | ​ | ​ | ​ | (8.5) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,051.4) | ​ | ​ | (1,059.9) | ​ | ​ | 3.4 | ​ | ​ | (1,056.5)
Changes in noncontrolling interests | ​ | ​ | ​ | ​ | ​ | 17.6 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 17.6 | ​ | ​ | (9.3) | ​ | ​ | 8.3
Stock options and awards | ​ |  | 3.0 | ​ | ​ | 318.8 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3.3 | ​ |  | 325.1 | ​ | ​ | ​ | ​ |  | 325.1
Reacquired shares | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (146.2) | ​ |  | (146.2) | ​ | ​ | ​ | ​ |  | (146.2)
Balance, December 31, 2020 | ​ |  | 362.6 | ​ |  | 6,235.0 | ​ |  | 8,243.0 | ​ |  | (1,994.4) | ​ |  | (6,679.7) | ​ |  | 6,166.5 | ​ |  | 35.0 | ​ |  | 6,201.5
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,129.9 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 1,129.9 | ​ |  | 14.1 | ​ |  | 1,144.0
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 359.6 | ​ | ​ | ​ | ​ |  | 359.6 | ​ |  | (3.2) | ​ |  | 356.4
Cash dividends declared (b) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (558.4) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (558.4) | ​ |  | (17.0) | ​ |  | (575.4)
Stock options and awards | ​ |  | 1.5 | ​ | ​ | 229.6 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2.1 | ​ |  | 233.2 | ​ | ​ | ​ | ​ |  | 233.2
Reacquired shares | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (106.6) | ​ |  | (106.6) | ​ | ​ | ​ | ​ |  | (106.6)
Balance, December 31, 2021 | ​ |  | 364.1 | ​ |  | 6,464.6 | ​ |  | 8,814.5 | ​ |  | (1,634.8) | ​ |  | (6,784.2) | ​ |  | 7,224.2 | ​ |  | 28.9 | ​ |  | 7,253.1
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,091.7 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,091.7 | ​ | ​ | 17.2 | ​ | ​ | 1,108.9
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (91.8) | ​ | ​ | ​ | ​ |  | (91.8) | ​ |  | (4.2) | ​ |  | (96.0)
Cash dividends declared (b) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (587.4) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (587.4) | ​ |  | (20.0) | ​ |  | (607.4)
Fair value adjustment of prior acquisition | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | - | ​ | ​ | 0.6 | ​ | ​ | 0.6
Stock options and awards |  |  | 0.6 | ​ | ​ | 115.6 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1.4 | ​ |  | 117.6 | ​ | ​ | ​ | ​ |  | 117.6
Reacquired shares | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (518.2) | ​ |  | (518.2) | ​ | ​ | ​ | ​ |  | (518.2)
Balance, December 31, 2022 | ​ | ​ | $364.7 | ​ | ​ | $6,580.2 | ​ | ​ | $9,318.8 | ​ | ​ | ($1,726.6) | ​ | ​ | ($7,301.0) | ​ | ​ | $7,236.1 | ​ | ​ | $22.5 | ​ | ​ | $7,258.6
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

| (a) | In 2020, upon adoption of ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Company reclassified the cumulative effect of applying the standard to retained earnings at the beginning of the period adopted.

| (b) | Dividends declared per common share were $2.06, $1.95, and $1.89 in 2022, 2021 and 2020, respectively.

​

​

COMMON STOCK ACTIVITY

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​ | 2020 |
​ | ​ | Common | ​ | Treasury | ​ | ​ | Common | ​ | Treasury | ​ | Common | ​ | Treasury |
Year ended December 31 |  | Stock |  | Stock | ​ | ​ | Stock |  | Stock |  | Stock |  | Stock |
Shares, beginning of year |  | 364,139,362 |  | (77,255,713) | ​ |  | 362,553,443 | ​ | (76,801,025) |  | 359,569,234 | ​ | (71,159,472) | ​
Stock options |  | 276,059 | ​ | 14,525 | ​ |  | 1,270,757 | ​ | 29,684 |  | 2,577,231 | ​ | 35,122 | ​
Stock awards |  | 296,420 | ​ | 17,794 | ​ |  | 315,162 | ​ | 17,760 | ​ | 406,978 | ​ | 40,122 | ​
Reacquired shares | ​ | - | ​ | (3,038,107) | ​ | ​ | - | ​ | (502,132) | ​ | - | ​ | (761,245) | ​
Separation of ChampionX | ​ | - | ​ | - | ​ | ​ | - | ​ | - | ​ | - | ​ | (4,955,552) | ​
Shares, end of year |  | 364,711,841 |  | (80,261,501) | ​ |  | 364,139,362 |  | (77,255,713) |  | 362,553,443 |  | (76,801,025) | ​

​

​

The accompanying notes are an integral part of the consolidated financial statements.

​

​

​

57

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

​

1. NATURE OF BUSINESS

​

Ecolab is a global leader in water, hygiene and infection prevention solutions and services that protect people and vital resources. The Company delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries.

​

The Company’s cleaning and sanitizing programs and products and pest elimination services support customers in the foodservice, food and beverage processing, hospitality, healthcare, government and education, retail, textile care and commercial facilities management sectors. The Company’s products and technologies are also used in water treatment, pollution control, energy conservation, refining, primary metals manufacturing, papermaking, mining and other industrial processes.

​

In June 2020, the Company completed the separation of its Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX business, followed immediately by the merger (the “Merger”) of ChampionX with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

​

As discussed in Note 5 Discontinued Operations, during 2020, the ChampionX business met the criteria to be reported as discontinued operations because the separation of the ChampionX business was a strategic shift in business that had a major effect on the Company's operations and financial results. Therefore, the Company reported the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations in 2020. Unless otherwise noted, the accompanying Notes to the Consolidated Financial Statements have all been revised to reflect the effect of the separation of ChampionX and all 2020 balances have been revised accordingly to reflect continuing operations only.

​

In December 2021, the Company acquired Purolite for total consideration of $3.7 billion in cash, net of cash acquired. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions, that is highly complementary to the Company’s current offering and critical to safe, high quality drug production and biopharma product purification in the life sciences industries. It also provides purification and separation solutions for critical industrial markets like microelectronics, nuclear power and food and beverage. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within the Company’s Life Sciences operating segment.

​

The Company is aligned into three reportable segments: Global Industrial, Global Institutional & Specialty, and Global Healthcare & Life Sciences as discussed in Note 19 Operating Segments and Geographical Information. Operating segments that were not aggregated and do not exceed the quantitative criteria to be separately reported have been combined into Other.

​

Except for the changes due to adoption of the new accounting standards, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements.

​

​

58

Table of Contents

2. SIGNIFICANT ACCOUNTING POLICIES

​

Principles of Consolidation

​

The consolidated financial statements include the accounts of the Company and all subsidiaries in which the Company has a controlling financial interest. Investments in companies, joint ventures or partnerships in which the Company does not have control but has the ability to exercise significant influence over operating and financial decisions, are reported using the equity method of accounting. The alternative method of accounting is used in circumstance where the Company’s investments in companies, joint ventures and partnerships neither provide it control or significant influence over the investee and for investments that do not have readily identifiable fair values. Investments accounted for under the alternative method are recorded at cost and adjusted for impairments, if any, or observable price changes of the same or similar securities issued by the investee. International subsidiaries are included in the financial statements on the basis of their U.S. GAAP November 30 fiscal year ends to facilitate the timely inclusion of such entities in the Company’s consolidated financial reporting. All intercompany transactions and profits are eliminated in consolidation.

​

Use of Estimates

​

The preparation of the Company’s financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. The Company’s critical accounting estimates include revenue recognition, litigation and environmental reserves, actuarially determined liabilities, income taxes, long-lived assets, intangible assets and goodwill.

​

Foreign Currency Translation

​

Financial position and reported results of operations of the Company’s non-U.S. dollar functional currency international subsidiaries are measured using local currencies as the functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect at each fiscal year end. The translation adjustments related to assets and liabilities that arise from changes in exchange rates from period to period are included in accumulated other comprehensive income (loss) in shareholders’ equity. Income statement accounts are translated at average rates of exchange prevailing during the year. As discussed in Note 19 Operating Segments and Geographic Information, the Company evaluates its international operations based on fixed rates of exchange; however, changes in exchange rates from period to period impact the amount of reported income from consolidated operations.

​

Concentration of Credit Risk

​

Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed to perform as contracted. The Company believes the likelihood of incurring material losses due to concentration of credit risk is minimal. The principal financial instruments subject to credit risk are as follows:

​

Cash and Cash Equivalents - The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The possibility of loss related to financial condition of major banks has been deemed minimal. Additionally, the Company’s investment policy limits exposure to concentrations of credit risk and changes in market conditions.

​

Accounts Receivable - A large number of customers in diverse industries and geographies, as well as the practice of establishing reasonable credit lines, limits credit risk. Based on historical trends and experiences, the allowance for expected credit losses is adequate to cover expected credit risk losses.

​

Foreign Currency and Interest Rate Contracts and Derivatives - Exposure to credit risk is limited by internal policies and active monitoring of counterparty risks. In addition, the Company uses a diversified group of major international banks and financial institutions as counterparties. The Company does not anticipate nonperformance by any of these counterparties.

​

Cash and Cash Equivalents

​

Cash equivalents include highly-liquid investments with a maturity of three months or less when purchased.

​

Accounts Receivable and Allowance for Expected Credit Losses

​

Accounts receivable are carried at the invoiced amounts, less an allowance for expected credit losses, and generally do not bear interest. The Company’s allowance for expected credit losses estimates the amount of expected future credit losses by analyzing accounts receivable balances by age and applying historical write-off and collection experience. The Company’s estimates separately consider macroeconomic trends, specific circumstances and credit conditions of customer receivables. Account balances are written off against the allowance when it is determined the receivable will not be recovered.

​

The Company’s allowance for the expected return of products shipped and credits related to pricing or quantities shipped was $59 million, $19 million, and $16 million as of December 31, 2022, 2021 and 2020, respectively. Returns and credit activity is recorded directly as a reduction to revenue.

​

59

Table of Contents

The following table summarizes the activity in the allowance for expected credit losses:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beginning balance | ​ | ​ | $52.8 | ​ | ​ | ​ | $68.4 | ​ | ​ | ​ | $38.8
Adoption of new standard | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 4.3
Bad debt expense | ​ |  | 38.1 | ​ | ​ |  | 15.0 | ​ | ​ |  | 57.7
Write-offs | ​ |  | (21.1) | ​ | ​ |  | (27.4) | ​ | ​ |  | (31.6)
Other (a) | ​ |  | 2.1 | ​ | ​ |  | (3.2) | ​ | ​ |  | (0.8)
Ending balance | ​ | ​ | $71.9 | ​ | ​ | ​ | $52.8 | ​ | ​ | ​ | $68.4

​

(a) | Other amounts are primarily the effects of changes in currency translations and acquired balances.

​

Inventory Valuations

​

Inventories are valued at the lower of cost or net realizable value. Certain U.S. inventory costs are determined on a last-in, first-out (“LIFO”) basis. LIFO inventories represented 29% and 27% of consolidated inventories as of December 31, 2022 and 2021, respectively. All other inventory costs are determined using either the average cost or first-in, first-out (“FIFO”) methods. Inventory values at FIFO, as shown in Note 6, approximate replacement cost.

​

Property, Plant and Equipment

​

Property, plant and equipment assets are stated at cost. Merchandising and customer equipment consists principally of various dispensing systems for the Company’s cleaning and sanitizing products, warewashing machines and process control and monitoring equipment. Certain dispensing systems capitalized by the Company are accounted for on a mass asset basis, whereby equipment is capitalized and depreciated as a group and written off when fully depreciated. The Company capitalizes both internal and external costs to develop or purchase computer software. Costs incurred for data conversion, training and maintenance associated with capitalized software are expensed as incurred. Expenditures for major renewals and improvements, which significantly extend the useful lives of existing plant and equipment, are capitalized and depreciated. Expenditures for repairs and maintenance are charged to expense as incurred. Upon retirement or disposition of plant and equipment, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in income.

​

Depreciation is charged to operations using the straight-line method over the assets’ estimated useful lives ranging from 5 to 40 years for buildings and leasehold improvements, 3 to 20 years for machinery and equipment, 3 to 20 years for merchandising and customer equipment and 3 to 7 years for capitalized software. The straight-line method of depreciation reflects an appropriate allocation of the cost of the assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. Depreciation expense was $619 million, $604 million and $594 million for 2022, 2021 and 2020, respectively.

​

Goodwill and Other Intangible Assets

​

Goodwill

​

Goodwill arises from the Company’s acquisitions and represents the excess of the fair value of the purchase consideration exchanged over the fair value of net assets acquired. The Company’s reporting units are largely its operating segments. Following the acquisition of Purolite in December 2021, the Company’s Life Sciences Operating Segment consists of the Purolite and Global Life Sciences Reporting Units. The Company assesses goodwill for impairment on an annual basis during the second quarter. If circumstances change or events occur that demonstrate it is more likely than not that the carrying amount of a reporting unit exceeds its fair value, the Company completes an interim goodwill impairment assessment of that reporting unit prior to the next annual assessment. If the results of an annual or interim goodwill impairment assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, the Company will recognize an impairment loss for the amount by which the reporting unit’s carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

​

During the second quarter of 2022, the Company completed its annual goodwill impairment assessment for eleven of its twelve reporting units using discounted cash flow analyses that incorporated assumptions regarding future growth rates, terminal values and discount rates. The Company’s goodwill impairment assessments for 2022 indicated the estimated fair values of each of these eleven reporting units exceeded the carrying amounts of the respective reporting unit by a significant margin. Given the recent acquisition of Purolite, the Company’s annual goodwill impairment assessment of the Purolite Reporting Unit was qualitative in nature and considered information regarding its operations, financial performance and the macroeconomic environment. After weighting both positive and negative information, it is more likely than not that the fair value of the Purolite Reporting Unit exceeds its carrying amount. No events were noted during the second half of 2022 that required completion of an interim goodwill impairment assessment for any of our twelve reporting units. There has been no impairment of goodwill in any of the periods presented.

​

60

Table of Contents

The changes in the carrying amount of goodwill for each of the Company’s reportable segments were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Global | ​ | Global | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Global | ​ | Institutional | ​ | Healthcare & | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | Industrial |  | & Specialty |  | Life Sciences | ​ | Other |  | Total | ​ |
December 31, 2020 | ​ | ​ | $4,287.9 | ​ | ​ | $564.1 | ​ | ​ | $909.8 | ​ | ​ | $245.1 | ​ | ​ | $6,006.9 | ​ | ​
Current year business combinations (a) | ​ |  | 6.9 | ​ | ​ | 17.2 | ​ | ​ | 2,123.2 | ​ | ​ | - | ​ | ​ | 2,147.3 | ​ | ​
Prior year business combinations (b) | ​ | ​ | (0.9) | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | (0.9) | ​ | ​
Effect of foreign currency translation | ​ |  | (23.8) | ​ | ​ | (4.8) | ​ | ​ | (58.8) | ​ | ​ | (2.0) | ​ | ​ | (89.4) | ​ | ​
December 31, 2021 | ​ | ​ | $4,270.1 | ​ | ​ | $576.5 | ​ | ​ | $2,974.2 | ​ | ​ | $243.1 | ​ | ​ | $8,063.9 | ​ | ​
Prior year business combinations (b) | ​ | ​ | 0.4 | ​ | ​ | - | ​ | ​ | 253.4 | ​ | ​ | - | ​ | ​ | 253.8 | ​ | ​
Effect of foreign currency translation | ​ | ​ | (188.7) | ​ | ​ | (8.9) | ​ | ​ | (102.2) | ​ | ​ | (5.2) | ​ | ​ | (305.0) | ​ | ​
December 31, 2022 | ​ | ​ | $4,081.8 | ​ | ​ | $567.6 | ​ | ​ | $3,125.4 | ​ | ​ | $237.9 | ​ | ​ | $8,012.7 | ​ | ​

​

(a) | Represents goodwill associated with current year acquistions. For 2021, approximately $2,209 million of goodwill related to businesses acquired is expected to be tax deductible related to the acquisitions of Purolite and National Wiper Alliance, Inc. (refer to Footnote 4 for additional information).

(b) | Represents purchase price allocation adjustments for acquisitions deemed preliminary as of the end of the prior year.

​

Other Intangible Assets

​

The Nalco trade name is the Company’s only indefinite life intangible asset, which is tested for impairment on an annual basis during the second quarter. During the second quarter of 2022, the Company completed its annual impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions regarding future sales projections, royalty rate and discount rates. The Company’s Nalco trade name impairment assessment for 2022 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. No events were noted during the second half of 2022 that required completion of an interim impairment assessment of our Nalco trade name. There has been no impairment of the Nalco trade name intangible asset since it was acquired.

​

The Company’s intangible assets subject to amortization include customer relationships, trademarks, patents and other technology primarily acquired through business acquisitions. The fair value of intangible assets acquired in business acquisitions are estimated primarily using discounted cash flow valuation methods at the time of acquisition. Intangible assets are amortized on a straight-line basis over their estimated lives. The weighted-average useful life of amortizable intangible assets was 15 years as of December 31, 2022 and 2021.

​

The weighted-average useful life by type of amortizable asset at December 31, 2022 were as follows:

​

(years)

​ | ​ | ​
Customer relationships |  | 15
Patents |  | 14
Trademarks |  | 13
Other technology |  | 12

​

The straight-line method of amortization reflects an appropriate allocation of the cost of the intangible assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. The Company evaluates the remaining useful life of its intangible assets subject to amortization each reporting period to determine whether events and circumstances warrant a change to the estimated remaining period of amortization. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the updated remaining useful life. Amortization expense related to other intangible assets during the last three years and future estimated amortization were as follows:

​

​ | ​ | ​ | ​
(millions) | ​ | ​ | ​
2020 | ​ | $219 | ​
2021 |  | 239 | ​
2022 |  | 320 |
2023 |  | 299 | ​
2024 |  | 291 | ​
2025 |  | 285 | ​
2026 |  | 271 | ​
2027 |  | 146 | ​

​

​

61

Table of Contents

Long-Lived Assets

​

The Company reviews its long-lived and amortizable intangible assets for impairment when significant events or changes in business circumstances indicate that the carrying amount of the assets, or asset group to which it is assigned, may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which the asset or asset group is being used or history of cash flow losses associated with the use of an asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s or asset group’s carrying value over its fair value.

​

In addition, the Company periodically reassesses the estimated remaining useful lives of its long-lived assets. Changes to estimated useful lives would impact the amount of depreciation and amortization recorded in earnings. The Company has not experienced significant changes in the carrying amount or estimated remaining useful lives of its long-lived or amortizable intangible assets.

​

Rental and Leases

​

Lessee

​

The Company determines whether a lease exists at the inception of the arrangement. In assessing whether a contract is or contains a lease, the Company evaluates whether the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company accounts for lease components separately from the nonlease components (e.g., common-area maintenance costs, property taxes, parking, etc.). Operating leases are recorded in operating lease assets, other current liabilities and operating lease liabilities in the Consolidated Balance Sheets.

​

Operating lease assets and operating lease liabilities are measured and recognized based on the present value of the future minimum lease payments over the estimated lease term at the lease commencement date. The Company uses the rate implicit in the lease when available or determinable. When the rate implicit in the lease is not determinable, the Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the present value of future payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease liability and are recognized as incurred. The Company identified real estate, vehicles and other equipment as the primary classes of its leases. Certain leases with a similar class of underlying assets are accounted for as a portfolio of leases.

​

The Company does not record operating lease assets or liabilities for leases with terms of twelve months or less. Those lease payments are recognized in the Consolidated Statements of Income over the lease term as incurred.

​

Many of the Company’s leases include options to renew or cancel, which are at the Company’s sole discretion. Renewal terms can extend the lease term from one month to multiple years, whereas, cancellation terms can shorten the lease term by multiple years. The lease start date is the date when the leased asset is available for use and in possession of the Company. The lease end date, which includes any options to renew or cancel that are reasonably certain to be exercised, is based on the terms of the contract. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The Company’s lease agreements do not contain any material restrictive covenants.

​

Lessor

​

The Company accounts for lease and nonlease components separately. The nonlease components, such as product and service revenue, are accounted for under Topic 606 Revenue from Contracts with Customers, refer to Note 18 for more information. Revenue from leasing equipment is recognized on a straight-line basis over the life of the lease. Cost of sales includes the depreciation expense for assets under operating leases. The assets are depreciated over their estimated useful lives. Initial lease terms range from one year to five years and most leases include renewal options.

​

Lease contracts convey the right for the customer to control the equipment for a period of time as defined by the contract. There are no options for the customer to purchase the equipment and therefore the equipment remains the property of the Company at the end of the lease term. Refer to Note 14 for additional information regarding rental and leases.

​

Income Taxes

​

Income taxes are recognized during the period in which transactions enter into the determination of financial statement income, with deferred income taxes provided for the tax effect of temporary differences between the carrying amount of assets and liabilities and their tax bases. The Company records a valuation allowance to reduce its deferred tax assets when uncertainty regarding their realizability exists. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes. The Company records liabilities for income tax uncertainties in accordance with the U.S. GAAP recognition and measurement criteria guidance. The Company has elected the period cost method and considers the estimated global intangible low taxed income (“GILTI”) impact in tax expense. The Company recognizes interest and penalties related to income tax uncertainties in the income tax provision.

​

The CHIPS Act (CHIPS) was signed into U.S. law on August 9, 2022. CHIPS includes incentives for domestic semiconductor manufacturing for expenditures incurred after December 31, 2022. The Company continues to assess qualification for the new tax incentives but does not anticipate CHIPS to have a material impact on the Company’s financial statements.

​

62

Table of Contents

The Inflation Reduction Act (IRA) includes a corporate alternative minimum tax on certain large corporations, incentives to address climate change mitigation and other non-income tax provisions, including an excise tax on the repurchase of corporate stock. The IRA is effective January 1, 2023. The Company continues to assess the impact of the IRA and qualification for new tax incentives but does not anticipate the IRA to have a material impact on the Company’s financial statements.

​

Refer to Note 13 for additional information regarding income taxes.

​

Share-Based Compensation

​

The Company measures compensation expense for share-based awards at fair value at the date of grant and recognizes compensation expense over the service period for awards expected to vest. The majority of grants to retirement eligible recipients (age 55 with required years of service) are recorded to expense using the non-substantive vesting method and are fully expensed over a six-month period following the date of grant. In addition, the Company includes a forfeiture estimate in the amount of compensation expense being recognized based on an estimate of the number of outstanding awards expected to vest.

​

All excess tax benefits or deficiencies are recognized as discrete income tax items on the Consolidated Statements of Income. The extent of excess tax benefits is subject to variation in stock price and stock option exercises. Refer to Note 12 for additional information regarding equity compensation plans.

​

Restructuring Activities

​

The Company’s restructuring activities are associated with plans to enhance its efficiency, effectiveness and sharpen its competitiveness. These restructuring plans include net costs associated with significant actions involving employee-related severance charges, contract termination costs and asset write-downs and disposals. Employee termination costs are largely based on policies and severance plans, and include personnel reductions and related costs for severance, benefits and outplacement services. These charges are reflected in the quarter in which the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Contract termination costs include charges to terminate leases prior to the end of their respective terms and other contract termination costs. Asset write-downs and disposals include leasehold improvement write-downs, other asset write-downs associated with combining operations and disposal of assets. Refer to Note 3 for additional information regarding restructuring activities.

​

Revenue Recognition

​

Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing service.

​

Product and Sold Equipment

​

Revenue from product and sold equipment is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment.

​

Service and Lease Equipment

​

Revenue from service and leased equipment is recognized when the services are provided, or the customer receives the benefit from the leased equipment, which is over time. Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue for leased equipment is accounted for under Topic 842 Leases and recognized on a straight-line basis over the length of the lease contract.

​

Other Considerations

​

Contracts with customers may include multiple performance obligations. For contracts with multiple performance obligations, the consideration is allocated between products and services based on their stand-alone selling prices. Stand-alone selling prices are generally based on the prices charged to customers when the good or service is not bundled with other product or services or using an expected cost plus margin. Judgment is used in determining the amount of service that is embedded within the Company’s contracts, which is based on the amount of time spent on the performance obligation activities. The level of effort, including the estimated margin that would be charged, is used to determine the amount of service revenue. Depending on the terms of the contract, the Company may defer the recognition of revenue when a future performance obligation has not yet occurred.

​

Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue-producing transaction, which are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight are recognized in cost of sales when control over the product has transferred to the customer.

​

Other estimates used in recognizing revenue include allocating variable consideration to customer programs and incentive offerings, including pricing arrangements, promotions and other volume-based incentives at the time the sale is recorded. These estimates are based primarily on historical experience and anticipated performance over the contract period. Based on the certainty in estimating these amounts, they are included in the transaction price of the contracts and the associated remaining performance obligations. The Company recognizes revenue when collection of the consideration expected to be received in exchange for transferring goods or providing services is probable.

63

Table of Contents

The Company’s revenue policies do not provide for general rights of return. Estimates used in recognizing revenue include the delay between the time that products are shipped and when they are received by customers, when title transfers and the amount of credit memos issued in subsequent periods. Depending on market conditions, the Company may increase customer incentive offerings, which could reduce gross profit margins over the term of the incentive.

​

Earnings Per Common Share

​

The difference in the weighted average common shares outstanding for calculating basic and diluted earnings attributable to Ecolab per common share is a result of the dilution associated with the Company’s equity compensation plans. As noted in the table below, certain stock options and units outstanding under these equity compensation plans were not included in the computation of diluted earnings attributable to Ecolab per common share because they would not have had a dilutive effect.

​

The computations of the basic and diluted earnings attributable to Ecolab per share amounts were as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions, except per share) | ​ | 2022 | ​ | 2021 | ​ | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income from continuing operations attributable to Ecolab | ​ | ​ | $1,091.7 | ​ | ​ | ​ | $1,129.9 | ​ | ​ | ​ | $967.4
Net loss from discontinued operations, net of tax | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | (2,172.5)
Net income (loss) attributable to Ecolab | ​ | ​ | $1,091.7 | ​ | ​ | ​ | $1,129.9 | ​ | ​ | ​ | ($1,205.1)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average common shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic |  |  | 285.2 | ​ | ​ |  | 286.3 | ​ | ​ |  | 287.0
Effect of dilutive stock options and units |  |  | 1.4 | ​ | ​ |  | 2.8 | ​ | ​ | ​ | 3.3
Diluted |  |  | 286.6 | ​ | ​ |  | 289.1 | ​ | ​ |  | 290.3
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings (loss) attributable to Ecolab per common share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic EPS | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | ​ | $3.83 | ​ | ​ | ​ | $3.95 | ​ | ​ | ​ | $3.37
Discontinued operations | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ​ | ($7.57)
Earnings (loss) attributable to Ecolab | ​ | ​ | $3.83 | ​ | ​ | ​ | $3.95 | ​ | ​ | ​ | ($4.20)
Diluted EPS | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | ​ | $3.81 | ​ | ​ | ​ | $3.91 | ​ | ​ | ​ | $3.33
Discontinued operations | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ​ | ($7.48)
Earnings (loss) attributable to Ecolab | ​ | ​ | $3.81 | ​ | ​ | ​ | $3.91 | ​ | ​ | ​ | ($4.15)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Anti-dilutive securities excluded from the computation of diluted EPS |  |  | 3.9 | ​ | ​ |  | 1.9 | ​ | ​ |  | 1.9
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts do not necessarily sum due to rounding. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Discontinued Operations

​

Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. The ChampionX business met the criteria to be reported as discontinued operations because it was a strategic shift in business that had a major effect on the Company’s operations and financial results. The ChampionX business is presented on the Consolidated Statements of Income as discontinued operations. Refer to Note 5, Discontinued Operations, for additional information.

​

​

64

Table of Contents

Other Significant Accounting Policies

​

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

​

​ | ​ | ​
Policy | ​ | Note
Fair value measurements |  | 8
Derivatives and hedging transactions |  | 9
Share-based compensation |  | 12
Research and development expenditures | ​ | 15
Legal contingencies |  | 16
Pension and post-retirement benefit plans | ​ | 17
Reportable segments | ​ | 19

​

New Accounting Pronouncements

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Standards That Are Not Yet Adopted:
​ |  | ​ |  | ​ |  | Required |  | ​ |
​ | ​ | Date of | ​ | ​ | ​ | Date of | ​ | Effect on the | ​
Standard |  | Issuance | ​ | Description |  | Adoption |  | Financial Statements | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ASU 2021-08 - Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers | ​ | October 2021 | ​ | Update to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. | ​ | January 1, 2023. | ​ | The Company is currently evaluating any potential future impacts on the Company's financial statements, any such changes would be prospective. | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Standards That Were Adopted:
​ |  | Date of |  | ​ |  | Date of |  | Effect on the
Standard |  | Issuance | ​ | Description |  | Adoption |  | Financial Statements
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ASU 2020-04 - Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting ASU 2021-01 - Reference Rate Reform (Topic 848): Scope ASU 2022-06 - Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 | ​ | March 2020 | ​ | Certain LIBOR rates, widely used reference rates for pricing financial products, were discontinued on December 31, 2021. This standard provides optional expedients and exceptions if certain criteria are met when accounting for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. | ​ | Application of guidance is optional until the options and expedients expire on December 31, 2024. | ​ | The Company evaluated contracts whose terms previously included references to LIBOR or one of its equivalents and identified two contracts requiring modifications of the interest rate provisions included therein. The Company applied certain of the expedients included in ASC 848 allowing the Company to account for the contract modifications prospectively. There were no financial statement impacts at the time of modification.
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ASU 2021 -10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance | ​ | November 2021 | ​ | Update to increase the transparency of government assistance including annual disclosure of the types of assistance accounted for under a grant or contribution method of accounting, an entity’s accounting for the assistance, and the effect of the assistance on an entity’s financial statements. | ​ | Annual period beginning January 1, 2022. | ​ | The adoption of this standard did not have a significant impact on the Company's financial statements.

​

​

No other new accounting pronouncement issued or effective has had or is expected to have a material impact on the Company’s consolidated financial statements.

​

​

65

Table of Contents

3. SPECIAL (GAINS) AND CHARGES

​

Special (gains) and charges reported on the Consolidated Statements of Income included the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
Cost of sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ |  | $21.4 | ​ | ​ |  | $24.7 | ​ | ​ | ​ | $7.4 | ​
Acquisition and integration activities | ​ | ​ | 25.0 | ​ | ​ | ​ | 4.2 | ​ | ​ | ​ | 3.9 | ​
COVID-19 activities, net | ​ | ​ | 16.3 | ​ | ​ | ​ | 64.7 | ​ | ​ | ​ | 12.5 | ​
Russia/Ukraine | ​ | ​ | 7.2 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other | ​ | ​ | - | ​ | ​ | ​ | 0.3 | ​ | ​ | ​ | 24.4 | ​
Cost of sales subtotal | ​ |  | 69.9 | ​ | ​ |  | 93.9 | ​ |  |  | 48.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ |  | 85.8 | ​ | ​ |  | 11.9 | ​ | ​ | ​ | 71.4 | ​
Acquisition and integration activities | ​ | ​ | 14.5 | ​ | ​ | ​ | 29.9 | ​ | ​ | ​ | 8.5 | ​
Disposal and impairment activities | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 41.4 | ​
COVID-19 activities, net | ​ | ​ | 10.2 | ​ | ​ | ​ | 42.4 | ​ | ​ | ​ | 23.6 | ​
Russia/Ukraine | ​ | ​ | 5.9 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other | ​ |  | 24.1 | ​ | ​ |  | 18.4 | ​ | ​ | ​ | 34.7 | ​
Special (gains) and charges subtotal | ​ |  | 140.5 | ​ | ​ |  | 102.6 | ​ |  |  | 179.6 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income subtotal | ​ | ​ | 210.4 | ​ | ​ | ​ | 196.5 | ​ | ​ | ​ | 227.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other (income) expense | ​ | ​ | 50.6 | ​ | ​ | ​ | 37.2 | ​ | ​ | ​ | 0.4 | ​
Interest expense, net | ​ | ​ | - | ​ | ​ | ​ | 33.1 | ​ | ​ | ​ | 83.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total special (gains) and charges | ​ | ​ | $261.0 | ​ | ​ | ​ | $266.8 | ​ | ​ | ​ | $312.0 | ​

​

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with the Company’s internal management reporting.

​

Restructuring Activities

​

Restructuring activities are primarily related to the Europe Program, Institutional Advancement Program, Accelerate 2020 and other immaterial restructuring programs which are described below. These activities have been included as a component of cost of sales, special (gains) and charges, other (income) expense and interest expense, net on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

​

Europe Program

​

In November 2022 the Company approved a Europe cost savings program (the “Europe Program”). In connection with these actions, the Company expects to incur pre-tax charges of $130 million ($110 million after tax). The Europe Program charges are expected to be primarily cash expenditures related to severance and asset disposals. Actual costs may vary from these estimates depending on actions taken.

​

In 2022 the Company recorded total restructuring charges of $67.2 million ($56.0 million after tax) primarily related to severance. The liability related to the Europe Program was $62.0 million as of December 31, 2022 and is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

​

Restructuring activity related to the Europe Program since inception of the underlying actions includes the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Employee |  |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | Termination | ​ | Asset | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | Costs |  | Disposals |  | Other |  | Total
2022 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | 67.2 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 67.2 | ​
Net cash payments | ​ |  | (5.2) | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | (5.2) | ​
Restructuring liability, December 31, 2022 | ​ | ​ | $62.0 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ​ | $62.0 | ​

​

On February 14, 2023, the Company expanded its previously announced Europe cost savings program to focus on its Institutional and Healthcare businesses in other regions. In connection with the expanded program, the Company now expects to incur pre-tax charges of $195 million ($150 million after tax). The Company expects that these restructuring actions will be completed by 2024. Program actions include headcount reductions from terminations, not filing certain open positions and facility closures.The expanded program charges are expected to be primarily cash expenditures related to severance and asset disposals.

​

66

Table of Contents

Institutional Advancement Program

​

The Company approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance the Company’s Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging the Company’s ongoing investments in digital technology. In February 2021, the Company expanded the Institutional Plan, and expect that these restructuring charges will be completed in 2023, with total anticipated costs of $70 million ($55 million after tax). The remaining costs are expected to be primarily cash expenditures for severance and non-cash related costs to equipment disposals. Actual costs may vary from these estimates depending on actions taken.

​

Certain activities contemplated in this Institutional Plan were previously approved in 2020 and included as part of Accelerate 2020. These activities were reclassified to the Institutional Plan. During 2022, 2021 and 2020, the Company recorded restructuring charges of $6.3 million ($4.8 million after tax), $12.6 million ($10.2 million after tax) and $35.2 million ($26.4 million after tax), respectively, primarily related to severance, disposals of equipment and office closures. The Company has recorded $54.1 million ($41.4 million after tax) of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $1.9 million and $5.1 million as of December 31, 2022 and 2021, respectively, and is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

​

Restructuring activity related to the Institutional Plan since inception of the underlying actions includes the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee |  |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | Termination | ​ | Asset | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | Costs |  | Disposals |  | Other |  | Total
2020 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | $25.6 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $9.6 | ​ | ​ | ​ | $35.2 | ​
Net cash payments | ​ | ​ | (0.9) | ​ | ​ | ​ | - | ​ | ​ | ​ | (9.6) | ​ | ​ | ​ | (10.5) | ​
Restructuring liability, December 31, 2020 | ​ | ​ | 24.7 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 24.7 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2021 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense (income) and accrual | ​ | ​ | ($1.8) | ​ | ​ | ​ | $8.5 | ​ | ​ | ​ | $5.9 | ​ | ​ | ​ | $12.6 | ​
Net cash payments | ​ |  | (19.0) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (4.7) | ​ | ​ | ​ | (23.7) | ​
Non-cash net charges | ​ |  | - | ​ | ​ | ​ | (8.5) | ​ | ​ | ​ | - | ​ | ​ | ​ | (8.5) | ​
Restructuring liability, December 31, 2021 | ​ |  | 3.9 | ​ | ​ | ​ | - | ​ | ​ | ​ | 1.2 | ​ | ​ | ​ | 5.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense (income) and accrual |  |  | 1.2 | ​ | ​ | ​ | 4.9 | ​ | ​ | ​ | 0.2 | ​ | ​ |  | 6.3 | ​
Net cash payments |  |  | (3.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | (0.8) | ​ | ​ |  | (4.6) | ​
Non-cash net charges |  |  | - | ​ | ​ | ​ | (4.9) | ​ | ​ | ​ | - | ​ | ​ |  | (4.9) | ​
Restructuring liability, December 31, 2022 | ​ | ​ | $1.3 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $0.6 | ​ | ​ | ​ | $1.9 | ​

​

Accelerate 2020

​

During 2018, the Company formally commenced a restructuring plan Accelerate 2020 (“the A2020 Plan”), to leverage technology and systems investments and organizational changes. The goals of the Plan are to further simplify and automate processes and tasks, reduce complexity and management layers, consolidate facilities and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, the Company expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. The Company completed the plan with actual costs of $254 million ($198 million after tax) when revised for continuing operations.

​

The Company recorded restructuring charges of $9.9 million ($8.4 million after tax), $5.3 million ($6.2 million after tax) and $41.8 million ($33.0 million after tax) in 2022, 2021 and 2020, respectively, primarily related to severance. Of these expenses, $0.3 million ($0.2 million after tax) during 2020 is recorded in other (income) expense and related to pension settlements and curtailments. The liability related to this Restructuring Plan was $18.1 million and $32.7 million as of December 31, 2022 and 2021, respectively. The Company has recorded $254.4 million ($198.4 million after tax) of cumulative restructuring charges under the Plan. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

​

​

67

Table of Contents

Restructuring activity related to the A2020 Plan since inception of the underlying actions includes the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Employee |  |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | Termination | ​ | Asset | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | Costs |  | Disposals |  | Other |  | Total
Restructuring liability, December 31, 2019 | ​ | ​ | $94.0 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $1.5 | ​ | ​ | ​ | $95.5 | ​
2020 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | 29.5 | ​ | ​ | ​ | 7.8 | ​ | ​ | ​ | 4.5 | ​ | ​ | ​ | 41.8 | ​
Net cash payments | ​ |  | (56.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | (1.0) | ​ | ​ | ​ | (57.8) | ​
Non-cash charges | ​ |  | - | ​ | ​ | ​ | (7.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | (7.8) | ​
Effect of foreign currency translation | ​ |  | 0.1 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 0.1 | ​
Restructuring liability, December 31, 2020 | ​ | ​ | 66.8 | ​ | ​ | ​ | - | ​ | ​ | ​ | 5.0 | ​ | ​ | ​ | 71.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2021 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | 4.3 | ​ | ​ | ​ | 0.3 | ​ | ​ | ​ | 0.7 | ​ | ​ | ​ | 5.3 | ​
Net cash payments | ​ |  | (39.1) | ​ | ​ | ​ | - | ​ | ​ | ​ | (5.0) | ​ | ​ |  | (44.1) | ​
Non-cash charges | ​ |  | - | ​ | ​ | ​ | (0.3) | ​ | ​ | ​ | - | ​ | ​ |  | (0.3) | ​
Restructuring liability, December 31, 2021 | ​ | ​ | 32.0 | ​ | ​ | ​ | - | ​ | ​ | ​ | 0.7 | ​ | ​ | ​ | 32.7 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense (income) and accrual | ​ | ​ | 5.4 | ​ | ​ | ​ | 1.9 | ​ | ​ | ​ | 2.6 | ​ | ​ | ​ | 9.9 | ​
Net cash payments | ​ |  | (21.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | (0.8) | ​ | ​ | ​ | (22.6) | ​
Non-cash charges | ​ |  | - | ​ | ​ | ​ | (1.9) | ​ | ​ | ​ | - | ​ | ​ | ​ | (1.9) | ​
Restructuring liability, December 31, 2022 | ​ | ​ | $15.6 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $2.5 | ​ | ​ | ​ | $18.1 | ​

​

Other Restructuring Activities

​

During 2022, 2021, and 2020, the Company recorded other restructuring charges of $23.8 million ($17.9 million after tax), $18.7 million ($17.0 million after tax), and $1.8 million ($1.2 million after tax), respectively, related to other immaterial restructuring activity. The charges are comprised primarily of severance and asset write-offs.

​

The restructuring liability balance for all other restructuring plans excluding Europe Program, the A2020 Plan and the Institutional Plan was $23.2 million and $4.6 million as of December 31, 2022 and 2021, respectively. The increase in liability was driven primarily by severance expense. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2022 related to all other restructuring plans excluding the Europe Program, the A2020 Plan and Institutional Plan were $5.2 million.

​

Acquisition and integration related costs

​

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2022 include $14.5 million ($11.4 million after tax) related primarily to the Purolite Corporation (“Purolite”) acquisition and consist of integration related costs and advisory and legal fees. Acquisition and integration related costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2022 included $25.0 million ($19.6 million after tax) related primarily to the recognition of fair value step-up in Purolite inventory and other integration related costs.

​

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income include $29.9 million ($23.5 million after tax) in 2021. Charges are related primarily to the Purolite acquisition and consisted of deal costs, integration costs and advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2021 include $4.2 million ($3.3 million after tax) and are related to the recognition of fair value step-up in the Purolite inventory. In conjunction with its acquisitions, the Company incurred $0.8 million ($0.6 million after tax) of special (gains) and charges reported in interest expense in 2021.

​

During 2020, acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income include $8.5 million ($6.9 million after tax). Charges are related to the Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), Bioquell PLC (“Bioquell”) and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs and advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales on the Consolidated Statements of Income in 2020 include $3.9 million ($3.2 million after tax) and are related to recognition of fair value step-up in CID Lines inventory, severance and the closure of a facility. In conjunction with its acquisitions, the Company incurred $0.7 million ($0.6 million after tax) of special (gains) and charges reported in interest expense in 2020.

​

68

Table of Contents

Disposal and impairment charges

​

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statements of Income include $41.4 million ($41.5 million after tax) in 2020. During 2020, the Company recorded a $28.6 million ($28.6 million after tax) impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, the Company recorded charges of $12.8 million ($12.9 million after tax) related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees during 2020.

​

COVID-19 activities

​

The Company recorded inventory reserves of $15.0 million and $60.0 million during 2022 and 2021, respectively, for excess sanitizer inventory and estimated disposal costs. The Company recorded charges of $2.4 million, $36.8 million and $57.1 million during 2022, 2021 and 2020, respectively, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. The Company recorded charges of $9.8 million, $16.5 million and $2.4 million related to employee COVID-19 testing and related expenses during 2022, 2021 and 2020, respectively. In addition, the Company received subsidies and government assistance, which were recorded as a special (gain) and charges of ($0.7) million, ($6.2) million and ($23.4) million during 2022, 2021 and 2020, respectively. COVID-19 pandemic charges are recorded in product and equipment cost of sales, service and lease cost of sales, and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges related to COVID-19 pandemic were $20.2 million, $81.3 million and $27.4 million during 2022, 2021 and 2020, respectively.

​

Russia/Ukraine

​

In light of Russia’s invasion of Ukraine and the sanctions against Russia by the United States and other countries, the Company has made the determination that it will limit the Company’s Russian business to operations that are essential to life, providing minimal support for the Company’s healthcare, life sciences, food and beverage and certain water businesses. The Company incurred charges of $13.1 million ($12.6 million after tax) during 2022, primarily related to recoverability risk of certain assets in both Russia and Ukraine.

​

Other operating activities

​

Other operating activities recorded in special charges of $24.1 million ($18.2 million after tax) in 2022, $18.4 million ($14.1 million after tax) in 2021 and $34.7 million ($33.9 million after tax) in 2020 relate primarily to legal reserves and certain legal charges, which are recorded in special (gains) and charges on the Consolidated Statements of Income. In 2020, other operating activities recorded in special charges of $24.4 million ($16.0 million after tax) were recorded in product and equipment cost of sales on the Consolidated Statements of Income related to a Healthcare product recall in Europe.

​

The Company also recorded a $7.2 million special charge in 2020 related to the separation of ChampionX as a tax expense on the Consolidated Statements of Income.

​

Other (income) expense

​

During 2022 and 2021, the Company incurred pension settlement expense recorded in other (income) expense on the Consolidated Statements of Income of $50.6 million ($38.2 million after tax) and $37.2 million ($28.7 million after tax), respectively, related to U.S. pension plan lump-sum payments to retirees.

​

Interest expense, net

​

During 2021 and 2020, the Company recorded special charges of $32.3 million ($28.4 million after tax) and $83.1 million ($64.0 million after tax), respectively, in interest expense on the Consolidated Statements of Income related to debt issuance and refinancing charges.

​

​

69

Table of Contents

​

4. ACQUISITIONS AND DISPOSITIONS

​

Acquisitions

​

The Company makes business acquisitions that align with its strategic business objectives. The assets and liabilities of acquired businesses are recorded in the Consolidated Balance Sheets based on estimates of the fair value of assets acquired, liabilities assumed and noncontrolling interests acquired as of the acquisition date. Goodwill is recognized in the amount that the purchase consideration paid exceeds the fair value of the net assets acquired. Purchase consideration includes both cash paid and the fair value of noncash consideration exchanged, including stock and/or contingent consideration exchanged, and is reduced by the amount of cash or cash equivalents acquired. Acquisitions during 2021 and 2020 were not significant to the Company’s consolidated financial statements; therefore, pro forma financial information is not presented.

​

2022 Activity

​

No acquisitions occurred during 2022.

​

2021 Activity

​

Purolite Acquisition

​

On December 1, 2021, the Company acquired Purolite for total consideration of $3,706 million in cash, net of cash acquired. Purolite is a US-based business that is a leading and fast-growing global provider of resins for the separation and purification of solutions that is highly complementary to the Company’s current offering and critical to safe, high quality drug production and biopharma product purification in the life sciences industries. It also provides purification and separation solutions for critical industrial markets like microelectronics, nuclear power and food and beverage. Prior to acquisition, Purolite prepared its consolidated financial statements pursuant to the requirements of UK GAAP.

​

The Purolite acquisition has been accounted for as a business combination with the assets acquired and liabilities assumed recognized at fair value as of the acquisition date. The fair values of intangible assets acquired were estimated using discounted cash flow analyses appropriate in the circumstances for the nature of the assets being valued. The valuation models incorporated projections of future cash flows and other valuation assumptions. Significant inputs and assumptions used in the Company’s customer relationship intangible asset valuations include projected revenues, contributory asset charges, tax savings due to amortization, income tax rates, customer attrition rates and discount rates. Significant inputs and assumptions used in the Company’s tradename and acquired technology intangible asset valuations include projected revenues, future asset utilities, royalty rates, tax saving due to amortization, income tax rates and discount rates.

​

The Company incurred certain transaction and integration costs associated with the acquisition that were expensed and were recorded in the Consolidated Statements of Income. Further information related to the Company’s special (gains) and charges is included in Note 3.

​

Purolite purchase accounting was finalized in the fourth quarter of 2022. The following table summarizes the final value of Purolite assets acquired and liabilities assumed, net of cash acquired, as of the acquisition date:

​

​ | ​ | ​ | ​ | ​
(millions) | ​ | December 1, 2021
Tangible assets | ​ | ​ | $361.9 | ​
Identifiable intangible assets | ​ | ​ | ​ | ​
Customer relationships | ​ | ​ | 870.0 | ​
Other technologies | ​ |  | 285.0 | ​
Trademarks | ​ | ​ | 73.0 | ​
Total assets acquired | ​ |  | 1,589.9 | ​
​ | ​ |  | ​ | ​
Goodwill | ​ | ​ | 2,260.6 | ​
​ | ​ | ​ | ​ | ​
Total liabilities | ​ | ​ | 144.8 | ​
Total consideration transferred to sellers, net of cash acquired | ​ |  | $3,705.7 | ​

​

During 2022, the Company recorded purchase accounting adjustments associated with the finalization of the purchase accounting for its acquisition of Purolite. As a result of these purchase accounting adjustments, the Company made $7.2 million of acquisition-related payments, acquisition related net tangible assets decreased by $54.0 million, definite-lived intangible assets decreased by $185.4 million and goodwill increased by $246.6 million.

​

Tangible assets acquired primarily consist of accounts receivable of $61.6 million, property, plant and equipment of $156.5 million and inventory of $122.4 million. Liabilities assumed primarily consist of deferred tax liabilities of $38.2 million and current liabilities of $77.6 million. Identified intangible assets primarily consist of customer relationships, acquired technologies, and trade names and are being amortized over weighted average lives of 17, 14, and 5 years, respectively, with a weighted average life of 15 years.

​

​

70

Table of Contents

Goodwill of $2,260.6 million arising from the acquisition consists largely of the synergies and economies of scale expected through adding complementary geographies and innovative products to the Company’s Life Sciences businesses. Purolite became part of the Global Healthcare & Life Sciences reportable segment. Goodwill of $2,146.3 million is deductible for income tax purposes.

​

Other Acquisitions

​

In December 2020, the Company acquired VanBaerle Hygiene AG (“VanBaerle”), a Switzerland-based business which sells cleaning products and related services to restaurants, long-term care facilities, hotels and laundries primarily for institutional applications. VanBaerle became part of the Global Institutional & Specialty reporting segment. The purchase price included immaterial amounts of holdback and contingent consideration, the remaining amounts of which were settled prior to December 31, 2022. Purchase accounting was finalized in the fourth quarter of 2021.

​

In February 2021, the Company acquired TechTex Holdings Limited (“TechTex”), a U.K.-based business which sells wet and dry wipes and other nonwovens products primarily for life sciences and healthcare applications. TechTex became part of the Global Healthcare & Life Sciences reporting segment. The purchase price included an immaterial holdback amount that was settled prior to December 31, 2021. Purchase accounting was finalized in the first quarter of 2022.

​

In July 2021, the Company acquired National Wiper Alliance, Inc. (“NWA”), a U.S.-based business which sells wipes for healthcare and institutional applications. NWA became part of the Global Healthcare & Life Sciences reporting segment. Purchase accounting was finalized in the third quarter of 2022.

​

In September 2021, the Company acquired EPN Water Col, Ltd. (“EPN”), a South Korean-based business which sells chemical products and manages installations at water treatment chemical injection facilities. EPN became part of the Global Industrial reporting segment. Purchase accounting was finalized in the fourth quarter of 2022.

​

The goodwill related to the acquisitions of VanBaerle, TechTex, or EPN is not tax deductible, whereas the goodwill arising from the acquisition of NWA is tax deductible.

​

2020 Activity

​

CID Lines Acquisition

​

On May 11, 2020, the Company acquired CID Lines for total consideration of $506.9 million in cash, net of cash acquired. CID Lines, a Belgian-based business is a leading global provider of livestock biosecurity and hygiene solutions.

​

The CID Lines acquisition has been accounted for as a business combination with the assets acquired and liabilities assumed recognized at fair value as of the acquisition date. The Company incurred certain transaction and integration costs associated with the acquisition that were expensed and recorded in the Consolidated Statements of Income. Further information related to the Company’s special (gains) and charges is included in Note 3.

​

CID Lines purchase accounting was finalized in the second quarter of 2021. The following table summarizes the final value of CID Lines assets acquired and liabilities assumed, net of cash acquired, as of the acquisition date:

​

​ | ​ | ​ | ​ | ​
(millions) | ​ | May 11, 2020
Tangible assets | ​ | ​ | $54.1 | ​
Identifiable intangible assets | ​ | ​ | ​ | ​
Customer relationships | ​ | ​ | 147.5 | ​
Trademarks | ​ |  | 58.6 | ​
Acquired technologies and product registrations | ​ |  | 47.7 | ​
Total assets acquired | ​ |  | 307.9 | ​
​ | ​ |  | ​ | ​
Goodwill | ​ | ​ | 274.8 | ​
​ | ​ | ​ | ​ | ​
Total liabilities | ​ | ​ | 97.2 | ​
Total consideration transferred to sellers, net of cash acquired | ​ |  | $485.5 | ​

​

Tangible assets acquired primarily consist of accounts receivable of $30.1 million, property, plant and equipment of $7.7 million and inventory of $16.3 million. Liabilities assumed primarily consist of deferred tax liabilities of $64.8 million and current liabilities of $32.4 million. Identified intangible assets primarily consist of customer relationships, trademarks, and acquired technology and product registrations and are being amortized over weighted average lives of 14, 14, and 16 years, respectively, with a weighted average life of 14 years.

Goodwill of $274.8 million arising from the acquisition consists largely of the synergies and economies of scale expected through adding complementary geographies and innovative products to the Company’s Food and Beverage businesses. CID Lines became part of the Global Industrial reportable segment. None of the goodwill recognized from the acquisition is expected to be deductible for income tax purposes.

​

71

Table of Contents

During 2021, the Company recorded purchase accounting adjustments associated with the finalization of the purchase accounting for its acquisition of CID Lines. As a result of these adjustments, the Company decreased goodwill recognized from the acquisition of CID Lines by $0.9 million.

​

Acquisitions

​

The components of the cash paid for other acquisitions, excluding the Purolite and CID Lines acquisitions (as further disclosed above), for 2022, 2021 and 2020, are shown in the following table:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020
Net tangible assets acquired | ​ | ​ | $- | ​ | ​ | ​ | $3.6 | ​ | ​ | ​ | $- | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Identifiable intangible assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Customer relationships |  |  | - | ​ | ​ | ​ | 75.0 | ​ | ​ | ​ | - | ​
Trademarks |  |  | - | ​ | ​ | ​ | 4.7 | ​ | ​ | ​ | - | ​
Non-compete agreements |  |  | - | ​ | ​ | ​ | 3.0 | ​ | ​ | ​ | - | ​
Other technologies | ​ | ​ | - | ​ | ​ | ​ | 1.5 | ​ | ​ | ​ | - | ​
Total intangible assets |  |  | - | ​ | ​ | ​ | 84.2 | ​ | ​ | ​ | - | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Goodwill |  |  | - | ​ | ​ |  | 140.6 | ​ | ​ | ​ | - | ​
Total aggregate purchase price |  |  | - | ​ | ​ |  | 228.4 | ​ | ​ |  | - | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Acquisition-related liabilities and contingent consideration (a) |  |  | - | ​ | ​ |  | (4.4) | ​ | ​ |  | - | ​
Total cash paid for acquisitions, including acquisition-related | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
liabilities and contingent consideration, net of cash acquired | ​ | ​ | $- | ​ | ​ | ​ | $224.0 | ​ | ​ | ​ | $- | ​

​

(a)Subsequent to the acquisitions, $1.4 in contingent consideration was remitted to the seller during 2021 and is included in investing activities on the Consolidated Statement of Cash Flows.

​

During 2022, the Company recorded purchase accounting adjustments associated with the finalization of the purchase accounting for its acquisitions of TechTex, NWA and EPN. As a result of these purchase accounting adjustments, acquisition related net tangible assets decreased by $1.6 million, definite-lived intangible assets decreased by $5.6 million, and goodwill increased by $7.2 million.

​

The weighted average useful lives of definite-lived intangible assets acquired from other acquisitions were 13 years for acquisitions completed in 2021.

​

Dispositions

​

In the second quarter of 2020, the Company completed the sale of Holchem, a U.K.-based supplier of hygiene and cleaning products and services for the food and beverage, foodservice and hospitality industries for total consideration of $106.6 million. Consideration consisted of $55.4 million of cash and the receipt of notes valued at $51.2 million from the acquirer. In the fourth quarter of 2020, all outstanding principal and interest on the notes was paid by the acquirer. After the recognition of transaction costs, the Company recognized an after-tax loss of $12.8 million, which was classified within special charges in the Consolidated Statements of Income. Holchem was included in the Global Industrial reportable segment prior to disposition.

​

As discussed in Note 5, the ChampionX separation met the criteria to be reported as discontinued operations. No other dispositions were significant to the Company’s consolidated financial statements for 2022, 2021 or 2020.

​

​

72

Table of Contents

5. Discontinued Operations

​

On June 3, 2020, the Company effected the split-off of ChampionX through an offer to exchange (the “Exchange Offer”) all shares of ChampionX common stock owned by Ecolab for outstanding shares of Ecolab common stock. In the Exchange Offer, which was oversubscribed, the Company accepted approximately 5.0 million shares of Ecolab common stock in exchange for approximately 122.2 million shares of ChampionX common stock. In the Merger, each outstanding share of ChampionX common stock was converted into the right to receive one share of Apergy common stock, and ChampionX survived the Merger as a wholly owned subsidiary of ChampionX Corporation. In connection with and in accordance with the terms of the Transaction, prior to the consummation of the Exchange Offer and the Merger, ChampionX distributed $527.4 million in cash to Ecolab.

​

The following is a summary of the assets and liabilities transferred to ChampionX as part of the separation:

​

​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​
(millions) | ​ | ​ | ​ | ​
Assets: | ​ |  | ​ | ​
Cash and cash equivalent | ​ |  | $60.6 | ​
Current assets | ​ |  | 810.5 | ​
Non-current assets | ​ |  | 3,222.3 | ​
​ | ​ | ​ | 4,093.4 | ​
Liabilities: | ​ | ​ | ​ | ​
Current liabilities | ​ | ​ | 313.0 | ​
Non-current liabilities | ​ | ​ | 293.7 | ​
​ | ​ | ​ | 606.7 | ​
​ | ​ | ​ | ​ | ​
Net assets distributed to ChampionX | ​ | ​ | ($3,486.7) | ​
Fair value of shares exchanged | ​ | ​ | 1,051.4 | ​
Cash received from ChampionX | ​ | ​ | 527.4 | ​
Consideration received less net assets | ​ | ​ | (1,907.9) | ​
​ | ​ | ​ | ​ | ​
ChampionX cumulative translation adjustment ("CTA") write-off | ​ | ​ | (229.9) | ​
Loss on separation | ​ | ​ | ($2,137.8) | ​
​ | ​ | ​ | ​ | ​

​

The Company accounted for this transaction as a sale and recognized a loss based on ChampionX net assets exceeding the effective proceeds.

​

The ChampionX business, as discussed in Note 1, met the criteria to be reported as discontinued operations because the separation of the ChampionX business was a strategic shift in business that had a major effect on the Company’s operations and financial results. The historical financial results of the ChampionX business are reflected in the Company’s consolidated financial statements as discontinued operations, for all periods presented, and assets and liabilities were retrospectively reclassified as assets and liabilities of discontinued operations.

​

Summarized results of the Company’s discontinued operations are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and equipment sales | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | $858.9
Service and lease sales | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 99.6
Net sales | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 958.5
Product and equipment cost of sales | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 621.7
Service and lease cost of sales | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 80.4
Cost of sales (including special charges) | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 702.1
Selling, general and administrative expenses | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 180.5
Special (gains) and charges | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 2,221.7
Operating income | ​ | ​ | - | ​ | ​ |  | - | ​ |  | (2,145.8)
Other (income) expense | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 0.3
Interest expense (income), net | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 0.2
Income before income taxes | ​ | ​ | - | ​ | ​ |  | - | ​ |  | (2,146.3)
Provision for income taxes | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 24.0
Net loss including noncontrolling interest | ​ | ​ | - | ​ | ​ |  | - | ​ |  | (2,170.3)
Net income attributable to noncontrolling interest | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 2.2
Net loss from discontinued operations, net of tax | ​ | ​ | $- | ​ | ​ | ​ | $- | ​ | ​ | ($2,172.5)

​

Special (gains) and charges of $2,221.7 million in 2020 primarily relate to the loss on sale, professional fees incurred to support the Transaction and restructuring charges specifically related to the ChampionX business. These charges have been included as a component of both cost of sales and special (gains) and charges in discontinued operations.

​

The Company also recognized discrete tax expense primarily related to friction costs associated with ChampionX separation activity of $22.7 million during 2020 that is allocated within discontinued operations tax expense.

73

Table of Contents

In connection with the Transaction, the Company entered into agreements with ChampionX and Apergy to effect the separation and to provide a framework for the relationship following the separation, which included a Separation and Distribution Agreement, an Intellectual Property Matters Agreement, an Employee Matters Agreement, a Transition Services Agreement, and a Tax Matters Agreement. Transition services primarily involve the Company providing certain services to ChampionX related to general and administrative services for terms of up to 18 months following the separation. The amounts billed for transition services provided under the above agreements were $12.5 million and $14.3 million during 2021 and 2020, respectively.

​

The Company also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales, while purchases from ChampionX are recorded in inventory. Sales of product to ChampionX post-separation for 2022, 2021 and 2020 were $124.0 million, $139.4 million and $99.7 million, respectively. As of December 31, 2022, the Company had an outstanding accounts receivable balance for sales of product to ChampionX of $12.9 million.

​

74

Table of Contents

6. BALANCE SHEET INFORMATION

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31 | ​ | December 31
(millions) |  | 2022 | ​ | 2021
Accounts receivable, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ | ​ | $2,829.0 | ​ | ​ | ​ | $2,549.9 | ​
Allowance for expected credit losses and other accruals | ​ | ​ | (130.9) | ​ | ​ | ​ | (71.5) | ​
Total | ​ | ​ | $2,698.1 | ​ | ​ | ​ | $2,478.4 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Inventories | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Finished goods | ​ | ​ | $1,122.7 | ​ | ​ | ​ | $1,010.6 | ​
Raw materials and parts | ​ | ​ | 849.2 | ​ | ​ | ​ | 596.1 | ​
Inventories at FIFO cost | ​ | ​ | 1,971.9 | ​ | ​ | ​ | 1,606.7 | ​
FIFO cost to LIFO cost difference | ​ | ​ | (179.1) | ​ | ​ | ​ | (114.9) | ​
Total | ​ | ​ | $1,792.8 | ​ | ​ | ​ | $1,491.8 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other current assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Prepaid assets | ​ | ​ | $123.9 | ​ | ​ | ​ | $121.2 | ​
Taxes receivable | ​ | ​ | 184.1 | ​ | ​ | ​ | 151.3 | ​
Derivative assets | ​ | ​ | 57.5 | ​ | ​ | ​ | 61.4 | ​
Other | ​ | ​ | 39.2 | ​ | ​ | ​ | 23.1 | ​
Total | ​ | ​ | $404.7 | ​ | ​ | ​ | $357.0 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Property, plant and equipment, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Land | ​ | ​ | $161.3 | ​ | ​ | ​ | $159.2 | ​
Buildings and leasehold improvements | ​ | ​ | 1,126.9 | ​ | ​ | ​ | 1,134.1 | ​
Machinery and equipment | ​ | ​ | 1,966.3 | ​ | ​ | ​ | 1,968.7 | ​
Merchandising and customer equipment | ​ | ​ | 2,635.5 | ​ | ​ | ​ | 2,708.2 | ​
Capitalized software | ​ | ​ | 962.1 | ​ | ​ | ​ | 884.6 | ​
Construction in progress | ​ | ​ | 403.8 | ​ | ​ | ​ | 325.0 | ​
​ | ​ | ​ | 7,255.9 | ​ | ​ | ​ | 7,179.8 | ​
Accumulated depreciation | ​ | ​ | (3,962.5) | ​ | ​ | ​ | (3,891.3) | ​
Total | ​ | ​ | $3,293.4 | ​ | ​ | ​ | $3,288.5 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other intangible assets, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Intangible assets not subject to amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Trade names | ​ | ​ | $1,230.0 | ​ | ​ | ​ | $1,230.0 | ​
Intangible assets subject to amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Customer relationships | ​ | ​ | 3,292.8 | ​ | ​ | ​ | 3,444.6 | ​
Patents | ​ | ​ | 497.0 | ​ | ​ | ​ | 496.3 | ​
Trademarks | ​ | ​ | 404.0 | ​ | ​ | ​ | 561.1 | ​
Other technologies | ​ | ​ | 518.8 | ​ | ​ | ​ | 527.2 | ​
​ | ​ | ​ | 4,712.6 | ​ | ​ | ​ | 5,029.2 | ​
Accumulated amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Customer relationships | ​ | ​ | (1,581.7) | ​ | ​ | ​ | (1,440.9) | ​
Patents | ​ | ​ | (292.3) | ​ | ​ | ​ | (269.3) | ​
Trademarks | ​ | ​ | (202.5) | ​ | ​ | ​ | (170.3) | ​
Other technologies | ​ | ​ | (185.4) | ​ | ​ | ​ | (154.6) | ​
​ | ​ | ​ | (2,261.9) | ​ | ​ | ​ | (2,035.1) | ​
Net intangible assets subject to amortization | ​ | ​ | 2,450.7 | ​ | ​ | ​ | 2,994.1 | ​
Total | ​ | ​ | $3,680.7 | ​ | ​ | ​ | $4,224.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Deferred income taxes | ​ | ​ | $108.1 | ​ | ​ | ​ | $120.6 | ​
Pension | ​ | ​ | 118.4 | ​ | ​ | ​ | 114.6 | ​
Derivative asset | ​ | ​ | 44.5 | ​ | ​ | ​ | 29.4 | ​
Other | ​ | ​ | 264.1 | ​ | ​ | ​ | 281.4 | ​
Total | ​ | ​ | $535.1 | ​ | ​ | ​ | $546.0 | ​

​

75

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31 | ​ | December 31
(millions) |  | 2022 | ​ | 2021
Other current liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Discounts and rebates | ​ | ​ | $357.8 | ​ | ​ | ​ | $341.1 | ​
Dividends payable | ​ | ​ | 150.8 | ​ | ​ | ​ | 146.3 | ​
Interest payable | ​ | ​ | 58.7 | ​ | ​ | ​ | 47.7 | ​
Taxes payable, other than income | ​ | ​ | 162.9 | ​ | ​ | ​ | 154.2 | ​
Derivative liabilities | ​ | ​ | 21.9 | ​ | ​ | ​ | - | ​
Restructuring | ​ | ​ | 100.6 | ​ | ​ | ​ | 39.1 | ​
Contract liability | ​ | ​ | 116.5 | ​ | ​ | ​ | 91.7 | ​
Operating lease liabilities | ​ | ​ | 108.3 | ​ | ​ | ​ | 115.1 | ​
Other | ​ | ​ | 208.4 | ​ | ​ | ​ | 209.0 | ​
Total | ​ | ​ | $1,285.9 | ​ | ​ | ​ | $1,144.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accumulated other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unrealized gain (loss) on derivative financial instruments, net of tax | ​ | ​ | $3.7 | ​ | ​ | ​ | $4.9 | ​
Unrecognized pension and postretirement benefit expense, net of tax | ​ | ​ | (467.4) | ​ | ​ | ​ | (632.8) | ​
Cumulative translation, net of tax | ​ | ​ | (1,262.9) | ​ | ​ | ​ | (1,006.9) | ​
Total | ​ | ​ | ($1,726.6) | ​ | ​ | ​ | ($1,634.8) | ​

​

​

​

7. DEBT AND INTEREST

​

Short-term Debt

​

The following table provides the components of the Company’s short-term debt obligations, along with applicable interest rates as of December 31, 2022 and 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2022 | ​ | 2021
​ | ​ | ​ |  | ​ |  | Average |  |  | ​ |  | Average
​ | ​ | ​ | Carrying | ​ | Interest | ​ | Carrying | ​ | Interest
(millions) |  | ​ | Value | ​ | Rate | ​ | Value | ​ | Rate
Short-term debt | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Commercial paper | ​ | ​ | ​ | $- | ​ | ​ | - | % | ​ | ​ | $400.0 | ​ | ​ | 0.28 | %
Notes payable | ​ | ​ |  | 3.7 | ​ | ​ | 7.28 | % | ​ |  | 8.5 | ​ | ​ | 7.95 | %
Long-term debt, current maturities | ​ | ​ |  | 501.4 | ​ | ​ | ​ | ​ | ​ |  | 2.5 | ​ | ​ | ​ | ​
Total | ​ | ​ | ​ | $505.1 | ​ | ​ | ​ | ​ | ​ | ​ | $411.0 | ​ | ​ | ​ | ​

​

Line of Credit

​

As of December 31, 2022, the Company had in place a $2.0 billion multi-currency revolving credit facility which expires in April 2026. The credit facility has been established with a diverse syndicate of banks and supports the Company’s U.S. and Euro commercial paper programs. There were no borrowings under the Company’s credit facility as of December 31, 2022 and 2021.

​

The Company has $337 million of available bank supported letters of credit, surety bonds and guarantees available in support of its commercial business transactions of which $144 million is outstanding as of December 31, 2022.

​

Commercial Paper

​

The Company’s commercial paper program is used as a potential source of liquidity and consists of a $2.0 billion U.S. commercial paper program and a $2.0 billion Euro commercial paper program. The maximum aggregate amount of commercial paper that may be issued by the Company under its commercial paper programs may not exceed $2.0 billion.

​

The Company had $400 million outstanding commercial paper under its U.S. program as of December 31, 2021.

​

As of December 31, 2022, the Company’s short-term borrowing program was rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

​

Notes Payable

​

The Company’s notes payable consists of uncommitted credit lines with major international banks and financial institutions, primarily to support global cash pooling structures. As of December 31, 2022 and 2021, the Company had $3.7 million and $8.5 million, respectively, outstanding under these credit lines. Approximately $1,925 million and $1,628 million of these credit lines were available for use as of December 31, 2022 and 2021, respectively.

​

76

Table of Contents

Long-term Debt

​

The following table provides the components of the Company’s long-term debt obligations, along with applicable interest rates as of December 31, 2022 and 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  |  | 2022 | ​ |  |  | 2021 | ​ |  |  |
​ | ​ | ​ | ​ | ​ | ​ | ​ | Stated | ​ | Effective | ​ | ​ | ​ | ​ | Stated | ​ | Effective
​ | ​ | Maturity | ​ | Carrying | ​ | Interest | ​ | Interest | ​ | Carrying | ​ | Interest | ​ | Interest
(millions) | ​ | by Year | ​ | Value | ​ | Rate | ​ | Rate | ​ | Value | ​ | Rate | ​ | Rate
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Long-term debt | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Public notes (2022 principal amount) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Two year 2021 senior notes ($500 million) | ​ | 2023 | ​ | ​ | $498.7 | ​ | 0.90 | % | ​ | 1.19 | % | ​ | ​ | $497.2 | ​ | 0.90 | % | ​ | 1.19 | %
Seven year 2016 senior notes (€575 million) | ​ | 2024 | ​ | ​ | 596.9 | ​ | 1.00 | % | ​ | 1.03 | % | ​ | ​ | 649.3 | ​ | 1.00 | % | ​ | 1.19 | %
Ten year 2015 senior notes (€575 million) | ​ | 2025 | ​ |  | 596.7 |  | 2.63 | % | ​ | 2.81 | % | ​ |  | 649.7 |  | 2.63 | % | ​ | 2.87 | %
Ten year 2016 senior notes ($750 million) | ​ | 2026 | ​ | ​ | 721.1 | ​ | 2.70 | % | ​ | 3.21 | % | ​ | ​ | 744.9 | ​ | 2.70 | % | ​ | 2.89 | %
Ten year 2017 senior notes ($500 million) | ​ | 2027 | ​ | ​ | 433.9 | ​ | 3.25 | % | ​ | 4.77 | % | ​ | ​ | 488.4 | ​ | 3.25 | % | ​ | 2.89 | %
Six Year 2021 senior notes ($500 million) | ​ | 2027 | ​ | ​ | 496.5 | ​ | 1.65 | % | ​ | 1.83 | % | ​ | ​ | 495.7 | ​ | 1.65 | % | ​ | 1.84 | %
Five Year 2022 senior notes ($500 million) | ​ | 2028 | ​ | ​ | 492.7 | ​ | 5.25 | % | ​ | 5.36 | % | ​ | ​ | - | ​ | - | % | ​ | - | %
Ten year 2020 senior notes ($698 million) | ​ | 2030 | ​ | ​ | 653.5 | ​ | 4.80 | % | ​ | 3.72 | % | ​ | ​ | 709.1 | ​ | 4.80 | % | ​ | 4.06 | %
Ten year 2020 senior notes ($600 million) | ​ | 2031 | ​ | ​ | 555.2 | ​ | 1.30 | % | ​ | 1.70 | % | ​ | ​ | 593.4 | ​ | 1.30 | % | ​ | 1.39 | %
Eleven year 2021 senior notes ($650 million) | ​ | 2032 | ​ | ​ | 644.6 | ​ | 2.13 | % | ​ | 2.24 | % | ​ | ​ | 644.0 | ​ | 2.13 | % | ​ | 2.24 | %
Thirty year 2011 senior notes ($389 million) | ​ | 2041 | ​ | ​ | 384.5 |  | 5.50 | % | ​ | 5.62 | % | ​ | ​ | 384.3 |  | 5.50 | % | ​ | 5.63 | %
Thirty year 2016 senior notes ($200 million) | ​ | 2046 | ​ | ​ | 197.3 |  | 3.70 | % | ​ | 3.81 | % | ​ | ​ | 197.2 |  | 3.70 | % | ​ | 3.81 | %
Thirty year 2017 senior notes ($484 million) | ​ | 2047 | ​ | ​ | 425.5 | ​ | 3.95 | % | ​ | 4.79 | % | ​ | ​ | 424.3 | ​ | 3.95 | % | ​ | 4.80 | %
Thirty year 2020 senior notes ($500 million) | ​ | 2050 | ​ | ​ | 490.7 | ​ | 2.13 | % | ​ | 2.23 | % | ​ | ​ | 490.4 | ​ | 2.13 | % | ​ | 2.24 | %
Thirty year 2021 senior notes ($850 million) | ​ | 2051 | ​ | ​ | 838.9 | ​ | 2.70 | % | ​ | 2.78 | % | ​ | ​ | 838.5 | ​ | 2.70 | % | ​ | 2.78 | %
Thirty-four year 2021 senior notes ($685 million) | ​ | 2055 | ​ | ​ | 537.2 | ​ | 2.75 | % | ​ | 3.86 | % | ​ | ​ | 535.3 | ​ | 2.75 | % | ​ | 3.87 | %
Finance lease obligations and other | ​ | ​ | ​ |  | 12.8 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 8.0 | ​ | ​ | ​ | ​ | ​ | ​
Total debt | ​ | ​ | ​ |  | 8,576.7 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 8,349.7 | ​ | ​ | ​ | ​ | ​ | ​
Long-term debt, current maturities | ​ | ​ | ​ |  | (501.4) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (2.5) | ​ | ​ | ​ | ​ | ​ | ​
Total long-term debt | ​ | ​ | ​ | ​ | $8,075.3 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $8,347.2 | ​ | ​ | ​ | ​ | ​ | ​

​

Public Notes

​

In November 2022, the Company issued $500 million in aggregate principal five year fixed rate notes with a coupon rate of 5.25% (“New 5-Year Note”). The proceeds are intended to be used for general corporate purposes, which may include, without limitation, repayment of commercial paper borrowings or other indebtedness. The notes mature January 2028.

​

In December 2021, the Company issued $2.5 billion in notes to repay the $3.0 billion delayed draw term loan used to fund the Purolite acquisition. These notes were comprised of $500 million 0.9% notes due 2023, $500 million 1.65% notes due 2027, $650 million 2.125% notes due 2032, and $850 million 2.7% notes due 2051.

​

In August 2021, the Company completed a private offering of a $300 million aggregate principal 34-year fixed rate notes with a coupon rate of 2.75% (“New 34-year Notes”). Immediately following the offering, the Company completed a private offering to exchange a portion of the outstanding senior notes due 2030, 2041, 2046, 2047 (“Old Notes”), for $385 million of New 34-year Notes. In connection with the exchange offering, $387 million of Old Notes were validly tendered and subsequently cancelled.

​

During the fourth quarter of 2021, pursuant to a registration rights agreement pertaining to the New 34-year Notes, the Company filed a registration statement regarding an offer to exchange each series of the New 34-year Notes for new issues of notes registered under the U.S. Securities Act of 1933, as amended. The registration statement was declared effective, and substantially all of the New 34-year Notes were exchanged. The terms of each series of the new notes are substantially identical to the terms of the applicable series of New 34-year Notes, except that the new notes are registered as mentioned above and the transfer restrictions and registration rights and related special interest provisions applicable to the New 34-year Notes do not apply to the new notes.

​

The New 34-year Notes bear a lower fixed coupon rate on an extended maturity date, compared with the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the New 34-year Notes. The exchange was accounted for as a debt modification, and there were cash payments to the note holders of $118 million as a result of the exchange. Existing deferred financing costs associated with the Old Notes, as well as discounts associated with the New 34-year Notes aggregating $143 million, are being amortized over the term of the New 34-year Notes and recorded as interest expense.

​

In September 2021, the Company completed the retirement of the $500 million 2.375% Notes due 2022 and the $400 million 3.25% Notes due 2023 which was accounted for as a debt extinguishment. A make-whole premium of $25.0 million was expensed immediately and is reflected as a financing cash flow activity.

​

​

77

Table of Contents

The Company’s public notes may be redeemed by the Company at its option at redemption prices that include accrued and unpaid interest and a make-whole premium. Upon the occurrence of a change of control accompanied by a downgrade of the public notes below investment grade rating, within a specified time period, the Company would be required to offer to repurchase the public notes at a price equal to 101% of the aggregate principal amount thereof, plus any accrued and unpaid interest to the date of repurchase. The public notes are senior unsecured and unsubordinated obligations of the Company and rank equally with all other senior and unsubordinated indebtedness of the Company.

​

Covenants and Future Maturities

​

The Company is in compliance with all covenants under the Company’s outstanding indebtedness at December 31, 2022.

​

As of December 31, 2022, the aggregate annual maturities of long-term debt for the next five years were:

​

​ | ​ | ​ | ​
(millions) |  | ​ |
2023 | ​ | ​ | $501
2024 | ​ |  | 607
2025 | ​ |  | 597
2026 | ​ |  | 721
2027 | ​ |  | 930

​

Net Interest Expense

​

Interest expense and interest income incurred during 2022, 2021 and 2020 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020
Interest expense | ​ | ​ | $252.1 | ​ | ​ | ​ | $230.6 | ​ | ​ | ​ | $304.8 | ​
Interest income |  |  | (8.5) | ​ | ​ |  | (12.3) | ​ | ​ |  | (14.6) | ​
Interest expense, net | ​ | ​ | $243.6 | ​ | ​ | ​ | $218.3 | ​ | ​ | ​ | $290.2 | ​

​

Interest expense generally includes the expense associated with the interest on the Company’s outstanding borrowings. Interest expense also includes the amortization of debt issuance costs and debt discounts, which are both recognized over the term of the related debt.

​

During 2021, the Company issued, exchanged and retired certain long-term debt, incurring debt refinancing charges of $32.3 million ($28.4 million after tax), which are included as a component of interest expense, net on the Consolidated Statements of Income.

​

During 2020, the Company retired certain long-term debt, and incurred debt refinancing charges of $83.1 million ($64.0 million after tax), which are included as a component of interest expense, net on the Consolidated Statements of Income.

​

78

Table of Contents

8. FAIR VALUE MEASUREMENTS

​

The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, contingent consideration obligations, commercial paper, notes payable, foreign currency forward contracts, interest rate swap agreements, cross-currency swap derivative contracts and long-term debt.

​

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring the most observable inputs be used when available. The hierarchy is broken down into three levels:

​

Level 1 - Inputs are quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2 - Inputs include observable inputs other than quoted prices in active markets.

Level 3 - Inputs are unobservable inputs for which there is little or no market data available.

​

The carrying amount and the estimated fair value for assets and liabilities measured on a recurring basis were:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2022
(millions) | ​ | Carrying | ​ | Fair Value Measurements
​ |  | Amount |  | Level 1 | ​ | Level 2 |  | Level 3
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts |  |  | $118.9 | ​ | ​ | ​ | $- | ​ | ​ |  | $118.9 | ​ | ​ |  | $- | ​
Cross-currency swap derivative contracts | ​ | ​ | 58.7 | ​ | ​ | ​ | - | ​ | ​ | ​ | 58.7 | ​ | ​ | ​ | - | ​
​ |  |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | 83.3 | ​ | ​ | ​ | - | ​ | ​ | ​ | 83.3 | ​ | ​ | ​ | - | ​
Interest rate swap agreements | ​ | ​ | 181.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | 181.4 | ​ | ​ | ​ | - | ​
Cross-currency swap derivative contracts | ​ | ​ | 14.5 | ​ | ​ | ​ | - | ​ | ​ | ​ | 14.5 | ​ | ​ | ​ | - | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2021
(millions) | ​ | Carrying | ​ | Fair Value Measurements
​ |  | Amount |  | Level 1 | ​ | Level 2 |  | Level 3
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ |  | $94.5 | ​ | ​ | ​ | $- | ​ | ​ |  | $94.5 | ​ | ​ |  | $- | ​
Interest rate swap agreements | ​ | ​ | 1.8 | ​ | ​ | ​ | - | ​ | ​ | ​ | 1.8 | ​ | ​ | ​ | - | ​
Cross-currency swap derivative contracts | ​ | ​ | 9.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | 9.4 | ​ | ​ | ​ | - | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ |  | 12.6 | ​ | ​ | ​ | - | ​ | ​ | ​ | 12.6 | ​ | ​ | ​ | - | ​
Interest rate swap agreements | ​ | ​ | 10.1 | ​ | ​ | ​ | - | ​ | ​ | ​ | 10.1 | ​ | ​ | ​ | - | ​
Cross-currency swap derivative contracts | ​ | ​ | 1.6 | ​ | ​ | ​ | - | ​ | ​ | ​ | 1.6 | ​ | ​ | ​ | - | ​

​

The carrying value of foreign currency forward contracts are at fair value, which are determined based on foreign currency exchange rates as of the balance sheet date and classified within Level 2. The carrying value of interest rate swap agreements are at fair value, which are determined based on current forward interest rates as of the balance sheet date and are classified within Level 2. The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the Euro. The carrying value of the cross-currency swap derivative contracts are at fair value, which are determined based on the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs as of the balance sheet date and are classified within Level 2. For purposes of fair value disclosure above, derivative values are presented gross. Further discussion of gross versus net presentation of the Company's derivatives within Note 9.

​

Contingent consideration obligations are recognized and measured at fair value at the acquisition date and thereafter until settlement or expiration. Contingent consideration is classified within Level 3 as the underlying fair value is determined using income-based valuation approaches appropriate for the terms and conditions of each respective contingent consideration. The consideration expected to be transferred is based on the Company’s expectations of various financial measures. The ultimate payment of contingent consideration could deviate from current estimates based on the actual results of these financial measures. Contingent consideration during 2022, 2021 and 2020 were not significant to the Company’s consolidated financial statements.

​

The carrying values of accounts receivable, accounts payable, cash and cash equivalents, commercial paper and notes payable approximate fair value because of their short maturities, and as such are classified within Level 1.

​

The fair value of long-term debt is based on quoted market prices for the same or similar debt instruments (classified as Level 2). The carrying amount, which includes adjustments related to the impact of interest rate swap agreements, premiums and discounts, and deferred debt issuance costs, and the estimated fair value of long-term debt, including current maturities, held by the Company were:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2022 | ​ | December 31, 2021
​ | ​ | Carrying | ​ | Fair | ​ | Carrying | ​ | Fair
​ |  | Amount |  | Value |  | Amount |  | Value
Long-term debt, including current maturities | ​ | ​ | $8,576.6 | ​ | ​ | ​ | $7,643.6 | ​ | ​ | ​ | $8,349.7 | ​ | ​ | $9,085.3

79

Table of Contents

​

9. DERIVATIVES AND HEDGING TRANSACTIONS

​

The Company uses foreign currency forward contracts, interest rate swap agreements, cross-currency swap derivative contracts and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in foreign operations. The Company does not hold derivative financial instruments of a speculative nature or for trading purposes. The Company records derivatives as assets and liabilities on the balance sheet at fair value. Changes in fair value are recognized immediately in earnings unless the derivative qualifies and is designated as a hedge. Cash flows from derivatives are classified in the statement of cash flows in the same category as the cash flows from the items subject to designated hedge or undesignated (economic) hedge relationships. The Company evaluates hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be effective, hedge accounting is discontinued.

​

The Company is exposed to credit risk in the event of nonperformance of counterparties for foreign currency forward exchange contracts and interest rate swap agreements. The Company monitors its exposure to credit risk by using credit approvals and credit limits and by selecting major global banks and financial institutions as counterparties. The Company does not anticipate nonperformance by any of these counterparties, and therefore, recording a valuation allowance against the Company’s derivative balance is not considered necessary.

​

Derivative Positions Summary

​

Certain of the Company’s derivative transactions are subject to master netting arrangements that allow the Company to net settle contracts with the same counterparties. These arrangements generally do not call for collateral and as of the applicable dates presented in the following table, no cash collateral had been received or pledged related to the underlying derivatives.

​

The respective net amounts are included in other current assets, other assets, other current liabilities and other liabilities on the Consolidated Balance Sheets.

​

The following table summarizes the gross fair value and the net value of the Company’s outstanding derivatives:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Derivative Assets | Derivative Liabilities
​ | ​ | ​ | December 31 | ​ | December 31 | ​ | December 31 | ​ | December 31 | ​
(millions) |  | ​ | 2022 | ​ | 2021 |  | 2022 | ​ | 2021 |
Derivatives designated as hedging instruments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | ​ | $78.6 | ​ | ​ | ​ | $44.7 | ​ | ​ | $9.2 | ​ | ​ | ​ | $2.6 | ​
Interest rate swap agreements | ​ | ​ | ​ | - | ​ | ​ | ​ | 1.8 | ​ | ​ | 181.4 | ​ | ​ | ​ | 10.1 | ​
Cross-currency swap derivative contracts | ​ | ​ | ​ | 58.7 | ​ | ​ | ​ | 9.4 | ​ | ​ | 14.5 | ​ | ​ | ​ | 1.6 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivatives not designated as hedging instruments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | ​ | 40.3 | ​ | ​ | ​ | 49.8 | ​ | ​ | 74.1 | ​ | ​ | ​ | 10.0 | ​
Gross value of derivatives | ​ | ​ | ​ | 177.6 | ​ | ​ | ​ | 105.7 | ​ | ​ | 279.2 | ​ | ​ | ​ | 24.3 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross amounts offset in the Consolidated Balance Sheets | ​ | ​ | ​ | (75.6) | ​ | ​ | ​ | (14.9) | ​ | ​ | (75.6) | ​ | ​ | ​ | (14.9) | ​
Net value of derivatives | ​ | ​ | ​ | $102.0 | ​ | ​ | ​ | $90.8 | ​ | ​ | $203.6 | ​ | ​ | ​ | $9.4 | ​

​

The following table summarizes the notional values of the Company’s outstanding derivatives:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Notional Values
​ | ​ | ​ | December 31 | ​ | ​ | December 31
(millions) | ​ |  | 2022 | ​ |  | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | $5,745 | ​ | ​ | ​ | $4,059 | ​
Interest rate swap agreements | ​ | ​ | 1,500 | ​ | ​ | ​ | 1,250 | ​
Cross-currency swap derivative contracts | ​ | ​ | 650 | ​ | ​ | ​ | 482 | ​

​

​

​

Cash Flow Hedges

​

The Company utilizes foreign currency forward contracts to hedge the effect of foreign currency exchange rate fluctuations on forecasted foreign currency transactions, including inventory purchases and intercompany royalty, intercompany loans, management fee and other payments. These forward contracts are designated as cash flow hedges. The changes in fair value of these contracts are recorded in accumulated other comprehensive income (loss) (“AOCI”) until the hedged items affect earnings, at which time the gain or loss is reclassified into the same line item in the Consolidated Statements of Income as the underlying exposure being hedged. Cash flow hedged transactions impacting AOCI are forecasted to occur within the next year. For forward contracts designated as hedges of foreign currency exchange rate risk associated with forecasted foreign currency transactions, the Company excludes the changes in fair value attributable to time value from the assessment of hedge effectiveness. The initial value of the excluded component (i.e., the forward points) is amortized on a straight-line basis over the life of the hedging instrument and recognized in the same line item in the Consolidated Statements of Income as the underlying exposure being hedged for intercompany loans. For all other cash flow hedge types, the forward points are mark-to-market monthly and recognized in the same line item in the Consolidated Statements of Income as the underlying exposure being hedged. The difference between fair value changes of the excluded component and the amount amortized in the Consolidated Statements of Income is recorded in AOCI.

80

Table of Contents

Fair Value Hedges

​

The Company manages interest expense using a mix of fixed and floating rate debt. To help manage exposure to interest rate movements and to reduce borrowing costs, the Company may enter into interest rate swaps under which the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed upon notional principal amount. The mark-to-market of these fair value hedges is recorded as gains or losses in interest (income) expense and is offset by the gain or loss of the underlying debt instrument, which also is recorded in interest (income) expense. These fair value hedges are highly effective and thus, there is no impact on earnings due to hedge ineffectiveness.

​

In April 2022, the Company entered into an interest rate swap agreement that converted $250 million of its 4.8% debt from a fixed interest rate to a floating interest rate. In aggregate, the Company has entered into a series of interest rate swap agreements to convert $1.5 billion of its debt from a fixed interest rate to a floating interest rate. The fixed interest rates range from 1.3% to 4.8% and mature between 2026 and 2031. All of these interest rate swaps are designated as fair value hedges.

​

The following amounts were recorded in the Consolidated Balance Sheets related to cumulative basis adjustments for fair value hedges:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Line item in which the hedged item is included | ​ | Carrying amount of the hedged liabilities | ​ | Cumulative amount of the fair value hedging adjustment included in the carrying amount of the hedged liabilities
(millions) | ​ | 2022 |  | 2021 | ​ | 2020 | ​ | 2022 |  | 2021 | ​ | 2020
Long-term debt | ​ | ​ | $1,317.5 | ​ | ​ | ​ | $1,235.6 | ​ | ​ | $- | ​ | ​ | ($184.8) | ​ | ​ | ​ | ($12.1) | ​ | ​ | $-

​

Net Investment Hedges

​

The Company designates its outstanding €1,150 million ($1,194 million as of year-end 2022) senior notes (“Euronotes”) and related accrued interest as a hedge of its Euro denominated exposures from the Company’s investments in certain of its Euro denominated functional currency subsidiaries.

​

In October of 2022, the Company entered into a cross-currency swap derivative contract with a notional amount of €200 million maturing in 2026. In aggregate, the Company has entered into a series of cross-currency swap derivative contracts with a notional amount of €625 million maturing between 2026 and 2030. These cross-currency swap derivative contracts are designated as net investment hedge of the Company’s Euro denominated exposures from the Company’s investments in certain of its Euro denominated functional currency subsidiaries. The cross-currency swap derivative contracts exchange fixed-rate payments in one currency for fixed-rate payments in another currency. As of December 31, 2022, the Company had a €625 million ($650 million) cross-currency swap derivative contracts outstanding as a hedge of the Company’s net investment in foreign operations. The changes in the spot rate of these instruments are recorded in AOCI in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in AOCI. Any ineffective portions of net investment hedges are reclassified from AOCI into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense on the accompanying Consolidated Statements of Income consistent with the classification of interest expense attributable to the underlying debt.

​

The revaluation gains and losses on the Euronotes and cross-currency swap derivative, which are designated and effective as hedges of the Company’s net investments, have been included as a component of the cumulative translation adjustment account, and were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020
Revaluation gain (loss), net of tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Euronotes | ​ | ​ | $81.9 | ​ | ​ | ​ | $45.3 | ​ | ​ | ​ | ($87.7) | ​
Cross-currency swap derivative contracts | ​ | ​ | 26.4 | ​ | ​ | ​ | 6.3 | ​ | ​ | ​ | - | ​
Total revaluation gain (loss), net of tax | ​ | ​ | $108.3 | ​ | ​ | ​ | $51.6 | ​ | ​ | ​ | ($87.7) | ​

​

​

81

Table of Contents

Derivatives Not Designated as Hedging Instruments

​

The Company also uses foreign currency forward contracts to offset its exposure to the change in value of certain foreign currency denominated assets and liabilities held at foreign subsidiaries, primarily receivables and payables, which are remeasured at the end of each period. Although the contracts are effective economic hedges, they are not designated as accounting hedges. Therefore, changes in the value of these derivatives are recognized immediately in earnings, thereby offsetting the current earnings effect of the related foreign currency denominated assets and liabilities.

​

Effect of all Derivative Instruments on Income

​

The gain (loss) of all derivative instruments recognized in product and equipment cost of sales (“COS”), selling, general and administrative expenses (“SG&A”) and interest expense, net (“interest”) is summarized below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | 2022 | ​ | ​ | 2021 | ​ | 2020
(millions) | ​ | COS | ​ | SG&A | ​ | Interest | ​ |  | ​ | COS | ​ | SG&A | ​ | Interest | ​ | ​ | COS | ​ | SG&A | ​ | Interest
Gain (loss) on derivatives in cash flow hedging relationship: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amount of gain (loss) reclassified from AOCI to income | ​ | $6.4 | ​ | $95.0 | ​ | $- | ​ | ​ | ​ | ($11.0) | ​ | $47.6 | ​ | $- | ​ | ​ | $10.1 | ​ | ($108.3) | ​ | $-
Amount excluded from the assessment of effectiveness recognized in earnings based on changes in fair value | ​ | - | ​ | - | ​ | 13.9 | ​ | ​ | ​ | - | ​ | - | ​ | 21.0 | ​ | ​ | - | ​ | - | ​ | 27.5
Interest rate swap agreements | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amount of gain (loss) reclassified from AOCI to income | ​ | - | ​ | - | ​ | (2.3) | ​ | ​ | ​ | - | ​ | - | ​ | (2.3) | ​ | ​ | - | ​ | - | ​ | (2.4)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gain (loss) on derivatives not designated as hedging instruments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency forward contracts | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amount of gain (loss) recognized in income (a) | ​ | - | ​ | 62.0 | ​ | - | ​ | ​ | ​ | - | ​ | 73.7 | ​ | - | ​ | ​ | - | ​ | (12.3) | ​ | -
Total gain (loss) of all derivative instruments | ​ | $6.4 | ​ | $157.0 | ​ | $11.6 | ​ | ​ | ​ | ($11.0) | ​ | $121.3 | ​ | $18.7 | ​ | ​ | $10.1 | ​ | ($120.6) | ​ | $25.1
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

| (a) | Gain (loss) on derivatives not designated as hedging instruments recognized in income recorded in SG&A includes discontinued operations of $(2.5) for the year ended December 31, 2020.

​

​

​

82

Table of Contents

10. OTHER COMPREHENSIVE INCOME (LOSS) INFORMATION

​

Other comprehensive income (loss) includes net income, foreign currency translation adjustments, defined benefit pension and postretirement plan adjustments, gains and losses on derivative instruments designated and effective as cash flow hedges and non-derivative instruments designated and effective as foreign currency net investment hedges that are charged or credited to the AOCI account in shareholders’ equity.

​

The following table provides other comprehensive income (loss) information related to the Company’s derivatives and hedging instruments and pension and postretirement benefits. Refer to Note 9 for additional information related to the Company’s derivatives and hedging transactions. Refer to Note 17 for additional information related to the Company’s pension and postretirement benefits activity.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |  | 2020
Derivative and Hedging Instruments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unrealized gain (loss) on derivative & hedging instruments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amount recognized in AOCI | ​ | ​ | $112.9 | ​ | ​ | ​ | $87.5 | ​ | ​ | ​ | ($93.3) | ​
(Gain) loss reclassified from AOCI into income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
COS | ​ | ​ | (6.4) | ​ | ​ | ​ | 11.0 | ​ | ​ | ​ | (10.1) | ​
SG&A |  | ​ | (95.0) | ​ | ​ | ​ | (47.6) | ​ | ​ | ​ | 108.3 | ​
Interest (income) expense, net | ​ | ​ | (11.6) | ​ | ​ | ​ | (18.7) | ​ | ​ | ​ | (25.1) | ​
​ |  | ​ | (113.0) | ​ | ​ | ​ | (55.3) | ​ | ​ | ​ | 73.1 | ​
Other activity |  | ​ | 1.1 | ​ | ​ | ​ | (1.7) | ​ | ​ | ​ | (0.3) | ​
Tax impact |  | ​ | (2.2) | ​ | ​ | ​ | (4.5) | ​ | ​ | ​ | 3.5 | ​
Net of tax | ​ | ​ | ($1.2) | ​ | ​ | ​ | $26.0 | ​ | ​ | ​ | ($17.0) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Pension and Postretirement Benefits | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amount recognized in AOCI | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current period net gain (loss) | ​ | ​ | $83.3 | ​ | ​ | ​ | $270.7 | ​ | ​ | ​ | ($189.9) | ​
Amount reclassified from AOCI into income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Settlement charge | ​ | ​ | 51.6 | ​ | ​ | ​ | 38.8 | ​ | ​ | ​ | - | ​
Amortization of losses and prior period service credits, net | ​ | ​ | 47.7 | ​ | ​ | ​ | 78.6 | ​ | ​ | ​ | 68.1 | ​
​ |  | ​ | 182.6 | ​ | ​ | ​ | 388.1 | ​ | ​ | ​ | (121.8) | ​
Tax impact |  | ​ | (52.3) | ​ | ​ | ​ | (98.4) | ​ | ​ | ​ | 43.7 | ​
Net of tax | ​ | ​ | $130.3 | ​ | ​ | ​ | $289.7 | ​ | ​ | ​ | ($78.1) | ​

​

​

​

​

11. SHAREHOLDERS’ EQUITY

​

Authorized common stock, par value $1.00 per share, was 800 million shares at December 31, 2022, 2021 and 2020. Treasury stock is stated at cost. Dividends declared per share of common stock were $2.06 for 2022, $1.95 for 2021 and $1.89 for 2020.

​

The Company has 15 million shares, without par value, of authorized but unissued and undesignated preferred stock.

​

Share Repurchase Authorization

​

In February 2015 and November 2022, the Company’s Board of Directors authorized the repurchase of up to 20 million and 10 million, respectively, additional shares of its common stock, including shares to be repurchased under Rule 10b5-1. As of December 31, 2022, 12,917,097 shares remained to be repurchased under the Company’s repurchase authorization. The Company intends to repurchase all shares under its authorization, for which no expiration date has been established, in open market or privately negotiated transactions, subject to market conditions.

​

Share Repurchases

​

During 2022, 2021 and 2020, the Company reacquired 3,038,107, 502,132 and 761,245 shares, respectively, of its common stock, of which 2,933,090, 389,759 and 565,064, respectively, related to share repurchases through open market or private purchases, and 105,017, 112,373 and 196,181, respectively, related to shares withheld for taxes on exercise of stock options and vesting of stock awards and units.

​

The IRA was signed into U.S. law on August 16, 2022 and is effective January 1, 2023. The IRA includes an excise tax on the repurchase of corporate stock. The Company does not anticipate the excise tax to have a material impact on the Company’s financial statements.

​

Separation of ChampionX

​

In June 2020, the Company effected the split-off of ChampionX through the Exchange Offer and all shares of ChampionX common stock owned by Ecolab were exchanged for outstanding shares of Ecolab common stock. In the Exchange Offer, which was oversubscribed, the Company accepted 4,955,552 shares of Ecolab common stock in exchange for approximately 122,200,000 shares of ChampionX common stock.

83

Table of Contents

12. EQUITY COMPENSATION PLANS

​

The Company’s equity compensation plans provide for grants of stock options, performance-based restricted stock units (“PBRSUs”) and non-performance-based restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). Common shares available for grant as of December 31, 2022, 2021 and 2020 were 5,475,903, 7,544,458 and 8,644,262, respectively. The Company generally issues authorized but previously unissued shares to satisfy stock option exercises and stock award vesting.

​

The Company’s annual long-term incentive share-based compensation program is made up of 50% stock options and 50% PBRSUs. The Company also periodically grants RSUs. Total compensation expense related to all share-based compensation plans was $87.8 million ($74.8 million net of tax benefit), $89.5 million ($75.4 million net of tax benefit) and $81.0 million ($67.7 million net of tax benefit) for 2022, 2021 and 2020, respectively. As of December 31, 2022, there was $150.7 million of total measured but unrecognized compensation expense related to non-vested share-based compensation arrangements granted under all of the Company’s plans. That cost is expected to be recognized over a weighted-average period of 2.2 years.

​

Stock Options

​

Stock options are granted to purchase shares of the Company’s stock at the average daily share price on the date of grant. These options generally expire within ten years from the grant date. The Company generally recognizes compensation expense for these awards on a straight-line basis over the three year vesting period. Stock option grants to retirement eligible recipients are attributed to expense using the non-substantive vesting method.

​

A summary of stock option activity and average exercise prices is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 |  | 2020 |
​ |  | Number of |  | Exercise | ​ | ​ | Number of | ​ | Exercise | ​ | Number of | ​ | Exercise |
​ | ​ | Options | ​ | Price (a) | ​ |  | Options | ​ | Price (a) | ​ | Options | ​ | Price (a) |
Outstanding, beginning of year |  | 6,217,161 | ​ | ​ | $160.91 | ​ | ​ | 6,802,415 | ​ | ​ | $144.20 |  | 9,042,320 | ​ | ​ | $121.72 | ​
Granted |  | 1,228,673 | ​ | ​ | 148.79 | ​ | ​ | 812,853 | ​ | ​ | 223.85 |  | 931,750 | ​ | ​ | 220.95 | ​
Exercised |  | (294,228) | ​ | ​ | 101.08 | ​ | ​ | (1,306,998) | ​ | ​ | 110.91 |  | (2,733,130) | ​ | ​ | 97.52 | ​
Canceled |  | (120,503) | ​ | ​ | 210.26 | ​ | ​ | (91,109) | ​ | ​ | 192.49 |  | (91,660) | ​ | ​ | 166.67 | ​
Separation of ChampionX |  | - | ​ | ​ | - | ​ | ​ | - | ​ | ​ | - |  | (346,865) | ​ | ​ | 126.37 | ​
Outstanding, end of year |  | 7,031,103 | ​ | ​ | $160.45 | ​ | ​ | 6,217,161 | ​ | ​ | $160.91 |  | 6,802,415 | ​ | ​ | $144.20 | ​
Exercisable, end of year |  | 5,168,161 | ​ | ​ | $155.45 | ​ | ​ | 4,604,922 | ​ | ​ | $141.21 |  | 5,051,927 | ​ | ​ | $125.08 | ​
Vested and expected to vest, end of year |  | 6,886,450 | ​ | ​ | $160.31 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

| (a) | Represents weighted average price per share.

​

The total aggregate intrinsic value of options (the amount by which the stock price exceeded the exercise price of the option on the date of exercise) that were exercised during 2022, 2021 and 2020 was $21.0 million, $148.1 million and $298.7 million, respectively.

​

The total aggregate intrinsic value of options outstanding as of December 31, 2022 was $62.3 million, with a corresponding weighted-average remaining contractual life of 6.4 years. The total aggregate intrinsic value of options exercisable as of December 31, 2022 was $62.3 million, with a corresponding weighted-average remaining contractual life of 5.3 years. The total aggregate intrinsic value of options vested and expected to vest as of December 31, 2022 was $62.3 million, with a corresponding weighted-average remaining contractual life of 6.4 years.

​

The lattice (binomial) option-pricing model is used to estimate the fair value of options at grant date. The Company’s primary employee option grant occurs during the fourth quarter. The weighted-average grant-date fair value of options granted and the significant assumptions used in determining the underlying fair value of each option grant, on the date of grant were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2021 | ​ | 2020
Weighted-average grant-date fair value of options | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
granted at market prices | ​ | ​ | $37.04 | ​ | ​ | ​ | $47.65 | ​ | ​ | ​ | $44.16 | ​
Assumptions | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Risk-free rate of return | ​ | ​ | 3.5 | % | ​ | ​ | 1.2 | % | ​ |  | 0.5 | %
Expected life |  |  | 6 | years | ​ |  | 6 | years | ​ |  | 6 | years
Expected volatility | ​ | ​ | 23.5 | % | ​ | ​ | 23.0 | % | ​ |  | 23.0 | %
Expected dividend yield | ​ | ​ | 1.4 | % | ​ | ​ | 0.9 | % | ​ |  | 0.9 | %

​

The risk-free rate of return is determined based on a yield curve of U.S. treasury rates from one month to ten years and a period commensurate with the expected life of the options granted. Expected volatility is established based on historical volatility of the Company’s stock price. The expected dividend yield is determined based on the Company’s annual dividend amount as a percentage of the average stock price at the time of the grant.

​

84

Table of Contents

PBRSUs, RSUs and RSAs

​

The expense associated with PBRSUs is based on the average of the high and low share price of the Company’s common stock on the date of grant, adjusted for the absence of future dividends. The awards vest based on the Company achieving a defined performance target and with continued service for a three year period. Upon vesting, the Company issues shares of its common stock such that one award unit equals one share of common stock. The Company assesses the probability of achieving the performance target and recognizes expense over the three year vesting period when it is probable the performance target will be met. PBRSU awards granted to retirement eligible recipients are attributed to expense using the non-substantive vesting method. The awards are generally subject to forfeiture in the event of termination of employment.

​

The expense associated with shares of non-performance based RSUs and RSAs is based on the average of the high and low share price of the Company’s common stock on the date of grant, adjusted for the absence of future dividends and is amortized on a straight-line basis over the periods during which the restrictions lapse. The Company currently has RSUs that vest over periods between 12 and 60 months. The awards are generally subject to forfeiture in the event of termination of employment.

​

A summary of non-vested PBRSUs and restricted stock activity is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | PBRSU | ​ | Grant Date | ​ | RSAs and | ​ | Grant Date
​ | ​ | Awards | ​ | Fair Value (a) | ​ | RSUs | ​ | Fair Value (a)
December 31, 2019 |  | 1,116,898 | ​ | ​ | ​ | $139.83 | ​ |  | 265,513 | ​ | ​ | ​ | $149.46 | ​
Granted |  | 202,187 | ​ | ​ | ​ | 215.23 | ​ | ​ | 62,693 | ​ | ​ | ​ | 203.09 | ​
Vested / Earned |  | (333,676) | ​ | ​ | ​ | 112.78 | ​ | ​ | (81,150) | ​ | ​ | ​ | 130.72 | ​
Canceled | ​ | (26,285) | ​ | ​ | ​ | 157.32 | ​ | ​ | (15,996) | ​ | ​ | ​ | 162.51 | ​
Separation of ChampionX |  | (44,494) | ​ | ​ | ​ | 142.10 | ​ | ​ | (67,377) | ​ | ​ | ​ | 161.82 | ​
December 31, 2020 |  | 914,630 | ​ | ​ | ​ | $165.76 | ​ |  | 163,683 | ​ | ​ | ​ | $172.92 | ​
Granted |  | 176,297 | ​ | ​ | ​ | 223.77 | ​ | ​ | 130,807 | ​ | ​ | ​ | 211.12 | ​
Vested / Earned |  | (271,731) | ​ | ​ | ​ | 131.74 | ​ | ​ | (48,977) | ​ | ​ | ​ | 160.84 | ​
Canceled | ​ | (30,667) | ​ | ​ | ​ | 178.46 | ​ | ​ | (13,239) | ​ | ​ | ​ | 192.12 | ​
December 31, 2021 |  | 788,529 | ​ | ​ | ​ | $189.96 | ​ |  | 232,274 | ​ | ​ | ​ | $195.95 | ​
Granted | ​ | 291,496 | ​ | ​ | ​ | 142.24 | ​ | ​ | 240,370 | ​ | ​ | ​ | 146.90 | ​
Vested / Earned | ​ | (232,210) | ​ | ​ | ​ | 152.63 | ​ | ​ | (68,864) | ​ | ​ | ​ | 163.81 | ​
Canceled | ​ | (24,645) | ​ | ​ | ​ | 207.05 | ​ | ​ | (18,683) | ​ | ​ | ​ | 201.39 | ​
December 31, 2022 | ​ | 823,170 | ​ | ​ | ​ | $181.68 | ​ |  | 385,097 | ​ | ​ | ​ | $170.50 | ​

​

(a) | Represents weighted average price per share.

​

85

Table of Contents

13. INCOME TAXES

​

Income before income taxes consisted of:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020
United States (U.S.) | ​ |  | $295.6 |  | ​ |  | $277.7 |  | ​ |  | $100.5 |
International |  | ​ | 1,047.8 | ​ | ​ | ​ | 1,136.5 | ​ | ​ | ​ | 1,060.9 | ​
Total | ​ | ​ | $1,343.4 | ​ | ​ | ​ | $1,414.2 | ​ | ​ | ​ | $1,161.4 | ​

​

The provision (benefit) for income taxes consisted of:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 |  | 2020
U.S. federal and state | ​ |  | $145.7 | ​ | ​ | ​ | $30.9 | ​ | ​ | ​ | ($43.9) |
International |  | ​ | 231.4 | ​ | ​ | ​ | 240.2 | ​ | ​ | ​ | 259.8 | ​
Total current |  | ​ | 377.1 | ​ | ​ | ​ | 271.1 | ​ | ​ | ​ | 215.9 | ​
U.S. federal and state |  | ​ | (78.9) | ​ | ​ | ​ | 3.6 | ​ | ​ | ​ | 12.0 | ​
International |  | ​ | (63.7) | ​ | ​ | ​ | (4.5) | ​ | ​ | ​ | (51.3) | ​
Total deferred |  | ​ | (142.6) | ​ | ​ | ​ | (0.9) | ​ | ​ | ​ | (39.3) | ​
Provision for income taxes | ​ | ​ | $234.5 | ​ | ​ | ​ | $270.2 | ​ | ​ | ​ | $176.6 | ​

​

The Company’s overall net deferred tax assets and deferred tax liabilities were comprised of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31 (millions) |  | 2022 |  | 2021
Deferred tax assets | ​ |  | ​ |  | ​ |  | ​ |
Pension and post-retirement benefits | ​ | ​ | $87.0 | ​ | ​ | ​ | $136.8 | ​
Other accrued liabilities | ​ | ​ | 129.6 | ​ | ​ | ​ | 135.6 | ​
Lease liability |  |  | 109.2 | ​ | ​ |  | 101.3 | ​
Credit carryforwards | ​ | ​ | 97.8 | ​ | ​ | ​ | 81.8 | ​
Capitalization of R&D costs | ​ | ​ | 84.5 | ​ | ​ | ​ | - | ​
Loss carryforwards |  |  | 67.2 | ​ | ​ |  | 59.6 | ​
Share-based compensation |  |  | 51.2 | ​ | ​ |  | 44.7 | ​
Deferred income | ​ | ​ | 59.6 | ​ | ​ | ​ | 44.8 | ​
Other, net |  |  | 98.8 | ​ | ​ |  | 71.0 | ​
Valuation allowance |  |  | (65.2) | ​ | ​ |  | (50.3) | ​
Total deferred tax assets |  |  | 719.7 | ​ | ​ |  | 625.3 | ​
Deferred tax liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Intangible assets |  |  | (611.1) | ​ | ​ |  | (631.0) | ​
Property, plant and equipment |  |  | (319.7) | ​ | ​ |  | (333.5) | ​
Lease asset | ​ | ​ | (109.1) | ​ | ​ | ​ | (100.3) | ​
Financing | ​ | ​ | (33.5) | ​ | ​ | ​ | (34.2) | ​
Other, net |  |  | (43.8) | ​ | ​ |  | (27.7) | ​
Total deferred tax liabilities |  |  | (1,117.2) | ​ | ​ |  | (1,126.7) | ​
Net deferred tax liabilities balance | ​ | ​ | ($397.5) | ​ | ​ | ​ | ($501.4) | ​

​

As of December 31, 2022 the Company has tax effected federal, state and international net operating loss carryforwards of $2.5 million, $16.1 million and $48.6 million, respectively, and a tax effected federal tax capital loss carryforward of $9.4 million which will be available to offset future taxable income. The federal and state loss carryforwards of $18.6 million expire from 2023 to 2043. The international loss carryforwards of $9.9 million expire from 2023 to 2043 and $38.7 million have no expiration. The federal capital loss carryforwards of $9.4 million expire from 2023 to 2026. The tax loss carryforwards expiring in 2023 are not material.

​

Additionally, the Company has $97.8 million of credit carryforwards that are primarily related to U.S. foreign tax credits and various state credits. The U.S. foreign tax credit carryforwards of $71.1 million expire from 2029 to 2032 and the state credit carryforwards of $21.3 million expire from 2023 to 2037. Other international tax credit carryforwards of $5.4 million do not expire. The tax credit carryforwards expiring in 2023 are not material.

​

The Company has valuation allowances on certain deferred tax assets of $65.2 million and $50.3 million at December 31, 2022 and 2021, respectively. The increase in valuation allowance from year end 2021 to year end 2022 was primarily due to U.S. state tax attributes, foreign net operating losses and other deferred tax assets.

​

The Company obtained tax benefits from a tax holiday in the Dominican Republic. The Company received a permit of operation, which expires in April 2036, from the National Council of Free Zones of Exportation for the Dominican Republic. Companies operating under the Free Zones are not subject to income tax in the Dominican Republic on export income. The Company had a tax incentive awarded by the Signapore Economic Development Board. This incentive provided for a preferential 10% tax rate on certain headquarter income which expired in January 2021. The tax reduction as the result of the tax holidays for 2022 was $5.8 million ($0.02 per diluted share), 2021 was $2.9 million ($0.01 per diluted share) and 2020 was $26.9 million ($0.09 per diluted share).

​

86

Table of Contents

A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective income tax rate is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 | ​ | 2021 | ​ | 2020
Statutory U.S. rate | ​ | 21.0 | % | ​ | 21.0 | % | ​ | 21.0 | %
State income taxes, net of federal benefit | ​ | 1.3 |  | ​ | 0.6 |  | ​ | 0.4 | ​
Foreign operations | ​ | (0.8) |  | ​ | (0.6) |  | ​ | (1.3) | ​
Excess stock benefits | ​ | (0.4) | ​ | ​ | (2.0) | ​ | ​ | (4.9) | ​
R&D credit | ​ | (1.4) |  | ​ | (1.3) |  | ​ | (1.1) | ​
Foreign derived intangible income | ​ | (1.8) | ​ | ​ | (1.6) | ​ | ​ | (0.2) | ​
Change in valuation allowance | ​ | 0.7 |  | ​ | 0.5 |  | ​ | 0.6 | ​
Legal entity rationalization | ​ | (1.5) | ​ | ​ | - | ​ | ​ | - | ​
One-time transfer of intangibles | ​ | - | ​ | ​ | 1.8 | ​ | ​ | - | ​
Other, net | ​ | 0.4 |  | ​ | 0.7 |  | ​ | 0.7 | ​
Effective income tax rate | ​ | 17.5 | % | ​ | 19.1 | % | ​ | 15.2 | %

​

The change in the Company’s effective income tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of the Company’s historical effective income tax rates, as amounts included in special (gains) and charges are derived from tax jurisdictions with rates that vary from the statutory U.S. rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of the Company’s effective income tax rate in the future.

​

The Company’s 2022 effective tax rate of 17.5% includes $53.7 million of net tax benefits on special (gains) and charges, and net tax benefit of $11.8 million associated with discrete items. Discrete items included a deferred tax benefits of $14.6 million associated with utilization of tax attributes as a result of legal entity rationalization and share-based compensation excess tax benefits of $6.0 million. The amount of the excess tax benefit is subject to variation in stock price and award exercises. The remaining discrete tax expense of $8.8 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements and other changes in estimates.

​

The Company’s 2021 effective tax rate of 19.1% includes $53.3 million of net tax benefits on special (gains) and charges, and net tax expense of $5.8 million associated with discrete items. During 2021, the Company recorded a discrete tax benefit of $29.1 million related to share-based compensation excess tax benefits. Additionally, the Company recorded $34.9 million discrete tax charges including a non-cash deferred tax charge of $25.1 million associated with transferring certain intangible property between affiliates. The remaining $9.8 million tax expense primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements and other changes in estimates.

​

The Company’s 2020 effective tax rate of 15.2% includes $57.9 million of net tax benefits on special (gains) and charges, and net tax benefits of $55.8 million associated with discrete items. During 2020, the Company recorded a discrete tax benefit of $57.3 million related to share-based compensation excess tax benefits. The Company recorded changes in reserves in non-U.S. and U.S. jurisdictions due to audit settlements and the expiration of statutes of limitations which resulted in a $9.8 million tax benefit. Additionally, the Company recognized a net tax expense of $11.3 million primarily related to the filing of prior year federal, state and foreign tax returns and other income tax adjustments.

​

During 2022, the Company recorded a deferred tax liability of $12.1 million as part of purchase accounting associated with the pre-acquisition undistributed earnings of Purolite that are not considered permanently reinvested. A deferred tax liability of $6.8 million remains as of December 31, 2022. The Company otherwise continues to assert permanent reinvestment of the undistributed earnings of international affiliates unless the earnings can be remitted in a net income tax benefit or tax-neutral manner. If there are policy changes, the Company would record the applicable taxes in the period of change. Due to the complexity of the legal entity structure, the number of legal entities and jurisdictions involved, and the complexity of the laws and regulations, the Company believes it is not practicable to estimate the amount of additional taxes which may be payable upon distribution of these undistributed earnings. Accordingly, no deferred taxes have been provided for withholding taxes or other taxes on permanently reinvested earnings.

​

A reconciliation of the beginning and ending amount of gross liability for unrecognized tax benefits is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | 2022 |  | 2021 | ​ | 2020
Balance at beginning of year | ​ | ​ | $25.1 | ​ | ​ | ​ | $20.7 | ​ | ​ | ​ | $27.0 | ​
Additions based on tax positions related to the current year |  | ​ | 2.7 | ​ | ​ |  | 3.8 | ​ | ​ |  | 3.3 | ​
Additions for tax positions of prior years |  |  | 3.6 | ​ | ​ |  | 3.0 | ​ | ​ |  | - | ​
Current year acquisitions | ​ | ​ | - | ​ | ​ | ​ | 4.4 | ​ | ​ | ​ | - | ​
Reductions for tax positions of prior years |  |  | (1.5) | ​ | ​ |  | - | ​ | ​ |  | (1.1) | ​
Reductions for tax positions due to statute of limitations |  |  | (0.7) | ​ | ​ |  | (3.0) | ​ | ​ |  | (9.1) | ​
Settlements |  |  | (3.4) | ​ | ​ |  | (3.7) | ​ | ​ |  | - | ​
Foreign currency translation |  |  | (0.9) | ​ | ​ |  | (0.1) | ​ | ​ |  | 0.6 | ​
Balance at end of year | ​ | ​ | $24.9 | ​ | ​ | ​ | $25.1 | ​ | ​ | ​ | $20.7 | ​

​

The total amount of unrecognized tax benefits, if recognized would affect the effective tax rate by $23.1 million as of December 31, 2022, $22.8 million as of December 31, 2021 and $18.3 million as of December 31, 2020.

​

87

Table of Contents

The Company files U.S. federal income tax returns and income tax returns in various U.S. state and non- U.S. jurisdictions. With few exceptions, the Company is no longer subject to state and foreign income tax examinations by tax authorities for years before 2017. The IRS has completed examinations of the Company’s U.S. federal income tax returns through 2016, and the years 2017 through 2020 are currently under audit. In addition to the U.S. federal examination, there is ongoing audit activity in several U.S. state and foreign jurisdictions. The Company anticipates changes to uncertain tax positions due to closing of various audits and statutes closing on years mentioned above. The Company does not believe these changes will result in a material impact during the next twelve months. Decreases in the Company’s gross liability could result in offsets to other balance sheet accounts, cash payments, and adjustments to tax expense. The occurrence of these events and/or other events not included above within the next twelve months could change depending on a variety of factors.

​

The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. The Company had $4.0 million, $3.2 million and $4.1 million of accrued interest, including minor amounts for penalties, at December 31, 2022, 2021 and 2020, respectively.

​

​

14. RENTALS AND LEASES

​

Lessee

​

The Company leases sales and administrative office facilities, distribution centers, research and manufacturing facilities, as well as vehicles and other equipment under operating leases. Certain of the Company’s lease arrangements are finance leases, which are immaterial individually and in the aggregate.

​

The Company’s operating lease cost was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
Operating lease cost* | ​ | ​ | $196.9 | ​ | ​ | ​ | $179.4 | ​ | ​ | ​ | $183.8 | ​

​

*Includes immaterial short-term and variable lease costs

​

Future maturity of operating lease liabilities as of December 31, 2022 were as follows:

​

​ | ​ | ​ | ​
​ | ​ | ​ | ​
(millions) | ​ | ​ | ​
2023 | ​ |  | $124
2024 | ​ |  | 98
2025 | ​ |  | 75
2026 | ​ |  | 53
2027 | ​ | ​ | 32
Thereafter | ​ |  | 121
Total lease payments | ​ | ​ | 503
Less: imputed interest | ​ | ​ | 57
Present value of lease liabilities | ​ | ​ | $446

​

The Company’s operating leases term and discount rate were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31 | ​ | December 31 | ​ | December 31
​ | ​ | 2022 | ​ | 2021 | ​ | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average remaining lease terms (years) | ​ | ​ | 6.71 | ​ | ​ | ​ | 5.99 | ​ | ​ | ​ | 5.52 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average discount rate | ​ | ​ | 2.98% | ​ | ​ | ​ | 3.07% | ​ | ​ | ​ | 3.72% | ​

​

The Company’s other lease information was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31 | ​ | December 31 | ​ | December 31
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
Cash paid for amounts included in the measurement of lease liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating cash flows from operating leases | ​ | ​ | $157.3 | ​ | ​ | ​ | $157.0 | ​ | ​ | ​ | $164.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Leased assets obtained in exchange for new operating lease liabilities | ​ | ​ | 202.7 | ​ | ​ | ​ | 116.8 | ​ | ​ | ​ | 60.4 | ​

​

​

88

Table of Contents

Lessor

​

The Company leases warewashing and water treatment equipment to customers under operating leases.

​

Gross assets under operating leases recorded in Property, plant and equipment, net is $1,288.3 million and $1,223.3 million, and related accumulated depreciation is $811.2 million and $767.3 million, as of December 31, 2022 and 2021, respectively.

​

The Company’s operating lease revenue was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020
Operating lease revenue* | ​ | ​ | $466.7 | ​ | ​ | ​ | $412.5 | ​ | ​ | ​ | $356.3 | ​

​

*Includes immaterial variable lease revenue

​

Future revenue from operating leases for existing contracts as of December 31, 2022 were as follows:

​ | ​ | ​ | ​
​ | ​ | ​ | ​
(millions) | ​ | ​ | ​
2023 | ​ |  | $370
2024 | ​ |  | 269
2025 | ​ |  | 207
2026 | ​ |  | 140
2027 | ​ | ​ | 71
Thereafter | ​ |  | 41
Total lease revenue | ​ | ​ | $1,098

​

The Company mitigates the risk of residual value subsequent to the lease term by redeploying assets. As such, the Company expects to receive revenue from the operating lease assets through the remaining useful life and therefore subsequent to the initial contract termination date.

​

​

15. RESEARCH AND DEVELOPMENT EXPENDITURES

​

Research expenditures that relate to the development of new products and processes, including significant improvements and refinements to existing products, are expensed as incurred. Such costs were $190 million in 2022, $186 million in 2021 and $185 million in 2020. The Company did not participate in any material customer sponsored research during any of the years.

​

​

16. COMMITMENTS AND CONTINGENCIES

​

The Company is subject to various claims and contingencies related to, among other things, workers’ compensation, general liability (including product liability), automobile claims, health care claims, environmental matters and lawsuits. The Company is also subject to various claims and contingencies related to income taxes, which are discussed in Note 13. The Company also has contractual obligations including lease commitments, which are discussed in Note 14.

​

The Company records liabilities when a contingent loss is probable and can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred.

​

Insurance

​

Globally, the Company has insurance policies with varying deductible levels for property and casualty losses. The Company is insured for losses in excess of these deductibles, subject to policy terms and conditions and has recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. The Company is self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. The Company determines its liabilities for claims on an actuarial basis.

​

Litigation and Environmental Matters

​

The Company and certain subsidiaries are party to various lawsuits, claims and environmental actions that have arisen in the ordinary course of business. These include from time to time antitrust, employment, commercial, patent infringement, tort, product liability and wage hour lawsuits, as well as possible obligations to investigate and mitigate the effects on the environment of the disposal or release of certain chemical substances at various sites, such as Superfund sites and other operating or closed facilities. The Company has established accruals for certain lawsuits, claims and environmental matters. The Company currently believes that there is not a reasonably possible risk of material loss in excess of the amounts accrued related to these legal matters. Because litigation is inherently uncertain, and unfavorable rulings or developments could occur, there can be no certainty that the Company may not ultimately incur charges in excess of recorded liabilities. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Company’s results of operations or cash flows in the period in which they are recorded.

89

Table of Contents

The Company currently believes that such future charges related to suits and legal claims, if any, would not have a material adverse effect on the Company’s consolidated financial position.

​

TPC Group Litigation

​

On November 27, 2019, a Butadiene production plant owned and operated by TPC Group, Inc. in Port Neches, Texas, experienced an explosion and fire that resulted in personal injuries, the release of chemical fumes and extensive property damage to the plant and surrounding areas in and near Port Neches, Texas.

​

Nalco Company LLC, a subsidiary of Ecolab, supplied process chemicals to TPC used in TPC’s production processes. Nalco did not operate, manage, maintain or control any aspect of TPC’s plant operations.

​

In connection with its provision of process chemicals to TPC, Nalco has been named in numerous lawsuits stemming from the plant explosion. Nalco has been named a defendant, along with TPC and other defendants, in multi-district litigation (“MDL”) proceedings pending in Orange County, Texas, alleging among other things claims for personal injury, property damage and business losses (In re TPC Group Litigation – A2020-0236-MDL, Orange County, Texas). In addition, numerous other lawsuits have been filed against Nalco, including TPC Group v. Nalco, E0208239, Jefferson County, Texas, a subrogation claim by TPC’s insurers seeking reimbursement for property damage losses. Over 5,000 plaintiffs (including the subrogation matter) currently have asserted claims against Nalco.

​

All of these cases make similar allegations and seek damages for personal injury, property damage, business losses and other damages, including exemplary damages. The Company expects all these cases will be consolidated for pretrial purposes into the Orange County MDL referenced above. Due to the large number of plaintiffs, the early stage of the litigation and the fact that many of the claims do not specify an amount of damages, any estimate of any loss or range of losses cannot be made at this time.

​

On June 1, 2022, TPC and seven of its affiliated companies filed for bankruptcy under Chapter 11 (Case No. 22-10493-CTG, United States Bankruptcy Court for the District of Delaware). In connection with the bankruptcy cases, TPC disclosed an estimated range of its liability related to the Port Neches incident to individuals and homeowners (including subrogation claims) of approximately $152 million to $520 million. As part of their bankruptcy plan, TPC and its affiliates announced a settlement which allows the MDL plaintiffs a $500 million claim solely for purposes of claim allowance in the chapter 11 case and distribution of value pursuant to TPC’s bankruptcy plan. Other key terms of the settlement between TPC and the MDL plaintiffs include the establishment of a settlement trust for the benefit of certain general unsecured creditors, which is funded with $30 million and the assignment of TPC’s claims and causes of action, if any, against certain third parties, including Nalco, related to the TPC plant explosion. As part of the bankruptcy process, TPC and its debtor affiliates received a discharge of all MDL related claims, as did certain non-debtor affiliates to the extent third parties did not opt out of the non-debtor releases. Nalco opted out of these releases, preserving any direct causes of action it may have against non-debtors. Furthermore, the allowance of the $500 million claim should have no effect on any claims or defenses asserted against or by Nalco in the MDL litigation. On December 1, 2022, the bankruptcy court confirmed the TPC bankruptcy plan, including the approval of the settlement and establishment of the aforementioned settlement trust. On December 16, 2022, the TPC bankruptcy plan went effective.

​

The Company believes the claims asserted against Nalco in the lawsuits stemming from the TPC plant explosion are without merit and intends to defend the claims vigorously. The Company also believes any potential loss should be covered by insurance subject to deductibles. However, the Company cannot predict the outcome of these lawsuits, the involvement the Company might have in these matters in the future or the potential for future litigation.

​

Environmental Matters

​

The Company is currently participating in environmental assessments and remediation at approximately 25 locations, the majority of which are in the U.S., and environmental liabilities have been accrued reflecting management’s best estimate of future costs. Potential insurance reimbursements are not anticipated in the Company’s accruals for environmental liabilities.

​

​

17. RETIREMENT PLANS

​

Pension and Postretirement Health Care Benefits Plans

​

The Company has a non-contributory, qualified, defined benefit pension plan covering the majority of its U.S. employees. The Company also has U.S. non-contributory, non-qualified, defined benefit pension plans, which provide for benefits to employees in excess of limits permitted under its pension plans. The U.S. non-qualified plans are not funded and the recorded benefit obligations for the non-qualified plans were $86 million and $114 million at December 31, 2022 and 2021, respectively. The measurement date used for determining the U.S. pension plan assets and obligations is December 31.

​

Various international subsidiaries have defined benefit pension plans. International plans are funded based on local country requirements. The measurement date used for determining the international pension plan assets and obligations is November 30, the fiscal year end of the Company’s international subsidiaries.

​

The Company provides postretirement health care and life insurance benefits to certain U.S. employees and retirees. The U.S. postretirement health care plans are contributory based on years of service and choice of coverage (family or single), with retiree contributions adjusted annually. The Company also maintains several U.S. postretirement life insurance plans. The measurement date used to determine the U.S. postretirement health care and life insurance plan assets and obligations is December 31. Certain employees

90

Table of Contents

outside the U.S. are covered under government-sponsored programs, which are not required to be fully funded. The expense and obligation for providing international postretirement health care benefits are not significant.

​

The following table sets forth financial information related to the Company’s pension and postretirement benefit plans:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | U.S. | ​ | International | ​ | U.S. Postretirement |
​ | ​ | Pensions | ​ | Pensions | ​ | Benefits |
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2022 | ​ | 2021 | ​ | 2022 | ​ | 2021 |
Accumulated benefit obligation, end of year | ​ | ​ | $1,799.0 | ​ | ​ | ​ | $2,462.7 | ​ | ​ | $1,171.1 | ​ | ​ | ​ | $1,696.2 | ​ | ​ | $115.5 | ​ | ​ | ​ | $155.4 | ​
Projected benefit obligation | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Projected benefit obligation, beginning of year |  | ​ | $2,462.7 | ​ | ​ | ​ | $2,728.4 | ​ | ​ | $1,779.7 | ​ | ​ | ​ | $1,834.2 | ​ | ​ | $155.4 | ​ | ​ | ​ | $172.4 | ​
Service cost |  | ​ | 40.8 | ​ | ​ | ​ | 43.9 | ​ | ​ | 28.4 | ​ | ​ | ​ | 31.4 | ​ | ​ | 0.8 | ​ | ​ | ​ | 1.0 | ​
Interest cost |  | ​ | 65.3 | ​ | ​ | ​ | 51.4 | ​ | ​ | 22.0 | ​ | ​ | ​ | 17.3 | ​ | ​ | 3.3 | ​ | ​ | ​ | 2.9 | ​
Participant contributions |  | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 3.0 | ​ | ​ | ​ | 2.9 | ​ | ​ | 3.7 | ​ | ​ | ​ | 3.3 | ​
Plan amendments |  | ​ | - | ​ | ​ | ​ | - | ​ | ​ | - | ​ | ​ | ​ | 0.7 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Actuarial (gain) loss |  | ​ | (479.8) | ​ | ​ | ​ | (79.6) | ​ | ​ | (436.8) | ​ | ​ | ​ | (25.3) | ​ | ​ | (33.7) | ​ | ​ | ​ | (12.1) | ​
Assumed through acquisitions | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 15.1 | ​ | ​ | ​ | 34.0 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other events | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | - | ​ | ​ | ​ | 4.3 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Benefits paid |  | ​ | (290.0) | ​ | ​ | ​ | (281.4) | ​ | ​ | (54.3) | ​ | ​ | ​ | (68.5) | ​ | ​ | (14.0) | ​ | ​ | ​ | (12.1) | ​
Foreign currency translation |  | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (135.2) | ​ | ​ | ​ | (51.3) | ​ | ​ | - | ​ | ​ | ​ | - | ​
Projected benefit obligation, end of year |  | ​ | $1,799.0 | ​ | ​ | ​ | $2,462.7 | ​ | ​ | $1,221.9 | ​ | ​ | ​ | $1,779.7 | ​ | ​ | $115.5 | ​ | ​ | ​ | $155.4 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Plan assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fair value of plan assets, beginning of year | ​ | ​ | $2,376.8 | ​ | ​ | ​ | $2,372.9 | ​ | ​ | $1,219.9 | ​ | ​ | ​ | $1,148.0 | ​ | ​ | $5.2 | ​ | ​ | ​ | $5.7 | ​
Actual returns on plan assets | ​ | ​ | (430.3) | ​ | ​ | ​ | 276.8 | ​ | ​ | (218.3) | ​ | ​ | ​ | 107.5 | ​ | ​ | (0.8) | ​ | ​ | ​ | 0.6 | ​
Company contributions | ​ | ​ | 12.0 | ​ | ​ | ​ | 8.5 | ​ | ​ | 38.3 | ​ | ​ | ​ | 40.7 | ​ | ​ | 12.8 | ​ | ​ | ​ | 11.0 | ​
Participant contributions | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 3.0 | ​ | ​ | ​ | 2.9 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Acquired through acquisitions | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | 15.1 | ​ | ​ | ​ | 12.9 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Benefits paid | ​ | ​ | (290.0) | ​ | ​ | ​ | (281.4) | ​ | ​ | (54.3) | ​ | ​ | ​ | (68.5) | ​ | ​ | (14.0) | ​ | ​ | ​ | (12.1) | ​
Foreign currency translation | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (98.6) | ​ | ​ | ​ | (23.6) | ​ | ​ | - | ​ | ​ | ​ | - | ​
Fair value of plan assets, end of year | ​ | ​ | $1,668.5 | ​ | ​ | ​ | $2,376.8 | ​ | ​ | $905.1 | ​ | ​ | ​ | $1,219.9 | ​ | ​ | $3.2 | ​ | ​ | ​ | $5.2 | ​
Funded Status, end of year | ​ | ​ | ($130.5) | ​ | ​ | ​ | ($85.9) | ​ | ​ | ($316.8) | ​ | ​ | ​ | ($559.8) | ​ | ​ | ($112.3) | ​ | ​ | ​ | ($150.2) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts recognized in the Consolidated Balance Sheets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other assets | ​ | ​ | $- | ​ | ​ | ​ | $28.2 | ​ | ​ | $118.6 | ​ | ​ | ​ | $86.5 | ​ | ​ | $- | ​ | ​ | ​ | $- | ​
Other current liabilities | ​ | ​ | ($9.2) | ​ | ​ | ​ | (14.8) | ​ | ​ | (28.6) | ​ | ​ | ​ | (27.0) | ​ | ​ | (7.6) | ​ | ​ | ​ | (5.5) | ​
Postretirement healthcare and pension benefits | ​ | ​ | ($121.3) | ​ | ​ | ​ | (99.3) | ​ | ​ | (406.8) | ​ | ​ | ​ | (619.3) | ​ | ​ | (104.7) | ​ | ​ | ​ | (144.7) | ​
Net liability | ​ | ​ | ($130.5) | ​ | ​ | ​ | ($85.9) | ​ | ​ | ($316.8) | ​ | ​ | ​ | ($559.8) | ​ | ​ | ($112.3) | ​ | ​ | ​ | ($150.2) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts recognized in accumulated other comprehensive loss (income): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unrecognized net actuarial loss (gain) | ​ | ​ | $411.9 | ​ | ​ | ​ | $396.8 | ​ | ​ | $279.7 | ​ | ​ | ​ | $485.7 | ​ | ​ | ($43.6) | ​ | ​ | ​ | ($11.7) | ​
Unrecognized net prior service (benefits) costs | ​ | ​ | (21.2) | ​ | ​ | ​ | (25.8) | ​ | ​ | 0.3 | ​ | ​ | ​ | (0.2) | ​ | ​ | - | ​ | ​ | ​ | - | ​
Tax (benefit) expense | ​ | ​ | (100.8) | ​ | ​ | ​ | (95.3) | ​ | ​ | (66.5) | ​ | ​ | ​ | (117.8) | ​ | ​ | 7.7 | ​ | ​ | ​ | 1.2 | ​
Accumulated other comprehensive loss (income), net of tax | ​ | ​ | $289.9 | ​ | ​ | ​ | $275.7 | ​ | ​ | $213.5 | ​ | ​ | ​ | $367.7 | ​ | ​ | ($35.9) | ​ | ​ | ​ | ($10.5) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Change in accumulated other comprehensive loss (income): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of net actuarial gain (loss) | ​ | ​ | ($30.2) | ​ | ​ | ​ | ($56.2) | ​ | ​ | ($22.7) | ​ | ​ | ​ | ($28.7) | ​ | ​ | $0.6 | ​ | ​ | ​ | ($0.7) | ​
Amortization of prior service credits | ​ | ​ | 4.5 | ​ | ​ | ​ | 6.9 | ​ | ​ | 0.1 | ​ | ​ | ​ | 0.1 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Current period net actuarial loss (gain) | ​ | ​ | 97.0 | ​ | ​ | ​ | (203.0) | ​ | ​ | (147.8) | ​ | ​ | ​ | (56.1) | ​ | ​ | (32.5) | ​ | ​ | ​ | (12.3) | ​
Current period prior service costs | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | - | ​ | ​ | ​ | 0.7 | ​ | ​ | - | ​ | ​ | ​ | - | ​
Curtailments and settlements | ​ | ​ | (51.6) | ​ | ​ | ​ | (35.3) | ​ | ​ | - | ​ | ​ | ​ | (3.5) | ​ | ​ | - | ​ | ​ | ​ | - | ​
Tax (benefit) expense | ​ | ​ | (5.5) | ​ | ​ | ​ | 69.8 | ​ | ​ | 51.3 | ​ | ​ | ​ | 25.4 | ​ | ​ | 6.5 | ​ | ​ | ​ | 3.2 | ​
Foreign currency translation | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (35.1) | ​ | ​ | ​ | (12.7) | ​ | ​ | - | ​ | ​ | ​ | - | ​
Other comprehensive loss (income) | ​ | ​ | $14.2 | ​ | ​ | ​ | ($217.8) | ​ | ​ | ($154.2) | ​ | ​ | ​ | ($74.8) | ​ | ​ | ($25.4) | ​ | ​ | ​ | ($9.8) | ​

​

Estimate amounts in accumulated other comprehensive loss expected to be reclassified to net period cost during 2023 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | U.S. Post- |
​ | ​ | U.S. | ​ | International | ​ | Retirement | ​
(millions) | ​ | Pensions | ​ | Pensions | ​ | Benefits |
Net actuarial loss (gain) | ​ | ​ | $0.2 | ​ | ​ | ​ | $11.6 | ​ | ​ | ​ | ($3.1) | ​ | ​
Net prior service benefits | ​ | ​ | (4.6) | ​ | ​ | ​ | (0.3) | ​ | ​ | ​ | - | ​ | ​
Total | ​ | ​ | ($4.4) | ​ | ​ | ​ | $11.3 | ​ | ​ | ​ | ($3.1) | ​ | ​

​

Service cost is included with employee compensation cost in either cost of sales and selling, general and administrative expenses in the Consolidated Statements of Income based on employee roles in the Company while all non-service components are included in other (income) expense in the Consolidated Statements of Income.

91

Table of Contents

The aggregate projected benefit obligation, accumulated benefit obligation and fair value of pension plan assets for plans with accumulated benefit obligations in excess of plan assets were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, (millions) |  | 2022 |  | 2021 | ​
Aggregate projected benefit obligation | ​ | ​ | $2,392.1 | ​ | ​ | ​ | $1,022.3 | ​
Accumulated benefit obligation | ​ |  | 2,355.8 | ​ | ​ |  | 964.5 | ​
Fair value of plan assets | ​ |  | 1,828.1 | ​ | ​ |  | 280.9 | ​

​

These plans include the U.S. non-qualified pension plans which are not funded as well as various international pension plans which are funded consistent with local practices and requirements.

​

For the year ended December 31, 2022, the year-over-year decrease in the Company’s consolidated net benefit obligations was due to decreases in both pension liabilities and pension plan assets. Pension liabilities decreased on a global basis primarily due to increases in pension discount rates used to discount projected pension benefit payments. The Company’s pension discount rates are largely determined based on observable yields of investment grade corporate bonds or government issued debt-securities. Yields on these securities increased sharply in 2022 due, in part, to actions taken by many central banks to curb global inflation. The Company’s pension plan assets are reported at fair value. The fair value of the Company’s pension assets decreased on a global basis primarily due to unfavorable returns on the Company’s equity and fixed income investments.

​

For the year ended December 31, 2021, the year-over-year decrease in the Company’s consolidated net benefit obligations was due to decreases in pension liabilities and increases in pension plan assets. Pension liabilities decreased primarily due to increases in discount rates used to discount projected benefit payments. The Company’s pension discount rates are largely determined based on observable yields on investment grade corporate bonds and govement issued debt-securities which increased in many geographies year-over-year. The fair value of the Company’s pension assets increased year-over-year as asset returns outpaced pension distributions due to strong returns for equitities and fixed income investments.

​

Net Periodic Benefit Costs and Plan Assumptions

​

Pension and postretirement benefits expense for the Company’s operations were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | U.S. | ​ | International | ​ | U.S. Postretirement
​ | ​ | Pensions | ​ | Pensions | ​ | Benefits
(millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020
Service cost (a) | ​ | ​ | $40.8 | ​ | ​ | ​ | $43.9 | ​ | ​ | $68.4 | ​ | ​ | $28.4 | ​ | ​ | ​ | $31.4 | ​ | ​ | $30.8 | ​ | ​ | $0.8 | ​ | ​ | ​ | $1.0 | ​ | ​ | $1.2
Interest cost on benefit obligation |  | ​ | 65.3 | ​ | ​ |  | 51.4 | ​ | ​ | 70.3 | ​ |  | 22.0 | ​ | ​ |  | 17.3 | ​ |  | 22.3 | ​ |  | 3.3 | ​ | ​ |  | 2.9 | ​ |  | 4.4
Expected return on plan assets |  | ​ | (144.4) | ​ | ​ |  | (152.3) | ​ | ​ | (152.9) | ​ |  | (69.8) | ​ | ​ |  | (70.7) | ​ |  | (63.9) | ​ |  | (0.3) | ​ | ​ |  | (0.4) | ​ |  | (0.4)
Recognition of net actuarial loss (gain) | ​ | ​ | 30.2 | ​ | ​ |  | 56.7 | ​ | ​ | 51.9 | ​ |  | 22.8 | ​ | ​ |  | 28.7 | ​ |  | 26.1 | ​ |  | (0.6) | ​ | ​ |  | 0.7 | ​ |  | 0.1
Amortization of prior service benefit | ​ | ​ | (4.5) | ​ | ​ | ​ | (6.9) | ​ | ​ | (7.4) | ​ | ​ | (0.1) | ​ | ​ | ​ | (0.1) | ​ | ​ | (0.1) | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | (11.0)
Curtailments and settlements (b) | ​ | ​ | 51.6 | ​ | ​ | ​ | 35.3 | ​ | ​ | 2.5 | ​ | ​ | - | ​ | ​ | ​ | 3.5 | ​ | ​ | 2.2 | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | -
Total expense (benefit) | ​ | ​ | $39.0 | ​ | ​ | ​ | $28.1 | ​ | ​ | $32.8 | ​ | ​ | $3.3 | ​ | ​ | ​ | $10.1 | ​ | ​ | $17.4 | ​ | ​ | $3.2 | ​ | ​ | ​ | $4.2 | ​ | ​ | ($5.7)

​

| (a) | Service cost includes discontinued operations of $2.5 for the year ended December 31, 2020.

| (b) | $50.6 and $37.2 of settlement expense was recognized as special charges in 2022 and 2021, respectively.

​

During 2022 and 2021, the Company incurred settlement expense in the U.S. of $51.6 million ($38.9 million after tax) and $35.3 million ($26.8 million after tax), respectively, related to lump-sum payments to retirees in its U.S. pension plans. In addition to the U.S. qualifited plan settlements in 2022 and 2021, we have historically recognized settlements and curtailment gains and losses associated with our U.S. nonqualified pension plans and International pension plans, the amounts of which have been historically not material. These charges have been included as a component of other (income) expense on the Consolidated Statements of Income.

​

92

Table of Contents

Pension and postretirement health care benefits plan assumptions for the Company were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Plan Assumptions | ​ | U.S. | ​ | International | ​ | U.S. Postretirement | ​
​ | ​ | Pensions | ​ | Pensions | ​ | Benefits | ​
(percent) |  | 2022 | ​ | 2021 | ​ | 2020 |  | 2022 | ​ | 2021 | ​ | 2020 | ​ | 2022 | ​ | 2021 | ​ | 2020 | ​
Weighted-average actuarial assumptions | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
used to determine benefit obligations | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
as of year end: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Discount rate | ​ | 5.17 | % | ​ | 2.86 | % | ​ | 2.48 | % | ​ | 3.70 | % | ​ | 1.45 | % | ​ | 1.13 | % | ​ | 5.14 | % | ​ | 2.75 | % | ​ | 2.37 | % | ​
Projected salary increase | ​ | 4.03 |  | ​ | 4.03 |  | ​ | 4.03 |  | ​ | 2.81 |  | ​ | 2.42 |  | ​ | 2.12 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average actuarial assumptions | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
used to determine net cost: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest credit rate for cash balance plans | ​ | 1.56 | ​ | ​ | 0.87 | ​ | ​ | 1.81 | ​ | ​ | N/A | ​ | ​ | N/A | ​ | ​ | N/A | ​ | ​ | N/A | ​ | ​ | N/A | ​ | ​ | N/A | ​ | ​
Discount rate | ​ | 2.86 |  | ​ | 2.49 |  | ​ | 3.20 |  | ​ | 1.46 |  | ​ | 1.37 |  | ​ | 1.84 |  | ​ | 2.75 |  | ​ | 2.37 |  | ​ | 3.16 | ​ | ​
Expected return on plan assets | ​ | 7.00 |  | ​ | 7.00 |  | ​ | 7.25 |  | ​ | 6.18 |  | ​ | 6.24 |  | ​ | 6.24 |  | ​ | 7.00 |  | ​ | 7.00 |  | ​ | 7.25 | ​ | ​
Projected salary increase | ​ | 4.03 |  | ​ | 4.03 |  | ​ | 4.03 |  | ​ | 2.47 |  | ​ | 2.31 |  | ​ | 2.81 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Discount rate assumptions for the U.S. plans are developed using a bond yield curve constructed from a population of high-quality, non-callable, corporate bonds with maturities ranging from six months to thirty years. Discount rates are estimated for the U.S. plans based on the timing of the expected benefit payments.

​

The Company measures service and interest costs by applying the specific spot rates along that yield curve to the plans’ liability cash flows. The Company believes this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve.

​

The expected long-term rate of return used for the U.S. plans is based on the respective pension plan’s asset mix. The Company considers expected long-term real returns on asset categories, expectations for inflation, and estimates of the impact of active management of the assets in determining the expected long-term rate of return to use. The Company also considers historical returns.

​

The expected long-term rate of return used for the Company’s international plans is determined in each local jurisdiction and is based on the assets held in that jurisdiction, the expected rate of returns for the type of assets held and any guaranteed rate of return provided by the investment. The other assumptions used to measure the international pension obligations, including discount rate, vary by country based on specific local requirements and information.

​

The Company uses mortality tables appropriate in the circumstances, which generally are the recent available mortality tables as of the respective U.S. and international measurement dates. The Company’s year-end U.S. valuations reflect mortality tables that estimate the impacts of COVID in an endemic state. This represents a change from prior year when the impact of COVID on future mortality could not be reasonably estimated.

​

For postretirement benefit measurement purposes as of December 31, 2022, the annual rates of increase in the per capita cost of covered health care were assumed to be 6.75% for pre-65 costs. Post-65 costs are no longer used. The rates are assumed to decrease each year until they reach 4.5% in 2032 and remain at those levels thereafter. Health care costs for certain employees which are eligible for subsidy by the Company are limited by a cap on the subsidy.

​

Plan Asset Management

​

The Company’s U.S. investment strategy and policies are designed to maximize the possibility of having sufficient funds to meet the long-term liabilities of the qualified pension plan, while achieving a balance between the goals of asset growth of the qualified pension plan and keeping risk at a reasonable level. Investment income is not a primary goal of the policy.

​

The asset allocation position reflects the Company’s ability and willingness to accept relatively more short-term variability in the performance of the qualified pension plan asset portfolio in exchange for the expectation of better long-term returns, lower pension costs and better funded status in the long run. The U.S. qualified pension plan’s asset are diversified across a number of asset classes and securities. Selected individual portfolios within the asset classes may be undiversified while maintaining the diversified nature of total plan assets. The Company has no significant concentration of risk in its U.S. qualified pension plan assets.

​

Assets of funded international retirement plans are managed in each local jurisdiction and asset allocation strategy is set in accordance with local rules, regulations and practices; therefore, no overall target asset allocation is presented. Although foreign equity securities are all considered international for the Company, some equity securities are considered domestic for the local plan. The funds are invested in a variety of equities, bonds and real estate investments and, in some cases, the assets are managed by insurance companies which may offer a guaranteed rate of return. The Company has no significant concentration of risk in the assets of its international pension plans.

​

The fair value hierarchy is used to categorize investments measured at fair value in one of three levels in the fair value hierarchy. This categorization is based on the observability of the inputs used in valuing the investments. Refer to Note 8 for definitions of these levels.

​

​

93

Table of Contents

The fair value of the Company’s U.S. qualified pension plan assets were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value as of | ​ | Fair Value as of
(millions) | ​ | December 31, 2022 | ​ | December 31, 2021
​ |  | Level 1 |  | Level 2 |  | Total | ​ | Level 1 |  | Level 2 |  | Total
Cash | ​ | ​ | $54.8 | ​ | ​ | $- | ​ | ​ | $54.8 | ​ | ​ | $43.6 | ​ | ​ | $- | ​ | ​ | $43.6
Equity securities: | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​
Large cap equity |  |  | 237.1 | ​ | ​ | - | ​ | ​ | 237.1 | ​ |  | 412.2 | ​ | ​ | - | ​ | ​ | 412.2
Small cap equity |  |  | 15.4 | ​ | ​ | 25.1 | ​ | ​ | 40.5 | ​ |  | 21.3 | ​ | ​ | 40.7 | ​ | ​ | 62.0
International equity |  |  | 37.4 | ​ | ​ | 17.2 | ​ | ​ | 54.6 | ​ |  | 62.9 | ​ | ​ | 28.0 | ​ | ​ | 90.9
Fixed income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core fixed income |  |  | 145.5 | ​ | ​ | 646.5 | ​ | ​ | 792.0 | ​ |  | 510.7 | ​ | ​ | 589.7 | ​ | ​ | 1,100.4
High-yield bonds |  |  | 33.4 | ​ | ​ | - | ​ | ​ | 33.4 | ​ |  | 49.0 | ​ | ​ | - | ​ | ​ | 49.0
Emerging markets |  |  | - | ​ | ​ | 25.4 | ​ | ​ | 25.4 | ​ |  | - | ​ | ​ | 36.6 | ​ | ​ | 36.6
Total investments at fair value | ​ |  | 523.6 | ​ | ​ | 714.2 | ​ |  | 1,237.8 | ​ |  | 1,099.7 | ​ | ​ | 695.0 | ​ |  | 1,794.7
Investments measured at net asset value | ​ |  | ​ | ​ | ​ | ​ | ​ |  | 433.9 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 587.3
Total | ​ | ​ | $523.6 | ​ | ​ | $714.2 | ​ | ​ | $1,671.7 | ​ | ​ | $1,099.7 | ​ | ​ | $695.0 | ​ | ​ | $2,382.0

​

The Company had no Level 3 assets as part of its U.S. qualified pension plan assets as of December 31, 2022 or 2021.

​

The allocation of the Company’s U.S. qualified pension plan assets plans were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Target Asset | ​ | ​ | ​ | ​ | ​ |
Asset Category | ​ | Allocation | ​ | Percentage
​ | ​ | Percentage | ​ | of Plan Assets
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31 |  | 2022 | ​ | 2021 |  | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash | ​ | - | % | ​ | - | % | ​ | 3 | % | ​ | 2 | %
Equity securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Large cap equity | ​ | 21 | ​ | ​ | 21 | ​ | ​ | 14 | ​ | ​ | 17 | ​
Small cap equity | ​ | 3 |  | ​ | 3 |  | ​ | 2 |  | ​ | 3 | ​
International equity | ​ | 13 |  | ​ | 10 |  | ​ | 9 |  | ​ | 10 | ​
Fixed income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core fixed income | ​ | 48 |  | ​ | 48 |  | ​ | 47 |  | ​ | 46 | ​
High-yield bonds | ​ | 3 |  | ​ | 3 |  | ​ | 2 |  | ​ | 2 | ​
Emerging markets | ​ | 2 |  | ​ | 4 |  | ​ | 2 |  | ​ | 2 | ​
Other: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Real estate | ​ | 3 |  | ​ | 3 |  | ​ | 4 |  | ​ | 4 | ​
Private equity | ​ | 5 |  | ​ | 5 |  | ​ | 15 |  | ​ | 11 | ​
Distressed debt | ​ | 2 | ​ | ​ | 3 | ​ | ​ | 2 | ​ | ​ | 3 | ​
Total | ​ | 100 | % | ​ | 100 | % | ​ | 100 | % | ​ | 100 | %

​

The fair value of the Company’s international plan assets for its defined benefit pension plans were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value as of |  | ​ | Fair Value as of
(millions) | ​ | December 31, 2022 |  | ​ | December 31, 2021
​ |  | Level 1 |  | Level 2 |  | Total |  | ​ | Level 1 |  | Level 2 |  | Total
Cash | ​ | $9.9 | ​ | $- | ​ | $9.9 | ​ | ​ | $7.2 | ​ | $- | ​ | $7.2
Equity securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
International equity | ​ | - | ​ | 219.3 | ​ | 219.3 | ​ | ​ | - | ​ | 490.1 | ​ | 490.1
Fixed income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Corporate bonds |  | - | ​ | 158.5 | ​ | 158.5 | ​ | ​ | 9.7 | ​ | 220.0 | ​ | 229.7
Government bonds |  | - | ​ | 365.9 | ​ | 365.9 | ​ | ​ | 7.2 | ​ | 298.5 | ​ | 305.7
Insurance company accounts | ​ | - | ​ | 106.2 | ​ | 106.2 | ​ | ​ | - | ​ | 121.2 | ​ | 121.2
Total investments at fair value | ​ | 9.9 | ​ | 849.9 | ​ | 859.8 | ​ | ​ | 24.1 | ​ | 1,129.8 | ​ | 1,153.9
Investments measured at net asset value | ​ | ​ | ​ | ​ | ​ | 45.3 | ​ | ​ | ​ | ​ | ​ | ​ | 66.0
Total | ​ | $9.9 | ​ | $849.9 | ​ | $905.1 | ​ | ​ | $24.1 | ​ | $1,129.8 | ​ | $1,219.9

​

​

​

94

Table of Contents

The Company had no Level 3 assets as part of its international plan assets as of December 31, 2022 or 2021.

​

The allocation of plan assets of the Company’s international plan assets for its defined benefit pension plans were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Percentage
Asset Category | ​ | of Plan Assets
​ | ​ | ​ | ​ | ​ | ​ | ​
December 31 | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​
Cash | ​ | 1 | % | ​ | 1 | %
Equity securities: | ​ | ​ | ​ | ​ | ​ | ​
International equity | ​ | 24 | ​ |  | 40 | ​
Fixed income: | ​ | ​ | ​ | ​ | ​ | ​
Corporate bonds | ​ | 18 | ​ |  | 19 | ​
Government bonds | ​ | 40 | ​ |  | 25 | ​
Total fixed income | ​ | 58 | ​ |  | 44 | ​
Other: | ​ | ​ | ​ | ​ | ​ | ​
Insurance contracts | ​ | 12 | ​ |  | 10 | ​
Debt securities | ​ | - | ​ | ​ | 2 | ​
Real estate | ​ | 5 | ​ | ​ | 3 | ​
Total | ​ | 100 | % | ​ | 100 | %

​

Cash Flows

​

As of year-end 2022, the Company’s estimate of pension and postretirement benefits expected to be paid in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter are as follows:

​

​ | ​ | ​ | ​ | ​
(millions) | ​ | All Plans | ​
2023 | ​ | ​ | $207 | ​
2024 | ​ |  | 220 | ​
2025 | ​ |  | 224 | ​
2026 | ​ |  | 226 | ​
2027 | ​ |  | 229 | ​
2028 - 2032 | ​ |  | 1,151 | ​

​

Depending on plan funding levels, the U.S. qualified pension plan provides certain terminating participants with an option to receive their pension benefits in the form of a lump sum payout.

​

The Company is currently in compliance with all funding requirements of its U.S. pension and postretirement benefit plans. There were no voluntary contributions made to its non-contributory qualified U.S. pension plan. The Company is required to fund certain international pension benefit plans in accordance with local legal requirements. The Company estimates contributions to be made to its international plans will approximate $41 million in 2023.

​

The Company seeks to maintain balance in its U.S. assets that meet the long-term funding requirements identified by the projections of the pension plans’ actuaries while simultaneously satisfying the fiduciary responsibilities prescribed in ERISA. The Company also takes into consideration the tax deductibility of contributions to the benefit plans.

​

Savings Plan and ESOP

​

The Company provides a 401(k) savings plan for the majority of its U.S. employees under the Company’s 401(k) savings plans, the Ecolab Savings Plan and ESOP (the “Ecolab Savings Plan”).

​

Effective December 31, 2020, the Ecolab Savings Plan and ESOP for Traditional Benefit Employees (the “Traditional Plan”) merged into and became part of the Ecolab Savings Plan. Following the merger, participants in the Traditional Plan became participants in the Ecolab Savings Plan and $1,710 million of net assets of the Traditional Plan transferred to the Ecolab Savings Plan.

​

Under the Ecolab Savings Plan, Employee before-tax contributions of up to 4% of eligible compensation are matched 100% by the Company and employee before-tax contributions over 4% and up to 8% of eligible compensation are matched 50% by the Company.

​

The Company’s matching contributions are 100% vested immediately. The Company’s matching contribution expense was $81.6 million, $78.2 million and $72.4 million in 2022, 2021 and 2020, respectively.

​

95

Table of Contents

18. REVENUES

​

Revenue Recognition

​

Product and Sold Equipment

​

Product revenue is generated from sales of cleaning, sanitizing, water treatment, process treatment and colloidal silica products. In addition, the Company sells equipment which may be used in combination with its specialized products. Revenue recognized from product and sold equipment is recognized at the point in time when the obligations in the contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment.

​

Service and Lease Equipment

​

Service and lease equipment revenue is generated from providing services or leasing equipment to customers. Service offerings include installing or repairing certain types of equipment, activities that supplement or replace headcount at the customer location, or fulfilling deliverables included in the contract. Global Industrial segment services are associated with water treatment and paper process applications. Global Institutional & Specialty services include cleaning and sanitizing programs and wash process solutions. Global Healthcare & Life Sciences segment services include pharmaceutical, personal care, infection and containment control solutions. Revenues included in Other primarily related to services designed to detect, eliminate and prevent pests. Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized over time using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue recognized from leased equipment primarily relates to warewashing and water treatment equipment recognized on a straight-line basis over the length of the lease contract pursuant to Topic 842 Leases. In the second quarter ended June 30, 2020, the Company provided a one-time lease billing suspension of approximately $38 million to certain restaurant customers within the Institutional Segment, in recognition of the impact of the COVID-19 pandemic. There was no substantial change to the consideration expected to be received under the lease arrangement. Refer to Note 14 for additional information related to lease equipment.

​

Practical Expedients and Exemptions

​

The revenue standard can be applied to a portfolio of contracts with similar characteristics if it is reasonable that the effects of applying the standard at the portfolio level would not be significantly different than applying the standard at the individual contract level. The Company applies the portfolio approach primarily within each operating segment by geographical region. Application of the portfolio approach was focused on those characteristics that have the most significant accounting consequences in terms of their effect on the timing of revenue recognition or the amount of revenue recognized. The Company determined the key criteria to assess with respect to the portfolio approach, including the related deliverables, the characteristics of the customers and the timing and transfer of goods and services, which most closely aligned within the operating segments. In addition, the accountability for the business operations, as well as the operational decisions on how to go to market and the product offerings, are performed at the operating segment level.

​

The following table shows principal activities, separated by reportable segments, from which the Company generates its revenue. The reportable segments have been revised to align with the Company’s reportable segments in the current year. Corporate segment includes sales to ChampionX under the Master Cross Supply and Product Transfer agreements entered into as part of the ChampionX Separation. For more information about the Company’s reportable segments, refer to Note 19.

​

Net sales at public exchange rates by reportable segment were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​
(millions) |  | 2022 | ​ | 2021 |  | 2020 |
Global Industrial | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and sold equipment |  | ​ | $5,937.0 | ​ | ​ | ​ | $5,372.0 | ​ | ​ | $5,052.3 |
Service and lease equipment |  | ​ | 868.0 | ​ | ​ | ​ | 865.8 | ​ | ​ | 818.5 |
Global Institutional & Specialty |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
Product and sold equipment | ​ | ​ | 3,645.1 | ​ | ​ | ​ | 3,265.5 | ​ | ​ | 2,968.7 | ​
Service and lease equipment | ​ | ​ | 776.8 | ​ | ​ | ​ | 690.4 | ​ | ​ | 584.5 | ​
Global Healthcare & Life Sciences | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and sold equipment | ​ | ​ | 1,398.3 | ​ | ​ | ​ | 1,068.9 | ​ | ​ | 1,071.4 | ​
Service and lease equipment | ​ | ​ | 112.2 | ​ | ​ | ​ | 112.7 | ​ | ​ | 110.5 | ​
Other | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and sold equipment | ​ | ​ | 342.1 | ​ | ​ | ​ | 308.9 | ​ | ​ | 274.5 | ​
Service and lease equipment | ​ | ​ | 984.5 | ​ | ​ | ​ | 909.7 | ​ | ​ | 809.8 | ​
Corporate | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product and sold equipment | ​ | ​ | 123.7 | ​ | ​ | ​ | 138.0 | ​ | ​ | 99.7 | ​
Service and lease equipment | ​ | ​ | 0.1 | ​ | ​ | ​ | 1.2 | ​ | ​ | 0.3 | ​
Total | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total product and sold equipment | ​ | ​ | $11,446.2 | ​ | ​ | ​ | $10,153.3 | ​ | ​ | $9,466.6 | ​
Total service and lease equipment | ​ | ​ | 2,741.6 | ​ | ​ | ​ | 2,579.8 | ​ | ​ | 2,323.6 | ​

96

Table of Contents

Net sales at public exchange rates by geographic region were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Global Industrial | ​ | Global Institutional & Specialty
(millions) |  | 2022 | ​ | 2021 |  | 2020 |  | ​ | 2022 | ​ | 2021 |  | 2020 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
United States | ​ | ​ | $2,945.1 | ​ | ​ | ​ | $2,603.0 | ​ | ​ | $2,564.3 | ​ | ​ | ​ | $3,050.0 | ​ | ​ | ​ | $2,721.8 | ​ | ​ | $2,400.4 |
Europe |  | ​ | 1,373.6 | ​ | ​ | ​ | 1,367.1 | ​ | ​ | 1,262.6 | ​ | ​ | ​ | 624.0 | ​ | ​ | ​ | 557.9 | ​ | ​ | 510.3 |
Asia Pacific |  | ​ | 830.1 | ​ | ​ | ​ | 802.5 | ​ | ​ | 747.2 | ​ | ​ | ​ | 212.6 | ​ | ​ | ​ | 201.2 | ​ | ​ | 203.9 |
Latin America |  | ​ | 621.7 | ​ | ​ | ​ | 551.5 | ​ | ​ | 491.7 | ​ | ​ | ​ | 162.3 | ​ | ​ | ​ | 135.0 | ​ | ​ | 128.3 |
Greater China | ​ | ​ | 419.3 | ​ | ​ | ​ | 394.9 | ​ | ​ | 333.0 | ​ | ​ | ​ | 124.5 | ​ | ​ | ​ | 132.3 | ​ | ​ | 114.9 | ​
India, Middle East and Africa | ​ | ​ | 419.4 | ​ | ​ | ​ | 344.4 | ​ | ​ | 314.1 | ​ | ​ | ​ | 54.6 | ​ | ​ | ​ | 44.2 | ​ | ​ | 39.8 | ​
Canada | ​ | ​ | 195.8 | ​ | ​ | ​ | 174.4 | ​ | ​ | 157.9 | ​ | ​ | ​ | 193.9 | ​ | ​ | ​ | 163.5 | ​ | ​ | 155.6 | ​
Total | ​ | ​ | $6,805.0 | ​ | ​ | ​ | $6,237.8 | ​ | ​ | $5,870.8 | ​ | ​ | ​ | $4,421.9 | ​ | ​ | ​ | $3,955.9 | ​ | ​ | $3,553.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Global Healthcare & Life Sciences | ​ | Other
(millions) | ​ | 2022 | ​ | 2021 |  | 2020 |  | ​ | 2022 | ​ | 2021 |  | 2020 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
United States | ​ | ​ | $612.5 | ​ | ​ | ​ | $442.3 | ​ | ​ | $432.6 | ​ | ​ | ​ | $816.0 | ​ | ​ | ​ | $719.9 | ​ | ​ | $645.7 |
Europe | ​ | ​ | 688.8 | ​ | ​ | ​ | 647.2 | ​ | ​ | 643.6 | ​ | ​ | ​ | 272.7 | ​ | ​ | ​ | 264.9 | ​ | ​ | 228.8 |
Asia Pacific | ​ | ​ | 92.8 | ​ | ​ | ​ | 59.6 | ​ | ​ | 69.8 | ​ | ​ | ​ | 76.1 | ​ | ​ | ​ | 72.4 | ​ | ​ | 64.8 |
Latin America | ​ | ​ | 24.7 | ​ | ​ | ​ | 1.8 | ​ | ​ | 6.1 | ​ | ​ | ​ | 51.9 | ​ | ​ | ​ | 50.4 | ​ | ​ | 50.3 |
Greater China | ​ | ​ | 61.0 | ​ | ​ | ​ | 6.3 | ​ | ​ | 3.6 | ​ | ​ | ​ | 78.8 | ​ | ​ | ​ | 80.0 | ​ | ​ | 63.4 | ​
India, Middle East and Africa | ​ | ​ | 25.0 | ​ | ​ | ​ | 18.1 | ​ | ​ | 19.8 | ​ | ​ | ​ | 10.3 | ​ | ​ | ​ | 11.6 | ​ | ​ | 14.4 | ​
Canada | ​ | ​ | 5.7 | ​ | ​ | ​ | 6.3 | ​ | ​ | 6.4 | ​ | ​ | ​ | 20.8 | ​ | ​ | ​ | 19.4 | ​ | ​ | 16.9 | ​
Total | ​ | ​ | $1,510.5 | ​ | ​ | ​ | $1,181.6 | ​ | ​ | $1,181.9 | ​ | ​ | ​ | $1,326.6 | ​ | ​ | ​ | $1,218.6 | ​ | ​ | $1,084.3 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Corporate | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 | ​ | 2021 |  | 2020 |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
United States | ​ | ​ | $107.5 | ​ | ​ | ​ | $98.2 | ​ | ​ | $75.2 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Europe | ​ | ​ | 3.0 | ​ | ​ | ​ | 3.9 | ​ | ​ | 4.8 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Asia Pacific | ​ | ​ | 4.1 | ​ | ​ | ​ | 5.5 | ​ | ​ | 2.8 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Latin America | ​ | ​ | 7.3 | ​ | ​ | ​ | 24.6 | ​ | ​ | 13.1 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Greater China | ​ | ​ | 0.1 | ​ | ​ | ​ | 2.3 | ​ | ​ | 0.9 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
India, Middle East and Africa | ​ | ​ | 0.3 | ​ | ​ | ​ | 3.4 | ​ | ​ | 2.5 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Canada | ​ | ​ | 1.5 | ​ | ​ | ​ | 1.3 | ​ | ​ | 0.7 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total | ​ | ​ | $123.8 | ​ | ​ | ​ | $139.2 | ​ | ​ | $100.0 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Net sales by geographic region were determined based on origin of sale. There were no sales from a single foreign country or individual customer that were material to the Company’s consolidated net sales. Sales of warewashing products were approximately 12%, 10%, and 11% of consolidated net sales in 2022, 2021 and 2020, respectively.

​

Contract Liability

​

Payments received from customers are based on invoices or billing schedules as established in contracts with customers. Accounts receivable are recorded when the right to consideration becomes unconditional. The contract liability relates to billings in advance of performance (primarily service obligations) under the contract. Contract liabilities are recognized as revenue when the performance obligation has been performed, which primarily occurs during the subsequent quarter.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31 | ​ | December 31
(millions) |  | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contract liability as of beginning of the year |  | ​ | $91.7 | ​ | ​ | ​ | $80.4
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue recognized in the year from: |  | ​ | ​ | ​ | ​ | ​ | ​
Amounts included in the contract liability at the beginning of the year |  | ​ | (91.7) | ​ | ​ | ​ | (80.4)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Increases due to billings excluding amounts recognized as revenue during the year ended | ​ | ​ | 116.5 | ​ | ​ | ​ | 91.6
Business combinations | ​ | ​ | - | ​ | ​ | ​ | 0.1
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contract liability as of end of year | ​ | ​ | $116.5 | ​ | ​ | ​ | $91.7

97

Table of Contents

​

19. OPERATING SEGMENTS AND GEOGRAPHIC INFORMATION

​

The Company’s organizational structure consists of global business unit and global regional leadership teams. The Company’s eleven operating segments follow its commercial and product-based activities and are based on engagement in business activities, availability of discrete financial information and review of operating results by the Chief Operating Decision Maker at the identified operating segment level.

​

The Company’s operating segments that share similar economic characteristics and future prospects, nature of the products and production processes, end-use markets, channels of distribution and regulatory environment have been aggregated into three reportable segments: Global Industrial, Global Institutional & Specialty and Global Healthcare & Life Sciences. The Company’s operating segments that do not meet the quantitative criteria to be separately reported have been combined into Other. The Company provides similar information for Other as the Company considers the information regarding its underlying operating segments as useful in understanding its consolidated results.

​

The Company’s operating segments are aggregated as follows:

​

Global Industrial

​

Includes the Water, Food & Beverage, Paper, and Downstream operating segments. It provides water treatment and process applications, and cleaning and sanitizing solutions primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, pulp and paper, commercial laundry, global petroleum and petrochemical industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics.

​

Global Institutional & Specialty

​

Includes the Institutional and Specialty operating segments. It provides specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government and education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics.

​

Global Healthcare & Life Sciences

​

Includes the Healthcare and Life Sciences operating segments. It provides specialized cleaning and sanitizing products to the healthcare, personal care and pharmaceutical industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics.

​

Other

​

Includes the Pest Elimination operating segment which provides services to detect, eliminate and prevent pests, such as rodents and insects, the CTG operating segment which produces and sells colloidal silica, which is comprised of nano-sized particles of silica in water used primarily for binding and polishing applications and the Textile Care operating segment which provides products and services that manage the entire wash process through custom designed programs, premium products, dispensing equipment, water and energy management and reduction, and real time data management.

​

Corporate

​

Consistent with the Company’s internal management reporting, Corporate amounts in the table below include sales to ChampionX under the Master Cross Supply and Product Transfer agreements entered into as part of the ChampionX Separation, as discussed in Note 5. Corporate also includes intangible asset amortization specifically from the Nalco and Purloite acquistions and special (gains) and charges, as discussed in Note 3, that are not allocated to the Company’s reportable segments.

​

Comparability of Reportable Segments

​

The Company made immaterial changes, including the movement of certain customers and cost allocations between reportable segments. These changes are reflected in the “Other” column in the table below.

​

​

98

Table of Contents

The Company evaluates the performance of its non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on its international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. The “Fixed Currency Rate Change” column shown in the following table reflects the impact on previously reported values related to fixed currency exchange rates established by management at the beginning of 2022 and have been updated from the 2021 rates reflected in the Company’s 2021 Form 10-K. The difference between the fixed currency exchange rates and the actual currency exchanges rates is reported within the “Effect of foreign currency translation” row in the table below. The “Other” column in the table reflects immaterial changes between segments, primarily cost allocations.

​

The impact of the preceding changes on previously reported full year 2021 and 2020 reportable segment net sales and operating income is summarized as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2021
​ |  | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | 2021 Reported | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Fixed | ​ | ​ | ​ | 2021 Reported
​ | ​ | Valued at 2021 |  | ​ | ​ |  | Currency | ​ |  | Valued at 2022
(millions) | ​ | Management Rates |  | Other | ​ |  | Rate Change | ​ |  | Management Rates
Net Sales | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​
Global Industrial | ​ | ​ | $6,304.9 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | ($218.1) | ​ | ​ | ​ | ​ | $6,086.8
Global Institutional & Specialty | ​ | ​ | 3,978.2 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (69.4) | ​ | ​ | ​ | ​ | 3,908.8
Global Healthcare & Life Sciences | ​ | ​ | 1,195.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (45.8) | ​ | ​ | ​ | ​ | 1,149.6
Other | ​ | ​ | 1,226.9 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (25.9) | ​ | ​ | ​ | ​ | 1,201.0
Corporate | ​ | ​ | 139.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (2.0) | ​ | ​ | ​ | ​ | 137.4
Subtotal at fixed currency rates | ​ | ​ | 12,844.8 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (361.2) | ​ | ​ | ​ | ​ | 12,483.6
Effect of foreign currency translation | ​ | ​ | (111.7) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 361.2 | ​ | ​ | ​ | ​ | 249.5
Consolidated reported GAAP net sales | ​ | ​ | $12,733.1 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $12,733.1
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial | ​ | ​ | $1,031.0 | ​ | ​ | ​ | $4.0 | ​ | ​ | ​ | ​ | ($49.3) | ​ | ​ | ​ | ​ | $985.7
Global Institutional & Specialty | ​ | ​ | 556.9 | ​ | ​ | ​ | (3.8) | ​ | ​ | ​ | ​ | (7.4) | ​ | ​ | ​ | ​ | 545.7
Global Healthcare & Life Sciences | ​ | ​ | 160.9 | ​ | ​ | ​ | (0.9) | ​ | ​ | ​ | ​ | (7.7) | ​ | ​ | ​ | ​ | 152.3
Other | ​ | ​ | 187.3 | ​ | ​ | ​ | 0.7 | ​ | ​ | ​ | ​ | (4.0) | ​ | ​ | ​ | ​ | 184.0
Corporate | ​ | ​ | (318.6) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 2.0 | ​ | ​ | ​ | ​ | (316.6)
Subtotal at fixed currency rates | ​ | ​ | 1,617.5 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (66.4) | ​ | ​ | ​ | ​ | 1,551.1
Effect of foreign currency translation | ​ | ​ | (18.9) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 66.4 | ​ | ​ | ​ | ​ | 47.5
Consolidated reported GAAP operating income | ​ | ​ | $1,598.6 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $1,598.6

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2020 Reported |  | ​ | ​ | ​ | ​ |  | ​ | Fixed | ​ | ​ |  | 2020 Reported
​ | ​ | Valued at 2021 |  | Segment | ​ |  | Currency | ​ |  | Valued at 2022
(millions) | ​ | Management Rates |  | Change | ​ |  | Rate Change | ​ |  | Management Rates
Net Sales | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​
Global Industrial | ​ | ​ | $6,048.2 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | ($202.5) | ​ | ​ | ​ | ​ | $5,845.7
Global Institutional & Specialty | ​ | ​ | 3,629.0 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (69.2) | ​ | ​ | ​ | ​ | 3,559.8
Global Healthcare & Life Sciences | ​ | ​ | 1,241.1 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (51.0) | ​ | ​ | ​ | ​ | 1,190.1
Other | ​ | ​ | 1,103.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (23.6) | ​ | ​ | ​ | ​ | 1,079.8
Corporate | ​ | ​ | 100.6 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (1.2) | ​ | ​ | ​ | ​ | 99.4
Subtotal at fixed currency rates | ​ | ​ | 12,122.3 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (347.5) | ​ | ​ | ​ | ​ | 11,774.8
Effect of foreign currency translation | ​ | ​ | (332.1) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 347.5 | ​ | ​ | ​ | ​ | 15.4
Consolidated reported GAAP net sales | ​ | ​ | $11,790.2 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $11,790.2
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial | ​ | ​ | $1,123.1 | ​ | ​ | ​ | $1.4 | ​ | ​ | ​ | ​ | ($45.4) | ​ | ​ | ​ | ​ | $1,079.1
Global Institutional & Specialty | ​ | ​ | 324.0 | ​ | ​ | ​ | (1.6) | ​ | ​ | ​ | ​ | (6.1) | ​ | ​ | ​ | ​ | 316.3
Global Healthcare & Life Sciences | ​ | ​ | 218.3 | ​ | ​ | ​ | (0.5) | ​ | ​ | ​ | ​ | (10.2) | ​ | ​ | ​ | ​ | 207.6
Other | ​ | ​ | 132.8 | ​ | ​ | ​ | 0.7 | ​ | ​ | ​ | ​ | (2.9) | ​ | ​ | ​ | ​ | 130.6
Corporate | ​ | ​ | (349.7) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 2.0 | ​ | ​ | ​ | ​ | (347.7)
Subtotal at fixed currency rates | ​ | ​ | 1,448.5 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (62.6) | ​ | ​ | ​ | ​ | 1,385.9
Effect of foreign currency translation | ​ | ​ | (52.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 62.6 | ​ | ​ | ​ | ​ | 9.8
Consolidated reported GAAP operating income | ​ | ​ | $1,395.7 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $1,395.7

​

​

99

Table of Contents

Reportable Segment Information

​

Financial information for each of the Company’s reportable segments were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Net Sales | ​ | ​ | Operating Income (Loss)
(millions) | ​ | 2022 | ​ | 2021 | ​ | 2020 | ​ | ​ | 2022 | ​ | 2021 | ​ | ​ | 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial | ​ | ​ | $6,944.0 | ​ | ​ | ​ | $6,086.8 | ​ | ​ | $5,845.7 | ​ | ​ | ​ | $977.0 | ​ | ​ | ​ | $985.7 | ​ | ​ | ​ | $1,079.1
Global Institutional & Specialty | ​ | ​ | 4,480.0 | ​ | ​ | ​ | 3,908.8 | ​ | ​ | 3,559.8 | ​ | ​ | ​ | 634.5 | ​ | ​ | ​ | 545.7 | ​ | ​ | ​ | 316.3
Global Healthcare & Life Sciences | ​ | ​ | 1,570.0 | ​ | ​ | ​ | 1,149.6 | ​ | ​ | 1,190.1 | ​ | ​ | ​ | 205.0 | ​ | ​ | ​ | 152.3 | ​ | ​ | ​ | 207.6
Other | ​ | ​ | 1,355.0 | ​ | ​ | ​ | 1,201.0 | ​ | ​ | 1,079.8 | ​ | ​ | ​ | 212.8 | ​ | ​ | ​ | 184.0 | ​ | ​ | ​ | 130.6
Corporate | ​ | ​ | 124.1 | ​ | ​ | ​ | 137.4 | ​ | ​ | 99.4 | ​ | ​ | ​ | (416.7) | ​ | ​ | ​ | (316.6) | ​ | ​ | ​ | (347.7)
Subtotal at fixed currency | ​ | ​ | 14,473.1 | ​ | ​ | ​ | 12,483.6 | ​ | ​ | 11,774.8 | ​ | ​ | ​ | 1,612.6 | ​ | ​ | ​ | 1,551.1 | ​ | ​ | ​ | 1,385.9
Effect of foreign currency translation | ​ | ​ | (285.3) | ​ | ​ | ​ | 249.5 | ​ | ​ | 15.4 | ​ | ​ | ​ | (50.1) | ​ | ​ | ​ | 47.5 | ​ | ​ | ​ | 9.8
Consolidated reported GAAP | ​ | ​ | $14,187.8 | ​ | ​ | ​ | $12,733.1 | ​ | ​ | $11,790.2 | ​ | ​ | ​ | $1,562.5 | ​ | ​ | ​ | $1,598.6 | ​ | ​ | ​ | $1,395.7

​

The profitability of the Company’s operating segments is evaluated by management based on operating income.

​

The Company has an integrated supply chain function that serves all of its reportable segments. As such, asset and capital expenditure information by reportable segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each reportable segment’s operating results, it is not discretely identifiable.

​

Geographic Information

​

Long-lived assets, which includes property, plant and equipment and right of use assets, at public exchange rates by geographic region were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Long-Lived Assets, net
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(millions) | ​ | 2022 |  | 2021 |
United States | ​ | ​ | $2,508.9 | ​ | ​ | ​ | $2,416.4 | ​
Europe |  | ​ | 574.3 | ​ | ​ | ​ | 580.7 | ​
Asia Pacific | ​ | ​ | 210.3 | ​ | ​ | ​ | 237.1 | ​
Greater China |  | ​ | 176.6 | ​ | ​ | ​ | 186.4 | ​
Latin America |  | ​ | 146.5 | ​ | ​ | ​ | 137.9 | ​
India, Middle East and Africa | ​ | ​ | 64.1 | ​ | ​ | ​ | 60.2 | ​
Canada |  | ​ | 60.9 | ​ | ​ | ​ | 66.5 | ​
Total | ​ | ​ | $3,741.6 | ​ | ​ | ​ | $3,685.2 | ​
​ |  | ​ |  |  |  | ​ |  | ​

​

Geographic data for long-lived assets is based on physical location of those assets. Refer to Note 18 for net sales by geographic region.

​

​

​

100

Table of Contents

20. QUARTERLY FINANCIAL DATA (UNAUDITED)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | First |  | Second |  | Third |  | Fourth |  | ​ | ​ |
(millions, except per share) | ​ | Quarter | ​ | Quarter | ​ | Quarter | ​ | Quarter | ​ | Year
2022 |  |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ |
Net sales | ​ | ​ | $3,266.7 | ​ | ​ | $3,580.6 | ​ | ​ | $3,669.3 | ​ | ​ | $3,671.2 | ​ | ​ | $14,187.8 | ​
Operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales (a) | ​ | ​ | 2,073.4 | ​ | ​ | 2,211.1 | ​ | ​ | 2,291.6 | ​ | ​ | 2,254.9 | ​ | ​ | 8,831.0 | ​
Selling, general and administrative expenses | ​ | ​ | 914.7 | ​ | ​ | 940.1 | ​ | ​ | 876.9 | ​ | ​ | 922.1 | ​ | ​ | 3,653.8 | ​
Special (gains) and charges | ​ | ​ | 24.1 | ​ | ​ | 3.6 | ​ | ​ | 17.8 | ​ | ​ | 95.0 | ​ | ​ | 140.5 | ​
Operating income | ​ | ​ | 254.5 | ​ | ​ | 425.8 | ​ | ​ | 483.0 | ​ | ​ | 399.2 | ​ | ​ | 1,562.5 | ​
Other (income) expense (b) | ​ | ​ | (18.8) | ​ | ​ | (19.5) | ​ | ​ | 5.7 | ​ | ​ | 8.1 | ​ | ​ | (24.5) | ​
Interest expense, net | ​ | ​ | 53.0 | ​ | ​ | 56.0 | ​ | ​ | 65.1 | ​ | ​ | 69.5 | ​ | ​ | 243.6 | ​
Income before income taxes | ​ | ​ | 220.3 | ​ | ​ | 389.3 | ​ | ​ | 412.2 | ​ | ​ | 321.6 | ​ | ​ | 1,343.4 | ​
Provision for income taxes | ​ | ​ | 45.6 | ​ | ​ | 76.6 | ​ | ​ | 60.2 | ​ | ​ | 52.1 | ​ | ​ | 234.5 | ​
Net income including noncontrolling interest | ​ | ​ | 174.7 | ​ | ​ | 312.7 | ​ | ​ | 352.0 | ​ | ​ | 269.5 | ​ | ​ | 1,108.9 | ​
Net income attributable to noncontrolling interest | ​ | ​ | 2.8 | ​ | ​ | 4.4 | ​ | ​ | 4.9 | ​ | ​ | 5.1 | ​ | ​ | 17.2 | ​
Net income attributable to Ecolab | ​ | ​ | $171.9 | ​ | ​ | $308.3 | ​ | ​ | $347.1 | ​ | ​ | $264.4 | ​ | ​ | $1,091.7 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings attributable to Ecolab per common share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | $ 0.60 | ​ | ​ | $ 1.08 | ​ | ​ | $ 1.22 | ​ | ​ | $ 0.93 | ​ | ​ | $ 3.83 | ​
Diluted | ​ | ​ | $ 0.60 | ​ | ​ | $ 1.08 | ​ | ​ | $ 1.21 | ​ | ​ | $ 0.93 | ​ | ​ | $ 3.81 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average common shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | 286.2 | ​ | ​ | 285.1 | ​ | ​ | 284.9 | ​ | ​ | 284.6 | ​ | ​ | 285.2 | ​
Diluted | ​ | ​ | 288.1 | ​ | ​ | 286.6 | ​ | ​ | 286.3 | ​ | ​ | 285.8 | ​ | ​ | 286.6 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2021 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net sales | ​ | ​ | $2,885.0 | ​ | ​ | $3,162.7 | ​ | ​ | $3,320.8 | ​ | ​ | $3,364.6 | ​ | ​ | $12,733.1 | ​
Operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales (a) | ​ | ​ | 1,712.0 | ​ | ​ | 1,844.0 | ​ | ​ | 2,016.7 | ​ | ​ | 2,043.1 | ​ | ​ | 7,615.8 | ​
Selling, general and administrative expenses | ​ | ​ | 862.9 | ​ | ​ | 853.3 | ​ | ​ | 832.0 | ​ | ​ | 867.9 | ​ | ​ | 3,416.1 | ​
Special (gains) and charges | ​ | ​ | 12.8 | ​ | ​ | 17.6 | ​ | ​ | 6.3 | ​ | ​ | 65.9 | ​ | ​ | 102.6 | ​
Operating income | ​ | ​ | 297.3 | ​ | ​ | 447.8 | ​ | ​ | 465.8 | ​ | ​ | 387.7 | ​ | ​ | 1,598.6 | ​
Other (income) expense (b) | ​ | ​ | (17.0) | ​ | ​ | 2.5 | ​ | ​ | (13.0) | ​ | ​ | (6.4) | ​ | ​ | (33.9) | ​
Interest expense, net (c) | ​ | ​ | 51.7 | ​ | ​ | 45.6 | ​ | ​ | 76.4 | ​ | ​ | 44.6 | ​ | ​ | 218.3 | ​
Income before income taxes | ​ | ​ | 262.6 | ​ | ​ | 399.7 | ​ | ​ | 402.4 | ​ | ​ | 349.5 | ​ | ​ | 1,414.2 | ​
Provision for income taxes | ​ | ​ | 66.1 | ​ | ​ | 86.1 | ​ | ​ | 73.8 | ​ | ​ | 44.2 | ​ | ​ | 270.2 | ​
Net income including noncontrolling interest | ​ | ​ | 196.5 | ​ | ​ | 313.6 | ​ | ​ | 328.6 | ​ | ​ | 305.3 | ​ | ​ | 1,144.0 | ​
Net income attributable to noncontrolling interest | ​ | ​ | 2.9 | ​ | ​ | 2.8 | ​ | ​ | 4.1 | ​ | ​ | 4.3 | ​ | ​ | 14.1 | ​
Net income attributable to Ecolab | ​ | ​ | $193.6 | ​ | ​ | $310.8 | ​ | ​ | $324.5 | ​ | ​ | $301.0 | ​ | ​ | $1,129.9 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings attributable to Ecolab per common share | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | $ 0.68 | ​ | ​ | $ 1.09 | ​ | ​ | $ 1.13 | ​ | ​ | $ 1.05 | ​ | ​ | $ 3.95 | ​
Diluted | ​ | ​ | $ 0.67 | ​ | ​ | $ 1.08 | ​ | ​ | $ 1.12 | ​ | ​ | $ 1.04 | ​ | ​ | $ 3.91 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average common shares outstanding | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | 286.0 | ​ | ​ | 286.0 | ​ | ​ | 286.4 | ​ | ​ | 286.7 | ​ | ​ | 286.3 | ​
Diluted | ​ | ​ | 288.8 | ​ | ​ | 288.8 | ​ | ​ | 289.2 | ​ | ​ | 289.5 | ​ | ​ | 289.1 | ​

​

​

Per share amounts do not necessarily sum due to changes in the calculation of shares outstanding for each discrete period and rounding. Gross profit is calculated as net sales minus cost of sales.

​

| (a) | Cost of sales includes special charges of $52.9, $1.7, $7.1 and $8.2 in Q1, Q2, Q3 and Q4 of 2022, respectively, and $19.6, $3.7, $52.9 and $17.7 in Q1, Q2, Q3 and Q4 of 2021, respectively.

| (b) | Other (income) expense includes special charges of $24.8 and $25.8 in Q3 and Q4 of 2022, respectively, and $19.6, $7.0 and $10.6 in Q2, Q3 and Q4 of 2021, respectively.

| (c) | Interest expense, net includes special charges of $32.3 and $0.8 in Q3 and Q4 of 2021, respectively.

​

​

101

Table of Contents

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

​

None.

​

​

Item 9A. Controls and Procedures.

​

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

​

As of December 31, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Chairman and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended). Based upon that evaluation, our Chairman and Chief Executive Officer and our Chief Financial Officer concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

​

Management’s Report on Internal Control Over Financial Reporting

​

Refer to page 50 of this Annual Report for “Management’s Report on Internal Control Over Financial Reporting.”

​

Report of Registered Public Accounting Firm

​

Refer to page 51 of this Annual Report for the “Report of Independent Registered Public Accounting Firm.”

​

Changes in Internal Control Over Financial Reporting.

​

During the period October 1 - December 31, 2022 there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

​

​

Item 9B. Other Information.

​

None.

​

​

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

​

Not applicable.

​

​

​

102

Table of Contents

PART III

Item 10. Director s, Executive Officers and Corporate Governance.

​

Information about our directors is incorporated by reference from the discussion under the heading “Proposal 1: Election of Directors” located in the Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading “Corporate Governance,” and sub-headings “Board Committees” and “Audit Committee,” located in the Proxy Statement. Information about our Code of Conduct is incorporated by reference from the discussion under the heading “Corporate Governance” located in the Proxy Statement. Information regarding our executive officers is presented under the heading “Information about our Executive Officers” in Part I, Item 1 of this Form 10-K, and is incorporated herein by reference.

​

​

Item 11. Executive Compensation.

​

Information appearing under the following headings of the Proxy Statement is incorporated herein by reference:

​

| ● | Director Compensation for 2022

| ● | Compensation Risk Analysis

| ● | Compensation & Human Capital Management Committee Interlocks and Insider Participation

| ● | Compensation & Human Capital Management Committee Report

| ● | Compensation Discussion and Analysis

| ● | Summary Compensation Table for 2022

| ● | Grants of Plan-Based Awards for 2022

| ● | Outstanding Equity Awards at Fiscal Year End for 2022

| ● | Option Exercises and Stock Vested for 2022

| ● | Pension Benefits for 2022

| ● | Non-Qualified Deferred Compensation for 2022

| ● | Potential Payments Upon Termination or Change in Control

| ● | Pay Ratio Disclosure

​

​

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

​

Information appearing under the heading entitled “Security Ownership” located in the Proxy Statement is incorporated herein by reference. Information appearing under the heading entitled “Equity Compensation Plan Information” located in the Proxy Statement is incorporated herein by reference.

​

A total of 286,521 shares of Common Stock held by our directors and executive officers, some of whom may be deemed to be “affiliates” of the Company, have been excluded from the computation of market value of our Common Stock on the cover page of this Form 10-K. This total represents that portion of the shares reported as beneficially owned by our directors and executive officers as of June 30, 2022 which are actually issued and outstanding.

​

​

Item 13. Certain Relationships and Related Transactions, and Director Independence.

​

Information appearing under the headings entitled “Director Independence Standards and Determinations” and “Related Person Transactions” located in the Proxy Statement is incorporated herein by reference.

​

​

Item 14. Principal Accounting Fees and Services.

​

Information appearing under the heading entitled “Audit Fees” located in the Proxy Statement is incorporated herein by reference.

​

​

103

Table of Contents

PART IV

​

Item 15. Exhibit and Financial Statement Schedules.

​

Do | ​ | ​ | ​
​ | The following information required under this item is filed as part of this report:
(a)(1) | Financial Statements. | ​
​ | Document: | Page:
​ | (i) | Report of Independent Registered Public Accounting Firm. (PCAOB ID 238) | 51
​ | (ii) | Consolidated Statements of Income for the years ended December 31, 2022, 2021 and 2020. | 53
​ | (iii) | Consolidated Statements of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020. | 54
​ | (iv) | Consolidated Balance Sheets at December 31, 2022 and 2021. | 55
​ | (v) | Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020. | 56
​ | (vi) | Consolidated Statements of Equity for the years ended December 31, 2022, 2021 and 2020. | 57
​ | (vii) | Notes to Consolidated Financial Statements. | 58

​

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(a)(2) | ​ | Financial Statement Schedules.
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | All financial statement schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or the accompanying notes to the consolidated financial statements. The separate financial statements and summarized financial information of subsidiaries not consolidated and of fifty percent or less owned persons have been omitted because they do not satisfy the requirements for inclusion in this Form 10-K.
​ | ​ | ​ | ​ | ​ | ​ | ​
(a)(3) | ​ | The documents below are filed as exhibits to this Report. We will, upon request and payment of a fee not exceeding the rate at which copies are available from the Securities and Exchange Commission, furnish copies of any of the following exhibits to stockholders.
​ | ​ | ​ | ​ | ​ | ​ | ​
(2.1) | ​ | Agreement and Plan of Merger and Reorganization, dated December 18, 2019, by and among Ecolab Inc., ChampionX Holding Inc., Apergy Corporation and Athena Merger Sub, Inc. | ​ | Incorporated by reference to Exhibit (2.1) of our Form 8-K, dated December 18, 2019. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(2.2) | ​ | Separation and Distribution Agreement, dated December 18, 2019, by and among Ecolab Inc., ChampionX Holding Inc. and Apergy Corporation. | ​ | Incorporated by reference to Exhibit (2.2) of our Form 8-K, dated December 18, 2019. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(2.3) | ​ | Stock and Asset Purchase Agreement, dated October 28, 2021, by and among Ecolab Inc., Purolite Corporation, a Delaware corporation (“Purolite”), Stefan E. Brodie and Don B. Brodie (the “Founder Sellers” and together with Purolite, the “Sellers”) and Stefan E. Brodie, solely in his capacity as the representative of the Sellers. | ​ | Incorporated by reference to Exhibit (2.1) of our Form 8-K, dated December 1, 2021. (File No. 001-9328)
​ | ​ | ​ | ​ | ​
(3.1) | ​ | Restated Certificate of Incorporation of Ecolab Inc., dated January 2, 2013. | ​ | Incorporated by reference to Exhibit (3.2) of our Form 8-K, dated January 2, 2013. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(3.2) | ​ | By-Laws, as amended through December 3, 2015. | ​ | Incorporated by reference to Exhibit (3.1) of our Form 8-K, dated December 3, 2015. (File No. 001-9328)

104

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.1) | ​ | Common Stock. | ​ | See Exhibits (3.1) and (3.2)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.2) | ​ | Amended and Restated Indenture, dated January 9, 2001, between Ecolab Inc. and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor in interest to J.P. Morgan Trust Company, N.A. and Bank One, N.A.), as Trustee. | ​ | Incorporated by reference to Exhibit (4)(A) of our Form 8-K, dated January 23, 2001. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.3) | ​ | Second Supplemental Indenture, dated December 8, 2011, between Ecolab Inc., Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor in interest to J.P. Morgan Trust Company, N.A. and Bank One, N.A.), as original trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated December 5, 2011. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.4) | ​ | Form of 5.500% Notes due 2041. | ​ | Included in Exhibit (4.3) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.5) | ​ | Indenture, dated January 12, 2015, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit 4.1 of our Form 8-K, dated January 15, 2015. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.6) | ​ | Second Supplemental Indenture, dated July 8, 2015, by and among Ecolab Inc., Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee, Elavon Financial Services Limited, UK Branch, as paying agent, and Elavon Financial Services Limited, as transfer agent and registrar. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated July 8, 2015. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.7) | ​ | Form of 2.625% Euro Notes due 2025. | ​ | Included in Exhibit (4.6) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.8) | ​ | Fourth Supplemental Indenture, dated October 18, 2016, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated October 13, 2016. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.9) | ​ | Forms of 2.700% Notes due 2026 and 3.700% Notes due 2046. | ​ | Included in Exhibit (4.8) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.10) | ​ | Fifth Supplemental Indenture, dated December 8, 2016, by and among Ecolab Inc., Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee, Elavon Financial Services DAC, UK Branch, as paying agent, and Elavon Financial Services DAC, as transfer agent and registrar. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated December 1, 2016. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.11) | ​ | Form of 1.000% Euro Notes due 2024. | ​ | Included in Exhibit (4.10) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.12) | ​ | Seventh Supplemental Indenture, dated November 27, 2017, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated November 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.13) | ​ | Form of 3.250% Notes due 2027. | ​ | Included in Exhibit (4.12) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.14) | ​ | Form of 3.950% Notes due 2047. | ​ | Included in Exhibit (4.12) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.15) | ​ | Eighth Supplemental Indenture, dated March 24, 2020, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on March 24, 2020. (File No. 001-9328)
​ | ​ | ​ | ​ | ​
(4.16) | ​ | Form of 4.800% Notes due 2030. | ​ | Included in Exhibit (4.15) above.
​ | ​ | ​ | ​ | ​ | ​ | ​

105

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.17) | ​ | Ninth Supplemental Indenture, dated August 13, 2020, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K filed by Ecolab Inc. on August 13, 2020. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.18) | ​ | Form of 1.300% Notes due 2031. | ​ | Included in Exhibit (4.17) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.19) | ​ | Form of 2.125% Notes due 2050. | ​ | Included in Exhibit (4.17) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.20) | ​ | Tenth Supplemental Indenture, dated August 18, 2021, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on August 19, 2021. (File No. 001-9328)
​ | ​ | ​ | ​ | ​
(4.21) | ​ | Form of 2.750% Notes due 2055. | ​ | Included in Exhibit (4.20) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.22) | ​ | Eleventh Supplemental Indenture, dated December 15, 2021, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K filed by Ecolab Inc. on December 15, 2021. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.23) | ​ | Form of 0.900% Notes due 2023. | ​ | Included in Exhibit (4.22) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.24) | ​ | Form of 1.650% Notes due 2027. | ​ | Included in Exhibit (4.22) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.25) | ​ | Form of 2.125% Notes due 2032. | ​ | Included in Exhibit (4.22) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.26) | ​ | Form of 2.700% Notes due 2051. | ​ | Included in Exhibit (4.22) above.
​ | ​ | ​ | ​ | ​ | ​ | ​
(4.27) | ​ | Twelfth Supplemental Indenture, dated as of November 17, 2022, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee. | ​ | Incorporated by reference to Exhibit (4.2) of our Form 8-K filed by Ecolab Inc. on November 17, 2022. (File No. 001 9328)
​ | ​ | ​ | ​ | ​
(4.28) | ​ | Form of 5.250% Notes due 2028. | ​ | Included in Exhibit (4.27) above.
​ | ​ | ​ | ​ | ​
(4.29) | ​ | Description of Securities. | ​ | Incorporated by reference to Exhibit (4.20) of our Form 10-K Annual Report for the year ended December 31, 2019. (File No. 001-9328)
​ | ​ | ​
​ | ​ | Copies of other constituent instruments defining the rights of holders of our long-term debt are not filed herewith, pursuant to Section (b)(4)(iii) of Item 601 of Regulation S-K, because the aggregate amount of securities authorized under each of such instruments is less than 10% of our total assets on a consolidated basis. We will, upon request by the Securities and Exchange Commission, furnish to the Commission a copy of each such instrument.
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.1) | ​ | Third Amended and Restated $2.0 billion 5-Year Revolving Credit Facility, dated as of April 16, 2021, among Ecolab Inc., the lenders party thereto, the issuing lenders party thereto, Bank of America, N.A., as administrative agent and swing line bank, and Citibank, N.A., JPMorgan Chase Bank, N.A. and MUFG Bank, Ltd., as co-syndication agents. | ​ | Incorporated by reference to Exhibit (10.1) of our Form 8-K, dated April 20, 2021. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​

106

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.2) | ​ | Documents comprising global Commercial Paper Programs. | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | (i) | U.S. $2,000,000,000 Euro-Commercial Paper Programme.
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (a) | Amended and Restated Dealer Agreement, dated 9 June 2017, between Ecolab Inc., Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L., Ecolab NL 10 B.V. and Ecolab NL 11 B.V. (as Issuers), Ecolab Inc. (as Guarantor in respect of the notes issued by Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L. and Ecolab NL 10 B.V. and Ecolab NL 11 B.V.), Credit Suisse Securities (Europe) Limited (as Arranger), and Citibank Europe plc, UK Branch, Credit Suisse Securities (Europe) Limited, Citigroup Global Markets Europe AG, Credit Suisse Securities Sociedad de Valores S.A. and Credit Suisse International (as Dealers). | ​ | Incorporated by reference to Exhibit (10.1)(a) of our Form 10-Q for the quarter ended June 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (b) | Amended and Restated Note Agency Agreement, dated 9 June 2017, between Ecolab Inc., Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L., Ecolab NL 10 B.V. Ecolab NL 11 B.V. (as Issuers), Ecolab Inc. (as Guarantor in respect of the notes issued by Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L., Ecolab NL 10 B.V. and Ecolab NL 11 B.V.), and Citibank, N.A., London Branch (as Issue and Paying Agent). | ​ | Incorporated by reference to Exhibit (10.1)(b) of our Form 10-Q for the quarter ended June 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (c) | Deed of Covenant made on 9 June 2017 by Ecolab Inc., Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L., Ecolab NL 10 B.V. and Ecolab NL 11 B.V. (as Issuers). | ​ | Incorporated by reference to Exhibit (10.1)(c) of our Form 10-Q for the quarter ended June 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (d) | Deed of Guarantee made on 9 June 2017 by Ecolab Inc. (in respect of notes issued by Ecolab Lux 1 S.À R.L., Ecolab Lux 2 S.À R.L., Ecolab NL 10 B.V. and Ecolab NL 11 B.V.). | ​ | Incorporated by reference to Exhibit (10.1)(d) of our Form 10-Q for the quarter ended June 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | (ii) | U.S. $2,000,000,000 U.S. Commercial Paper Program.
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (a) | Form of Commercial Paper Dealer Agreement for 4(a)(2) Program, dated September 22, 2014. The dealers for the program are Barclays Capital Inc., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, BofA Securities, Inc., Mizuho Securities USA LLC, and Wells Fargo Securities, LLC. | ​ | Incorporated by reference to Exhibit (10.1)(a) of our Form 10-Q for the quarter ended September 30, 2014. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (b) | Issuing and Paying Agent Agreement, dated September 18, 2017, between Ecolab Inc. and U.S. Bank National Association, as Issuing and Paying Agent (as successor, effective as of June 7, 2021, to MUFG Union Bank, N.A.). | ​ | Incorporated by reference to Exhibit (10.1)(a) of our Form 10 Q for the quarter ended September 30, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | (c) | Corporate Commercial Paper – Master Note, dated June 7, 2021, together with annex thereto. | ​ | Incorporated by reference to Exhibit (10.3)(ii) of our Form 10 Q for the quarter ended June 30, 2021. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.3) | † | (i) | Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013. | ​ | Incorporated by reference to Exhibit (10.6) of our Form 10-K Annual Report for the year ended December 31, 2013. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​

107

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (ii) | Declaration of Amendment, dated May 5, 2016, to Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013. | ​ | Incorporated by reference to Exhibit (10.1) of our Form 10-Q for the quarter ended June 30, 2016. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iii) | Master Agreement Relating to Periodic Options, as amended, effective as of May 1, 2004. | ​ | Incorporated by reference to Exhibit (10)D(ii) of our Form 10-Q for the quarter ended June 30, 2004. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iv) | Amendment No. 1 to Master Agreement Relating to Periodic Options, as amended, effective as of May 2, 2008. | ​ | Incorporated by reference to Exhibit (10)B of our Form 10-Q for the quarter ended September 30, 2008. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.4) | † | Form of Director Indemnification Agreement. Substantially identical agreements are in effect as to each of our directors. | ​ | Incorporated by reference to Exhibit (10)I of our Form 10-K Annual Report for the year ended December 31, 2003. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.5) | † | (i) | Ecolab Executive Death Benefits Plan, as amended and restated, effective as of March 1, 1994. | ​ | Incorporated by reference to Exhibit (10)H(i) of our Form 10-K Annual Report for the year ended December 31, 2006. See also Exhibit (10.12) hereof. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (ii) | Amendment No. 1 to Ecolab Executive Death Benefits Plan, effective as of July 1, 1997. | ​ | Incorporated by reference to Exhibit (10)H(ii) of our Form 10-K Annual Report for the year ended December 31, 1998. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iii) | Second Declaration of Amendment to Ecolab Executive Death Benefits Plan, effective as of March 1, 1998. | ​ | Incorporated by reference to Exhibit (10)H(iii) of our Form 10-K Annual Report for the year ended December 31, 1998. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iv) | Amendment No. 3 to the Ecolab Executive Death Benefits Plan, effective as of August 12, 2005. | ​ | Incorporated by reference to Exhibit (10)B of our Form 8-K, dated December 13, 2005. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (v) | Amendment No. 4 to the Ecolab Executive Death Benefits Plan, effective as of January 1, 2005. | ​ | Incorporated by reference to Exhibit (10)H(v) of our Form 10-K Annual Report for the year ended December 31, 2009. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (vi) | Amendment No. 5 to the Ecolab Executive Death Benefits Plan, effective as of May 6, 2015. | ​ | Incorporated by reference to Exhibit 10.2 of our Form 10-Q for the quarter ended June 30, 2015. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​
​ | † | (vii) | Amendment No. 6 to the Ecolab Executive Death Benefits Plan, effective as of June 23, 2017. | ​ | Incorporated by reference to Exhibit 10.1(vii) of Ecolab’s Form 8-K dated June 23, 2017. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.6) | † | (i) | Ecolab Executive Long-Term Disability Plan, as amended and restated, effective as of January 1, 1994. | ​ | Incorporated by reference to Exhibit (10)I of our Form 10-K Annual Report for the year ended December 31, 2004. See also Exhibit (10.12) hereof. (File No. 001-9328).
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (ii) | Amendment No. 1 to the Ecolab Executive Long-Term Disability Plan, effective as of August 21, 2015. | ​ | Incorporated by reference to Exhibit 10.1 of our Form 10-Q for the quarter ended September 30, 2015. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.7) | † | (i) | Ecolab Supplemental Executive Retirement Plan, as amended and restated, effective as of January 1, 2022. | ​ | Incorporated by reference to Exhibit (10.7)(i) of our Form 10-K Annual Report for the year ended December 31, 2021. (File No. 001 9328).
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.8) | † | (i) | Ecolab Mirror Savings Plan, as amended and restated, effective as of January 1, 2022. | ​ | Incorporated by reference to Exhibit (10.8)(i) of our Form 10-K Annual Report for the year ended December 31, 2021. (File No. 001 9328).
​ | ​ | ​ | ​ | ​ | ​ | ​

108

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.9) | † | (i) | Ecolab Mirror Pension Plan, as amended and restated, effective as of January 1, 2022. | ​ | Incorporated by reference to Exhibit (10.9)(i) of our Form 10-K Annual Report for the year ended December 31, 2021. (File No. 001 9328).
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.10) | † | (i) | Ecolab Inc. Administrative Document for Non-Qualified Plans, as amended and restated, effective as of January 1, 2022. | ​ | Incorporated by reference to Exhibit (10.10)(i) of our Form 10-K Annual Report for the year ended December 31, 2021. (File No. 001 9328).
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.11) | † | (i) | Ecolab Inc. Change in Control Severance Compensation Policy, as amended and restated, effective as of February 26, 2010. | ​ | Incorporated by reference to Exhibit (10) of our Form 8-K, dated February 26, 2010. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (ii) | Amendment No. 1 to Ecolab Inc. Change-in-Control Severance Policy, as amended and restated, effective as of February 26, 2010. | ​ | Incorporated by reference to Exhibit (10.18)(ii) of our Form 10-K Annual Report for the year ended December 31, 2011. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.12) | † | Description of Ecolab Management Incentive Plan. | ​ | Incorporated by reference to Exhibit (10.16) of our Form 10-K Annual Report for the year ended December 31, 2015. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.13) | † | (i) | Ecolab Inc. 2010 Stock Incentive Plan, as amended and restated, effective as of May 2, 2013. | ​ | Incorporated by reference to Exhibit (10.1) of our Form 8-K, dated May 2, 2013. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (ii) | Declaration of Amendment, effective as of February 22, 2019, to Ecolab Inc. 2010 Stock Incentive Plan, as amended and restated, effective as of May 2, 2013. | ​ | Incorporated by reference to Exhibit (10.3) of our Form 10-Q, dated May 2, 2019. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iii) | Sample form of Non-Statutory Stock Option Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted May 6, 2010. | ​ | Incorporated by reference to Exhibit (10)B of our Form 8-K, dated May 6, 2010. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (iv) | Sample form of Restricted Stock Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted May 6, 2010. | ​ | Incorporated by reference to Exhibit (10)C of our Form 8-K, dated May 6, 2010. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (v) | Sample form of Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted August 4, 2010. | ​ | Incorporated by reference to Exhibit (10)A of our Form 10-Q, for the quarter ended September 30, 2010. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (vi) | Sample form of Performance-Based Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted December 3, 2019. | ​ | Incorporated by reference to Exhibit (10.15)(ix) of our Form 10-K Annual Report for the year ended December 31, 2019. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (vii) | Sample form of Performance-Based Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted December 3, 2020. | ​ | Incorporated by reference to Exhibit (10.13)(ix) of our Form 10-K Annual Report for the year ended December 31, 2020. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | † | (viii) | Sample form of Performance-Based Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted December 1, 2021. | ​ | Incorporated by reference to Exhibit (10.13)(ix) of our Form 10-K Annual Report for the year ended December 31, 2021. (File No. 001 9328).
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.14) | † | Policy on Reimbursement of Incentive Payments, as amended February 22, 2019. | ​ | Incorporated by reference to Exhibit (10.16) of our Form 10-K Annual Report for the year ended December 31, 2018. (File No. 001-9328)
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.15) | † | Form of Nalco Company Death Benefit Agreement and Addendum to Death Benefit Agreement. | ​ | Incorporated by reference from Exhibit (99.2) on Form 8-K of Nalco Holding Company filed on May 11, 2005. (File No. 001-32342)
​ | ​ | ​ | ​ | ​ | ​ | ​

109

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​
--- | --- | --- | --- | --- | --- | ---
Exhibit No.: |  | Document: |  | Method of Filing:
​ | ​ | ​ | ​ | ​ | ​ | ​
(10.16) | † | Employment Transition Severance Agreement, dated November 16, 2022 between Ecolab Inc. and Timothy Mulhere. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​
(21.1) | ​ | List of Subsidiaries. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(23.1) | ​ | Consent of Independent Registered Public Accounting Firm. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(24.1) | ​ | Powers of Attorney. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(31.1) | ​ | Rule 13a-14(a) CEO Certification. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(31.2) | ​ | Rule 13a-14(a) CFO Certification. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(32.1) | ​ | Section 1350 CEO and CFO Certifications. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.INS) | ​ | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.SCH) | ​ | Inline XBRL Taxonomy Extension Schema. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.CAL) | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.DEF) | ​ | Inline XBRL Taxonomy Extension Definition Linkbase. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.LAB) | ​ | Inline XBRL Taxonomy Extension Label Linkbase. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(101.PRE) | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase. | ​ | Filed herewith electronically.
​ | ​ | ​ | ​ | ​ | ​ | ​
(104) | ​ | Cover Page Interactive Data File. | ​ | Formatted as Inline XBRL and contained in Exhibit 101.

​

† This exhibit is an executive compensation plan or arrangement.

​

​

Item 16. Form 10-K Summary.

​

None.

​

​

110

Table of Contents

SIGNATURES

​

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Ecolab Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 24th day of February, 2023.

​

​ | ECOLAB INC.
​ | (Registrant)
​ | ​
​ | ​
​ | By: | /s/ Christophe Beck
​ | ​ | Christophe Beck
​ | ​ | Chairman and Chief Executive Officer

​

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Ecolab Inc. and in the capacities indicated, on the 24th day of February, 2023.

​

​

/s/ Christophe Beck | ​ | Chairman and Chief Executive Officer
Christophe Beck | ​ | (Principal Executive Officer and Director)
​ | ​ | ​
​ | ​ | ​
/s/ Scott D. Kirkland | ​ | Chief Financial Officer
Scott D. Kirkland | ​ | (Principal Financial Officer)
​ | ​ | ​
​ | ​ | ​
/s/ Jennifer J. Bradway | ​ | Senior Vice President and Corporate Controller
Jennifer J. Bradway | ​ | (duly authorized officer and Principal Accounting Officer)
​ | ​ | ​
​ | ​ | ​
/s/ Lanesha T. Minnix | ​ | Directors
Lanesha T. Minnix | ​ | ​
​ | ​ | ​
as attorney-in-fact for: | ​ | ​
Shari L. Ballard, Barbara J. Beck, Jeffrey M. Ettinger, Eric M. Green, Arthur J. Higgins, Michael Larson, David W. MacLennan, Tracy B. McKibben, Lionel L. Nowell, III, Victoria J. Reich, Suzanne M. Vautrinot and John J. Zillmer | ​ | ​

​

​

​

​

​

​

111